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Abstract 
Gestational diabetes mellitus (GDM) is defined as a glucose intolerance of varying 
severity with first recognition during pregnancy. The prevalence of GDM is 
increasing worldwide, largely attributable to the dramatic rise in maternal obesity, 
resulting in several maternal and fetal complications. The maternal metabolic 
adaptation during pregnancy is challenged by maternal obesity, resulting in β cell 
dysfunction and exaggerated insulin resistance in women with GDM. However, the 
exact cellular mechanisms involved in the development of GDM are not yet 
completely understood. Increasing evidence from clinical and experimental studies 
has suggested that adipose tissue dysfunction could be one of the underlying 
mechanisms for the metabolic abnormalities observed in women with GDM. 
However, most of the published literature on this topic has been focused on plasma 
measures of adipocyte-derived adipokines and how they are linked to insulin 
resistance. Functional measures of adipocytes, such as adipocyte size, lipolysis, 
insulin sensitivity and direct measurement of adipocyte secretory function, have not 
been widely studied in GDM. Failure to efficiently increase the adipocyte cell number 
(hyperplasia) rather than increase size (hypertrophy) in order to store excess free 
fatty acids (FFA), and the subsequent failure to suppress adipocyte lipolysis when 
FFA demands are low, is believed to be a key mechanism in the development of 
type 2 diabetes in the non-pregnant. Similarly, this could be a major candidate 
pathway for pregnancy complicated by GDM, leading to the observed higher plasma 
FFA and higher plasma pro-inflammatory cytokine concentrations, which may result 
from exaggerated adipocyte insulin resistance and inflammation. Therefore, the 
hypothesis tested in this thesis was that GDM results from defective expansion of 
SAT adipocytes, resulting in adipocyte hypertrophy. Subsequently, there is 
increased adipocyte lipolysis and inflammatory adipokine secretion. 
The aim of this thesis was, firstly, to explore the epidemiological evidence for the 
role of maternal obesity in the development of GDM and other maternal and fetal 
complications, specifically in the highly diverse local Greater Glasgow and Clyde 
population. Data from the Scottish Morbidity Record 2 (SMR02) and the Scottish 
Care Information – Diabetes Mellitus (SCI-diabetes) databases for pregnant women 
between 2010 and 2015 was combined, and the prevalence of maternal obesity and 
GDM established among 38,178 births. The associated risks for several adverse 
pregnancy outcomes among women with maternal obesity and GDM in the Greater 
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Glasgow and Clyde population were calculated. It was found that in the local 
population maternal obesity and GDM were at higher prevalence (22.3% and 2.2%, 
respectively) compared to recent historical studies, and are associated with an 
increase in the incidence of a range of adverse pregnancy outcomes. Furthermore, 
the resulting adverse maternal and fetal complications of both first trimester 
maternal obesity and GDM were likely to be a considerable burden on clinical 
resources. Assessment of the long-term implications of maternal and fetal 
complications secondary to GDM and maternal obesity was not included, and a 
prospective follow-up analysis of this cohort is recommended. 
The second aim of this thesis was to determine the evidence for the role of failure 
of adipocyte expansion in the development of underlying metabolic abnormalities in 
women with GDM. Several functional measures of adipocyte expansion were 
assessed, including adipocyte size, lipolytic function, adipokine secretion, and the 
expression of genes involved in adipocyte physiology and biochemistry. 
Subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) biopsies 
from non-labouring women with GDM (n=22) and healthy (n=22) BMI-matched 
controls, undergoing elective caesarean section, were collected. Maternal blood 
was collected prior to delivery and maternal phenotyping was carried out by the 
assessment of plasma glucose, insulin, plasma lipids (triglyceride, cholesterol, 
glycerol and non-esterified fatty acids), pregnancy hormones (estradiol and 
progesterone), liver enzymes (gamma-glutamyl transferase, alanine 
aminotransferase and aspartate aminotransferase), plasma inflammatory cytokines 
and oxidised low-density lipoprotein (oxLDL), a biomarker of lipotoxicity. Maternal 
BMI at booking was recorded from the patient notes, along with other demographic 
information. Fetal weight and sex were recorded after the baby was delivered. 
Adipocyte isolation and sizing were carried out. The ex vivo lipolytic activity (basal 
and β adrenergic- stimulated lipolysis, and insulin suppression of lipolysis) and 
adipokine production (basal and lipopolysaccharide stimulated conditions) were 
assessed in isolated adipocytes. The adipocyte expression of genes involved in 
adipocyte differentiation, lipid storage, lipid and glucose metabolism and 
angiogenesis were also performed by RT-qPCR. 
In GDM, VAT adipocytes had higher mean adipocyte diameter ((control) 62.9[3.8] 
vs (GDM) 75.5[11.6] µm, p=0.004) and volume ((control) 0.00007[0.00000002] vs 
(GDM) 0.00012[0.0000005] mm3, p=0.003) compared to controls. VAT adipocytes 
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from women with GDM had higher basal lipolysis compared to controls (0.02[0.02] 
vs 0.07[0.07] glycerol mmol/hr/ug of DNA, p=0.001). The fat cell insulin sensitivity 
index (FCISI), a measure of adipocyte insulin suppression of lipolysis, was six times 
lower in the VAT adipocytes of women with GDM, but failed to reach statistical 
significance ((control) 62[204] vs (GDM) 35[52] FCISI, p=0.61). In contrast, there 
were no differences observed in SAT adipocytes with regard to adipocyte size, 
lipolysis and FCISI between the two groups. Hypertrophic expansion of VAT 
adipocytes may be one of the contributors to the increased basal lipolysis rate seen 
in this depot. This will favour portal release of fatty acids, and could be an important 
factor in triggering metabolic abnormalities associated with liver fat accumulation in 
obese pregnant women. Thus, dysfunctional VAT adipocytes may represent an 
important event contributing to the emergence of metabolic dysfunction in women 
with GDM. 
The study of isolated VAT adipocyte adipokine secretion in basal or activated (LPS-
stimulated) conditions in a subset of healthy and GDM women did not show any 
differences in VAT adipocyte adipokine release in GDM compared to controls. 
However, these results should be interpreted with caution, because of the small 
sample size. Therefore, further tissue collection is recommended in order to 
increase the power of the study. Further investigation of macrophage and other 
immune cell contribution to adipose tissue inflammation in women with GDM is 
warranted. Isolated adipocyte gene expression analysis in both SAT and VAT 
showed that women with GDM had significantly higher insulin receptor (INSR) 
expression in both SAT (9.0(3.1) vs 11.7(3.7) INSR percentage expression relative 
to PPIA, p= 0.031) and VAT (10.8(3.6) vs 15.8(5.6) INSR percentage expression 
relative to PPIA, p= 0.022) compared to controls. There were no differences in the 
expression of other genes involved in adipocyte differentiation, lipid storage, lipid 
and glucose metabolism and angiogenesis in isolated SAT and VAT adipocytes for 
women with GDM compared to controls. 
The final aim was to assess the role, in early pregnancy, of very low-density 
lipoprotein (VLDL) as a potential maternal plasma carrier of the extremely important 
long chain polyunsaturated fatty acid (LC-PUFA) docosahexaenoic acid (DHA), 
required by the fetus for neuronal development. During pregnancy, there is a three-
fold increase in VLDL synthesis by the liver. The liver is the primary site for de novo 
LC-PUFA synthesis, which is shown to be increased in early pregnancy; therefore, 
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VLDL could be the carrier of DHA at early pregnancy. Infants born to mothers with 
GDM had lower DHA levels, and were shown to have lower cognitive performance, 
partly attributed to lower placental transfer of DHA in GDM. However, the underlying 
mechanism for defective DHA metabolism and transport in GDM pregnancy is not 
fully understood. Using an archival plasma collection of women undergoing frozen 
embryo transfer (FET), fasting blood samples were collected at approximately day 
10 following the last menstrual period (LMP) (pre-luteinizing hormone (LH) surge), 
and on days 18, 29 and 45 post-LH surge from women who were successful in 
getting pregnant (n= 27). VLDL FA composition was assessed by gas 
chromatography in women who were successful in getting pregnant and women 
who were not. There was no evidence for VLDL being the main carrier of DHA at 
the critical time of neuronal tube closure, as DHA concentration in VLDL and VLDL 
DHA enrichment was unchanged over time. A reduction in VLDL particle number 
(measured by apo-B concentration) by 18 days post-LH surge was observed 
(p<0.001), which was then recovered to pre-LH surge level by 45 days post-LH 
surge. It is likely that DHA is carried by other lipoproteins such as HDL, as is 
observed in the non-pregnant population. Further investigation of the main 
lipoprotein carrier for DHA during pregnancy, and the study of its metabolism and 
transport in GDM pregnancy, is needed. 
In conclusion, GDM and maternal obesity are associated with increased risk of 
adverse pregnancy outcomes. Effective intervention strategies are required for 
weight control prior to pregnancy. The data presented in this thesis provides 
evidence that in GDM, VAT adipocytes expand in a hypertrophic manner, and have 
increased basal lipolysis. Hypertrophic expansion of VAT adipocytes may be linked 
to systemic insulin resistance. Thus, defective VAT adipocyte expansion might have 
a role in the underlying pathophysiology of GDM. Further studies on the role of 
adipocyte differentiation and ectopic fat storage in normal and complicated human 
pregnancy are warranted. DHA is not transported by VLDL in early pregnancy. 
Further investigation of the main carrier of DHA during pregnancy, and the study of 
DHA metabolism in pregnancies complicated by GDM, is needed. 
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Chapter 1 Introduction and Literature Review 
1.1 Maternal obesity 
Rapidly increasing rates of obesity worldwide represent a major health concern. 
Maternal obesity is a well-established risk factor for adverse pregnancy outcomes 
such as gestational diabetes (GDM), preeclampsia (PE), miscarriage and 
Caesarean section. Obesity can be classified by BMI into three classes, according 
to World Health Organization (WHO) criteria: obese class 1 (30–34.99 kg/m²), obese 
class 2 (35–39.99kg/m²) and obese class 3 (≥ 40 kg/m²) (World Health Organization, 
2000). In the United Kingdom, there are no population-wide data that directly 
estimates maternal BMI just before pregnancy. In Scotland, a study examining 
maternal obesity using a national dataset from 1981 to 2012 reported a 21.1% 
prevalence of maternal obesity (Collier et al., 2017). Another observational study of 
the Scottish population for all singleton pregnancies between 2003 and 2010 
reported a 19.6% prevalence of maternal obesity (Denison et al., 2014). In England 
in 2010, the incidence of first-trimester maternal obesity has doubled over the last 
19 years since 2010 from 7.6% to 15.6% (Heslehurst et al., 2010a). Another study 
examined the trends of obesity among the Glasgow population in 1990 compared 
to 2002-2004 and found there was a significant increase in the proportion of women 
who were obese (BMI> 30 kg/m2) at booking, from 9.4% to 18.9%. This trend of 
increasing maternal obesity is a warning sign, and this issue needs to be addressed 
in order to avoid serious implications for obstetric care. 
Maternal obesity has adverse outcomes for both mother and baby, and it can lead 
to a repeated cycle of metabolic risk between generations (O'Reilly and Reynolds, 
2013). Obese mothers are at higher risk of type 2 diabetes mellitus (T2DM) 
development later in life (Kim et al., 2002). The offspring of obese mothers are at 
higher risk of childhood obesity via programming effects, as reviewed by Freeman 
(2010). The increased prevalence of maternal obesity is associated with an 
observed increase of pre-existing conditions among mothers, such as T2DM and 
chronic hypertension (HTN), which could potentially increase fetal and maternal 
adverse outcomes. Pre-existing T2DM increases the risk of congenital 
malformation, pregnancy loss, fetal macrosomia (Inkster et al., 2006) and poor 
maternal outcomes, such as PE, caesarean delivery and retinopathy progression 
(Morrison et al., 2016a, Morrison et al., 2016b). Pre-existing chronic HTN increases 
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the risk of preeclampsia, caesarean section and preterm delivery (Chappell et al., 
2008). 
Pre-pregnancy, obese women are more likely to suffer from infertility than normal-
weight women (Gesink Law et al., 2006). This can be related to ovulatory 
dysfunction due to increased insulin resistance (Chavarro et al., 2007). In early 
pregnancy, obese mothers had a 30% increased chance of having a miscarriage 
(Marchi et al., 2015). Maternal obesity is associated with increased risk of congenital 
malformations, such as neural tube defects and cardiovascular, orofacial and limb 
anomalies (Marchi et al., 2015). 
From mid-pregnancy onwards, obese women are more likely to develop 
complications such as GDM and PE. Obese mothers have four- to nine-fold 
increased risk of developing GDM during pregnancy (Poston et al., 2016), and this 
risk is linearly related to obesity class (Kim et al., 2016). Both maternal obesity and 
GDM are associated with maternal and fetal adverse outcomes, such as large for 
gestational age babies (LGA), macrosomia, shoulder dystocia, caesarean delivery 
and NICU admission. In a study assessing pregnancy outcomes in GDM mothers 
by obesity class, mode of treatment and glycaemic control, pregnancy outcomes 
were found to be compromised, independent of all other factors (Yogev and Langer, 
2008). Several studies highlighted the importance of gestational weight gain over 
pre-pregnancy BMI regarding the risk of LGA babies in GDM obese mothers (Santos 
et al., 2016b, Santos et al., 2016a). 
PE is a hypertensive disorder during pregnancy. It is considered to be the leading 
cause of maternal and fetal morbidity and mortality, occurring in approximately 1–
8% of pregnancies. Obesity is a risk factor for PE. An obese mother has 3–10 times 
increased risk of developing PE compared to normal pregnant women (Marchi et 
al., 2015). PE presents risk of convulsion, kidney failure, liver failure and death for 
the mother, and premature delivery and intra-uterine growth restriction (IUGR) for 
the baby. An increase in pre-pregnancy BMI is associated with a higher risk of 
developing PE. Compared with women with a BMI of 21, the risk of preeclampsia 
doubles at a BMI of 26 (OR 2.1), triples at a BMI of 30 (OR 2.9), and increases 
further with severe obesity (OR 3.5) (Bodnar et al., 2005). Furthermore, women with 
higher BMI were found to be at risk of developing severe PE (Stone, 1994). 
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1.2 Gestational diabetes – the clinical problem 
GDM was defined by the WHO as ‘glucose intolerance resulting in hyperglycaemia 
of variable severity with first onset during pregnancy’. This definition applies even if 
this condition continues after pregnancy and does not exclude the possibility that 
glucose intolerance could be undiagnosed at the start of pregnancy. By contrast, 
the American Diabetes Association (ADA) recently redefined GDM as ‘diabetes 
diagnosed in the second or third trimester of pregnancy that is not clearly overt 
diabetes’ (American Diabetes Association, 2015). Therefore, women with glucose 
intolerance in the first trimester are classified as T2DM. The global prevalence of 
diabetes mellitus is increasing rapidly worldwide, affecting people at different stages 
in life. In 2010, an estimated 285 million people in the world had T2DM (Shaw et al., 
2010). This number is expected to rise in 2030 to reach 439 million, making T2DM 
one of the most critical public health challenges, and a major burden on health care 
systems worldwide. GDM risk factors include family history of T2DM, ethnicity, 
maternal age, obesity, and past history of GDM and macrosomia. Gestational 
diabetes is a heterogeneous disorder and has adverse maternal and fetal 
consequences. The majority of β-cell dysfunction observed in GDM is due to a 
pathophysiology similar to that observed in T2DM. GDM prevalence figures are 
affected by the geographic population, GDM screening intensity, and the employed 
diagnostic criteria. A recent review of global estimates of GDM suggested that the 
Middle East and North Africa had the highest prevalence, with median estimates of 
12.9%, whereas Europe had the lowest estimates of 5.8% (Zhu and Zhang, 2016). 
Recent analysis showed that the prevalence of GDM among the Scottish population 
was only 1.9%. 
There are two common screening approaches in use: universal screening or 
selective screening at mid-pregnancy (24–28 weeks of gestation). Early screening 
is recommended for high-risk individuals in order to rule out pre-existing diabetes 
and prevent possible fetal and maternal complications. The Hyperglycaemia and 
Adverse Pregnancy Outcomes (HAPO) study was conducted in response to the 
need for internationally agreed diagnostic criteria for GDM, based upon their 
predictive value for adverse pregnancy outcomes. Based on this observational 
study, the International Association of Diabetes and Pregnancy Study Groups 
(IADPSG) (Metzger et al., 2010) proposed a universal screening method using a 
75g glucose load test at 24–28 weeks of gestation. Increases in each of the three 
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values (fasting blood glucose ≥ 5.1, 1 hour ≥ 10.0, 2 hours ≥ 8.5 mmol/L) on the 
75g, 2-hour oral glucose tolerance test were associated with graded increases in 
the likelihood of pregnancy outcomes, such as LGA, caesarean section, high fetal 
insulin levels and increased neonatal fat content. A diagnosis of GDM can be made 
if one result of blood glucose levels reaches one or more of the previously mentioned 
values. These new criteria resulted in an 18% increase in GDM prevalence. The 
widespread use of the IADSPG criteria would result in nearly 1 in 5 pregnant women 
being classified as GDM (Metzger et al., 2010). However, the implementation of 
these new criteria to diagnose GDM has not yet been proven to be effective in terms 
of cost-effectiveness. Recent studies (Welch, 2011, Chen et al., 2009) suggested 
that the use of a two-step approach (first a non-fasting 50g glucose challenge test, 
to be followed, if positive (7.8 mmol/L), by a fasting 100g oral glucose tolerance test 
(OGTT)) is more cost-effective. Another study (Werner et al., 2012) suggested that 
IADPSG criteria could be more effective if post-partum care and monitoring were 
included in the cost-effectiveness analysis. The IADPSG criteria were adopted by 
the WHO, the American Diabetes Association (ADA) (2011), and the International 
Federation of Gynaecology and Obstetrics (FIGO), but not by the American College 
of Obstetricians and Gynecologists (ACOG) (2013), or the National Institute for 
Health and Care Excellence (NICE) (Bilous, 2015) (Table 1-1). In the UK, NICE 
proposed another criterion based on health economic analysis, using a wide range 
of glucose thresholds, and published new clinical guidelines in 2015. The NICE 
analysis did not support the cost-effectiveness of IADPSG criteria (Bilous, 2015). In 
the NICE guidelines, GDM is diagnosed if: fasting blood glucose (FBG) ≥ 5.6 
mmol/L, or 2-hour glucose after a 75g OGTT ≥ 7.8 mmol/L. The Scottish 
Intercollegiate Guidelines Network (SIGN), in their 2010 recommendations, advised 
screening with clinical risk factors for GDM at booking, with HBA1c or fasting 
glucose (The Scottish Intercollegiate Guidelines network, 2010). At 24–28 weeks of 
gestation, all high-risk women should undergo a 75-g OGTT with the IADPSG 
criteria used for diagnosis, and all low-risk women should undergo the fasting 
plasma glucose testing.
 
 
Table 1-1 Different international guidelines for gestational diabetes screening and diagnosis 
Current 
criteria 
 
IADPSG, 
2010 
(Metzger et 
al., 2010) 
WHO, 2013 ADIPS, 2013 
(Nankervis et 
al., 2014) 
SIGN, 
2010 
NICE, 2015 
(Thompson 
et al., 2013) 
 
ACOG*, 
2013 
(Obstetricians and 
Gynecologists, 2013) 
Initial 
screen 
Universal Universal Universal Risk 
factors 
Risk 
factors 
Universal 
Biochemical 
test 
75g OGTT 75g OGTT 75g OGTT 75g 
OGTT 
75g OGTT 1- 50 g GCT≥ 7.8 
or 7.5 
2- 100 OGTT 
Diagnostic 
threshold 
for GDM 
(mmol/L) 
fasting 
 
 
 
≥ 5.1 
 
 
 
≥ 5.1 
 
 
 
≥ 5.1 
 
 
 
≥ 5.1 
 
 
 
≥5.6 
 
 
 
5.3 or 5.8 
1 hour ≥ 10 ≥ 10 ≥ 10 ≥ 10 N/A 10 or 10.6 
2 hours ≥ 8.5 ≥ 8.5 ≥ 8.5 ≥ 8.5 ≥7.8 8.6 or 9.2 
3 hours N/A N/A N/A N/A N/A 7.8 or 8.0 
Required 
abnormal 
value 
 
1 
 
1 
 
1 
 
1 
 
1 
 
2 
IADPSG – International Association of Pregnancy Study Group; WHO – World Health Organization; ADIPS – Australian Diabetes in Pregnancy Society; SIGN - Scottish 
Intercollegiate Guidelines Network; NICE – National Institute for Health and Clinical Excellence; ACOG – American College of Obstetricians and Gynecologists. ACOG 
endorsed either the National Diabetes Data Group (NDDG) or Coustan and Carpenter criteria.
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There are several adverse outcomes associated with GDM. The many differences 
in the reported associations of GDM with adverse outcomes are due to the lack of 
universal agreement on GDM screening, diagnostic criteria, and the best 
methodology to screen or diagnose GDM. In GDM, there are increased risks of 
perinatal mortality, macrosomia, birth trauma, shoulder dystocia, and metabolic and 
cardiovascular complications in untreated GDM. A retrospective study suggested 
that unrecognised GDM is an independent risk factor for perinatal morbidity after 
controlling for confounders, and that dietary control of GDM decreases perinatal 
morbidity (Adams et al., 1998). A recent meta-analysis (Horvath et al., 2010), 
including two of the most important randomised controlled trials – the Australian 
Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) (Crowther et al., 
2005) and the Maternal Fetal Medicine Unit Network (MFMU) (Landon et al., 2009) 
– showed that the pregnancy outcomes improved by treating GDM are a reduction 
in macrosomia (OR 0.38), large for gestational age infants (LGA) (OR 0.48) and 
shoulder dystocia (OR 0.40). 
The adverse consequences of GDM for mothers are mainly the development of 
T2DM post-pregnancy, preeclampsia and caesarean delivery. Studies have 
suggested that up to 50% of GDM mothers developed overt T2DM, with the highest 
occurrence rate in the first five years following delivery (Bellamy et al., 2009). Other 
factors such as glycaemic status during pregnancy, gestational weight gain, and 
obstetric complications such as PE are known to influence the future risk of diabetes 
(Kwak et al., 2013). A recent systematic review and meta-analysis of 95,750 women 
showed that the future risk of diabetes is mainly influenced by gestational glycaemic 
status, and that both hypertensive disorders in pregnancy and preterm delivery in 
GDM pregnancies were associated with future onset of T2DM (Rayanagoudar et 
al., 2016a, Rayanagoudar et al., 2016b). Therefore, postnatal counselling of women 
with GDM regarding the risk of future diabetes should be individualised. Catalano et 
al. (1991) suggested that 50% of GDM mothers remained insulin-resistant following 
delivery. This suggests that GDM diagnosis is a good opportunity for intervention 
and prevention of T2DM, and slowing its epidemic progress. 
Fetal outcomes are improved after treating GDM. Adequate glycaemic control 
enhances perinatal outcomes in GDM (Crowther et al., 2005). This can be achieved 
by the use of oral hypoglycaemic drugs such as metformin, and/or by the use of 
insulin to manage maternal blood glucose levels. Metformin is a second-generation 
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biguanide that has been shown to be effective in T2DM. Metformin was found to 
provide adequate glycaemic control in GDM mothers, resulting in reduced weight 
gain and lower frequency of neonatal hypoglycaemia. In a large randomised 
controlled trial (RCT) (Rowan et al., 2008), there was no difference between 
metformin and insulin in the level of glycaemic control and pregnancy outcomes. 
The degree of glycaemic control has a key role regarding the degree to which 
pregnancy outcomes in GDM are improved (Langer et al., 1994). 
The matter of which criteria are the most clinically useful and cost-effective remains 
controversial. Some studies have attempted to examine pregnancy complications in 
women fulfilling different criteria in order to address this. However, there are few 
studies that have assessed the differences between IADPSG and NICE criteria in 
the same population. It is important to note that the populations of these studies are 
usually populations treated under one or other criteria, making interpretation more 
challenging. For example, a retrospective study (Meek et al., 2015) assessed the 
neonatal and obstetric outcomes in 25,543 live singleton births from a single centre 
in Cambridge, using IADPSG and NICE 2015 criteria for GDM diagnosis; GDM 
prevalence was 4.13% (NICE) and 4.62% (IADPSG). This study showed that 167 
women tested negative using NICE criteria, but positive using IADPSG criteria. 
These women had a higher risk of LGA OR 3.12 (95% CI 2.44–3.98), caesarean 
delivery OR 1.44 (95% CI 1.15–1.81) and polyhydramnios OR 6.90 (95% CI 3.94–
12.08) compared to healthy pregnant women. This study concluded that the 
IADPSG criteria identify women at higher risk of GDM complications, and the 
number of cases needed to treat one case of LGA is 5.8. A similar study conducted 
at a centre in Croatia included 4,646 women (Djelmis et al., 2016); GDM prevalence 
was 23.1% (IADPSG) and 17.8% (NICE). Women with FBG (5.1–5.5 m.mol/l) had 
higher risk of LGA OR 3.7 (95% CI 2.0–4.6) and caesarean delivery OR 1.8 (95% 
CI 1.3–2.3) compared to the control group. These women were at greater risk of 
maternal and neonatal adverse outcomes, and were not diagnosed by NICE criteria. 
One issue must be addressed when comparing the results of the previous two 
studies. In the Cambridge study, NICE criteria were used to diagnose GDM, which 
means that the IADPSG-positive women were untreated. The Croatia study was 
analysed in the time period when IADPSG criteria were used to diagnose GDM, 
which means that IADPSG-positive women were treated. This could possibly 
account for the high caesarean section rates in the Cambridge study. However, it is 
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difficult to reach conclusions with regard to use of the IADPSG and NICE criteria 
when each study used different selection criteria. 
Ethnicity has long been recognized as a risk factor for GDM development. Several 
ethnicities were recognized to have a higher risk for GDM such as Hispanic, African, 
Native American, South and East Asian (Berkowitz et al., 1992). It is recommended 
that women from high risk group get screened for GDM as soon as feasible and to 
repeat at 24-28 weeks of gestation (International Association of Diabetes and 
Pregnancy Study Groups, 2010). Therefore, the regional prevalence of GDM varies 
from 10.4% in Africa to 24.2% in South Asia (Ogurtsova et al., 2017). Furthermore, 
the prevalence of GDM among various ethnic group varies considerably. Sanchalika 
and Teresa (2015) showed in a large retrospective study that among South Asian 
women living in New Jersey, Bangladeshi women had highest rate of GDM followed 
by Indians, Sri Lankans and Pakistanis. There are also differences in GDM 
pregnancy outcomes between different ethnicities. It was reported previously that 
South Asian women had lower preterm birth and LGA rates than white women, but 
higher small for gestational age infants (Sanchalika and Teresa, 2015).  
1.3 Maternal metabolic adaptation to pregnancy in 
healthy, obese and GDM pregnancy 
1.3.1 Healthy pregnancy 
In early pregnancy, there is an increase in maternal lipogenesis and fat 
accumulation, which was found to account for most of the conceptus-free weight 
gain (Herrera, 2002b). This was suggested to result from the development of 
hyperphagia and a relative increase in lipoprotein lipase in early pregnancy, which 
increases fat storage. There is increased insulin sensitivity in early pregnancy due 
to high estrogen levels. Insulin strongly inhibits lipolysis at adipose tissue with the 
suppression of hormone-sensitive lipase. The acquired adipose tissue is a source 
of fatty acid supply during late gestation, which is required to support rapid fetal 
growth (Herrera, 2002b). In a previous study, where maternal body composition was 
assessed by hydrodensitometry, there was a significant increase in fat mass in lean 
women with normal glucose tolerance during pregnancy (Catalano et al., 1998). This 
relationship was significant only for the period before conception up to early 
gestation, and not late pregnancy (Catalano et al., 1998). The mechanism 
underlying this observed relationship between insulin sensitivity and weight gain in 
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early pregnancy remains unknown. Healthy normal-weight women gain around 
3.8 kg of fat during pregnancy, but there is high inter-individual variability. 
At mid-gestation, a time of increasing fetal demand, the maternal body switches 
from anabolic lipogenesis to a catabolic lipolytic, insulin-resistant state (Figure 1-1). 
This is a physiological response to preserve glucose, as the primary fuel for fetal 
metabolism, by reducing maternal carbohydrate utilisation. Due to increased total 
energy expenditure at late gestation (Catalano et al., 1998), any reduction in 
maternal carbohydrate utilisation is substituted by fat utilisation, as an alternative 
source of energy. Consequently, lipid metabolism is markedly altered. The 
increased insulin resistance at late gestation increases lipolysis, which enhances 
the availability of free fatty acids (FFA) and glycerol (the main substrate for 
gluconeogenesis) for both maternal and fetal use (Huda et al., 2009). During healthy 
pregnancy there is an increase in plasma cholesterol and triglyceride (TAG) 
concentration by 20–25% and 200–400%, respectively (Huda et al., 2009). This 
increase in TAG was found to be due to a three-fold increase in very low-density 
lipoprotein (VLDL) synthesis from 14 weeks of gestation to the end of pregnancy. 
This increase in TAG incorporation into VLDL by the liver is augmented by the effect 
of estrogen. Insulin resistance decreases lipoprotein lipase activity, the enzyme 
responsible for VLDL clearance from the plasma and TAG uptake from VLDL by 
peripheral tissues. As a result, VLDL remains longer in the plasma, which increases 
LDL accumulation. This potentially can lead to the appearance of small dense low-
density lipoproteins (sdLDL). Plasma LDL concentration increases during late 
pregnancy by 70%. At 28 weeks of gestation, HDL is also increased by 40% 
compared to 14-week gestation levels (Fahraeus et al., 1985). This is attributed to 
the effect of estrogen, which promotes ApoA-I production by the liver, thereby 
increasing HDL formation. Furthermore, accelerated transfer of TAG to lipoproteins 
of higher density is attributed to the long exposure to cholesteryl ester transfer 
protein (CETP). The increase in HDL is suggested to be a protective mechanism to 
counteract any detrimental effects of pregnancy hyperlipidaemia (Huda et al., 2009). 
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Figure 1-1 Maternal adipose tissue response to metabolic changes during early and late 
pregnancy. 
In early pregnancy, increased insulin sensitivity promotes fat storage, via high LPL activity, and 
reduces lipolysis at adipocytes, via inhibition of HSL, promoting fat storage. In late pregnancy, due 
to the physiological insulin resistance of pregnancy, there is no insulin suppression of HSL, which 
accelerates lipolysis and VLDL formation, and consequently its conversion by hepatic lipase to LDL, 
and there is reduced LPL by insulin resistance. LPL: lipoprotein lipase, HSL: hormone-sensitive 
lipase. 
There is evidence of oxidative stress during healthy pregnancy. Oxidative stress is 
defined as an imbalance between prooxidant mediators, such as free radicals and 
oxidised lipids, and antioxidant mechanisms, which include superoxide dismutases, 
glutathione peroxidases, catalase and peroxiredoxins, modulating enzyme systems 
which act as the first‐line defence against ROS (Karihtala and Soini, 2007). Toescu 
et al. (2002) studied oxidative stress during healthy pregnancy and recruited non-
pregnant women to form a control group. Plasma lipid hydroperoxides (LHP) were 
measured at first, second and third trimester, and 8 weeks postpartum. There was 
no significant difference in LHP between the two groups in early pregnancy, but LHP 
continued to increase in the second trimester, and reached abnormally high levels 
in the third trimester, a level comparable to that observed in diabetic patients with 
vascular disease. This increase was associated with the predominance of sdLDL 
subfractions (high LDL score). The LHP levels returned to baseline levels by 8 
weeks postpartum. This data showed that during late pregnancy there is an increase 
in sdLDL particles and an increase in oxidative damage (Toescu et al., 2002). This 
could potentially harm the vascular endothelium and accelerate inflammatory 
processes. 
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Pregnancy is characterised by physiological systemic inflammation. During 
pregnancy, the balance between cell-mediated immunity (Th1) and humoral 
immunity (Th2) is strongly shifted towards the predominance of Th2 cytokines (IL-
5, IL-10 and IL-13), which have a potentially protective role in pregnancy (Challis et 
al., 2009). Inflammatory processes towards late pregnancy alter this balance and 
lead to a progressive shift back towards Th1 cytokines (IL-2, IFN-gamma and 
lymphotoxin), which initiates and intensifies the inflammatory cytokine production 
involved in adverse pregnancy outcomes (Challis et al., 2009). In pregnancy there 
are increased levels of inflammatory markers, particularly in the third trimester, such 
as TNF-α, which may be major mediators for pregnancy-induced insulin resistance. 
TNF-α promotes IR by suppressing tyrosine phosphorylation of the insulin receptor 
and its substrate-insulin receptor substrate-1 (IRS-1) via inhibition of tyrosine kinase 
(Hotamisligil et al., 1994). Furthermore, it diminishes the expression of glucose 
transporter type 4 (GLUT 4) in adipose tissue and skeletal muscle. The pro-
inflammatory activity of TNF-α in beta cells of the pancreas plays a key role in their 
apoptosis, contributing to T2DM development (Akash et al., 2018). 
Healthy pregnancy is associated with enhanced vascular function. The vascular 
endothelium has a major role in maintaining vascular function despite the metabolic 
and inflammatory changes during pregnancy. The vascular endothelium is involved 
in the control of various functions such as inflammation, vascular tone, permeability, 
thrombosis, platelet and leukocyte adhesion and aggregation. Disturbances in 
endothelium function have been associated with pregnancy complications such as 
preeclampsia. Vascular function can be determined by both endothelial cell 
production of vasoactive substances and smooth muscle responsiveness – termed 
endothelium-dependent and endothelium-independent function, respectively – and 
they can be assessed ex vivo by the use of endothelium-dependent agonists 
(acetylcholine and bradykinin) and endothelium-independent agonists (sodium 
nitroprusside and nitro-glycerine). These vascular responses are often tested in 
different vascular beds, which makes it difficult to compare endothelial function 
assessed in different studies. 
Enhanced endothelial function during healthy pregnancy was apparent from 10 
weeks of gestation (Savvidou et al., 2000). There was an increase in endothelium-
dependent function in lean pregnant mothers, which remained improved up to 4 
months postpartum (Stewart et al., 2007b). This has been demonstrated in several 
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studies using flow-mediated dilatation (FMD). FMD is an in vivo assessment method 
used to assess macrovascular function, in which the brachial (most commonly), 
femoral or radial artery diameter changes in response to increased flow (shear 
stress) are measured using high resolution ultrasound. This is a non-invasive 
method dependent on nitric oxide (NO) release from endothelial cells to assess 
endothelium-dependent vascular function. Lack of standardisation and intra-
observer variability are the major limitations of this technique. After 30 weeks of 
gestation, a fall in FMD was observed and negatively correlated with an increase in 
brachial artery resting diameter at this time point (Savvidou et al., 2000). A positive 
correlation between maternal plasma TAG and FMD suggested that enhanced 
vascular function in pregnancy is dependent on the hyperlipidaemia status 
(Saarelainen et al., 2006). Laser Doppler imaging/flowmetry (LDF) is a non-invasive 
in vivo method used to assess microvascular function by the measurement of 
cutaneous perfusion accompanied by iontophoresis of acetylcholine and sodium 
nitroprusside. The assessment of microvascular function during pregnancy using 
laser Doppler imaging shows improved endothelium-dependent and endothelium-
independent vascular function (Stewart et al., 2007b). Microvascular function in 
isolated arteries can be assessed in vitro by wire myography. This method was 
found to have a strong correlation with other studies using brachial artery FMD, and 
is suggested to be more sensitive (Endemann and Schiffrin, 2004). Wire myography 
studies on pregnant women confirmed the improved FMD in small resistance 
arteries isolated from pregnant women compared to non-pregnant women (Cockell 
and Poston, 1997). 
1.3.2 Obese pregnancy 
Metabolic adaptation during pregnancy is exaggerated in obese mothers. There is 
a significant increase in fat mass in obese mothers during pregnancy, but 
interestingly this is to a lesser extent than that observed in lean mothers. This is 
most likely related to lower insulin sensitivity in early pregnancy in obese mothers 
(Okereke et al., 2004). Fat mass accretion is variable among obese women, ranging 
from 2 to 13.1 kg (Okereke et al., 2004). The progressive decline in insulin sensitivity 
during healthy pregnancy is magnified in obese mothers. Both central and peripheral 
insulin sensitivity are reduced in obese pregnant women (Catalano et al., 1992). 
Peripheral insulin sensitivity is 40% lower in obese mothers, leading to an increase 
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in pregnancy hyperinsulinemia in this population that could potentially lead to 
increased vascular inflammation and oxidative stress. 
Due to reduced insulin suppression of HSL in late gestation and lower levels of LPL, 
the release of FFA from adipocytes increases, which leads to VLDL enrichment with 
TAG (Alvarez et al., 1996). Interestingly, this causes TAG enrichment in HDL and 
LDL particles that have low TAG content under non-pregnant conditions. CETP 
transfers TAG from VLDL particles to lipoproteins of higher density (LDL and HDL), 
and the transfer of cholesteryl esters (CE) from HDL to apolipoprotein B (apoB)-
containing particles (VLDL and LDL) (Knopp et al., 1998). In the liver, hepatic lipase 
hydrolyses HDL-associated TAG, and also phospholipids, inducing the formation of 
smaller HDL particles that can be easily cleared by the kidney (Alvarez et al., 1996). 
Higher plasma LDL enriched in TAG can lead to the production of easily oxidised 
sdLDL particles, which leads to the production of oxidised LDL (oxLDL) particles 
(Griffin et al., 1994). OxLDL is highly atherogenic because of its reduced affinity for 
the native LDL receptor. OxLDL can be taken up by macrophages promoting the 
formation of foam cells and development of early atherosclerotic lesions (Clausen 
et al., 2001). This can initiate endothelial dysfunction and, ultimately, vascular 
occlusion. These pathways explain the development of metabolic syndrome 
features in obese pregnancy characterised by elevated plasma concentrations of 
TAG and VLDL and decreased plasma HDL concentration (Figure 1-2). 
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Figure 1-2: Changes in lipoprotein metabolism during obese pregnancy leads to development 
of metabolic syndrome features. 
Due to VLDL enrichment with TAG in obese pregnancy, CETP transfers TAG from VLDL to LDL and 
HDL particles in exchange for CE. The hepatic lipase in the liver leads to more release of TAG from 
HDL particles, which shrink in size and can be easily cleared by the kidney. When LDL particles 
become smaller in size this leads to the production of sdLDL, which can be easily oxidised to oxLDL. 
This can lead to the development of metabolic syndrome features. CETP: Cholesterol Ester Transfer 
Protein, HDL: High density lipoprotein, LDL: Low-density lipoprotein, sdLDL: small density LDL, 
oxLDL: oxidised LDL, TAG: triglycerides, CE: cholesteryl ester. 
An obese mother tends to enter pregnancy with pre-existing chronic inflammation 
and endothelial activation. Adiposity is a key factor implicated in the low-grade, 
chronic inflammation that is observed in obese mothers. In a study comparing obese 
and lean pregnant women’s inflammatory markers, CRP demonstrated a strong 
relationship with overweight in pregnant women, as early as the tenth week of 
pregnancy (Kac et al., 2011). Obesity-driven inflammation could be implicated in the 
pathogenesis of adverse pregnancy outcomes such as preeclampsia. Circulating 
inflammatory factors could activate and damage endothelial cells in the maternal 
systemic circulation. Increased levels of inflammatory cytokines such as TNF-α can 
promote the activation of adhesion molecules (VCAM-1) via activation of 
transcription factor NF-Kβ (Zhou et al., 2007). This can increase monocyte adhesion 
to endothelial cells and the development of vascular inflammation. Furthermore, 
impaired release of the vasodilator nitric oxide and increased concentrations of the 
vasoconstrictor endothelin-1 in maternal obesity resulted in vascular dysfunction 
(Rao et al., 2014b, Rao et al., 2014a). 
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Laser Doppler imaging was used in a longitudinal study to assess microvascular 
vascular function in lean and obese women, and revealed that although there was 
a similar pattern of improvement in vascular function during pregnancy, obese 
mothers had significantly lower endothelium-dependent and -independent vascular 
function than lean women (Stewart et al., 2007b). In the postpartum period, 
endothelium-dependent function in obese mothers declined to first-trimester levels 
and failed to maintain the gestational improvement, whereas in lean women it 
remained at an enhanced level (Stewart et al., 2007b). In another study, myometrial 
arteries isolated from obese mothers (BMI>36kg/m²) showed reduced relaxation in 
response to bradykinin compared to vessels obtained from pregnant non-obese 
women (BMI<30 kg/m²) (Myers et al., 2006). 
1.3.3 GDM pregnancy 
Increased insulin resistance during late gestation in healthy women is accompanied 
by increased insulin production from β-cells to maintain euglycemia; if this does not 
occur then GDM can develop. GDM is a pregnancy metabolic complication resulting 
from increased insulin resistance during pregnancy. Glucose homeostasis is 
impaired in GDM. Inadequate β-cell compensation for insulin resistance has been 
found in women with GDM, suggesting that β-cell dysfunction is a common feature 
of GDM (Buchanan, 2001). Mechanisms that lead to β-cell failure in women with 
GDM are yet to be identified. The frequent occurrence of chronic insulin resistance 
in women who have or had GDM suggests that the propensity for β-cells to fail in 
the presence of insulin resistance may be a common feature of the disease (Prentki 
and Nolan, 2006). The same mechanism may be involved in the progression from 
GDM to T2DM and in the pathogenesis of T2DM in general. Other factors such as 
maternal and placental hormones, genetic predisposition, and suboptimal lifestyle 
might contribute to the development of GDM (Prentki and Nolan, 2006). 
In a longitudinal study comparing body composition in lean, normal glucose tolerant 
(NGT) mothers and lean GDM mothers, there was a significant increase in weight 
in both groups over time, but no significant difference between the two groups 
(Catalano et al., 1998). However, GDM mothers had significantly smaller increases 
in body fat (1.3 kg, P=0.04) and percentage of fat (1.6%, P=0.02) than lean NGT 
mothers (2 kg and 3.6%, respectively) (Catalano et al., 1998). Total weight gain was 
2.5 kg less than that of NGT women. This could be related to the decreased pre-
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gravid insulin sensitivity in GDM women, which limited their ability to conserve 
energy expenditure and increase body fat (Okereke et al., 2004). 
GDM mothers had higher concentrations of VLDL particles and a lower number of 
large HDL particles compared to healthy pregnant women controls (Mokkala et al., 
2019). Interestingly, the study of Mokkala et al. (2019) found that the most predictive 
biomarker for GDM at early pregnancy was higher concentrations of small HDL 
particles. Other studies have reported that small HDL particles are associated with 
type 1 diabetes (Gourgari et al., 2018), inflammation (Phillips et al., 2018), and 
dyslipidaemias, probably due to impaired capacity to esterify cholesterol (Hernáez 
Camba et al., 2019). In healthy pregnancies, maternal glycemia before delivery 
correlates with neonatal weight and fat mass (Metzger et al., 2008). However, in 
women with well-controlled GDM, both maternal plasma TAG and NEFA, rather than 
maternal glucose, are positively correlated with neonatal weight and fat mass 
(Schaefer‐Graf et al., 2011, Schaefer-Graf et al., 2008). This indicates that maternal 
dyslipidaemia in GDM may enhance the maternal fatty acid transfer to the fetus 
contributing to increased fetal adipose tissue mass and the consequent risk of 
developing macrosomia (Figure 1-3). 
 
Figure 1-3: Maternal adipose tissue metabolism during early and late pregnancy in GDM. 
In GDM, women start pregnancy with some degree of insulin resistance due to pre-pregnancy 
obesity. At late gestation, there is a pronounced increase in insulin resistance due to failure of β-cell 
compensation with an increased insulin requirement during pregnancy leading to hyperglycaemia. 
There is pronounced production of VLDL carrying more TAG more than normal pregnancy (explained 
in figure 1-1), which probably contributes to fetal macrosomia via delivery of fatty acids to the 
placenta. In GDM, TAG-rich VLDL exchanges TAG and CE with HDL and leads to production of 
sdLDL, which is more easily oxidised and leads to the production of atherogenic oxLDL. 
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The literature for vascular function studies during pregnancy in GDM women is 
limited. With the use of wire myography, impaired endothelium-dependent 
microvascular function was indicated by impaired relaxation to acetylcholine in small 
arteries isolated from normotensive GDM mothers compared to normotensive non-
diabetic pregnant women (Knock et al., 1997). The microvascular response in newly 
diagnosed GDM mothers (33 weeks of gestation) was assessed using LDF, and no 
significant difference was found between women with or without GDM during 
pregnancy (Pontes et al., 2015). 
1.4 Docosahexaenoic acid (DHA) 
There are two families of long chain polyunsaturated fatty acids (LC-PUFA) derived 
from two essential fatty acids (EFA), the n-6 and n-3 families. The main EFA of the 
n-6 family is linoleic acid (LA; 18:2 n-6), while that of the n-3 family is α-linolenic acid 
(18:3 n-3). LA and ALA cannot be synthesised in the human body and must be 
obtained from the diet. Both EFAs can undergo desaturation and elongation in 
humans to produce LC-PUFA with 20 or 22 carbon atoms (Figure 1-4). LA is 
endogenously converted to arachidonic acid (AA; C20:4 n-6), whereas ALA can be 
converted to eicosapentaenoic acid (EPA; C20:5 n-3 and DHA; C22:6 n-3) (Rustan 
and Drevon, 2001). However, excess of certain FA may affect the availability of 
others, and may lead to consequent adverse outcomes to the fetus (Herrera, 
2002a). Humans can synthesise AA from its precursor, the essential fatty acid LA. 
The parallel synthetic pathways for AA and DHA share common enzymes, and 
delta-6 desaturase is the enzyme responsible for the initial desaturation of both LA 
and ALA (Burdge and Wootton, 2002). Given that human dietary intake of LA is 
eight times greater than that of ALA (Meyer, 2016), the synthesis of AA 
predominates. Women can produce more DHA from ALA than men, suggesting its 
potentially important role in female reproduction (Burdge and Wootton, 2002). 
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Figure 1-4 PUFA synthesis pathway. 
Adapted from (Meyer and Freeman, 2017), journal permission is pending. 
Fatty acids are needed by the fetus to control the fluidity and permeability of cell 
membranes, as a source of energy, and as precursors of bioactive compounds such 
as eicosanoids. Although all fatty acids can be used as energy sources, the LC-
PUFAs are predominantly used for structural and metabolic functions (Herrera and 
Ortega-Senovilla, 2018). The LC-PUFAs, AA and DHA are important structural fatty 
acids in neural tissue. During pregnancy, there is increased accretion of maternal, 
placental and fetal tissues, and consequently the LC-PUFA requirements of 
pregnant women and their developing fetuses are high. The fetal requirements for 
AA and DHA are especially high during the third trimester, due to the rapid synthesis 
of brain tissue (Martinez, 1992). As the fetus may have a limited capacity to 
synthesise DHA, and requires essential FA to do it, the fetus depends primarily on 
placental transfer, and thus on the maternal supply of DHA (Innis, 1991). 
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DHA is the predominant LC-PUFA in phospholipids in the neural membranes of the 
cerebral cortex and in the photoreceptors of the retina (Guesnet and Alessandri, 
2011). Both retinal function and learning ability become permanently impaired if the 
accumulation of DHA during intrauterine life is insufficient (Innis, 1991), indicating 
that the supply of DHA during pregnancy is critical for these functions. Of particular 
importance for fetal growth and development is AA, which is alone among the 
plasma fatty acids of premature infants in showing a significant linear positive 
correlation with birth weight (Koletzko and Braun, 1991). This growth-promoting 
effect of AA could be related to its function as a precursor of prostaglandins and 
other eicosanoids, or to its structural roles in membrane phospholipids. 
It was previously demonstrated that maternal NEFA can cross the placenta by 
passive diffusion without prior modification or protein-mediated transport (Herrera, 
2002a). Several studies have demonstrated placental selectivity of FA transfer and 
a strong preference of the placental plasma membrane binding sites for LC-PUFA 
was observed (Campbell et al., 1996). LC-PUFA storage in fetal adipose tissue 
provides an important source of LC-PUFA during the critical first months of postnatal 
life. The placenta has a pivotal role for the selective transport of DHA from maternal 
diet and body stores to the fetus. Several studies have associated various fatty acid 
transport and binding proteins (FATP) with the preferential DHA transfer, but the 
importance of the different lipolytic enzymes has also been shown. However, the 
exact mechanisms and the interaction of these factors remains elusive (Hanebutt et 
al., 2008). 
As discussed previously, maternal obesity is characterised by greater FA flux from 
adipose tissue stores. The maternal FA flux affects the placental lipid uptake, but 
the role of placental tissue in moderating this transfer is yet to be clarified. In GDM 
compared to normoglycemic pregnancies, there was a higher accumulation of lipid 
droplets in placental tissue (Tewari et al., 2011). In addition, there was reduced 
mitochondrial FA oxidation by 20% in placentas from women with GDM compared 
to healthy controls, contributing to enhanced triglyceride content within the placenta. 
It is also important to consider that the functionality of the placenta may affect the 
fetal levels of key FA such as LC-PUFA. It was found that LPL activity is increased 
in placentas from GDM pregnancies, and positively correlated to TAG and NEFA in 
the offspring of mothers with GDM (Dubé et al., 2013). These changes could 
adversely affect the fetal metabolism and predispose the fetus to future metabolic 
Chapter 1  20 
 
diseases. Thus, it is important to control dyslipidemia in pregnant women to avoid 
increased neonatal fat accretion and disturbed LC-PUFA transport to the fetus, 
which could have implications for the fetal neurodevelopment and the later risk of 
obesity. 
1.5 Non-pregnant adipose tissue 
Adipose tissue is a critical organ in maintaining energy homeostasis under 
conditions of excess nutritional intake by storing it in the form of TAG in the fed state 
(lipogenesis). In prolonged starvation, adipose tissue releases FFA to meet the body 
energy demands (lipolysis). These processes are controlled by insulin and 
epinephrine, which regulate lipogenic and lipolytic enzymes. There are two major 
types of adipose tissue in humans: white adipose tissue (WAT) and brown adipose 
tissue (BAT). WAT comprises two major depots according to their anatomical 
distribution: subcutaneous adipose tissue (SAT) localised beneath the skin, and 
visceral adipose tissue (VAT) distributed in the abdominal cavity. The gluteofemoral 
depot is the predominant subcutaneous depot in humans, while the predominant 
visceral depot is the omental depot. Important differences in depot function exist 
between these categories, as discussed below in 1.5.3 and 1.5.4. Adipose tissue is 
a heterogeneous tissue containing several cell types in addition to adipocytes and 
preadipocytes, collectively called the stromal vascular fraction (SVF). The SVF 
includes endothelial cells, fibroblasts, histiocytes, adipose tissue-derived 
mesenchymal stem cells (ADMSC), immune cells and adipose tissue macrophages 
(ATM). The discovery that adipose tissue is capable of secreting various hormones 
and cytokines, named collectively as adipokines, changed our understanding of 
adipose tissue (Kershaw and Flier, 2004). 
1.5.1 Adipose tissue lipid storage 
Adipose tissue stores FA in the form of TAG in the lipid droplet. TAG is formed from 
three FA molecules esterified on the backbone of a glycerol molecule. FA stored in 
TAG can be released by lipase enzymes (as discussed in section 1.5.5) to oxidative 
organs according to energy demand (Braun and Severson, 1992). The FA stored in 
adipocyte lipid droplets originate from the diet and from de novo lipogenesis 
(synthesis of FA from glucose) in adipocytes or in the liver. In the post-prandial state, 
TAG from the diet is absorbed by enterocytes and delivered as chylomicrons in the 
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lymphatic ducts, which later enter the bloodstream. The synthesised TAG by the 
liver is transported in the blood by VLDL. Chylomicrons and VLDL are TAG-rich 
lipoproteins that are too large to cross the endothelium of the blood vasculature 
surrounding the adipocytes. LPL is an enzyme synthesised by adipocytes that is 
exported to the luminal surface of adipocytes to hydrolyse TAG in TAG-rich 
lipoproteins into FA (Braun and Severson, 1992). Once the FA is liberated from 
TAG-rich lipoproteins, it enters the adipocytes by several protein-mediated uptake 
mechanisms, including fatty acid transport protein (FATPpm), the human scavenger 
receptor CD36, and the plasma membrane fatty acid binding protein (FABP) (Hajri 
and Abumrad, 2002). Intracellularly, another family of FATPs transport the FA from 
the cytoplasm to various compartments (Hajri and Abumrad, 2002). FA must be 
activated into acyl-CoA to be esterified and stored in adipocyte lipid droplets, a 
process catalysed by acyl-CoA synthase (ACS) (Ellis et al., 2010). Once activated, 
FA can be stored in the form of TAG in adipocyte lipid droplets through the glycerol-
3-phosphate pathway. This pathway starts with esterification of the first acyl-CoA on 
glycerol-3-phosphate molecule to form lysophosphatidic acid (Takeuchi and Reue, 
2009). Then, the second acyl-CoA is esterified to form phosphatidic acid. The 
phosphatidic acid is then dephosphorylated to form diacylglycerol (DAG), and then 
the third acyl-CoA is added to synthesise one molecule of TAG (Takeuchi and Reue, 
2009). 
1.5.2 Adipocyte differentiation (adipogenesis) 
Adipogenesis is the process whereby ADMSC restrict their fate to the adipogenic 
lineage and become triglyceride-filled mature adipocytes. There are two phases of 
adipogenesis. The determination phase involves commitment of ADMSC to the 
adipocyte lineage. This results in the conversion of the stem cell to a pre-adipocyte 
that exhibits no morphological changes, but has lost the potential to differentiate into 
other cell types. This commitment is then followed by the differentiation phase, 
where the pre-adipocyte develops the characteristics of a mature adipocyte, and 
acquires the machinery necessary for lipid transport and synthesis, insulin 
sensitivity, and the secretion of adipokines. 
The nuclear hormone receptor PPARγ is characterised as the master regulator of 
adipogenesis. The expression of PPARγ is sufficient to induce adipocyte 
differentiation in fibroblasts (Tontonoz et al., 1994). No factor has been discovered 
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that promotes adipogenesis in the absence of PPARγ. These findings are consistent 
with the observation that most pro-adipogenic factors seem to function at least in 
part by activating PPARγ expression or activity. Adipogenesis promotes healthy 
adipose tissue expansion while limiting hypoxia, chronic inflammation and fibrosis 
(Kusminski et al., 2012). Evidence from mouse models suggests that improved 
metabolic health in animals can be induced by promoting the healthy expansion of 
fat mass by adipogenesis (Combs et al., 2004). These findings imply that obesity-
associated metabolic disturbances are not due to adiposity per se, but probably are 
a result of an insufficient capacity of adipose tissue to expand by adipogensis. 
1.5.3 Adipocyte hypertrophy vs hyperplasia 
There are two modes of adipocyte expansion: adipocyte hyperplasia and adipocyte 
hypertrophy. An increased requirement to store fat stimulates the expansion of 
adipocyte numbers by increasing pre-adipocyte differentiation into mature 
adipocytes (adipogenesis) capable of storing excess TAG efficiently (Hoffstedt et 
al., 2010). This adipocyte hyperplastic expansion is associated with greater insulin 
sensitivity and normal glucose and lipid profile (Veilleux et al., 2011). Adipocyte 
hypertrophy is an alternative form of adipocyte expansion, where adipocytes are 
increased in size to contain the larger lipid droplet rather than increasing the number 
of adipocytes. Hypertrophic expansion of adipocytes is less metabolically 
favourable. Hypertrophic adipocytes have impaired cellular functions, restricting 
their ability to store TAG. Hypertrophic adipocytes are insulin-resistant, and any 
stored TAG is increasingly broken down and released as FA (Tchoukalova et al., 
2010b). Adipocyte hypertrophy generates areas of tissue hypoxia, thus adipocytes 
become hypoxic and show necrotic changes, which leads to macrophage infiltration, 
inducing inflammatory cytokine production (Skurk et al., 2007). Dysfunctional 
hypertrophic adipocytes result in higher circulating plasma FA turnover and 
accumulation in ectopic sites and lipotoxicity, which has a deleterious effect on 
metabolic health. Adipocyte hypertrophic expansion has been associated with 
dyslipidaemia and insulin resistance (Kim et al., 2015). The exact cellular 
mechanisms involved in the metabolic disturbances demonstrated by larger 
adipocytes are not well understood. 
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1.5.4 Depot differences in adipocyte expansion 
Considering that the main function of WAT is the storage of excess energy, SAT is 
considered to be the main storage site for TAG and a safer depot to store fat than 
VAT. In the SAT depot, fat mass increases predominantly through adipocyte 
hyperplasia, whereas hypertrophy is predominantly observed in VAT (Joe et al., 
2009). The lower differentiation potential of VAT progenitors relative to SAT could 
potentially explain the preferential adipocyte hypertrophy expansion in the VAT 
depot. Increased adipocyte hyperplasia in SAT is thought to be a result of the greater 
number and activity of precursor cells (Tchoukalova et al., 2010a). Moreover, if there 
is a reduction in precursor cell division in SAT, i.e. SAT dysfunction, it compromises 
SAT expansion, leading to systemic insulin resistance and metabolic disturbance 
(Kim et al., 2014). Arner et al. (2013) provided evidence that in obese human 
subjects an increase in VAT mass involves an increase in VAT adipocyte number, 
as well as adipocyte size. Similarly, in mice, Jeffery et al. (2015) observed increased 
adipocyte number in VAT after 8 weeks of a high-fed diet. Taken together, these 
results suggest that there is increased SAT proliferative capacity under physiological 
conditions, whereas in obesity, VAT adipogenesis may occur in the context of SAT 
dysfunctional ability to expand. 
1.5.5 Adipose tissue lipolytic function 
During lipolysis, TAG is hydrolysed into diacylglyceride (DAG), monoacylglyceride 
(MAG) and glycerol, releasing one FA molecule at each step. Three lipases are 
involved in TAG hydrolysis: HSL, adipose tissue triglyceride lipase (ATGL) and 
monoacylglycerol lipase (MGL), respectively(Ribet et al., 2010). The hydrolysis 
process is followed by the transport of NEFA and glycerol to the bloodstream, and 
then on to other tissues. Glycerol is mainly transported to the liver for 
gluconeogenesis, while NEFA is transported to skeletal muscle, the heart, the liver, 
or re-esterified by adipocytes into TAG (Ribet et al., 2010). 
The catecholamines are the primary mediators of adrenergic signalling in adipose 
tissue. The catecholamines can both stimulate and inhibit lipolysis depending on 
their relative affinity for different adrenergic receptor subtypes. Thus, stimulation of 
lipolysis requires the activation of β-adrenergic receptors on the surface of the 
adipocyte, while anti-lipolytic signals are transmitted by the α2-adrenergic receptors. 
Both α2- and β-adrenergic receptors belong to the G-protein-coupled receptor 
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family. The G-protein associated with α2-adrenergic receptors contain the inhibitory 
(Gi) subunit, while β-adrenergic receptors contain the stimulating (Gs) subunit 
(Lafontan and Berlan, 1993). The activation of the receptors causes the G-proteins 
to interact with adenylyl cyclase (AC), which is consequently inhibited by interaction 
with Gi and activated by interaction with Gs (Lafontan and Berlan, 1993). Activation 
of β-adrenergic receptors results in AC activation and conversion of ATP to cAMP, 
resulting in an increase in intracellular cAMP levels, which activates protein kinase 
A (PKA). Activated PKA phosphorylates the lipid droplet-associated protein perilipin 
1 (PLIN1) (Greenberg et al., 1991) and cytoplasmic HSL (Garton et al., 1988). 
Phosphorylation of PLIN1 promotes the release of a potent co-activator of ATGL, 
which is the comparative gene identification-58 (CGI-58) (Granneman et al., 2009). 
This facilitates the activation of ATGL and initiates the stimulation of lipolysis. 
Furthermore, PKA-mediated phosphorylation of HSL causes a rapid activation and 
translocation of the lipase from the cytosol to the surface of the lipid droplets. The 
lipase docks with the phosphorylated PLIN1 and thereby gains access to its DAG 
substrate, which is being generated by ATGL  (Figure 1-5) (Wang et al., 2009). 
 
Figure 1-5 Hormonal regulation of adipocyte lipolysis 
Adipocyte lipolysis is stimulated by activation of β adrenergic receptors which stimulates cAMP 
production and consequently activates PKA. PKA phosphorylates HSL and perilipins, stimulating 
the hydrolysis of TAG to MAG. This results in NEFA and glycerol production. Insulin suppresses 
adipocyte lipolysis by suppression of PKA production by stimulation of PDE3B and cAMP 
hydrolysis.  
The observed depot-specific differences in catecholamine responsiveness can be 
explained by differences in the expression of plasma membrane lipolytic β 
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adrenergic receptors (β1 and β2) and α2-adrenergic anti-lipolytic receptors in 
adipocytes from different adipose tissue depots (Mauriege et al., 1987). It is 
understood that omental adipocytes have higher lipolytic activity compared to SAT 
adipocytes, due to reduced insulin action and lower availability of the anti-lipolytic 
alpha 2-adrenoreceotor in VAT adipocytes (Goldrick and McLoughlin, 1970). The 
converse is true for SAT, which shows less response to catecholamine-induced 
lipolysis, due to higher availability of the anti-lipolytic alpha 2-adrenoreceptors 
compared to VAT (Wahrenberg et al., 1989). Insulin has a major role in the inhibition 
of lipolysis in adipocytes (as explained above). In the SAT depot, there is increased 
adipocyte sensitivity to the insulin suppression of lipolysis (Jensen, 2008). VAT 
adipocyte lipolysis was shown to be more resistant to insulin suppression than SAT 
adipocytes in humans (Mauriege et al., 1987). 
It is well established that increased adipocyte size contributes to higher basal 
lipolysis rate (Goldrick and McLoughlin, 1970). In a study that used cell fractionation 
by a flotation technique to separate large and small adipocytes from the same 
healthy individual, lipolytic activity of larger adipocytes was shown to be higher in 
unstimulated (basal), hormone-stimulated (adrenergic) and hormone-inhibited 
(insulin) conditions. Furthermore, there was higher protein expression of HSL, ATGL 
and perilipin in larger adipocytes compared to small adipocytes, independent of the 
donor characteristics (Laurencikiene et al., 2011). Therefore, enhanced lipolytic 
activity might provide the link between adipocyte hypertrophy and the associated 
metabolic disturbances, such as systemic insulin resistance. 
1.5.6 Adipose tissue secretory function 
Adipocytes, SVF and immune cells resident in adipose tissue are capable of 
producing several adipokines, contributing to the regulation of energy expenditure, 
insulin sensitivity, appetite control, adipogenesis, adipocyte function, and immune 
cell migration to adipose tissue (Schling and Löffler, 2018). These adipokines act 
via autocrine and paracrine signalling pathways. Changes in adipose tissue function 
and adipocyte size could promote changes in the secretory function, and 
subsequent secondary changes in the target organs of these adipokines (White and 
Ravussin, 2019). Adipose tissue expresses a variety of adipokines: pro-
inflammatory adipokines (such as TNF-α, CRP, IL-1, IL-6 and IL-8) and adipose 
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tissue-specific adipokines (such as leptin, adiponectin, resistin and visfatin) 
(Fantuzzi, 2005).  
Leptin is secreted from adipocytes during the fed state and acts on the 
hypothalamus to regulate energy balance and appetite control (Matarese et al., 
2005). The plasma leptin levels correlate positively with the body fat mass and more 
leptin is released from hypertrophic adipocytes compared to smaller adipocytes 
(Lönnqvist et al., 1997). Adiponectin is the only adipokine considered to have 
insulin-sensitising ability. Adiponectin functions to promote peripheral insulin 
sensitivity, therefore, its reduction is associated with insulin resistance and 
hyperinsulinemia (Kubota et al., 2002). Adiponectin plasma level is reduced with 
increasing adiposity (Guenther et al., 2014). Furthermore, adiponectin is reported to 
elicit systemic anti-inflammatory effects (Ouchi and Walsh, 2007).The release of 
these adipokines (except adiponectin) by adipocytes, or the macrophages that 
infiltrate adipose tissue, leads to a chronic inflammatory state (Pessin and Kwon, 
2013). With the development of adipose tissue inflammation, the pattern of 
adipokine secretion is significantly altered towards a pro-inflammatory and 
atherogenic profile.  
The VAT depot has a higher secretory capacity than the SAT depot (Hocking et al., 
2010). This difference is an intrinsic feature, due to VAT different cellular 
components compared to SAT. Differences in the secretory function of adipocyte 
depot is addressed in more detail in Chapter 5. Several components of human 
adipose tissue secretory function remain unknown, or their actions remain poorly 
understood due to the complexity of paracrine interactions between several cellular 
types in adipose tissue. The human adipose tissue secretory function is an area of 
research that has expanded rapidly. 
1.5.7 The adipose tissue expandability hypothesis (the overspill 
hypothesis) 
Adipose tissue dysfunction in terms of adipocyte size, number and lipolytic function 
may underlie obesity-associated metabolic abnormalities (Gustafson et al., 2009). 
In individuals with impaired SAT expandability, the so-called overspill hypothesis 
suggests that impaired SAT expandability initiates fat accumulation in VAT, primarily 
as an alternative site for fat storage to minimise the deleterious effect of systemic 
FA. This then contributes to later development of hepatic and peripheral insulin 
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resistance, due to increased FA flux from VAT and ectopic fat deposition in organs 
such as the liver, pancreas and heart (Drolet et al., 2008). Ectopic fat deposition can 
lead to lipotoxic effects such as impaired cellular signalling, dysfunction and possibly 
cellular death (Summers, 2006) (Figure 1-6). Moreover, the portal hypothesis 
suggests that the anatomical location of VAT could contribute to the associated 
metabolic risk, because visceral fat directly transports FA to the liver in the portal 
circulation without peripheral tissue uptake (Jensen, 2008), leaving the liver 
exposed to portal FA and the inflammatory cytokines released from VAT, 
contributing to insulin resistance. 
 
Figure 1-6 The consequences of adipose tissue limited expandability according to the 
overspill hypothesis. 
Limited adipocyte ability to expand may lead to FA overflow from SAT to VAT, as an alternative site 
for fat storage. VAT is an active depot, with exaggerated lipolytic response. Thus, the direct liver 
exposure to portal FA and adipokines from VAT may enhance hepatic insulin resistance and ectopic 
fat deposition in the liver. This could enhance the liver secretion of VLDL particles rich in TAG, which 
could consequently enhance lipid deposition in non-adipose tissue organs with increasing insulin 
resistance, and might contribute to fetal macrosomia in pregnant women due to enhanced FA 
delivery to the fetus through the placenta. 
1.5.8 Ectopic fat 
Ectopic fat is defined as the storage of TAG in tissues other than adipose tissue that 
normally contain only small amounts of fat, such as the liver, skeletal muscle, the 
heart and the pancreas. Since adipocytes are the only cell specialised in fat storage, 
the reduced ability to store FA triggers lipotoxicity in other tissues (Weinberg, 2006). 
FA may enter deleterious pathways once it accumulates in non-adipose tissue. TAG 
may function as a storage site for long chain saturated FA and their metabolic flux 
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may favour the synthesis of complex lipids such as ceramides, DAG and CEs 
(Summers, 2006). The accumulation of complex lipids results in endoplasmic 
reticulum stress and insulin resistance, which affect organ function (Summers, 
2006). 
Lipid ‘spillover’ to non-adipose tissues may occur in response to over-accumulation 
of FA in adipocytes, exceeding the adipocyte hypertrophy and hyperplasia 
necessary to accommodate the increased influx of FA (Kusminski et al., 2009). 
While some non-adipose tissues have the compensatory capability to enhance FA 
oxidation in response to modest FA surplus, such as the liver (Mason, 1998) and 
skeletal muscle, other tissues such as pancreatic β-cells (Shimabukuro et al., 1998) 
and the myocardium (Szczepaniak et al., 2007) have limited FA oxidation 
capabilities. Ectopic fat accumulation in oxidative organs such as the liver and 
skeletal muscles results in enhanced systemic insulin resistance. Stefan et al. 
(2008) assessed total body fat, SAT and VAT with magnetic resonance tomography, 
and ectopic fat deposition in the liver and skeletal muscles with proton magnetic 
resonance spectroscopy in insulin-sensitive and insulin-resistant obese individuals. 
Although VAT mass did not differ across obese individuals, obese insulin-sensitive 
individuals had 54% less fat accumulation in the liver than the equally obese insulin-
resistant group. These findings indicated the predominant role of fatty liver in the 
regulation of glucose and lipid metabolism, and the development of insulin 
resistance as a consequence for ectopic fat deposition in the liver. Furthermore, the 
lack of liver fat can be used as a key determinant of metabolically benign obesity 
and maintained insulin sensitivity in obese individuals. 
Ectopic fat deposition in other non-adipose organs can be illustrated by the intrinsic 
differences between lipid droplet (LD) composition in adipocytes or other ectopic 
tissues. The lipid droplet-associated proteins (LDAP) are present only in adipocytes, 
not in ectopic sites of lipid accumulation (Brasaemle, 2007). These proteins, such 
as perilipin1, FSP27 (CIDEC) and caveolin-1, are abundantly present in adipocyte 
LD and function, primarily as regulators of lipid metabolism, by protecting the LD 
from degradation by cytosolic lipases (Brasaemle et al., 2000). Indeed, the absence 
of perilipin expression in animal models greatly increases basal FA release, 
suggesting its role in the control of lipase access to LD, in a manner that is 
responsive to the metabolic status of adipocytes (Tansey et al., 2001). Perilipin null 
mice are lean, and resistant to diet-induced obesity, due to accelerated adipose 
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tissue lipolysis (Tansey et al., 2001). Interestingly, perilipin null mice had glucose 
intolerance and peripheral insulin resistance, highlighting that lipid mobilisation from 
adipose tissue is critical in the control of glucose homeostasis (Tansey et al., 2004). 
1.5.9 Non-pregnant adipose tissue in obesity 
Adult human obesity is associated with an increase in hypertrophic adipocytes, 
which trigger metabolic disorders such as insulin resistance, metabolic syndrome 
and T2DM. There is a remarkable increase of fat mass in both SAT and VAT depots 
in obese women. Adipocyte hypertrophy due to excess TAG accumulation results 
in an imbalance between adipogenesis and lipolysis in adipocytes. The adipogenic 
capacity in human obesity remains a debatable subject (as discussed in section 
1.5.4); however, adipose tissue lipolysis is an important process in determining 
circulating FA levels. The adipose tissue of obese individuals with enlarged 
adipocytes is less responsive to insulin, which reduces anti-lipolytic action in these 
cells (Salans et al., 1968). The reason for this diminished responsiveness to insulin 
is presently unknown. A reduction of insulin receptors (number, affinity and coupling) 
due to cell enlargement is one of the suggested reasons (Salans et al., 1968). 
Another explanation could be that the reduction in insulin responsiveness is a 
protective mechanism to control further cell enlargement, cell rupture and death. 
Adipocyte lipolytic activity also depends on the level of expression of adipocyte 
lipases. There is reduced ATGL activity and expression level in SAT for obese 
individuals. Moreover, the mRNA and protein levels of ATGL and HSL in SAT for 
insulin-resistant individuals are reduced compared to insulin-sensitive healthy 
individuals (Jocken et al., 2007). Variation in perilipin1 levels relative to adipocyte 
size may contribute to differences between basal lipolysis rate between fat depots 
(Sohn et al., 2018). Downregulated perilipin1 gene expression was observed in both 
the SAT and VAT samples of obese women compared to normal-weight women 
(Wang et al., 2003). 
A plethora of deleterious reactive lipids accumulate in non-adipose tissues in holding 
ectopic fat in obesity, and these contribute to the pathophysiology of insulin 
resistance, liver steatosis, impaired myocardial function and β-cell failure (van der 
Zijl et al., 2011, Shulman, 2014). Ectopic fat is extremely toxic to tissues, because 
it will favour the synthesis of complex metabolites such as ceramides, diacylglycerol 
(DAG) and cholesteryl esters (Shulman, 2014). These metabolites antagonise 
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insulin-signalling pathways and lead to insulin resistance and disturbed glucose 
metabolism within the tissue (Shulman, 2014). Furthermore, this may contribute to 
chronic inflammation, oxidative stress, disturbed mitochondrial function and 
programmed cell death. 
1.5.10 Other processes involved in adipose tissue dysfunction in 
obesity-related metabolic disorders 
1.5.10.1  Adipose tissue inflammation 
Dysregulated adipokine secretion is another feature of adipose tissue dysfunction 
which results in disturbed WAT homeostasis and dysregulated whole-body 
metabolism, such as in obesity (Divella et al., 2016). Adipocytes and SVF cells are 
capable of secreting pro-inflammatory factors. In obesity, there is altered adipose 
tissue cellularity (AT remodelling), secondary to adipocyte hypertrophy, cellular 
dysfunction and inflammation (Trayhurn, 2013). Farley et al. (2009) showed that 
maternal obesity is associated with macrophage infiltration in adipose tissue in 
response to hypertrophic necrotic adipocytes in a ‘crown-like structure’. The 
accumulation of CD 68(+) macrophages was documented in subcutaneous 
abdominal tissue in obese insulin-resistant women (Basu et al., 2011). 
The pro-inflammatory classical macrophages are named M1, while M2 have the 
anti-inflammatory phenotype (Zeyda and Stulnig, 2007). In obesity there is a shift 
towards the pro-inflammatory phenotype M1, which is considered to be the major 
contributor to the development of adipose tissue inflammation (Weisberg et al., 
2003). In contrast, M2 improves insulin sensitivity and suppresses the M1 
macrophage function. Adipose tissue responds to inflammatory signals such as FA 
and lipopolysaccharide (LPS) with induction of the inflammatory response through 
the activation of TLR-4 and the associated intracellular signalling pathway NF-ĸB. 
Similarly, macrophages respond to adipose tissue hypoxia with the production of 
cytokines and inflammatory mediators which can lead to upregulation of TLR-4, thus 
participating in a paracrine loop between the two cell types. The activation of these 
receptors in adipocytes alters mediators in the insulin-signalling cascade and 
glucose uptake, which leads to insulin resistance (Song et al., 2006). In situations 
of induced adipose tissue hypoxia (to mimic obesity), there is decreased production 
of the glucose transporter (GLUT4), which reduces the insulin-stimulated glucose 
uptake (Trayhurn, 2013). 
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Adipokines may provide the link between the changes in adipose tissue function 
and the development of systemic insulin resistance, dyslipidaemia and T2DM 
(Blüher, 2013). The production of adipokines in obese women could induce systemic 
insulin resistance with the decreased production of adiponectin, or increased 
production of cytokines such as IL-6 (Engeli et al., 2003). Increased inflammatory 
adipokine production in obesity can activate various signalling pathways that 
interfere with insulin signalling in adipocytes. Adipocyte insulin resistance 
contributes to adipose tissue dysfunction and systemic insulin resistance, observed 
during obesity and T2DM. 
1.5.10.2  ROS and endoplasmic reticulum (ER) stress 
Adipose tissue inflammation is not the only pathophysiological mechanism involved 
in obesity-related adipose tissue dysfunction. With increasing insulin resistance in 
obese pregnancy, there are increased stressors for adipose tissue, such as ROS, 
endoplasmic reticulum stress and adipose tissue hypoxia, which induce local 
inflammation in adipose tissue (Trayhurn, 2013). During obesity, the cellular 
antioxidant mechanisms in adipocytes were reported to have reduced ability to 
restore protein oxidative damage. Oxidised proteins are toxic to the cells. 
Proteasomal dysfunction results in protein oxidation and the unfolded protein 
response (UPR), which are major mechanisms in the development of insulin 
resistance (Diaz-Ruiz et al., 2015). Proteasomal dysfunction leads to obesity-
induced ER stress and insulin resistance in adipocytes through the activation of the 
c-Jun N-terminal Kinase (JNK) pathway (Otoda et al., 2013). ER stress is a condition 
characterised by the accumulation of misfolded proteins in the ER lumen, resulting 
from inflammation. ER stress is a well-known feature of insulin resistance and 
obesity (Yang et al., 2015). 
1.5.10.3  Hypoxia and angiogenesis 
Hypoxia is a well-known condition that increases the production of angiogenic 
factors. Adipocyte hypertrophic expansion resulting in cells of more than 100m 
exceeds the maximum cellular oxygen diffusion distance and creates an area of 
hypoxia. This could lead to adipocyte necrosis, and probably adipose tissue 
infiltration by immune cells such as macrophages and disturbed adipokine secretion 
(Goossens, 2008). Indeed, diet-induced weight loss following diet-induced obesity 
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is associated with reduced inflammation and improved oxygenation of adipose 
tissue in mice (Ye et al., 2007). 
Healthy adipose tissue expansion requires angiogenesis (Bouloumié et al., 2002). 
Adipose tissue plasticity requires constant growth and remodelling of adipose tissue 
blood vessels. The adipose tissue vasculature is important for adipose tissue 
metabolic and secretory function, as it facilitates interactions between the blood 
compartment and adipocytes. Adipose tissue angiogenesis is a complex process 
requiring balanced production of the extracellular matrix, endothelial cell 
proliferation and migration. Several angiogenic factors are produced by adipocytes 
and the SVF, such as vascular endothelial growth factor (VEGF) and fibroblast 
growth factor (FGF). VEGF gene expression is upregulated in adipocytes cultured 
in 1% oxygen (hypoxic condition) (Wang et al., 2007). Overweight and obese 
subjects have 44% lower capillary density and 58% lower VEGF compared to lean 
subjects. This might be due to lower PPARγ and higher collagen VI mRNA 
expression, which correlates with the lower adipose tissue oxygen partial pressure 
(Pasarica et al., 2009). Rupnick et al. (2002) showed that in conditions of impaired 
angiogenesis, there was inhibited adipose tissue accumulation. Gealekman et al. 
(2011) found a higher capillary density per adipocyte and higher angiogenic growth 
capacity in SAT compared to VAT. This supports the biological and metabolic 
variability between the two different WAT depots. 
1.6 Adipose tissue in pregnancy 
1.6.1 Adipose tissue adaptation to healthy pregnancy 
Changes in adipose tissue metabolic and endocrine function are central to maintain 
whole-body energy homeostasis during pregnancy. In response to the metabolic 
changes during pregnancy (previously described in section 1.3.1), adipose tissue 
undergoes dynamic remodelling. This includes changes in AT mass, AT expansion 
and adipokine secretion. 
During pregnancy, maternal body fat distribution moves from the lower body towards 
upper and central compartments, which are relatively resistant to insulin 
suppression of lipolysis (Stevens-Simon et al., 2001). Kinoshita and Itoh (2006) 
observed an increase in fat accumulation in VAT measured by ultrasound (US) in 
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lean healthy pregnant women towards the end of pregnancy. This observation is 
consistent with the observed hyperlipidaemic status during late pregnancy. 
In a cohort of healthy non-obese women, recruited pre-gravid and followed in early 
(8–12 weeks of gestation) and late (36–38 weeks of gestation) pregnancy, gluteal 
fat samples were obtained, and  Resi et al. (2012) observed that gluteal adipose 
tissue mass, adipocyte size and cell number significantly increased in late 
pregnancy compared with the pre-gravid measurements, but remained unchanged 
in early pregnancy. These results are consistent with a previous observation by 
Rebuffe-Scrive et al. (1985), who found higher LPL activity in the femoral region 
than in the abdominal region in pregnant women. This pattern favours triglyceride 
accumulation in the femoral adipocytes in pregnant women at early pregnancy. In 
contrast, lipolysis was considerably higher in the abdominal than in the femoral SAT 
adipocytes. Thus, it is possible that femoral adipose tissue may serve a specialised 
function in women, as an important source of energy supply during lactation. This is 
supported by the observation that women usually have a larger gluteal fat depot 
than men (Sjöström et al., 1972). Vesco et al. (2018b) assessed healthy pregnant 
women for ectopic fat deposition (intra-hepatic, intra-myocellular and extra-
myocellular) in early and late pregnancy with magnetic resonance spectroscopy, 
and found no evidence of ectopic fat deposition. Moreover, whole-body insulin 
sensitivity was measured by insulin clamp, and was not related to ectopic fat or fat 
mass measured by BODPOD. Thus, Vesco et al. (2018b) suggested that non-body 
composition factors appear to be the primary determinant of gestation-related insulin 
resistance. In a second study, Vesco et al. (2018a) showed that gestational weight 
gain in healthy pregnant women is not related to ectopic fat deposition during 
pregnancy. 
1.6.2 Adipose tissue in obese pregnancy 
Maternal obesity has been the driver for the interest in adipose tissue biology in 
pregnancy. Pre-gestational obesity has been shown to have a significant influence 
on adipose tissue distribution during pregnancy (Ehrenberg et al., 2003). There was 
an increase in VAT accumulation measured by ultrasound in overweight/obese 
pregnant women compared to lean pregnant controls (Straughen et al., 2013). This 
finding suggests the possibility that the observed differences in VAT deposition 
across pregnancy are related to the different metabolic adaptations to pregnancy 
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seen in overweight and obese women compared with lean women (as discussed in 
section 1.3.2). 
Adipocyte size and number in abdominal SAT was examined in a cohort of obese 
pregnant women, compared to normal pregnant women, during the first and third 
trimesters of pregnancy. The mean adipocyte size and the proportion of large 
adipocytes was higher in normal-weight women than obese women, and was 
accompanied by reduced adiponectin release (Svensson et al., 2016). In contrast, 
obese women had a higher proportion of small cells and lower proportion of large 
cells in the third trimester, suggestive of adipocyte recruitment, and maintained 
adiponectin levels. This study suggested that changes in adipose tissue cellularity 
during pregnancy in obese women help to protect against even more severe insulin 
resistance. Adipocyte lipolysis was increased in the third trimester compared to first-
trimester levels in both the lean and obese groups (Svensson et al., 2016). The 
increase in lipolysis levels from first trimester to third trimester was slightly higher in 
the obese group, but did not reach statistical significance. Although VAT fat mass 
was reported to be increased in obese pregnant women during pregnancy, VAT 
lipolysis has not been examined to the best of our knowledge. Increased VAT FA 
flux could potentially provide the link to the metabolic disturbances observed in 
obese women during pregnancy, as suggested by the overspill hypothesis 
discussed in 1.5.7. 
1.6.3 Adipose tissue and GDM pregnancy 
In a cohort of women with GDM (lean and obese) and healthy pregnant (lean and 
obese) controls, body composition was measured longitudinally at preconception, 
first trimester and third trimester by hydrodensitometry and serial skin fold 
measurement. Healthy lean women were noted to have significantly more peripheral 
fat, whereas healthy obese women accumulated adipose tissue more centrally 
(Ehrenberg et al., 2003). This pattern of adipose tissue accumulation over the 
course of pregnancy may contribute to the insulin-resistant state of obesity. In 
contrast, there were no significant differences in the pre-gravid body composition 
measures between GDM and control subjects in either the lean group or obese 
group. This suggests that pre-gravid obesity is more influential in body fat 
distribution than glucose tolerance status. Women with a previous history of GDM, 
followed for five years after the index pregnancy, had a higher VAT content 
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compared to non-GDM women (Lekva et al., 2015). There was a strong association 
of higher VAT content, with low β-cell function, indicating that the VAT compartment 
may contribute to the metabolic disturbances in women with a history of GDM in the 
long-term (Lekva et al., 2015). 
Rojas-Rodriguez et al. (2015) studied adipocyte size and capillary density in a small 
cohort of women with GDM (n=11), compared to healthy pregnant controls (n=3). In 
GDM, VAT adipocyte hypertrophy and reduced capillary density compared to 
controls was observed. This study suggested that VAT adipocyte hypertrophy is 
probably due to diminished hyperplastic potential in this depot. ADMSC were 
strongly associated with the AT capillary network, and a reduction in capillary 
density may underlie the diminished hyperplastic growth with subsequent VAT 
adipocyte hypertrophy (Rojas-Rodriguez et al., 2015). Functional studies of adipose 
tissue during GDM pregnancy are very limited, and to the best of our knowledge, 
adipocyte lipolysis in women with GDM has not been studied previously. 
1.6.3.1 Ectopic fat in GDM 
There is emerging evidence to suggest that ectopic fat deposition in the liver, 
skeletal muscle and pancreas could be one of the factors that causes IR in women 
with GDM. Non-alcoholic fatty liver disease (NAFLD) is characterised by the 
presence of fat within the liver in a person who does not drink significant amounts 
of alcohol (Angulo, 2002). A recent study examined the relationship between first-
trimester NAFLD (measured by ultrasound) and subsequent development of GDM, 
and revealed that NAFLD is an independent risk factor for GDM development (Lee 
et al., 2019). However, the molecular mechanisms linking hepatic fat accumulation 
and GDM development remained elusive. It could be that maternal hyperinsulinemia 
in women with GDM derives hepatic de novo lipogenesis and inhibits VLDL-TAG 
secretion from the liver, leading to hepatic steatosis. Additionally, obese mothers 
with GDM may experience greater portal NEFA flux from VAT stores, which has 
been found to preferentially increase fat accumulation in women with GDM (as 
discussed in 1.6.3). These mechanisms are speculative and require further 
investigation. Liver fat accumulation during pregnancy is probably the link between 
GDM and future risk of T2DM. Bozkurt et al. (2012) found that fatty liver is 
associated with subclinical inflammation in women with a previous history of GDM 
(3–6 months), and demonstrated that the fatty liver index (FLI) is predictive of 
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T2DM. Recently, Mehmood et al. (2018) demonstrated that there is a higher 
prevalence of liver fat in women with a previous history of GDM, and it is associated 
with an increased risk of pre-diabetes/diabetes among them. 
Vesco et al. (2019) assessed liver and muscle fat content in GDM using magnetic 
resonance spectroscopy (MRI). There was no increase in intra-hepatic, intra-
myocellular or extra-myocellar lipid content in women with GDM compared to 
healthy pregnant controls. However, this cohort of women had not demonstrated an 
increase in VAT accumulation during pregnancy. In contrast, women with a previous 
history of GDM were found to have higher intra-myocellular fat content compared to 
women with normal glucose tolerance (Kautzky-Willer et al., 2003). Kautzky-Willer 
et al. (2003) suggested that intra-myocellular fat content could serve as an additional 
parameter of increased diabetes risk, because it identified women with a previous 
history of GDM, and those women who were diagnosed earlier in pregnancy with 
GDM. It was suggested that a reduction in the compensatory insulin release from 
pancreatic β cells in obese women during pregnancy could be related to ectopic fat 
deposition in β cells (Giacca et al., 2011). However, there are no primary studies to 
confirm this yet. A decrease in β cell function was found to be associated with VAT 
mass in women with a history of GDM five years after the index pregnancy (Lekva 
et al., 2015). This may suggest that FA flux from VAT stores is the underlying 
mechanism for ectopic fat in the pancreas in women with GDM. 
1.7 Adipose tissue inflammation in healthy, obese and 
GDM pregnancy 
Compared to non-pregnant women, healthy pregnancy is characterised by mild 
elevations in both serum pro-and anti-inflammatory cytokine levels (Curry et al., 
2008). Christian and Porter (2014) examined the longitudinal changes in several 
plasma inflammatory markers during and after pregnancy; pregnancy was 
associated with higher levels of plasma IL-6 and TNF-α, but decreased CRP level, 
whereas obese women had higher CRP levels, and obesity predicted their plasma 
IL-6 levels. Serial gluteal fat samples were obtained from healthy non-obese 
women, sampled pre-gravid and in early (8–12 weeks of gestation) and late (36–38 
weeks of gestation) pregnancy. Adipose tissue transcriptomic analysis revealed 
early pregnancy molecular changes in the TLR4/NF-ĸB signalling pathway with 
respect to inflammatory adipokine genes (Resi et al., 2012). Furthermore, increased 
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expression of macrophage markers such as CD68 and CD14 emphasised the 
recruitment of the immune network in both early and late pregnancy. This biphasic 
pattern suggests that there could be an early enhancement of immune pathways as 
an initial step in pregnancy, proceeding the development of insulin resistance, which 
peaked in late pregnancy. This hypothesis would suggest that the activation of 
inflammatory pathways could be necessary to induce gestational insulin resistance 
towards the third trimester. Adipose tissue cytokines were suggested to contribute 
to the low-grade inflammation status at the third trimester of pregnancy. 
Maternal obesity is considered to be the primary driver of inflammation during 
pregnancy due to increased fat mass. An increase in TNF-α mRNA levels in the 
maternal SVF cells of obese women has been observed (Basu et al., 2011). 
Recently, the VAT depot in overweight and obese pregnant women was shown to 
be strongly associated with adipocyte hypertrophy and increased macrophage 
infiltration compared to SAT (Bravo-Flores et al., 2018). Macrophages recruited to 
adipose tissue might be a noticeable source of inflammatory cytokines in obese 
pregnancy (Challier et al., 2008). The activation of inflammatory pathways in 
adipocytes impairs triglyceride storage and increases the release of FFAs, an 
excess of which is known to induce insulin resistance in skeletal muscle and the 
liver in the non-pregnant population (Guilherme et al., 2008). Thus, adipose tissue 
inflammation appears to be a clinically important change that may occur in the 
adipose tissue of obese pregnant women who are metabolically challenged by 
pregnancy. Previous observations provide evidence for defective insulin signalling 
in the adipose tissue of obese pregnant NGT mothers, and adipose tissue 
inflammation is one of the suggested underlying mechanisms (Colomiere et al., 
2009). TNF-α induction of IRS-1 serine phosphorylation links inflammation to 
disturbed insulin action. One leading hypothesis for the role of cytokines such as 
TNF-α, adiponectin and resistin is that they link inflammation to metabolic changes 
by modifying insulin sensitivity (Matarese and La Cava, 2004). The sequence of 
events that leads to adipose inflammation, and how those events are regulated, is 
still poorly understood. 
Enhanced insulin resistance and inflammation are the main hallmarks of GDM. The 
macrophages infiltrating adipose tissue are laid out in a crown-like structure 
surrounding adipocytes in GDM (Cinti et al., 2005). It was previously identified that 
GDM is associated with increased macrophage infiltration in omental fat, rather than 
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SAT, compared to normal pregnancy (Harlev et al., 2014). In the same study, 
omental fat macrophages correlated positively with HOMA-IR, suggesting that low-
grade inflammation could contribute to the development of insulin resistance in 
GDM. Several pro-inflammatory adipokines were found to be increased in adipose 
tissue samples of women with GDM compared to controls. An increase in IL-6 
mRNA in the SAT of women with GDM has been reported previously (Kleiblova et 
al., 2010). Nucleotide-binding oligomerisation domain (NOD) is an intracellular 
molecule that recognises danger signals by initiating inflammation and the activation 
of NF-KB signalling. Lappas (2014b) observed increased NOD1 expression in the 
omental and subcutaneous fat of women with GDM compared to NGT women, 
suggesting its importance in the development of inflammation and IR in GDM. The 
pro-inflammatory cytokine IL-1β is cytokine that impairs insulin signalling in 
adipocytes. The inflammasome is a large protein complex that processes IL-1β to 
its active secreted form. Caspase-1 is a key factor in the inflammasome, activated 
under conditions of cellular stress, which leads to the maturation of IL-1β. A previous 
study confirmed that there is increased expression of caspase-1 and IL-1β in the 
adipose tissue of GDM women (Lappas, 2014a). This study highlighted the 
importance of caspase-1/IL-1β signalling in the development of insulin resistance in 
GDM by decreasing AMP-activated protein kinase (AMPK) activity in the adipose 
tissue of pregnant women. 
1.8 Project hypothesis 
The hypothesis tested in this thesis is that in women with GDM, SAT adipocytes 
have defective adipocyte expansion, resulting in adipocyte hypertrophy. 
Subsequently, there is increased lipolysis and inflammatory adipokine secretion. 
1.8.1 Study aims and objectives 
This thesis aimed to explore the epidemiological evidence for the role of maternal 
obesity in the development of GDM and other maternal and fetal complications, 
specifically in the highly diverse local Greater Glasgow and Clyde population. 
Additionally, this thesis aimed to compare SAT and VAT adipocyte size, adipocyte 
lipolytic function and adipokine secretion between GDM and healthy (BMI-matched) 
pregnant women. A final aim was to assess the role in early pregnancy of VLDL as 
a potential maternal plasma carrier of the extremely important long chain 
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polyunsaturated fatty acid docosahexaenoic acid (DHA), required by the fetus for 
neuronal development. 
Objective 1 (Chapter 3) 
To explore the epidemiological evidence that women with maternal obesity are at 
greater risk of GDM and maternal and fetal adverse outcomes in the Greater 
Glasgow and Clyde population, and to understand the clinical characteristics of the 
background population of the overall study. 
Objective 2 (Chapter 4) 
To compare adipocyte function in isolated SAT and VAT adipocytes of healthy and 
BMI-matched GDM women in the third trimester. The aspects of adipocyte function 
assessed were adipocyte size, adipocyte lipolytic function (basal and β adrenergic- 
stimulated lipolysis, and insulin suppression of lipolysis) and fat cell insulin 
sensitivity index (FCISI). To explore the relationship between maternal BMI, markers 
of maternal systemic insulin sensitivity and maternal plasma pregnancy hormone 
concentrations with SAT and VAT adipocyte size and lipolytic function. 
Objective 3 (Chapter 5) 
To compare adipocyte inflammation in basal or activated (LPS stimulated) 
conditions in isolated SAT and VAT adipocytes from healthy and BMI-matched GDM 
women in the third trimester. To assess plasma cytokine concentrations in both 
groups. 
Objective 4 (Chapter 6) 
To explore plasma lipoprotein VLDL fatty acid composition in healthy pregnant 
women prior to pregnancy and throughout early gestation. 
 
  40 
 
Chapter 2 Materials and methods 
2.1   Study participants 
Ethical approval for adipose function in GDM study was obtained from the West of 
Scotland Research Ethics Committee and Research and Development, NHS 
Greater Glasgow and Clyde reference number 11/AL/0017 .  All participants were 
fully informed of the study objectives and participation requirements by means of 
verbal communication and a written information sheet. Written consent was 
obtained from all participants. 
2.1.1 Recruitment 
Adipose tissue and blood samples were obtained from non-labouring healthy 
pregnant women at term (n=24) and non-labouring women with GDM (n=23) 
undergoing Caesarean section at the Queen Elizabeth University Hospital in 
Glasgow. The International Association of Diabetes and Pregnancy Study Groups 
(IADPSG) criteria  were utilized locally at Queen Elizabeth University Hospital 
(QEUH) to establish the diagnosis of GDM (Metzger et al., 2010). According to 
IADPSG criteria, a diagnosis of GDM can be made if one result of blood glucose 
levels reaches one or more of the following values (fasting blood glucose ≥ 5.1, 1 
hour≥ 10.0, 2 hours≥8.5 mmol/L) using a 75g glucose load test at 24-28 weeks of 
gestation. Treatment (diet, insulin, metformin or both insulin and metformin) was 
recorded for women with GDM. Women undergoing elective Caesarean section 
between 37+0 weeks to 39+6 weeks were eligible for this study. Women of all ages 
and ethnic groups were eligible while multiple pregnancies were excluded. Women 
were categorized according to the World Health Organization categorization of 
obesity to: normal weight (BMI=20-24.9 kg/m2), overweight (BMI=25-29.9 kg/m2) 
and obese (BMI ≥30kg/m2) (Nuttall, 2015) using booking BMI. Participants were 
excluded if they had any history of medical conditions such as cardiovascular or 
metabolic disease and other adverse pregnancy outcomes such as preeclampsia or 
intrauterine growth restriction. The study participants were not on regular medication 
such as antiemetic drugs, aspirin, low molecular weight heparin, thyroxine or blood 
pressure medications. 
The subject’s demographic characteristics and delivery information were recorded 
from the patient’s medical record. SAT samples were obtained by the obstetric 
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surgeon from the fat layer beneath the skin while VAT samples were obtained from 
greater omentum. The fresh adipose tissue was placed in warm buffer and quickly 
transported to the laboratory for adipocyte preparation.  
2.1.2 Tissue collection 
Maternal blood was collected prior to the Caesarean section by the anaesthetist in 
charge in a 20 ml syringe and handed in to the researcher. The blood then added 
to a selection of blood tubes with various additives including K2 EDTA, clot activator, 
sodium citrate, lithium heparin and potassium oxalate/sodium fluoride.  The blood 
tubes were transferred immediately to the pathology lab at QEUH for immediate 
centrifugation within approximately 20 minutes of blood collection. The blood tubes 
were centrifuged at 3000rpm for 15 minutes then the resultant plasma or serum 
were aliquoted into colour coded (to the appropriate additive) microtubes and stored 
at -80°C. The plasma obtained from the sodium citrate tube was transferred into 
Eppendorf tubes and were further centrifuged using microcentrifuge at 13000 rpm 
for 4 minutes to remove platelets. Then the supernatant was transferred in to 
microtubes with color-coded lids. The surgeon was briefed to collect subcutaneous 
adipose tissue (SAT) sample from the fat layer beneath the skin on entry of the 
abdominal cavity about the size of 50 pence coin (approximately 4-6 gm) and this 
was placed in a previously labelled collection tube containing warm collection buffer. 
After delivery of the baby and placenta, a sample of visceral adipose tissue (VAT) 
about the size of 50 pence coin was collected from greater omentum and placed 
immediately in a previously labelled collection tube with warm collection buffer. The 
adipose tissue was transported immediately to the laboratory by the researcher and 
processing was commenced immediately on arrival.   
2.1.3 Power calculation 
Power calculation for this study was carried out before commencing tissue 
collection. The primary outcome was adipocyte diameter (physical measure) while 
secondary outcomes were insulin suppression of lipolysis (functional measure), 
adipokine production by adipocytes (consequences of the previous changes). 
Adipocyte diameter has been studied recently in GDM (Rojas-Rodriguez et al., 
2015), but all other outcomes have not been assessed in the population of women 
with GDM. A formal power calculation for the adipocyte diameter requires up to n= 
7 per group for 80% power. We have no information about the effect size of the 
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insulin suppression of lipolysis in GDM but this was estimated using the effect size 
in preeclampsia. In preeclampsia  a previous study by our group found a significant 
difference in n=14 per group (Huda et al., 2014). Our power calculations suggests 
that we might find half the insulin resistance that we previoulsy observed in PE and 
we need closer to 60 per group to observe the same level of insulin resistance (Table 
2-1). Therefore, we aimed to collect a GDM group double the size of the PE group, 
that n=30 per group. 
Table 2-1 Power calculation 
 Control 
mean 
(SD) 
Test 
mean 
(SD) 
Standardized 
difference 
(control mean- 
test mean/ 
control mean) 
Standardized 
SD 
(control SD/ 
control mean) 
n per group 
 
for 80% 
power 
Adipocyte 
diameter 
(Rojas-
Rodriguez et 
al., 2015) 
 
4.16 
(1.38) 
7.48 
(2.98) 
0.79 0.40 GDM 6/7 
Insulin 
suppression 
of lipolysis 
(Huda et al., 
2014) 
 
65 52 PE= 0.8 
½ GDM=0.4 
1.57 PE 62 
GDM 123 
Adipose 
activated 
macrophage 
content 
(Huda et al., 
2017) 
 
9 (10) 18 (36) PE= 1 
½ GDM= 0.5 
0.94 PE 15/20 
GDM 
57/76 
Adipokine 
production 
by 
adipocytes 
(Huda et al., 
2017) 
31 (27) 62 (57) PE= 1 
½ GDM= 0.5 
0.92 PE= 15/19 
GDM= 
55/73 
      
2.2 Adipocyte preparation 
2.2.1 Buffers 
The following physiological buffers were prepared using distilled water and 
chemicals from VWR UK, unless otherwise stated. With the exception of Krebs 
Ringer- HEPES (KRH) buffer, all buffers were made within 14 to 18 hours before 
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sample collection and kept at 4⁰C overnight before collection, then warmed to 37°C 
on collection day. To confirm buffer stability using this approach, an experiment was 
conducted to compare buffer made fresh on the collection day and buffer made 
approximately 14 to 18 hours before sample collection using the same 
subcutaneous adipose tissue sample of healthy individuals (n=3). The experiment 
is detailed in section 2.4.5. 
2.2.1.1 Krebs Ringer - HEPES (KRH) Buffer 
KRH buffer consisted of 118mM NaCl (Merck, UK), 5mM NaHCO3, 4.7mM KCl, 
1.2mM KH2PO4, 1.2mM MgSO4.7H2O (Sigma, UK) and 25mM HEPES (Sigma, UK). 
The buffer was adjusted to pH 7.4, autoclaved and stored at 4°C. 
2.2.1.2 Wash buffer 
Wash buffer was KRH buffer containing 2.5mM CaCl2  and 151μM BSA, essentially 
FA free (Sigma-Aldrich, UK, cat.no. A6003).  
2.2.1.3 Collection buffer 
 Collection buffer was wash buffer containing D-glucose 3mM (Fisher Scientific, 
UK). 
2.2.1.4 Digestion buffer 
Digestion buffer consisted of 4ml collection buffer per 1g of adipose tissue plus 
2mg/ml collagenase (Type 1, Worthington biomedical corporation, UK, cat. no. 
L5004197) 
2.2.2 Collagenase digestion of adipose tissue and isolation of 
adipocytes 
If the adipose tissue samples were more than 6-8 g, a small piece of adipose tissue 
was flash frozen in liquid nitrogen and stored at -80°C until further use. The 
remaining unfrozen adipose tissue sample was placed in a petri dish with warm 
collection buffer. Scissors and forceps were used to remove any skin, visible blood 
vessels and fibrous tissue. The sample was dried quickly on filter paper and 
weighed. The weight of the tissue was used to determine the required volume of 
digestion buffer containing collagenase at 2mg/ml. The sample was then placed into 
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a 50ml centrifuge tube containing the digestion buffer and minced finely with 
scissors. Collagenase digestion occurred for 30mins at 37°C in a shaking water bath 
at 100 cycle per minute.  
After collagenase digestion the adipose-buffer mixture was filtered first through a 
plastic tea strainer (600μm pore) to remove any large pieces of undigested tissue. 
The digestate was then passed through a 400μm pore mesh. The adipocytes were 
allowed to float to the top and the buffer underneath was aspirated away using a 
20ml syringe and 18-gauge needle and replaced with fresh warm wash buffer of a 
similar volume. This process was repeated up to a maximum of four times, or until 
the buffer under the adipocytes was clear. The buffer was finally aspirated away as 
much as possible such that the adipocytes were suspended at approximately 90% 
cytocrit.  
The experimental tubes (15ml centrifuge tubes) were prepared to contain 900μl 
warm (37°C) wash buffer. The adipocyte cell suspension (100μl) was added to the 
experimental tubes followed by all other reagents. All experimental conditions were 
carried out in duplicate. The tubes were placed in a shaking water bath at 37°C with 
gentle agitation of 91 cycles per minute for 2 hours. Remaining adipocytes were 
frozen in aliquots at -80°C for subsequent DNA quantification and RNA isolation. 
2.2.3 Adipocyte DNA extraction 
DNA was isolated from a known volume of adipocyte cellular suspension from each 
preparation that had been flash frozen in liquid nitrogen and then transferred to a -
80°C freezer immediately after adipocyte isolation was carried out. Two aliquots of 
100µl adipocytes were thawed at room temperature and DNA was extracted using 
a Nucleospin DNA Lipid Tissue kit (Machery-Nagel, Germany) which utilizes 
Silica-membrane technology. Lipid-rich tissues can cause difficulties in DNA 
isolation by influencing the tissue disruption or changing the chemistry of the DNA 
isolation buffer. The Nucleospin DNA Lipid Tissue kit combined enzymatic lysis 
and mechanical disruption of lipid-rich tissues with the Nucleospin Bead Tubes 
which were used to obtain high DNA yields from adipocytes. Following the 
manufacturer’s protocol, 200µl of thawed adipocyte suspension was transferred to 
bead tube D (3mm steel balls) and 100µl of elution buffer BE was added to prepare 
the sample for lysis. Cell lysis was achieved by adding 40µl of lysis buffer LT, 10 µl 
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of liquid proteinase K and agitating the tubes in the bead tube holder (Vortex mixer, 
VV3, VWR) for 20minutes at full speed. The tube was spun afterward to clear the 
lid at 13000rpm for 30 seconds in a bench microcentrifuge. To adjust DNA binding 
conditions, 600µl of lysis buffer LT was added, vortexed and centrifuged as above. 
DNA binding was achieved by transferring the clear liquid supernatant 
(approximately 500-600µl) to a spin column placed inside a collection tube and then 
centrifuged as above. The silica membrane was washed twice, by adding 500µl of 
wash buffer BW and then 500µl of wash buffer B5 followed by centrifugation with 
discard of the flow through at each wash. Further centrifugation took place to dry 
the silica membrane and remove the residual wash buffer. DNA elution was 
completed by placing the spin column in an autoclaved Eppendorf tube and 100µl 
of warm elution buffer BE at 70°C was added to the column followed by incubation 
at room temperature for one minute and the tube was then centrifuged as above. 
The resultant eluate was then reused in another elution step to improve DNA yields. 
The DNA was then transferred to a new autoclaved Eppendorf tube and left 
incubating overnight in the fridge. DNA quantification by Nanodrop was carried out 
the following day after resuspension.  A 260/280 ratio of ~1.8 is generally accepted 
as “pure” for DNA. 
2.2.4 Normalising NEFA, glycerol and inflammatory cytokines to 
total DNA content 
Lipolysis rates as measured by NEFA and glycerol are influenced by adipocyte 
cellular density in each experimental condition. Therefore, DNA was extracted and 
quantified from a known volume of adipocytes cellular suspension. The adipocytes 
cell number is directly proportional to DNA content within the same volume. Lipolysis 
rates are expressed as per ug of DNA.  
2.3 Adipocyte sizing  
Equal volumes of unfixed fresh adipocyte cellular suspension (5μl) and KRH buffer 
(5μl) were mixed on a glass slide. The slide was placed under an Olympus BX50 
microscope connected to a 3-CCD colour camera (JVC) and 7-9 digital images of 
the adipocytes were captured on different fields at x10 magnification (Figure 2-1). 
Computer visualisation of images was carried out using Image-Pro Plus 4.0 and the 
images were analysed with Adobe Photoshop version 7.0. The internal diameters 
of 100 adipocytes were measured manually using a graticule that was calibrated 
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such that one pixel = 78μm. The diameters of the cells were determined in μm by 
the following equation: μm=Y/X*100, given that Y=cell diameter in pixels and X=78 
pixels. The volume of the cells in mm3 was calculated using the formula:  
(4/3) ∗3.14159∗(1/8)*(d3)/1000000000 
 Where d = adipocyte diameter in μm. One hundred adipocytes from the acquired 
images were randomly selected and their horizontal intracellular diameter was 
manually measured. Two blinded observers each measured 100 diameters for both 
GDM and BMI matched controls from which the mean diameter and volume of each 
adipocyte preparation was derived. 
 
Figure 2-1 : Example of a digital image captured of an isolated adipocyte suspension  
 
2.4 Lipolysis assay  
2.4.1 Lipolysis assay conditions 
2.4.1.1 Basal Lipolysis 
Experimental tubes contained only of wash buffer and adipocytes. 
2.4.1.2 Isoproterenol stimulation of basal lipolysis (isoproterenol only) 
The non-specific beta-adrenergic agonist isoproterenol (Sigma, UK, cat. no. 16604) 
was dissolved in KRH buffer to obtain a stock of 2mM. This stock was diluted by a 
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factor of 100 to give 0.02mM. Isoproterenol (10μl of 0.02mM) was added to the 
experimental tubes to give a final isoproterenol concentration of 200nM. 
2.4.1.3 Insulin inhibition of basal lipolysis (insulin only) 
Insulin solution human (Sigma-Aldrich, UK, 19278 – 300 Units/ml) (1.76μl) was 
added to 3ml of KRH buffer to produce insulin stock (1000nM). Insulin stock solution 
(10μL of 1000nM) was added to the adipocyte cellular suspension (total volume of 
1ml) to produce a final concentration of 10nM. 
2.4.1.4 Insulin inhibition of stimulated lipolysis (isoproterenol + insulin) 
Isoproterenol and insulin were prepared as above and 10μl of each were added to 
adipocyte cellular suspension.  The final concentration was 200nM for isoproterenol 
and 10nM for insulin. 
2.4.1.5 Lipopolysaccharide (LPS) 
Sterile balanced salt solution (1ml of autoclaved KRH buffer) was added to 1mg 
lipopolysaccharide from Escherichia coli O55:B5 (Sigma Aldrich, UK, L6529) 
powder to produce LPS stock (1mg/ml) frozen in 25µl aliquots and kept at -80 until 
needed. On the day of experiment, 10µl of 1mg/ml LPS stock were added to culture 
vial contains 900µl of wash buffer and 100µl of adipocyte cellular suspension to 
obtain final concentration of 10μg/ml. 
2.4.2 Timeline and dose response determination for lipolysis assay 
reagents 
Time course of lipolysis experiment and dose response curve of isoproterenol, 
insulin and lipopolysaccharide (LPS) was determined previously (unpublished 
Shahzya Huda).  
2.4.3 Assaying NEFA and glycerol as indicators of adipocyte net 
and total lipolysis respectively 
Both NEFA and glycerol concentrations in the medium below the adipocytes were 
assayed as indicators of lipolysis. Once released from the adipocytes, NEFA can be 
taken up by the adipocytes and re-esterified to triglyceride a process referred to as 
recycling. Hence assaying NEFA gives a measure of net lipolysis. Glycerol, 
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however, once released from the adipocytes cannot be reutilised by the adipocytes 
due to the minimal expression of glycerol kinase. As such, assaying glycerol gives 
a measure of total lipolysis.  
The medium below the adipocyte suspension was sampled at 2 hours for 
determination of NEFA and glycerol concentrations. Aliquots (5μl for NEFA and 10μl 
for glycerol) of the medium were added to individual wells of a 96 well plate. Each 
experimental condition was assayed for NEFA and glycerol in duplicate.  
2.4.3.1 Measuring NEFA concentrations 
NEFA concentrations were estimated using an enzymatic colorimetric NEFA assay 
kit (Wako, Alpha Laboratories, UK) using a protocol adapted for 96 well plate 
analysis. The kit provides substrates (coenzyme A and ATP) and enzymes (acyl-
CoA synthetase) that convert NEFA in the medium to acyl-CoA. The Acyl-CoA is 
oxidised to produce hydrogen peroxide, which in the presence of peroxidase yields 
a violet pigment. NEFA concentration was obtained by measuring the absorbance 
of the pigment on a spectrophotometer (Multiscan EX, Thermo Electron 
Corporation) at 550nm. The values are compared to a NEFA standard curve. The 
standard curve was obtained by making serial dilutions of a NEFA standard (Wako, 
Alpha Laboratories, UK) to achieve a concentration curve ranging from 0.1-
1mmol/L. 
2.4.3.2 Measuring glycerol concentrations 
Glycerol concentrations were determined by means of a colorimetric kit (Randox). 
The kit utilises a quinoneimine chromogen system whereby in the presence of 
glycerol kinase, peroxidase and glycerol phosphate oxidase, glycerol in the medium 
is converted to the product n-(4-antipyryl)-3-chloro-5-sulphonate-p-
benzoquinoneimine (ACSB). Production of ACSB yields an orange pigment. 
Glycerol concentration was obtained by measuring the absorbance of the pigment 
on a spectrophotometer (Multiscan EX, Thermo Electron Corporation) at 520nm. 
The values are compared to a glycerol standard curve. The standard curve was 
obtained by making serial dilutions of a glycerol standard (Sigma, UK, G7793) to 
achieve a concentration curve ranging from 10-400µmol/L. 
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2.4.4 Calculation of percent inhibition, percent stimulation and fat 
cell insulin sensitivity index (FCISI) 
The degree of lipolysis stimulation by isoproterenol was calculated as the 
percentage of release of NEFA or glycerol in the presence of isoprotenerol relative 
to basal lipolysis i.e. Percentage stimulation= ((lipolysis rate in presence of 
isoproterenol – basal lipolysis) / basal lipolysis)*100. 
The degree of lipolysis suppression by insulin was calculated as the percentage of 
release of NEFA or glycerol in the presence of insulin relative to basal release i.e. 
((basal lipolysis – lipolysis rate in the presence of insulin) / basal lipolysis)*100. 
FCISI is a direct measure of adipocyte insulin sensitivity. It can be calculated as 
the percentage suppression of isoproterenol stimulated lipolysis by insulin 
measured either as NEFA or glycerol release i.e. FCISI= ((lipolysis rate in 
presence of isoproterenol  – lipolysis rate in presence of isoproterenol and insulin) 
/ (lipolysis rate in presence of isoproterenol  – basal lipolysis))*100. 
2.4.5 Buffer stability 
For logistical reasons, preparation of buffer 14-18 hours in advance was 
advantageous due to the distance between the laboratory and QEUH hospital, while 
our standard protocol stated same day preparation.  To ensure buffer stability when 
made the day before, an experiment was conducted to compare buffer made fresh 
on the day of sample collection and buffer made approximately 14 to 18 hours before 
sample collection using the same subcutaneous adipose tissue sample from healthy 
pregnant women. Subcutaneous adipose tissue samples (n=3) were cut into 2 
pieces immediately after collection at the hospital in a petri dish using surgical 
scissors. One piece was placed in warm buffer made on the day of collection and 
the other one was placed in warm buffer made 14-18 hours before collection. The 
samples were then transferred immediately to the laboratory and adipocytes were 
isolated as described previously in section 2.2.2. Isoproterenol and insulin were 
prepared as above and added to adipocyte cellular suspension. Basal, isoproterenol 
stimulation of basal lipolysis, insulin inhibition of basal lipolysis and insulin inhibition 
of isoproterenol stimulated lipolysis conditions were carried out for each sample 
using buffer made on the day of collection or 14-18 hours before. After 2 hours 
incubation, the buffer below adipocytes were sampled for NEFA analysis to test if 
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there was an effect of earlier buffer preparation preparation on lipolysis. A two 
sample T test was carried out on NEFA lipolysis data corrected for DNA. There was 
no difference in basal lipolysis, isoproterenol stimulation of basal lipolysis, insulin 
inhibition of basal lipolysis and insulin inhibition of isoproterenol stimulated lipolysis 
between the two samples carried out using the two different buffer preparation 
approaches (Table 2-2).  
Table 2-2 NEFA release in response to different experimental conditions using buffer 
prepared the day before collection (DB) and buffer prepared on the same day of collection 
(SD) (n=3) 
Experimental 
condition 
Buffer DB 
NEFA Mean 
(SD) (n=3) 
Buffer SD 
NEFA Mean 
(SD) (n=3) 
P value 
Basal Lipolysis 
(mmol/l/ug of DNA) 
1.11 (0.72) 1.36 (1.17) 0.78 
Lipolysis rate in 
presence of 200nM 
isoproterenol 
(mmol/l/ug of DNA) 
2.28 (0.63) 2.67 (0.79) 0.55 
Lipolysis rate in 
presence of 10nM 
insulin (mmol/l/ug of 
DNA) 
0.72 (0.25) 0.61 (0.19) 0.59 
Lipolysis rate in 
presence of 
isoproterenol 200nM 
and 10nM insulin   
1.98 (0.68) 2.11 (0.65) 0.81 
 
2.5 Quantitative real-time PCR 
Quantitative real-time PCR (qRT-PCR) was used to quantitate the mRNA 
expression after pre-amplifcation of cDNA of genes of interest in adipocytes.  
2.5.1 Gene selection using Ingenuity Pathway Analysis (IPA) 
An Ingenuity Pathway Analysis (QIAGEN) search was carried out by Maria Hagan, 
an intercalated medicine BSc student, for her BSc dissertation at the University of 
Glasgow, to identify genes of interest for quantitation. This tool which includes an 
extensive and up-to-date library of signalling and metabolic pathways, was used to 
systematically approach the selection of genes to investigate in terms of differential 
expression.  Under “Genes and Chemicals”, the terms “insulin”, “progesterone” and 
“metformin” were searched individually, and the appropriate human gene or 
chemical was selected to create a “new pathway”. These search terms were 
Chapter 2  51 
 
selected due to the role of the insulin pathway in the currently understood disease 
process of GDM, and progesterone as the prominent hormone involved in maternal 
metabolic adaptation to pregnancy. As many GDM patients are effectively treated 
with the drug metformin, the involvement of these pathways in understanding of the 
pathophysiology of the condition may be beneficial. By selecting the options “Build” 
and “Grow”, all molecules which are known to be directly or indirectly downstream 
of the gene or molecule investigated were added to the pathway.  Using the option 
“Overlay”, a pre-existing dataset of genes expressed in adipose tissue was overlaid 
on the pathway, highlighting molecules which were both downstream of the gene of 
interest and expressed in adipose tissue. The three data sets (from “insulin”, 
“progesterone” and “metformin”) acquired from this analysis were compared 
manually in a Venn diagram to identify common genes expressed in these pathways 
in adipose tissue (Figure 2-2).  
 
Figure 2-2 Venn diagram to identify common genes expressed in relation to Insulin, Metformin 
and progesterone pathways in adipose tissue using Ingenuity Pathway Analysis (QIAGEN). 
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2.5.2 Isolation of total RNA 
The RNeasy Lipid Tissue Mini Kit (Qiagen) was used to isolate total RNA from frozen 
stored adipocytes, as per the manufacturer’s instructions. Briefly, 100μl of isolated 
adipocytes were homogenised in 1ml Qiazol lysis reagent using a hand-held 
homogeniser (Omni UH Motor Battery Pack & Charger, Camlab). The homogenate 
was transferred to a 1.5ml centrifuge tube and incubated at room temperature for 5 
minutes. Chloroform (200μl) was added to the homogenate and shaken vigorously 
for 15 seconds followed by incubation at room temperature for a further 3 minutes. 
The samples were subsequently centrifuged at 13000rpm for 15 minutes at 4°C 
using Beckman Coulter™ Microfuge 22R centrifuge. The upper aqueous phase 
(approximately 400μl) was transferred to a clean 1.5ml centrifuge tube, to which the 
same volume of 75% ethanol was added, and the sample was vortexed. The mixture 
was then transferred to RNeasy spin columns in batches and centrifuged for 15 
seconds at 10,000rpm in the microcentrifuge. The flow-through was discarded and 
this step repeated until the entire sample was processed. The column was then 
washed twice with  RPE buffer (500μl) (QIAGEN) and centrifuged at 10,000rpm for 
15 seconds and two minutes respectively.  The column membrane was dried by 
centrifugation at 10,000rpm for 1min. RNase-free water (30μl) was then added to 
the sample column prior to centrifugation at 10,000rpm for one minute. The 
concentration and quality of the eluted RNA was determined using a Nanodrop ND-
1000 spectrophotometer (Thermo Fisher Scientific). This produced a 260/280nm 
absorbance ratio and concentrations in ng/μl. A 260/280 ratio of ~2.0 is generally 
accepted as “pure” for RNA. The RNA was stored at -80°C until required. 
2.5.3 DNase treatment of isolated RNA 
A DNA-free kit (Ambion, cat. no.AM1906) was used to remove contaminating 
genomic DNA from the extracted RNA samples. Nuclease free water (6.5μl) was 
added to 15μl of RNA sample to make a final volume of 21.5μl. 10X DNase 1 buffer 
(2.5μl) was then added to the mixture and centrifuged at 13000rpm for 6 seconds at 
4°C using Beckman Coulter™ Microfuge 22R centrifuge. The mixture was then 
incubated for 30 minutes at 37°C in an OMN-E thermalcycler. Following this, DNase 
Inactivation Reagent was vortexed before adding 3ml and the aliquots were mixed. 
They were incubated for a further 2 minutes at room temperature. The samples were 
mixed again to re- suspend the DNase Inactivation Reagent. It was then removed 
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by centrifuging the samples at 13,000rpm for 1 minute using the microcentrifuge. 
The transparent supernatant layer containing RNA was transferred to a new tube, 
leaving the DNase Inactivation Reagent at the bottom. DNA-free RNA was stored 
at -80°C.  
2.5.4 cDNA synthesis  
To make complementary DNA (cDNA), RNA was reverse transcribed using a High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems, cat. no. 4368813) 
in the presence of ThermoFisher SUPERase:In (cat. no. 2696) RNase. DNase-
treated RNA samples and reagents were thawed and kept on ice for the duration of 
this procedure. The following volumes were added into a new Eppendorf tube to 
make 2x RT mastermix: 34μl of 10X RT buffer, 13.6μl of 25X dNTPs, 34μl of 10X 
random primers, 17μl of multiscribe reverse transcriptase (mRT), 17μl of 
SUPERase:In  and 54.4μl of nuclease free water. An additional control “No RT 
mastermix” was also prepared using the same volumes of reagents but without 
mRT. These were mixed by vortexing. 2X RT mastermix (5μl) was added to 5μl of 
each sample. They were then briefly centrifuged followed by incubation at 25°C for 
10 minutes. This was followed by incubation at 37°C for 120 minutes then 85°C for 
5 seconds using the ThermoFisher Hybaid PCR Express Thermal Cycler. The 
samples were stored at -20°C.  
2.5.5 Preamplification of cDNA and Test of Uniformity 
Due to the very small quantity of RNA which can be isolated from adipocytes, a very 
small quantity of cDNA is obtained from reverse transcription. The TaqMan PreAmp 
Master Mix Kit (Applied Biosystems, cat. no. 4384266) was used to increase the 
quantity of the cDNA targets for gene expression analysis. The preamplification 
product was used for TaqMan Real-Time PCR.  A pooled assay mix was prepared 
according to the manufacturer instructions containing the appropriate volume of 
Tris-EDTA (TE) PH 8 buffer (Ambion, cat. no. AM9849), primer probes of the genes 
to be investigated including Cyclin-dependant Kinase Inhibitor 1B (CDKN1B) the 
recommended endogenous uniformity reference gene and PPIA the endogenous 
control gene to be used in relative quantitation Real-Time PCR analysis. Pooled 
assay mix, TaqMan PreAmp Master Mix (2X), nuclease free water and the samples 
cDNA was added to a 96 well plate. The plate was centrifuged briefly in Jouan 
CR412 centrifuge, loaded into a thermocycler (StepOnePlus Real-Time PCR 
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System (Applied Biosystems)) and run for 10 preamplification cycles which was 
programmed to heat the samples at 95°C for 10 minutes followed by 10 cycles of 
95°C for 15 seconds and 60°C for 4 minutes. The resulting preamplified cDNA was 
diluted with TE buffer in a 1:5 ratio and stored at -20°C.  
It is vital that preamplification is uniform and this was tested for each of the TaqMan 
probes utilised, using a uniformity reaction plate to perform a relative quantitation 
run for a pre-amplified cDNA and a non-limited cDNA sample. This was carried out 
following the protocol published by ThermoFisher (ThermoFisher, 2012). Gene 
expressions of each gene were examined in duplicate non-pre-amplified cDNA 
samples and compared to duplicate pre-amplified samples using CDKN1B as a 
reference gene.  
Calculated threshold cycle (CT) values for the target genes and CDKN1B were 
obtained for different dilutions of pre-amplified and non-pre-amplified cDNA. ΔΔ CT 
values were used for analysis and obtained using the following calculations: 
Δ CT of sample = (Mean CT of target gene – mean CT of CDKN1B)  
ΔΔ CT of sample = (Δ CT pre-amplified cDNA - Δ CT of non-pre-amplified cDNA) 
The ΔΔ CT values for all the genes tested were within ±1.5 (Figure 2-3) and therefore 
preamplification was deemed successfully uniform. Applied Biosystems 
manufactured the gene probes was used (Table 2-3) and assured that >90% of the 
CDKN1B control is capable of amplifying uniformly (Applied Biosystems, 2009).  
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Figure 2-3 Preamplification test of uniformity results 
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Table 2-3 TaqMan gene expression assays 
 
 
Gene symbol TaqMan® gene expression assay Assay ID Source
PPIA Peptidyl-Protyl Isomerase A 4333763T Applied biosystems
FOXO1 Forkhead box protein 01 HS00231106_m1 Applied biosystems
CEBPB CCAAT/Enhancer binding protein beta HS00279023_S1 Applied biosystems
IGF1 Insulin-like growth factor 1 HS01547656_m1 Applied biosystems
FOS Fos protein HS99999140_m1 Applied biosystems
CCL2 C-C Motif Chemokine Ligand 2 HS00234140_m1 Applied biosystems
IGFBP5 Insulin-like growth factor- binding protein 5 HS00181213_m1 Applied biosystems
SCD Stearoyl-CoA desaturase HS01682761_m1 Applied biosystems
CD36 Platelet glycoprotein 4 HS00354519_m1 Applied biosystems 
LIPE Lipase E, Hormone Sensitive Type HS00193510_m1 Applied biosystems
CASP3 Caspase 3 HS00234387_m1 Applied biosystems
MAPK8 Mitogen-activated protein kinase 8 HS01548508_m1 Applied biosystems
CIDEC Cell death activator CIDE-3 HS01032998_m1 Applied biosystems
TNF Tumour necrosis factor alpha HS00174128_m1 Applied biosystems
PPARG Peroxisome proliferator- activated receptor gamma HS01115513_m1 Applied biosystems
SREBF1 Sterol regulatory element- binding protein 1 HS01088691_m1 Applied biosystems
SLC2A1 Solute carrier family 2, facilitated glucose transporter member 1 HS00892681_m1 Applied biosystems
LPL Lipoprotein lipase HS001173425_m1 Applied biosystems
PCK1 Phosphoenolpyruvate carboxykinase 1 HS00159918_m1 Applied biosystems
GCG Glucagon HS01031536_m1 Applied biosystems
TGFB1 Transforming growth factor beta 1 HS01031536_m1 Applied biosystems
ICAM1 Intercellular adhesion molecule 1 HS00164932_m1 Applied biosystems
VEGFA Vascular endothelial growth factor A HS00900055_m1 Applied biosystems
F3 Coagulation factor 3 HS01076029_m1 Applied biosystems
IGFBP2 Insulin-like growth factor- binding protein 2 HS01040719_m1 Applied biosystems
AKT1 RAC-alpha serine/threonine- protein kinase HS00178289_m1 Applied biosystems
IRS2 Insulin receptor substrate 2 HS00275843_S1 Applied biosystems
INSR Insulin receptor Hs00961554_m1 Applied biosystems
IGFBP3 Insulin-like growth factor- binding protein 3 HS00181211_m1 Applied biosystems 
IRS1  Insulin receptor substrate 1 HS00178563_m1 Applied biosystems
DDIT3 DNA Damage Inducible Transcript 3 HS01090850_m1 Applied biosystems
PTGS2 Prostaglandin-Endoperoxide Synthase 1 HS00153133_m1 Applied biosystems
PTGS1 Prostaglandin-Endoperoxide Synthase 2 HS00377726_m1 Applied biosystems
NOS3 Nitric Oxide Synthase 3 HS01574659_m1 Applied biosystems
IRA Insulin receptor isoform A 1770698B8 Applied biosystems (custom made)
IRB Insulin receptor isoform B 1771710A12 Applied biosystems (custom made)
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2.5.6 Insulin receptors isoforms A (IRA) and B (IRB) probes 
The mature human insulin receptor has two isoforms, IRA and IRB. They result from 
alternative splicing of the same primary transcript. IRA differs from IRB by exclusion 
of exon 11. A recent method to specifically measure IRA and IRB expression has 
been described by Huang and colleges (Huang et al., 2011). This method was 
based on TaqMan qRT-PCR. They designed qRT-PCR primer and probes for IRA 
and IRB. For the IRA assay, Haung and colleagues targeted the exon 10/12 junction 
region for the gene specific probe; the exon 10 coding region for the forward primer 
pairs; and the exon 12 coding regions for the reverse primer pairs. For IRB assay, 
they targeted the exon 11 interior coding region for the gene specific probe; exon 
11/12 junction for the forward primer pairs; and exon 12 for the reverse primer pairs. 
All probes were designed to incorporate a minor groove binding moiety (MGB) and 
were labelled with a fluorescent dye (FAM) for detection and a non-fluorescent 
quencher. We used the sequences for IRA and IRB primer/probe published by 
Huang et al. (2011), and primer/probes were custom ordered from Applied 
Biosystems (Table 2-3).  
The sequences for primers and probes were as follows:  
for IRA, probe sequence is 5’-TCCCCAGGCCATCT-3’; forward primer sequence is 
5’-TGAGGATTACCTGCACAACG-3’; reverse primer sequence is 5’- 
ACCGTCACATTCCCAACATC -3’. 
For IRB: probe sequence is 5’-CCGAGGACCCTAGGC-3’; forward primer sequence 
is 5’-CGTCCCCAGAAAAACCTCTTC-3’; reverse primer sequence is 5’-
GGACCTGCGTTTCCGAGAT-3’. 
This assay was proven to be more sensitive and specific for IRA and IRB isoforms 
compared to the commercially available Applied Biosystems assays which had a 
strong cross reaction and could not measure insulin receptors isoforms accurately 
(Huang et al., 2011).  
2.5.7 TaqMan RT-PCR 
Target gene expression was quantified relative to an endogenous control gene, 
PPIA (Neville et al., 2011), using TaqMan probes. A PCR reaction mixture was 
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prepared for each target gene (12.5µl of TaqMan Universal PCR Mastermix, 1.25µl 
target assay probe mixture and 5 µl of nuclease-free water) and 18.75µl of this was 
added to 6.25µl of diluted pre-amplified cDNA sample for a final reaction volume of 
25µl per well of a 96 well plate. PPIA endogenous controls and no-RT controls 
(using 6.25μl of water instead of cDNA) were carried out for all samples. Target 
gene expression of the pre-amplified cDNA samples were carried out in duplicate 
on 96-well plate and appropriate negative controls used. The plate was centrifuged 
briefly using Jouan CR412 centrifuge, loaded into a StepOnePlus Real-Time PCR 
System (Applied Biosystems) which completed a standard RT-PCR cycle i.e. 40 
cycles of 50º°C  for 2 minutes, 95°C  for 10 minutes and 40 cycles of 95°C  for 15 
seconds alternated with 60°C  for 1 minute. This produced an amplification plot. 
Average Ct values between the duplicate samples were obtained using SDS 
Software version 2.3. Expression of target genes was normalized to the endogenous 
control gene PPIA – previously shown to be a stable control gene for adipose tissue 
(Neville et al., 2011).These were converted to percentage expression relative to 
PPIA using the ΔCT method (CT value of target assay – CT value of PPIA).The 
calculation 2-ΔCT was used to determine the fold difference in expression relative to 
control, and the expression of the target assay was then expressed as a percentage 
relative to PPIA. Percent gene expression relative to control has an inter-assay CV 
<13% in adipocytes for a wide variety of target genes when carried out using a 
commercial primer process from Applied Biosystems (unpublished data from our 
lab). 
2.6 Adipocyte inflammation 
2.6.1 LPS 
Isolated adipocytes were incubated with LPS for 2 hours as outlined in section 
2.4.1.5. The medium underneath the adipocytes were aliquoted into two 300µl and 
frozen at -20°C for later analysis of adipokines. 
2.6.2 Multiplex bead arrays 
2.6.2.1 Assay principle  
For the quantification of cytokines and chemokines in biological samples, multiplex 
bead arrays are an efficient alternative to the traditional enzyme-linked 
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immunosorbent assays (ELISA). In a traditional ELISA only one cytokine at a time 
is studied. The total number of possible analytes studied can be limited by sample 
volume when using ELISA. Multiplex bead arrays allow simultaneous quantification 
of several analytes (up to 100) in the same sample, and generally no more than 50µl 
of sample is required for the entire panel.  
The principle of the multiplex bead assays is similar to that of ELISA based methods 
except that capture antibodies are covalently coupled to the surface of beads 
instead of the bottom of a 96-well plate. The bead conjugates are distinguished from 
one another by the fluorescent intensity ratio of two different fluorescent dyes 
embedded on each bead. Sample incubation is similar to ELISA, as well as the 
detection steps, which uses biotinylated detection antibodies and a streptavidin-
phycoerythrin (PE) conjugate reporter. Sample acquisition is performed using a 
specialised flow cytometer which performs a series of analyses similar to flow 
cytometric analysis of cell targets. Individual beads are first gated for the correct 
size, then the bead type is determined based on ratio of the two internal fluorescent 
dyes, and lastly the fluorescent intensity of the reporter is determined for each 
individual analyte. It correlates with the concentration of a given analyte in solution. 
A standard curve is generated to calculate the final analyte concentration. 
In the current study, kits utilizing magnetic bead technology were used. This 
technology is compatible with the MAGPIX® xPONENT 4.2 system, which uses a 
magnetic plate to capture all of the beads simultaneously in a monolayer, while two 
spectrally distinct light-emitting diodes (LEDs) illuminate the beads. One LED 
identifies the analyte that is being detected and, the second LED determines the 
magnitude of the PE-derived signal. Each well is imaged with a CCD camera system 
to capture a digital image and determine the fluorescence intensity of each bead. 
Analytes measured for VAT adipocytes are detailed in Table 2-4. 
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Table 2-4 Analytes measured for VAT adipocytes cytokine release in basal and LPS stimulated 
condition 
Pro-inflammatory  Anti-inflammatory  
Interferon Gamma (IFN-gamma)  
Interleukin 1-beta (IL-1β)  
Interleukin 8 (IL-8)  
Monocyte chemoattractant protein-1 
(MCP-1) Tumour necrosis factor alpha 
(TNF-α) 
 (by ELISA) 
Interleukin 10 (IL-10)  
Adiponectin (by ELISA) 
 
 
 
 
 
 
Both pro- and anti-inflammatory 
                   
Angiogenic factors 
Interleukin 6 (IL-6) Placental growth factor (PIGF)  
                                                                           
Vascular endothelial growth factor 
(VEGF) 
 
 
 
2.6.2.2 Preparation of reagents for multiplex bead array assays 
Preparation of antibody-immobilized beads  
Individual vials of beads were provided with the kits. Each antibody-bead vial was 
sonicated for 30 seconds then vortexed for 1 minute. From each antibody vial, 60 μl 
(150 μl for the PlGF singleplex kit) was added to the provided mixing bottle and the 
final volume was brought to 3 ml with bead diluent and the final mixture was 
vortexed.  
Preparation of Quality Controls  
Quality Control 1 (QC1) and Quality Control 2 (QC2) vials were reconstituted with 
250 µl of deionized water which were mixed, vortexed and allowed to sit for 10 
minutes. Then the controls were transferred to appropriately labelled 
microcentrifuge tubes.  
 
Preparation of Wash Buffer  
The 10X Wash Buffer was brought to room temperature and mixed to bring all salts 
into solution. Sixty ml of 10X Wash Buffer was diluted with 540 ml deionized water.  
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Preparation of Human Cytokine Standard 
 
The Human Cytokine Standard was reconstituted with 250 μl deionized water to 
give 10,000 pg/ml concentration of standard for all analytes. The vial was mixed and 
vortexed several times and allowed to sit for 10 minutes for complete reconstitution. 
This was used as the 10,000 pg/ml standard (standard 6).  
Preparation of Human Cytokine Working Standards 
Fife polypropylene microfuge tubes were labelled Standard 5, Standard 4, Standard 
3, Standard 2 and Standard 1. Two hundred μL of Assay Buffer was added to each 
of the fife tubes. Serial 1:5 dilutions were performed by adding 50μL of the Standard 
6 to the Standard 5 tube, mixed well and transferred 50μL of the Standard 5 to the 
Standard 4 tube, mixed well and transferred 50 μL of the Standard 4 tube to the 
Standard 3 tube, mixed well and transferred 50 μL of the Standard 3 tube to the 
Standard 2 tube, mixed well and transferred 50 μl of the Standard 2 tube to the 
Standard 1 tube, mixed well. The 0 pg/ml standard (Background) was Assay Buffer. 
Standard concentrations for each cytokine are shown in Table 2-5. 
Table 2-5 Standard concentration of MILLIPEX Map Human Cytokine/Chemokine 
Magnetic Bead Panel 
Standard concentration 
(pg/ml) 
Volume to add Volume of standard to 
add 
(Standard 6) 10,000 250 μl of deionized water 0 
(Standard 5) 2000 200 μl of Assay Buffer 50 μl of 10,000 pg/ml 
(Standard 4) 400 200 μl of Assay Buffer 50 μl of 2000 pg/ml 
(Standard 3) 80 200 μl of Assay Buffer 50 μl of 400 pg/ml 
(Standard 2) 16 200 μl of Assay Buffer 50 μl of 80 pg/ml 
(Standard 1) 3.2 200 μl of Assay Buffer 50 μl of 16 pg/ml 
 
Preparation of Human CVD panel 1 standard for PlGF measurement 
The Human CVD panel 1 Standard was reconstituted with 250 μl deionized water 
to give 2000 pg/ml concentration of standard for all analytes. The vial was mixed 
and vortexed several times and allowed to sit for 10 minutes for complete 
reconstitution. This was used as the 2000 pg/ml standard (standard 7).  
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Preparation of Human CVD panel 1 working standard for PIGF measurement 
Six polypropylene microfuge tubes were labelled as Standard 6, Standard 5, 
Standard 4, Standard 3, Standard 2 and Standard 1. Two hundred and fifty μL of 
Assay Buffer was added to each of the six tubes. Serial 1:3 dilutions were performed 
by adding 125 μL of the Stock Standard to the Standard 6 tube, mixed well and 
transferred 125 μL of the Standard 6 to the Standard 5 tube, mixed well and 
transferred 125 μL of the Standard 5 tube to the Standard 4 tube, mixed well and 
transferred 125 μL of the Standard 4 tube to the Standard 3 tube, mixed well and 
transferred 125 μL of the Standard 3 tube to the Standard 2 tube, mixed well and 
transfer 125 μL of the Standard 2 tube to the Standard 1 tube, mixed well. The 0 
pg/mL standard (Background) was Assay Buffer. Standard concentrations for PlGF 
are shown in Table 2-6. 
Table 2-6 Standard Concentration for MILLIPEX Map Human Cardiovascular 
Disease (CVD) Magnetic Bead Panel 1 (for PlGF measurement) 
Standard concentration 
(pg/ml) 
Volume to add Volume of standard to 
add 
(Standard 7) 2000 250 μl of deionized water 0 
(Standard 6) 666.7 250 μl of Assay Buffer 125 μl of 2000 pg/ml 
(Standard 5) 222.2 250 μl of Assay Buffer 125 μl of 666.7 pg/ml 
(Standard 4) 74.1 250 μl of Assay Buffer 125 μl of 222.2 pg/ml 
(Standard 3) 24.7 250 μl of Assay Buffer 125 μl of 74.1 pg/ml 
(Standard 2) 8.2 250 μl of Assay Buffer 125 μl of 24.7 pg/ml 
(Standard 1) 2.7 250 μl of Assay Buffer 125 μl of 8.2 pg/ml 
 
2.6.2.3  Multiplex bead array assay procedure  
The multiplex bead array assay procedure was carried out according to the 
manufacturer’s protocol and was similar for both multiplex and singleplex assay 
used apart from some volume differences which are highlighted below.  
Plate layout 
The following plate layout was used for all assays (Figure 2-4). Each 
standard/quality control was run in duplicate. Samples were run in singlecate due to 
limited resources. 
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Figure 2-4 Example of plate layout for multiplex bead arrays 
 
Multiplex procedure - day 1 
Into each well of the plate, 200 μl of Wash Buffer (100 μl for PlGF singleplex) was 
added. The plate was sealed and mixed on a plate shaker for 10 minutes at room 
temperature (20-25°C). The Wash Buffer was decanted, and residual removed from 
all wells by inverting the plate and tapping it smartly onto absorbent towels several 
times. The appropriate matrix for this experiment was the wash buffer used in our 
lipolysis experiment (see section 1.2.1) containing Krebs Ringer HEPES buffer -118 
mM NaCl, 5mM NaHCO3, 4.7 mM KCl, 1.2mM KH2PO4, 1.2mM MgSO4, 25mM 
HEPES) and 2.5mM CaCl2, 151mM BSA (Sigma, UK) at pH 7.4. This wash buffer 
was prepared fresh on the day of multiplex assay and 25 μl was added in to standard 
and QC wells. For each diluted standard or QC, 25 μl was added into the appropriate 
wells. The assay buffer was used for 0 pg/mL standard (background).  Assay buffer 
(25 μl) of was added to the sample wells. The samples (25 μl) were added into the 
sample wells. The Premixed Beads (25 μl) were added to each well and the bottle 
was shaken intermittently during addition to avoid beads settling. The plate was 
sealed and wrapped in foil and incubated with agitation on a plate shaker overnight 
(16-18 hrs) at 4°C. 
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Multiplex procedure - day 2 
The plate was placed on a handheld magnet (EMD Millipore Cat. no. 40-285) for 60 
seconds to allow complete settling of magnetic beads. The well contents were 
removed by gently decanting the plate into an appropriate waste beaker and gently 
tapping on absorbent pads to remove residual liquid. The plate was washed 2 times 
with 200 μL of Wash Buffer (3 times for PlGF singleplex) by removing the plate from 
magnet, adding wash buffer, shaking for 30 seconds, reattaching to magnet, letting 
beads settle for 60 seconds and removing well contents as previously described 
after each wash. Detection Antibodies (25 μl) was added per well (50 μl for PlGF 
singleplex). The plate was sealed, covered with foil and incubated with agitation on 
a plate shaker for 1 hour at room temperature (20-25°C). By keeping the well content 
during this step, 25 μl of Streptavidin-Phycoerythrin (50 μl for PIGF singleplex) was 
added to each well containing the 25 μl of Detection Antibodies (50 μl for PIGF 
singleplex). The plate was sealed, covered with foil and incubated with agitation on 
a plate shaker for 30 minutes at room temperature (20-25°C). The well contents 
were gently removed, and the plate was washed 2 times as above (3 times for PlGF 
singleplex). Drive fluid (150 μl) was added to all wells and the beads were 
resuspended on a plate shaker for 5 minutes (100 μl for PIGF singleplex). The plate 
was run on MAGPIX® with xPONENT® software. The Median Fluorescent Intensity 
(MFI) data was analysed using a 5-parameter logistic method (standard curve) and 
used to calculate analyte concentrations in samples and controls.  
2.6.2.4 Multiplex assay run 
The Luminex® MAGPIX® instrument was calibrated with the MAGPIX® Calibration 
Kit (EMD Millipore, cat. no. 40-049) and performance verified with the MAGPIX® 
Performance Verification Kit (EMD Millipore, cat. no.  40-050). The start-up, daily 
maintenance and probe height adjustment procedures were performed on the day 
of running the assays on the MAGPIX® machine.  
2.6.2.5 Generation of protocol using luminex xPONENT software 
Each type of kit has its own optimal settings (e.g. number of beads to be acquired, 
bead size, sample volume etc). To generate a protocol all the information required 
is contained in the Milliplex kit. The information needed to generate a protocol 
included the Milliplex Protocol booklet, QC sample Certificate of Analysis, Kit Lot 
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and Expiry Details, Standard Lot and Expiry Details, and QC sample Lot and Expiry 
Details. The sample IDs and plate layout couls also be added. Once the protocol 
was saved it could be used to run the assays at any time. The bead region and the 
quality control ranges are shown in (Table 2-7 and Table 2-8). 
Table 2-7 Antibody-Immobilized Magnetic Beads Region for MILLIPLEX map kits 
Analyte Luminex® 
Magnetic 
Bead Region 
IFN-gamma 25 
IL-10 27 
IL-1b 46 
IL-6 57 
IL-8 63 
MCP-1 67 
VEGF 78 
PLGF 52 
 
Table 2-8 The Quality Control ranges for MILLIPLEX® map kits 
Analyte QC level Expected 
range 
Units 
IFN-gamma Control 1 
Control 2 
110- 229 
575- 1167 
pg/ml 
IL-10 Control 1 
Control 2 
103- 215 
515- 1070 
pg/ml 
IL-1b Control 1 
Control 2 
108- 224 
535- 1111 
pg/ml 
IL-6 Control 1 
Control 2 
124- 258 
602- 1251 
pg/ml 
IL-8 Control 1 
Control 2 
108- 224 
521- 1082 
pg/ml 
MCP-1 Control 1 
Control 2 
120- 249 
589- 1224 
pg/ml 
VEGF Control 1 
Control 2 
106- 221 
538- 1117 
pg/ml 
PlGF Control 1 
Control 2 
29- 60 
177- 368 
pg/ml 
 
2.6.2.6 Data collection and analysis  
The Luminex xPONENT software was used to analyse the data. Standard curves 
and sample concentrations were calculated at the end of the acquisition step and 
were exported as a portable document file (.pdf). The exported file contained several 
read outs such as: median bead count per sample (not minus the background or 
corrected to standard curve), mean fluorescence intensity per sample (minus the 
background but not corrected to the standard curve), bead count for each sample 
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(minus the background), result pg/ml (normalised to standard curve and minus the 
background) and average MFI (normalised to standard curve and minus the 
background). Here “result” was used for analysis purposes. This is the result per 
sample minus the background and corrected to the standard curve. Following advice 
from Merck, bead counts ≤50 would be considered low and beads counts ≤35 would 
be considered void. Any samples with bead counts ≤35 were excluded.   
The standard curves for each analyte were generally sigmoidal and each had their 
own formula for best fit line depending on the binding behaviour of each antibody 
type (best fit is determined by the software). Samples were checked for their location 
on the standard curve and most samples fell within the linear range of the curve, but 
some fell out with the lower plateau. Bead count for these samples were assessed 
and if ≤35, were discounted. All our analytes QCs fell within the range provided by 
the manufacturer. Intra-assay precision was generated by the manufacturer from 
the mean of the %CV from 16 reportable results across two different concentrations 
of cytokines in single assay as follows: IL-6 2%, IL-8 1.9%, IL-10 1.6%, 1L-1β 2.3%, 
MCP-1 1.5%, IFN-gamma 1.6%, VEGF 3.7% and PIGF <10%. Inter-assay precision 
was generated by the manufacturer from the mean of the %CV’s from four 
reportable results across two different concentrations of cytokines across six 
different experiments as follows: IL-6 18.3%, IL-8 3.5%, IL-10 16.8%, 1L-1β 6.7%, 
MCP-1 7.9%, IFN-gamma 12%, VEGF 10.4% and PIGF <20%. 
2.7 Maternal blood phenotyping 
All analysis was carried out using plasma collected in the fasted state. Cholesterol 
and triglycerides were determined by enzymatic colorimetric assay on a Roche 
Cobas C311 analyser (Roche/Hitachi Cobas c systems, United Kingdom). Glucose 
was measured by Glucose hexokinase/ Glucose 6 phosphate dehydrogenase assay 
on a Roche Cobas C311 analyser (Roche/Hitachi Cobas c systems, United 
Kingdom). Insulin was measured by sandwich electrochemiluminescence 
immunoassay “ECLIA” using a Roche 411 Immunology analyser (cat. no. 
12017547122, Roche/Hitachi Cobas c systems, United Kingdom). CRP was 
measured by the immunoturbidimetric assay Cardiac C-Reactive Protein (Latex) 
High Sensitivity kit (Roche/Hitachi Cobas c systems, United Kingdom). Alanine 
Aminotransferase (ALT), Aspartate aminotransferase (AST), Glutamyl transferase 
(GGT) was measured using a Roche Cobas C311 analyser. NEFA in plasma was 
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measured by autoanalyzer. All tests listed above were carried out by Mrs. Josephine 
Cooney, in the Department of Metabolic Medicine, University of Glasgow. 
Glycerol in plasma was measured by enzymatic colorimetric assay using a glycerol 
assay (cat. no. GY105, Randox, UK), glycerol standard (cat. no. G7793, Sigma) and 
glycerol control (cat. no. GY1369, Randox, UK) the plate was read on a microplate 
spectrophotometer at 520 nm. IL-6 (HS600C), TNF-α (HSTA00E) and adiponectin 
(DRP300) were measured by quantative sandwich ELISA assay (R&D laboratories, 
UK). Oxidized LDL (oxLDL) was measured by sandwich ELISA (cat. no. 10114301, 
Mercodia, Sweden).  
2.7.1 Insulin resistance estimated by the homeostasis model 
assessment-estimated insulin resistance (HOMA-IR) 
The HOMA-IR was developed by Matthews et al. (1985). HOMA-IR has been widely 
used for the estimation of insulin resistance. HOMA-IR has been the most frequently 
employed technique both in clinical practice and in epidemiological studies, due to 
the simplicity of its determination and calculation. HOMA-IR was calculated using 
the following formula (fasting plasma insulin in mU/l X fasting plasma glucose in 
mmol/l)/22.5 (Wallace et al., 2004). Low HOMA-IR values indicate high insulin 
sensitivity, whereas high HOMA-IR values indicate low insulin sensitivity (insulin 
resistance) (Matthews et al., 1985).  
2.8 Early pregnancy study 
2.8.1 Subjects 
This study utilized plasma samples from an archival collection of women undergoing 
frozen embryo transfer (Meyer et al., 2016). This was a prospective, observational 
study conducted at Glasgow Royal Infirmary and was approved by the Local 
Research Ethics Committee (07/S0704/49). Plasma samples were collected from 
women undergoing frozen embryo transfer (FET) treatment for infertility and were 
recruited from the Assisted Conception Unit between October 2007 and April 2010 
(Meyer et al., 2016). Samples were stored at -80ºC.  
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2.8.2 Study design 
Women were eligible for the study if they had a regular menstrual cycle. Patients 
who had ovulation stimulation or induction were excluded. No progesterone 
supplementation or other hormonal supplements were given. All women were 
recommended to take 400 mg per day of folic acid in line with World Health 
Organization guidelines. Women were informed of the study when notifying the clinic 
nurse of their last menstrual period (LMP) date with a view to booking FET 
treatment. At day 10 after LMP, the women attended the Assisted Conception Unit 
to commence daily hormonal sampling to detect the luteinizing hormone (LH) surge 
in order to time embryo replacement. At this point women provided written informed 
consent and a basal blood sample. Embryo transfer was performed on day 3 post-
LH surge. Information on patient demographics and fertility history was collected 
from patient notes. Patient height and weight data were collected at the pre-LH 
surge visit. Body mass index (BMI) was calculated as weight in kg divided by height 
in meters squared. Fasting blood samples were collected at day 10 after LMP (pre-
LH surge) and on days 18, 29, and 45 post-LH surge. Plasma was collected by low-
speed centrifugation and frozen at -80°C within 2 hours.  
2.8.2.1 Preparation of density solution 
1.006 g/ml density solution was prepared by adding 11.4g NaCl, 0.1g EDTA, 1000ml 
distilled water (dH2O) and 1ml N NaOH. The solution density was checked using a 
PAAR DMA 35 Density meter (cat. no. 84138, Paar Scientific Ltd). 
2.8.2.2 Isolation of VLDL by sequential density ultracentrifugation 
EDTA plasma (500 μL) was overlaid with 500 μl density solution (density (d) <1.006 
g/mL) in 11*34mm Thick wall Polycarbonate Optima Ultracentrifuge tubes (cat. no. 
343778, Beckman Instruments Inc., UK). The samples were then transferred to a 
TLA 120.2 rotor and the lid secured. Using a Optima TLX Table-Top Ultracentrifuge 
the samples were centrifuged at 100,000 rpm (224000g) at 23
 o
C for 2.5 hours with 
4 deceleration.   
Using a drawn-out glass pipette, the top 500 µL fraction was removed from each 
tube by placing the pipette on the edge of the meniscus to ensure removing the very 
top fraction. The isolated VLDL (500 μL) was removed and divided into two tubes; 
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both were stored at -20
o
C. One was sent for lipoprotein composition analysis, and 
the other was used for FA extraction and later gas chromatography (GC) analysis.  
2.8.2.3 Lipoprotein composition analysis   
VLDL lipoprotein fraction triglycerides (TG), phospholipid (PL), total cholesterol 
(TC), free cholesterol (FC), cholesteryl ester (CE), were analysed by autoanalyzer 
and this was carried out by Mrs. Josephine Cooney, in department of Metabolic 
Medicine, University of Glasgow. 
2.8.3 Fatty acid extraction 
2.8.3.1 Preparation of reagents 
Methanol: toluene (4:1), with containing C21 fatty acid internal standard and 
butylated hydroxytoluene (BHT) was prepared via the following steps. First, 0.02 g 
of Heneicosanoic acid (H-5149, Sigma) was measured and transferred to a glass 
bottle. Second, in the fume hood, 100 ml of toluene (BDH, 102846G) was measured 
and added to the bottle. Third, 400 ml of methanol (BDH, 101586B) were added and 
mixed with amagnetic stirrer. Finally, 0.05g of butylated hydroxy toluene (BHT) 
(B1378, Sigma) were added and mixed with the previous solution under the fume 
hood. Potassium carbonate (K2CO3) 10% w/v solution (101964H, BDH) was 
prepared by mixing 100g of K2CO3 with 1L of distilled water.  
2.8.3.2 Procedure 
Fatty acids were extracted as described previously (Lepage and Roy, 1986). In a 
fume hood, 2 mL of methanol: toluene 4:1 (w/v) + 0.01% BHT and 0.2 mL of 0.2 
mg/mL 21:0 internal standard (Sigma-Aldrich, St. Louis, MO, USA) was added to 
200 μL of VLDL in a Pyrex glass culture tube with a Teflon lined screw cap (Bibby 
Sterilin, Staffordshire). Then 200 μL of acetyl chloride (100055V, BDH) was added 
slowly while vortexing and sealed with Teflon tape (Z-104388, Sigma). The tubes 
were heated on a heating block (DB.3D, TECHNE DRI-block) for 1 hour at 100
o
C in 
the fume hood. The tubes were then cooled in a water bath in a metal rack for 15 
minutes, after which 3 mL of 10% K2CO3 w/v solution was added and the tubes 
vortexed. Then,100μl toluene were added and mixed. Tubes were centrifuged for 
8min, at 3000 rpm at 5C using Jouan CR412 refrigerated centrifuge. The upper 
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toluene phase was transferred to a GC vial (Supelco) using a glass Pasteur pipette. 
Tubes were stored at - 20C until required for injection or transport.  
After VLDL isolation and FA extraction was carried out by the researcher, samples 
were shipped to our collaborator at Wollongong University in Australia and Gas 
Chromatography analysis was carried out by Nicola Zamai. 
2.8.4 Gas Chromatography (GC)  
The VLDL fatty acids were analysed by flame-ionization gas chromatography 
(model GC-17A; Shimadzu, Rydalmere, NSW, Australia). A 50 m x 0.25 mm internal 
diameter capillary column was used. Oven temperature was initially set at 150
o
C 
and rose to 170
o
C at a rate of 10
o
C/min, then to 200
o
C at a rate of 2
o
C/min, and 
finally to 211
o
C at a rate of 1.3
o
C/min. A 1 μL of sample was injected into the column, 
and individual fatty acids were identified by comparison with known fatty acid 
standards (Nu-Chek and Sigma, Sydney, NSW, Australia) and quantified by 
comparison with the 21:0 internal standard using Shimadzu analysis software 
(Class-VP 7.2.1 SP1).  
2.9 Statistical analysis 
Data distribution was assessed by Ryan Joiner test and was log or square root 
transformed where appropriate to achieve a normal distribution. Two sample T test 
was used for comparisons between groups (Control Vs GDM). Paired t test was 
used for comparison of SAT vs VAT. Data were expressed as mean and standard 
deviation. For non-parametric data, Mann-Whitney U test was used, and data were 
expressed as median and inter quartile range. To assess association between 
variables, Pearson’s correlation coefficient was used, and results were expressed 
as r value and P value. A P value of <0.05 was considered significant. Multiple 
testing was carried out using post hoc Tukey-Kramer honest significant difference 
(HSD) test. More specific detailed statistical analysis is provided within the relevant 
chapters. Minitab version 18 was used for experimental data analysis.  
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Chapter 3 Pregnancy outcomes in women with 
underweight, overweight and obese BMI and 
gestational diabetes in Greater Glasgow and 
Clyde, 2010 to 2015: a retrospective cohort 
using linked national datasets  
3.1 Introduction 
The worldwide prevalence of obesity has increased markedly over the past few 
decades posing serious threat to public health. Obesity among women who are 
pregnant is of particular concern as it carries additional risk for the baby. Obesity 
during pregnancy is defined as body mass index (BMI) >30 kg/m2. It affects 
between16 and 18% of the antenatal population as reported in two observational 
studies conducted between 2002 and 2004 in maternity units in Glasgow and north 
England, respectively (Kanagalingam et al., 2005, Heslehurst et al., 2010b). 
Maternal obesity has been recognised to affect maternal, fetal and neonatal 
outcomes. These include: preeclampsia (PE) (O’brien et al., 2003), gestational 
diabetes mellitus (GDM), operative delivery (Sebire et al., 2001b), fetal macrosomia, 
birth injury (Cedergren, 2004), stillbirth (Nohr et al., 2005) and neonatal intensive 
care unit (NICU) admission (Heslehurst et al., 2008). In addition to maternal obesity, 
being an overweight mother was also shown to increase the risk of several 
pregnancy complications such as GDM, caesarean delivery, fetal macrosomia 
(Abrams and Parker, 1988) and birth asphyxia related complications (Persson et al., 
2014). At the other end of the spectrum, being underweight has long been 
recognised as presenting increased risk of low fetal birth weight and preterm 
delivery (Sebire et al., 2001a). 
The incidence of gestational diabetes mellitus (GDM) is increasing worldwide, 
secondary to the epidemic rise in maternal obesity. GDM is a heterogeneous 
disorder with adverse maternal and fetal consequences. As discussed in the general 
introduction, metabolic complications during pregnancy such as maternal obesity, 
GDM and pre-eclampsia seems to be an early marker of disturbances in insulin 
sensitivity, lipid metabolism and endothelial function later in life. The development 
of pregnancy metabolic complication such as GDM and PE could predict the future 
risk of T2DM and CVD in the mother (Bilhartz et al., 2011). Research into the 
developmental origins of disease have suggested that intrauterine environment may 
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have significant influence on fetal growth and the later development of disease in 
the offspring (Barker, 1998). Childhood obesity poses a substantial risk of a future 
epidemic of CVD in early adulthood (Logue and Sattar, 2011). Thus, the higher 
prevalence of maternal obesity and GDM among women of reproductive age from 
high risk ethnicities or in socially deprived areas may have major health 
consequences across generations.  
Given the fact that many factors associated with increased maternal and fetal 
morbidity and mortality are not amenable to intervention, evidence has suggested 
that maternal weight control before pregnancy might offer an opportunity for 
reduction of gestational adverse outcomes. Therefore, the purpose of the analysis 
in this chapter was to assess the impact of first-trimester high (and low) BMI on the 
subsequent development of clinical complications later in pregnancy, in a 
retrospectively evaluated cohort of women representing a real-world sample of the 
general population in Greater Glasgow and Clyde. Using the Scottish Morbidity 
Record 2 (SMR02), maternal and fetal information was obtained about obstetric 
events. To derive a more robust diabetes status diagnosis, the data from SMR02 
was then merged with data from the Scottish Care Information – Diabetes Mellitus 
(SCI-diabetes) database using the patient ID held by the NHS Greater Glasgow & 
Clyde Safe Haven. This merge resulted in dataset containing no patient identifiable 
information and was provided to the researcher through a secure access portal. The 
study period was chosen from 2010- 2015 due to improved BMI recording compared 
to the period before and to avoid selective recording of women with higher BMI. 
Maternal BMI was examined as a categorical variable to provide better information 
about women at the extreme ends of the spectrum because BMI is not linearly 
associated with obstetric complications which tends to affect women with higher BMI 
(El-Chaar et al., 2013). The study subjects were mothers with different levels of 
socio-economic status, including women who lived in areas that were socially 
deprived.  
3.2 Aims 
1. To describe the characteristics of pregnant women with or without obesity 
and/or gestational diabetes.  
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2. To estimate the prevalence of obesity and gestational diabetes in pregnant 
women recorded within a single health board in the SMR02 and SCI-diabetes 
databases.  
3. To examine the outcomes of pregnancy in women who are underweight, 
overweight or obese compared to normal weight women. 
4. To examine the outcomes of pregnancy in women who develop GDM. 
3.3 Specific research questions 
1. What are the pregnancy outcomes and their frequency for women with 
gestational diabetes and those who are overweight or obese? 
2. How do obesity and gestational diabetes affect the following key outcomes 
from SMR02: mode of delivery, outcome of pregnancy (live, stillbirth), birth 
weight adjusted for sex, gestational age at delivery and parity (z score for 
birth weight), maternal smoking, parity, APGAR score at 5 minutes, feeding 
intention at discharge. 
3. How do outcomes compare depending on ethnicity, social deprivation 
(quintiles of the Scottish Index of Multiple Deprivation (SIMD)) and age?   
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3.4 Materials and methods 
3.4.1 Data source 
Approval for this study was obtained from NHS Greater Glasgow & Clyde Safe 
Haven GSH/16/DI/005. Anonymised data was retrieved retrospectively on all 
singleton deliveries in Greater Glasgow and Clyde, between 1 January 2010 and 1 
January 2016, from the SMR02 held at the Information Services Division (ISD) of 
NHS Scotland. An SMR02 dataset collects episode-level data of discharge 
information every time a mother had an obstetric event, and includes information on 
mother and baby characteristics, such as maternal age, maternal weight and height, 
baby birth weight, gestational age, mode of delivery, and outcome of pregnancy. 
The SMR02 covers all obstetric events in Scotland. This dataset has been shown 
to include 98.5% of births in comparison with the number of births registered by 
National Records of Scotland. The register is subject to regular data quality 
assessment, the most recent quality assurance showed that all data items were 90% 
or more complete in comparison with the medical record/Scottish Women Held 
Maternity Record (SWHMR), therefore, the register is considered robust 
(Information Services Division Scotland, 2010).  
Data on diabetes diagnoses was obtained from the SCI-diabetes dataset (McKnight 
et al., 2008). This dynamic clinical register was established in 2000, and currently 
collates demographic and clinical data for people with a diagnosis of diabetes in 
Scotland. From 2004 onwards, the coverage of the register was estimated to be 
99.5% for people diagnosed with diabetes in Scotland (Anwar et al., 2011). Diabetes 
type was defined in this register using an algorithm which utilises age at diagnosis, 
prescriptions data, and clinically assigned type of diabetes (Anwar et al., 2011).  
Information from SMR02 was linked with the national diabetes register SCI-diabetes 
network using the community health index number (CHI) to allow the identification 
of pregnancies in mothers with diabetes and subsequent perinatal outcomes. GDM 
diagnosis was coded in both clinical records of SCI-DM and SMR02. Data was 
extracted from the SCI-diabetes dataset in March 2017, which was then linked to 
the SMR02 hospital episode dataset by NHS Greater Glasgow and Clyde Safe 
Haven. This linkage produced a dataset with no patient-identifiable information and 
was provided to the researcher through secure Safe haven access. 
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3.4.2 Demographic information and clinical outcomes  
The following demographic information was extracted from SMR02 for every 
pregnant woman: maternal age, parity, height, weight, ethnicity, smoking status 
during pregnancy and deprivation category, at booking visit (~14 weeks pregnant). 
Maternal age was 100% complete in our cohort while there was only 0.2% missing 
information regarding parity. Maternal smoking information during pregnancy was 
81% complete in SMR02 and coded as current smoker, current non-smoker and 
unknown (Information Services Division Scotland, 2010).  
Maternal BMI was calculated from the mother’s height and weight (weight 
(kilograms)/ height2 (meter2), which were measured at the booking visit by a trained 
midwife. Within SMR02, height and weight were 72-79% complete (Information 
Services Division Scotland, 2010). This is due to some hospitals incorrectly mis-
assigned data for weight and duration of labour which lead to miss recorded BMI 
within the dataset. Furthermore, height was an optional data item which contributed 
to the missing BMI data. In our study height values were deemed valid within the 
range 100–250 cm, and weight was considered valid within the range 30–250 kg. 
Women were grouped into six BMI categories based on the WHO classification: 
underweight (UW<18.5 kg/m2), normal weight (NW=18.5–24.9 kg/m2), overweight 
(OW=25–29.9 kg/m2), obese class 1 (OB1=30–34.9 kg/m2), obese class 2 
(OB2=35–39.9 kg/m2) and obese class 3 (OB3≥40 kg/m2) (World Health 
Organization, 2000). The reference group for all analysis were women with normal 
weight. We also used BMI as a continuous variable to investigate associations over 
the entire range of body weight.  
Maternal deprivation was categorized using a tool for measurement of social 
deprivation, the SIMD 2009 deciles corrected version 2 (SIMD 2009v2), with 1 being 
the most deprived and 10 being the least deprived. The SIMD dataset identifies 
small areas where there are concentrations of multiple deprivations. It combines 
many indicators in several domains as a measure of multiple deprivation such as 
income, employment, education, housing, health, crime, and geographical access. 
Each data zone was ranked according to the overall score from a range of indicators 
which together creates the index. Ranks were grouped in categories such as deciles 
and quantiles. The SIMD 2009v2 used 2001 Data Zones which were introduced in 
2004 to replace post code as the key small area geography in Scotland (Information 
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Services Division Scotland, 2019). These Data Zones were divided in to 6,505 Data 
Zones containing 350 households and mean population size 800 people. In the 
current study, SIMD 2009v2-population weighted deciles that were calculated by 
ranking all Data Zones in Scotland from most to least deprived and then splitting 
them into ten deprivation deciles with approximately 10% of the Scottish population 
in each decile were used. This data item has only 3.6% missing information in our 
cohort.   
Maternal ethnicity was retrieved from SMR02 record and there was 33.8% missing 
information in our cohort. It was originally coded in 35 detailed categories which 
were then collapsed into the following seven categories of interest: White, South 
Asian, East Asian, (Caribbean, African or Black), Arab, mixed or other ethnicity 
(Figure 3-1). Ethnic group was the fifth most poorly recorded data item in SMR02 
with only 11% matching the information on the medical record/SWHMR (Information 
Services Division Scotland, 2010). This data item was mostly assessed by midwifes 
but not entered in the hospital Patient Administration System (PAS). Therefore, ISD 
strongly recommended after the latest data quality assurance in 2010 that ethnic 
group is recorded in the medical record SWHMR/PAS for SMR02 purposes.  
 
Figure 3-1 Ethnic group categorization in the current study based on SMR02 codes of 
ethnicity.  
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Maternal outcomes included mode of delivery (codes of interest were elective 
caesarean section (ELCS) and emergency caesarean section (EMCS)) and 
diabetes status (codes of interest were pre-existing DM and GDM). Mode of delivery 
and diabetes data items were retrieved from SMR02 and was 100% complete in our 
cohort and 85% complete in the most recent data quality assurance, compared to 
the SWHMR record (Information Services Division Scotland, 2010). Pregnant 
women with GDM were identified using SCI-diabetes and/or SMR02 diagnosis of 
GDM. In our cohort, we examined the accuracy levels of SMR02 in recording pre-
existing diabetes and GDM compared to SCI-diabetes record diagnosis for n= 
63,476 women after data cleaning and before application of the current study 
exclusion criteria detailed below in section 3.4.4. The number of women identified 
as cases in both datasets compared to the total number of cases identified in SCI-
diabetes diagnosis, were for type 1 diabetes mellitus (T1DM) 68/102, T2DM 52/101, 
maturity onset diabetes 1/4 and GDM 158/ 237. The accuracy of SMR02 in 
recording pre-existing diabetes and GDM compared to SCI-Diabetes are 58.4% and 
66.7% respectively Table 3-1. However, there was only 237 GDM cases recorded 
in SCI-Diabetes compared to 1024 GDM cases recoded in SMR02 and it could be 
that GDM diagnosis in SCI-diabetes is not as complete for the other types of 
diabetes in the SCI-diabetes record. Therefore, although SCI-Diabetes is the gold 
standard source for pre-existing diabetes diagnosis it is a poor source of GDM 
diagnosis. 
 
Type of 
diabetes 
SMR02 SCI-DM Number of 
cases 
identified 
in both 
Missing in 
SMR02 (but 
identified 
in SCI-DM) 
Missing in 
SCI-DM 
(but 
identified 
in SMR02) 
Type 1 
diabetes 
Pre-existing 
DM= 268* 
102 68 (66.7%) 34 (33.3%) Pre-existing 
DM= 61 
(22.7%)* 
Type 2 
diabetes 
Pre-existing 
DM= 268* 
101 52 (51.5%) 49 (43.6%) Pre-existing 
DM= 61 
(22.7%)* 
Maturity 
onset 
diabetes 
Pre-existing 
DM= 268* 
4 1 (25%) 3 (75%) Pre-existing 
DM= 61 
(22.7%)* 
Gestational 
diabetes 
1024 237 158 (66.7%) 
79 (50%) 
866 (84.5%) 
Table 3-1 Diabetes recording in SMR02 in comparison to SCI-Diabetes. 
Total number of subjects was (n= 63,476). Diabetes recording in SMR02 in comparison to SCI-
Diabetes as carried out after cleaning the data and before application of the current study exclusion 
criteria to include subjects with pre-existing diabetes in the comparison. * Type 1 diabetes, type 2 
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diabetes and maturity onset diabetes was recorded in one category in SMR02 as pre-existing 
diabetes. 
Offspring outcomes were extracted from the SMR02 record and included  
gestational age, birthweight, birth outcome (codes of interest were live birth, stillbirth 
and perinatal death), feeding intention at discharge (coded as breast, formula, mixed 
breast and formula or unknown) and APGAR score at 5 minutes (coded as score 
from 1 to 10), all were more than 99% complete in the cohort. Gestational age at 
birth was reported in completed weeks as estimated by the clinicians based on 
ultrasound dating scan at early pregnancy and last menstrual period date. 
Gestational age confirmation by ultrasound in early pregnancy is the usual practice 
in the UK and it has been more than 95% complete for pregnant women since the 
early 1990s (Campbell and Soothill, 1993). Gestational age at delivery was deemed 
valid if it was  43 and  22 weeks of gestation, 22 weeks is the lowest gestational 
age for infant’s survival after the recent advances in neonatal intensive care. Infant 
APGAR score was used as an index to evaluate the neonate’s overall health status 
and response to resuscitation. The resulting scores ranged from zero to 10 and were 
evaluated at 5 minutes after birth. Low infant APGAR score at 5 minutes is 
associated with an increased risk of neonatal and infant death (Zhu et al., 2015).  
Birth weight z score was calculated and adjusted for gestational age, sex and parity 
using a set of standard LMS-tables derived from Scottish data on 100,133 singleton 
births from the years 1998–2003 (Bonellie et al., 2008). Birthweight centiles are 
used to monitor the birthweight of an individual offspring in the context of the mean 
population birthweight when plotted against gestational age. These centiles were 
calculated using the LMS method which uses the Box-Cox power transformation to 
obtain normally distributed data within each group (Cole, 1988). This involves 
estimating three sets of values for each gestational age group, (L) the power 
transformation used to achieve normality, (M) the median birthweight and (S) the 
coefficient of variation of the data. The L, M and S values are estimated for each 
gestational age and then smoothed curves are fitted using cubic splines to give L(t), 
M(t) and S(t) where t is the gestational age (Bonellie et al., 2008). There were 227 
(0.6%) missing birthweight z scores due to missing information on birthweight, 
gestational age, baby sex and/or parity. 
The selection of covariates was based on the published literature, and bi-variable 
logistic regression analysis was performed to identify potentially confounding 
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factors. We considered the following factors to be potential confounders: continuous 
factors (maternal age at delivery, parity and z score of birth weight) and categorical 
variables (smoking during pregnancy, ethnicity, SIMD and APGAR score).  
3.4.3 Definitions 
Stillbirth was defined as a child born after 24 weeks of gestation, who did not breathe 
or show signs of life. 
Perinatal death was considered as a combination of stillbirth and death in the first 
week of life. 
Large for gestational age (LGA) infants were those weighing above the 90th centile 
at birth, corrected for gestational age, sex and parity.  
Delivery was considered preterm if gestation was less than 37 weeks and 
considered very preterm if gestation was less than 32 weeks.  
The APGAR score used as an index to evaluate the neonate’s overall health and 
response to resuscitation and is evaluated at 1, 5 and 10 minutes after birth.  
3.4.4 Data linkage 
The original dataset for analysis included 144,167 pregnancies. After exclusion of 
non-delivery admission (identified with missing delivery date),  65,054 pregnancies 
were identified in SMR02 between 1 January 2009 and 1 January 2016 (Figure 3-2). 
We excluded 354 pregnancies, as the maternal weight and height were mis-
recorded and out of the height (100–250 cm) and weight ranges (30–250 kg) we 
considered. Data for 64,700 pregnancies were merged with the SCI-diabetes 
database using patient ID. A further 968 pregnancies were removed due to twin 
pregnancy. Gestational age was either less than 22 weeks or more than 43 weeks 
for 192 pregnancies, which were removed. We included only the first pregnancy for 
each woman; therefore, 13,615 pregnancies, for women who had an additional 
pregnancy over the study period were not included. Due to the low number of 
pregnancies recorded in SMR02 in 2009 and 2016, those two calendar years were 
excluded from our analysis (Table 3-2).   
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Figure 3-2 Flow diagram for data cleaning and linkage. 
 
 
 
Table 3-2 BMI coverage over the study period after data merge (n= 64,700) 
 
 
BMI category 2009 2010 2011 2012 2013 2014 2015 2016
Missing BMI 831 (40.3) 3122 (44.6) 3757 (33) 4759 (41.8) 1468 (14.3) 149 (1.3) 98 (0.9) 0
Normal weight (BMI 18.5- 24.9) 667 (32.2) 1891 (27) 3726 (32.7) 3148 (27.6) 4301 (41.8) 5421 (47.9) 5290 (46.8) 2
Underweight (BMI< 18.5) 13 (0.6) 33 (0.5) 63 (0.6) 57 (0.5) 109 (1.1) 135 (1.2) 133 (1.2) 0
Overweight (BMI 25.0- 29.9) 314 (15.2) 1043 (14.9) 2209 (19.4) 1933 (16.9) 2492 (24.2) 3059 (27.1) 3166 (28) 2
Obesity class 1 (BMI 30- 34.9) 150 (7.2) 535 (7.6) 1039 (9.1) 941 (8.3) 1198 (11.6) 1579 (14) 1581 (14) 5
Obesity class 2 (BMI 35- 39.9) 64 (3.1) 260 (3.7) 411 (3.6) 387 (3.4) 505 (4.9) 644 (5.7) 675 (6) 0
Obesity class 3 (BMI≥ 40) 25 (1.2) 113 (1.6) 167 (1.5) 147 (1.3) 216 (2.1) 311 (2.8) 356 (3.1) 0
Total number of recorded pregnancies 2064 6997 11372 11372 10289 11298 11299 9
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3.4.5 Statistical analysis 
The association between maternal BMI and various maternal demographic 
characteristics and pregnancy outcomes were compared using ANOVA or 
univariate logistic regression analysis when appropriate. Descriptive data analysis 
was performed for all maternal and fetal variables of the study final dataset in section 
1.5.2. Continuous variables were summarised by mean ±SD and categorical 
variables by counts and percentages. Multivariate logistic regression models were 
applied to identify risk factors for GDM diagnosis, EMCS, ELCS, stillbirth, perinatal 
mortality, LGA infants, less than 7 APGAR score, preterm and very preterm delivery, 
adjusting for potential confounders. The relationship of maternal BMI category with 
several maternal, fetal, perinatal complications was expressed as an odds ratio 
(OR) and 95% confidence interval (95% CI) before and after adjustment for 
confounders. A two-sided p value < 0.05 was considered statistically significant. No 
imputations were made for missing data. Data handling and analysis was performed 
using RStudio version 3.3.0. 
3.5  Results 
3.5.1  Final dataset for analysis 
Over the study period, there were a total of 48,808 singleton deliveries (Figure 3-2). 
Maternal BMI was our primary dependent variable; therefore, all pregnancies with 
missing maternal weight or height recording (n=10,319) were excluded from our 
analysis (Figure 3-3). Of the 38,489 pregnancies that fulfilled our criteria, 311 
pregnancies were further excluded because they were identified as cases of pre-
existing diabetes using SMR02 (n=232) and SCI-Diabetes (n=79) codes (Figure 
3-3). The final cohort consisted of 38,178 singleton pregnancies recorded in SMR02 
with complete BMI data and no pre-existing diabetes. 
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Figure 3-3 Flow diagram for the study exclusions. 
 
3.5.2 Maternal BMI and clinical outcomes 
The maternal characteristics and the prevalence of maternal, delivery and neonatal 
outcomes are summarised in (Table 3-3). Fifty percent of pregnancies were 
classified as overweight or obese from the total cohort: 28.2% were overweight, 
13.8% were obese class 1, 5.9% were obese class 2, and 2.7% were obese class 
3. Pregnant women with overweight and obesity were older and more multiparous 
compared with normal-weight women. Furthermore, underweight, overweight and 
obese women formed a higher proportion of women in the most deprived SIMD and 
formed a lower proportion of women in the least deprived SIMD, compared with 
women of normal weight (P< 0.001). Mothers of African ethnic background was 
more likely to be overweight or obese, while, mothers of South Asian ethnicity were 
more likely to be underweight or overweight, but not obese. The proportion of 
maternal smoking during pregnancy appeared higher among underweight women 
but did not reach statistical significance.  
There were marked differences in pregnancy outcomes between overweight and 
obese mothers versus normal-weight mothers. Severely obese or underweight 
women delivered earlier than normal-weight women. Among them, the proportion of 
preterm delivery significantly increased, but not the proportion of very preterm 
delivery. Overweight and obese mothers formed a much greater proportion of those 
who had undergone ELCS and EMCS. Despite earlier delivery, mean birth weight 
was higher for the offspring of overweight and obese mothers (OW, 109g; OB1, 
132g; OB2, 157g; OB3, 148g higher compared to normal-weight mothers’ offspring 
mean birth weight). The same pattern was observed for birthweight adjusted for 
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baby sex, gestational age and parity, with the offspring of overweight women, obese 
class 1, obese class 2 and obese class 3 born at average weight 0.16 SD, 0.24 SD, 
0.34 SD, 0.41 SD higher than the offspring of normal-weight mothers, respectively. 
Similarly, the proportion of LGA infants was significantly higher (OW, 12%; OB1, 
14%; OB2, 17%; OB3, 20% vs NW 8%) across overweight and obese BMI 
categories. Furthermore, breast feeding intention rates at discharge were 
significantly lower, and there was a greater risk of breast-feeding cessation and 
early formula feeding in overweight and obese women. Unfortunately, there were 
84 stillborn infants over the study period, 41 infants were born to overweight and 
obese mothers, which was not statistically different from the normal-weight 
population. Similarly, there were 105 perinatal deaths during the study; 54 infants 
were born to overweight and obese mothers, which was not statistically different 
from figures for normal-weight mothers. 
 
 
Table 3-3 Maternal characteristics and obstetric outcomes over the study period (2010–2015) 
  
*significant increase p<0.05, **p<0.01, ***p<0.001 §significant reduction p<0.05, § § p<0.01, § § § p<0.001 ®reference category 
 
 
 
Table 3-4 Fetal outcomes over the study period (2010–2015) 
*significant increase p<0.05, **p<0.01, ***p<0.001 §significant reduction p<0.05, § § p<0.01, § § § p<0.001 ®reference category 
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Unadjusted odds ratios for the association between maternal BMI and several 
obstetric outcomes are shown in Table 3-5. Maternal overweight and obesity was 
strongly associated with risk of ELCS, EMCS and LGA. Mothers with morbid obesity 
are at greater risk of having an infant with APGAR score below 7, but this 
relationship disappeared after adjustment for confounders.  Underweight women 
had a greater risk for stillbirth, which disappeared after adjustment for confounders.
 
 
 
Table 3-5 Unadjusted odds ratios for the relationship of maternal BMI category and several maternal and fetal outcomes 
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In multivariate logistic regression analysis, maternal overweight and obesity 
remained strongly associated with the risk of ELCS, EMCS and LGA, after adjusting 
for maternal age, parity, smoking, ethnicity, and deprivation category (Figure 3-4, 
Figure 3-5, Figure 3-6). Only underweight (OR=1.91 [95%CI: 1.27, 2.77]) and obese 
class 2 (OR=1.26 [95%CI: 1.02, 1.53]) mothers showed a significant association 
with the risk of preterm, but not very preterm, delivery (Figure 3-7). Maternal BMI 
was not associated with less than 7 APGAR score, stillbirth or perinatal mortality in 
multivariate analysis (Figure 3-8, Figure 3-9, Figure 3-10). High parity was strongly 
associated with increased risk of ELSC (OR=1.35 [95%CI: 1.30, 1.39]) and 
significant reduction in EMCS risk (OR=0.48 [95%CI: 0.45, 0.49]) and reduced birth 
weight Z score (OR=0.92 [95%CI: 0.88, 0.96]). Smoking during pregnancy was 
associated with increased risk of EMCS (OR=1.16 [95%CI: 1.06, 1.27]) and 
premature delivery (OR=1.42 [95%CI: 1.25, 1.62]) and significant reduction in ELCS 
(OR=0.83 [95%CI: 0.74, 0.92]) and low birthweight z score (OR=0.54 [95%CI: 0.47, 
0.61]). 
   
Figure 3-4 Multiple logistic regression analysis evaluating the risk of elective caesarean 
section. 
*p<0.05, **p<0.01, ***p<0.001 
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Figure 3-5 Multiple logistic regression analysis evaluating the risk of emergency caesarean 
section. 
*p<0.05, **p<0.01, ***p<0.001 
 
 
   
Figure 3-6 Multiple logistic regression analysis evaluating the risk of large for gestational age 
(LGA). 
 *p<0.05, **p<0.01, ***p<0.001 
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Figure 3-7 Multiple logistic regression analysis evaluating the risk of preterm delivery. 
*p<0.05, **p<0.01, ***p<0.001 
 
Figure 3-8 Multiple logistic regression analysis evaluating the risk of APGAR <7. 
*p<0.05, **p<0.01, ***p<0.001 
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Figure 3-9 Multiple logistic regression analysis evaluating the risk of stillbirth  
*p<0.05, **p<0.01, ***p<0.001 
 
Figure 3-10 Multiple logistic regression analysis evaluating the risk of perinatal mortality 
*p<0.05, **p<0.01, ***p<0.001 
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3.5.3 GDM and clinical outcomes 
GDM affected 2.2% (840/38178) of pregnancies from the total cohort, and 3.6% 
(685/19274) of the overweight and obese pregnancies. Univariate logistic 
regression analysis for the likelihood of GDM and maternal BMI at booking showed 
a significant graded increased risk of GDM for overweight and obesity. GDM 
diagnosis was an independent risk factor for ELCS (OR=3.01 [95%CI: 2.5, 3.6]), 
EMCS (OR=1.95 [95%CI: 1.6, 2.3]) and preterm delivery (OR=1.9 [95%CI: 1.5, 
2.3]). 
The greatest increase in adjusted odds ratios for a complication associated with 
maternal overweight and obesity was observed for GDM after adjustment for 
maternal age at delivery, parity, smoking, ethnicity, and SIMD (Figure 3-11). 
Accordingly, a woman with booking BMI≥ 40 kg/m2 has a risk of GDM almost 
nineteen times greater than women of normal weight, after adjustment for 
confounders. Interestingly, South Asian (OR=3.19 [95%CI: 1.89, 5.14]) and Arab 
ethnicity (OR=14.79 [95%CI: 2.21, 56.54]) women were at significantly increased 
risk of GDM compared to those of white ethnicity. However, there were too few 
participants (n= 29) of Arab ethnicity for a meaningful multi-variable analysis. GDM 
risk increased significantly in mothers with the most deprived SIMD scores, (SIMD1, 
OR=3.43 [95%CI: 1.14, 14.43]; SIMD2, 7.66[95%CI: 2.72, 32.21]; SIMD3, 
6.02[95%CI: 2.04, 25.74]). 
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Figure 3-11 Multiple logistic regression analysis evaluating the risk of GDM during pregnancy. 
*p<0.05, **p<0.01, ***p<0.001 
3.6 Discussion  
The current study demonstrates that both high and low BMI are associated with 
increased odds of pregnancy adverse outcomes. The prevalence of maternal 
obesity was 22.3% which has increased compared to the previous analysis 
conducted in the Glasgow population in 2005 (Kanagalingam et al., 2005). Higher 
maternal BMI was strongly associated with several risks such as GDM, EMCS, 
ELCS and LGA babies. The prevalence of GDM was 2.2% in our cohort, however, 
although this is a low GDM prevalence but it has slightly increased by 0.3% 
compared to the Scottish prevalence since 2012 (Collier et al., 2017). However, 
GDM rate is very dependent on the screening pattern used and the rates of the 
current study could be an underestimate compared to populations implying the 
universal screening.  The ATLANTIC Diabetes in Pregnancy (DIP) program 
identified 12.4% prevalence of GDM within a cohort of Irish women in which 
universal screening was applied using the IADPSG criteria. In the current study 
pregnant women with GDM had increased risk of ELCS, EMCS, LGA baby and 
preterm delivery in our cohort. The present study confirmed the association of GDM 
with maternal BMI, maternal age, social deprivation and ethnicity. The cohort for this 
study was taken from a national dataset with regular proven data quality assessment 
which enabled us to obtain a large number of patients’ representative of the general 
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population. In particular, the results of this study were not confounded by other forms 
of pre-existing diabetes and twin pregnancy. Furthermore, each woman accounts 
for one pregnancy only and the effect of consecutive pregnancies during the study 
period was accounted for. 
The results of this study showed that 50.4% of the maternity population living in 
Greater Glasgow and Clyde were overweight or obese at the first trimester of their 
pregnancy, of which 28.1% were overweight and 22.3% were obese. From 2002 to 
2004, a previous observational study reported maternal obesity prevalence rate of 
18% in the Princess Royal Maternity Unit (PRMU) at Glasgow Royal Infirmary 
(Kanagalingam et al., 2005). However, the previous study cohort was randomly 
selected by medical record staff from one hospital in Glasgow. The current rates of 
maternal obesity confirm that the maternal obesity prevalence rate in the Glasgow 
population continues to be on a slow increasing trend over the last 15 years.  
Maternal obesity in the first trimester has significant implications for clinical practice. 
It results in a higher demand for high dependency care, and the complications that 
can arise for mother or child need to be managed. The NICE guideline recommends 
that pregnant women whose BMI is greater than 30 kg/m2 should be placed under 
the care of a consultant rather than a midwife, which places a huge burden on 
resources in maternity units (National Collaborating Centre for Women's and 
Children's Health, 2008). In our cohort, overweight and obese women are at higher 
risk of operative delivery (both ELCS and EMCS) and LGA infants. This possibly 
could lead to further complications such as shoulder dystocia and instrumental 
delivery due to LGA infants and wound infection following operative delivery. Only 
obese class 2 women showed a slight increase in risk of preterm delivery. However, 
different types of preterm birth (i.e. after spontaneous preterm labour, preterm 
premature rupture of membranes, or indicated labour) were not distinguished in our 
study. Secondary analysis of the  Maternal–Fetal Medicine Units Network (MFMUN) 
study showed that pre-pregnancy obesity was associated with a lower rate of 
spontaneous preterm birth (Hendler et al., 2005). Therefore, the higher preterm 
delivery risk observed in the current study among obese women class 2 could be 
secondary to other obstetric complications such as GDM and PE. In our cohort, first-
trimester obesity was not associated with stillbirth, perinatal mortality or APGAR 
score <7. Contrary to our results, a meta-analysis concluded that even modest 
increases in maternal BMI were associated with risk of stillbirth and perinatal 
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mortality suggesting that our study could be underpowered to observe this 
association (Aune et al., 2014).  
Maternal underweight, overweight and increasing levels of obesity show a striking 
positive relationship with social deprivation. The reverse was also true, higher SIMD 
levels were associated with a significant reduction in the risk of being underweight, 
overweight or obese. This highlights the inequalities in health that have been 
reported widely in previous research. A similar association was observed in a 
retrospective cohort of women living in Scotland from 2003–2010 (Denison et al., 
2014). Therefore, the mothers at higher clinical risk (severely obese) are those 
facing a higher level of health inequality. In our study, the most deprived women are 
at increased risk of GDM, EMCS and preterm delivery, and reduced risk of ELCS 
and LGA infants. Moreover, the association between deprivation and preterm 
delivery in our cohort was striking. We observed increasing risk of preterm delivery 
with increasing deprivation status. Although social deprivation, underweight and 
smoking were individually associated with preterm delivery, the risk between 
deprivation status and preterm delivery could be mediated via underweight and 
smoking. However, underweight and smoking, both modifiable risk factors, could be 
an important determinant of preterm delivery in the most deprived population. 
Although association does not infer causation, possible interventions to reduce 
maternal underweight and promote smoking cessation among the deprived 
population may be highly beneficial in adverse obstetric outcome reduction. The 
recent research of Mehra et al. (2019) observed a similar association, and 
suggested that hypertension and infection moderately determine this association. 
However, other factors related to area-level conditions, such as inadequate housing, 
transportation and violence, may influence pregnancy through psychological stress 
(Messer et al., 2013). In line with our results, a meta-analysis of seven studies on 
neighbourhood deprivation found that  the risk  for preterm birth was significantly 
increased in the most deprived neighbourhood quantiles, compared to the least 
(OR=1.23 [95%CI: 1.18, 1.25]) (Vos et al., 2014). The higher risk for EMCS among 
the socially deprived population could be related to the observed higher incidence 
of metabolic complications such as maternal obesity and GDM in this group. 
Ethnic minorities in Europe have been shown to have higher susceptibility to T2DM 
(Meeks et al., 2016) and CVD (Tran et al., 2011). Pregnancy can be considered to 
be a stress test to unmask the mother’s metabolic dysfunction and predict future 
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morbidity patterns that will affect both maternal and offspring health. There was a 
positive relationship between obesity and African ethnicity, which is representative 
of the black ethnicity relationship with obesity in the general population, where Black 
African and Black Caribbean women show the highest prevalence of obesity 
(Sproston and Mindell, 2006). While African mothers are very likely to be overweight 
or obese, GDM risk in the current study population disappeared after adjustment for 
confounders. Contrary to our results, a larger study in London, including 76,158 
pregnancies, found that women of Afro-Caribbean origin had increased risk of GDM 
in multivariate analysis (OR=1.44 [95%CI: 1.25, 1.65] (Khalil et al., 2013). The same 
study observed three-fold increased risk of PE in women of Afro-Caribbean origin. 
Although we did not have data on PE, but this could possibly explain the observed 
higher EMCS rate among African population in our study.  
Interestingly, our study showed a positive relationship between South Asian 
ethnicity and being underweight or overweight, but not obese pregnant women. 
There was an increased relationship between obesity and women of Asian ethnicity 
in the general population (Sproston and Mindell, 2006). In our study, although South 
Asian mothers tended to have lower BMI compared to the white population, they 
had significantly increased risk of GDM and EMCS probably reflecting increased 
testing for this population, and reduced risk of LGA infants and ELCS. On the other 
hand. Heslehurst et al. (2010b) observed a significantly reduced risk of being 
overweight or obese for pregnant Asian women in England. However, Heslehurst et 
al. (2010b) study involved a larger sample size, and this might have contributed to 
this inverse relationship which we did not observe. In addition, their study did not 
observe South Asian ethnicity as a separate group from other Asian backgrounds. 
Unfortunately, we did not possess data on PE, but it would be interesting to examine 
whether it is related to the increased risk of EMCS in South Asian and black mothers.  
At the other end of the spectrum, underweight women represented the only BMI 
category at significantly increased risk of stillbirth in our cohort, which remained 
consistent after adjustment for confounders. Underweight women are at greater risk 
of preterm delivery and reduced z score for their infant’s birthweight. These findings 
were consistent with other meta-analysis studies for different populations, including 
low- and middle-income countries (Rahman et al., 2015). However, these results 
should be interpreted with caution, due to the low number of events (3 stillbirth and 
9 preterm birth) among underweight women.  
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The results of this analysis have shown that the prevalence of GDM was 2.2% in 
our cohort. The Scottish prevalence of GDM was 1.9% on 2012 (Collier et al., 2017).  
This confirms that the reporting of GDM is low in the Glasgow population in similar 
rates to the national data although it is not clear whether this is probably due to lower 
reporting or testing or not. In our cohort, GDM diagnosis was associated with 
maternal BMI, maternal age, social deprivation and ethnicity. A study by Collier et 
al. (2017) showed similar associations although ethnicity was not studied in their 
analysis. They showed that maternal macrosomia was not associated with GDM. 
However, in our cohort, women with GDM had increased risk for a LGA baby. This 
is probably because we have used adjusted birthweight for gestational age, sex and 
parity rather than birth weight only for offspring of GDM mothers who tend to deliver 
earlier than healthy mothers. In this situation the birthweight alone may not be 
reflecting the real impact. Furthermore, we have used both SMR02 and SCI-
diabetes dataset diagnosis of GDM and excluded mothers with pre-existing diabetes 
from our analysis which could improve our GDM diagnosis accuracy.  
Overweight and obese women start pregnancy with greater insulin resistance than 
normal weight women (Catalano, 2010), and become highly insulin-resistant around 
mid- to late-gestation, which then can lead to metabolic complications such as GDM 
and PE. In the current cohort, the association between first-trimester BMI and GDM 
was strongly significant, with increasing levels of risk among higher BMI categories, 
and remained consistent after adjustment for confounders. South Asian women had 
a three-fold increased risk of GDM despite being at lower BMI. This observation was 
in line with the finding of Khalil et al. (2013), which also pointed to women of South 
Asian origin developing GDM at a younger age compared to those from Caucasian 
ethnic backgrounds. This suggests that lower BMI cut-off for obesity diagnosis in 
women of South Asian origin might not be sufficient to identify women at higher risk. 
The observed difference in body fat distribution between South Asian and 
Caucasian ethnicity could probably explain the previous results in which South 
Asians were found to accumulate fat more centrally rather mostly in subcutaneous 
fat such as Caucasians. Therefore, lower BMI cut off points were recommended to 
be used in South Asian population due to their high risk to develop T2DM at lower 
BMI compared to Caucasians. Another relevant aspect for ethnic differences is that 
a two- to three-fold higher prevalence of GDM is reported when applying IADPSG 
criteria, rather than WHO criteria, due to a lower fasting glucose cut-off in the former 
(Jenum et al., 2012). Previous evidence has shown that women of South Asian 
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origin have more abnormal fasting plasma glucose levels (Agarwal et al., 2010). 
Therefore, the application of IADPSG criteria to our cohort could be responsible for 
the observed association. In addition to adiposity and ethnicity, low socio-economic 
status in our cohort was strongly associated with GDM diagnosis. It could be that 
there are area level factors that we did not measure, such as the density of retail 
outlets for alcohol, tobacco, and unhealthy and healthy foods, which might explain 
this association. 
A GDM pregnancy implies a substantial risk of T2DM development later in life. 
Neonates of women of South Asian origin are of lower birth weight compared to the 
general population. When exposed to the current obesogenic environment, those 
neonates could be at higher risk of later obesity, T2DM and CVD. This study draws 
awareness to the notion that pregnancy can be considered as a natural stress test 
to reveal the maternal risk for future T2DM and CVD development. The increasing 
trend for maternal obesity and GDM prevalence among ethnic minority and socially 
deprived groups is of great concern.  
There are several limitations in our study. First, this study used routinely collected 
data, which relied on reliable coding, and did not include a laboratory measure of 
GDM diagnosis. Second, our analysis was adjusted for several maternal 
demographic confounders but not for maternal pre-existing conditions other than 
diabetes, such as operative delivery, which could probably amplify the effect of 
obesity in those individuals. Third, we used BMI as a measure of obesity. Emerging 
evidence has suggested that measures of abdominal obesity may be more 
important as an indicator of risk for metabolic disease than general adiposity. 
Several alternative anthropometric measures such as waist circumference, 
waist/hip ratio and skin fold thickness could have been used but these can be 
unreliable in pregnant women and difficult to record at a population level. Therefore, 
although BMI has limitations, it remains the practical option for large epidemiological 
studies. Finally, this study might not be representative of other settings, or 
generalizable to other populations but it does confirm the work of multiple previous 
investigations.  
A particular strength of our study is that it provides detailed demographic and 
obstetrics outcomes analysis among the greatly diverse Greater Glasgow and Clyde 
population, and highlights subgroups at higher risk of facing health inequalities. 
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Furthermore, we examined the associations between maternal obesity and a wide 
range of adverse pregnancy outcomes among ethnic minorities, an area which is 
still sparsely documented. Our analysis included social economic status and the 
effect of race on various obstetric outcomes which are not usually accounted for in 
previous research. We merged SMR02 and SCI-diabetes to obtain accurate data 
on diabetes status to diagnose GDM and accurately exclude woman with pre-
existing diabetes from confounding our findings.  
In conclusion, our study showed that in a single health board of Scotland’s 
population, there was a notable risk of maternal obesity and GDM, which 
predisposes mothers to several obstetric complications and adverse outcomes. 
Mothers with obesity and GDM receive higher obstetric interventions, including 
operative and earlier delivery. Average birthweight for the offspring of overweight 
and obese mothers is significantly increased, despite the increased rate of medical 
interventions among this group. Among ethnic minority groups and the most 
deprived areas, there was a significant risk of both adverse maternal and fetal 
outcomes. To reduce the risk of these adverse outcomes, it is important to identify 
the modifiable risk factors that can potentially be targeted for interventions. 
Behavioural interventions to control maternal weight during pregnancy have been  
shown to be significantly reduce the maternal weight gain during pregnancy but did 
not reduce the adverse pregnancy outcomes (Poston et al., 2015), therefore, 
effective intervention strategies are needed for weight control prior to pregnancy. 
Targeted intervention approaches towards the low-income population and ethnic 
minorities at higher metabolic risk could be highly effective in improving pregnancy 
outcomes. Wider analysis of maternal obesity rates and obstetric outcomes at 
national level could be beneficial in informing our clinical practice in the 
management of maternal obesity during pregnancy. Future research is required to 
address the economic costs associated with obesity and GDM during pregnancy 
including maternal hospitals costs for the mother and her neonate.  
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Chapter 4 Adipocyte lipolytic function in 
pregnancies complicated with gestational 
diabetes mellitus compared to healthy 
pregnancy 
4.1 Introduction 
Pregnancy requires substantial maternal metabolic adaptation to accommodate the 
demands of the growing fetus. Late pregnancy is characterized by physiological 
insulin resistance to adapt with increasing fetal demand to preserve glucose as the 
primary fuel for the fetus. Insulin resistance is a condition of reduced responsiveness 
to insulin in several tissues such liver, muscle and adipose tissue. As a result, insulin 
production from β-cells increases to maintain normal blood glucose levels. Insulin 
resistance is present in several conditions including T2DM and obesity. For obese 
women with subclinical decreased insulin sensitivity, pregnancy represents a 
metabolic stress test which may lead to development of pregnancy complications 
such as GDM and PE due to exaggerated insulin resistance. The decrease in insulin 
sensitivity with advancing gestation is not limited only to disturbed glucose 
metabolism but is also is observed in relation to lipid metabolism (Catalano et al., 
2002). There is a two to threefold increase in basal triglyceride and cholesterol 
concentrations with advancing gestation. The increases are more pronounced in 
women with GDM as compared with healthy pregnant women (Catalano et al., 
2002). The increase in plasma FFA concentration is related to the decreased ability 
of insulin to suppress lipolysis in late gestation. 
During pregnancy, there is an increased need to expand adipose tissue 
(lipogenesis) in early pregnancy and increase FA availability (lipolysis) in late 
pregnancy. These physiological changes are of great interest to study, in particular 
how adipocytes respond to these changes. The size of the adipocytes can change 
throughout life, depending on the amount of lipid stored. From in vitro experiments 
in non-pregnant individuals, it is well established that larger adipocytes are less 
sensitive to insulin action (Salans and Dougherty, 1971). Abdominal SAT adipocytes 
size was shown to be predictive of T2DM in non-pregnant women (Lonn et al., 
2010). In severely obese non-pregnant individuals both SAT and VAT adipocytes 
size was correlated with fatty liver (O'Connell et al., 2010). Despite the great impact 
of maternal obesity on gestational insulin resistance and the development of 
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subsequent metabolic complications among the mother and her fetus, there are few 
studies of human adipose tissue morphology and function during healthy and 
complicated pregnancy. Longitudinal studies of gluteal adipose tissue biopsies 
show that there was larger gluteal adipocytes with increased numbers of adipocytes 
during late gestation compared to early and pre-pregnancy samples (Resi et al., 
2012). Inherent defective adipocyte expansion in the face of pre-pregnancy obesity 
may be unmasked during pregnancy leading to pregnancy metabolic complications 
such as GDM. The functional measures of adipocytes were rarely studied in women 
with GDM such as adipocyte size and lipolytic function. Rojas-Rodriguez et al. 
(2015) found that women with GDM had omental (visceral) adipocyte hypertrophy 
and decreased capillary density compared to pregnant women with normal glucose 
tolerance. 
Insulin suppression of lipolysis is a direct measure of adipocyte insulin sensitivity, 
which was shown to be a major contributor to whole body insulin sensitivity. There 
was increased adipocytes sensitivity to insulin in adipocytes from non-pregnant 
females compared to males (Macotela et al., 2009). The adipocytes insulin 
sensitivity in females may account for their lower level of insulin resistance and 
diabetes risk despite similar or higher fat content than in males (Macotela et al., 
2009). Adipose tissue of obese non-pregnant subjects showed reduced response 
to insulin (Salans et al., 1968). After weight loss and reduction in adipose cell size, 
insulin sensitivity of the adipose tissue of obese patients was restored to normal. 
Adipose tissue insulin sensitivity was impaired in non-pregnant T2DM subjects 
(Kotronen et al., 2008). In the third trimester of pregnancy, there is enhanced insulin 
resistance. Pregnant  normal weight women in the third trimester were shown to 
have increased SAT adipocytes lipolysis measured by tracer catheterization 
(Diderholm et al., 2005) compared to the non-pregnant data (Kalhan et al., 2001). 
In overweight and obese pregnant women, it was demonstrated that there is 
resistance to insulin suppression of lipolysis and fat oxidation during euglycemic-
hyperinsulinemic clamping in third trimester compared to second trimester and 
postpartum (Sivan et al., 1999). Therefore, defective insulin suppression of lipolysis 
is suggested in pregnancies complicated with GDM. Moreover, the maternal 
dyslipidemia observed in GDM may result from enhanced subcutaneous adipocyte 
lipolysis in obese mothers. however, there are no previous studies on adipocyte 
lipolysis in women with GDM. Thus, we hypothesized that there is adipocyte 
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hypertrophy, adipocyte insulin resistance and increased adipocyte lipolysis in GDM 
over and above the effects of obesity. 
It has been suggested that SAT adipocyte storage capacity is diminished due to 
SAT adipocyte dysfunction in terms of hypertrophy and increased lipolysis, which 
lead to ectopic fat deposition in other organs. VAT can be regarded as an ectopic 
fat depot which acts as a source of excessive FA release and inflammatory 
cytokines to the liver through the portal circulation leading to hepatic fat 
accumulation. This in turn affect glucose and lipoprotein metabolism and contributes 
to the development of metabolic diseases. Fatty liver was independently associated 
with impaired glucose tolerance and T2DM, an association that was increased by 
adipose tissue insulin resistance (Jorge-Galarza et al., 2016). Recently hepatic 
steatosis index (HSI) was studied in women at early pregnancy and the results were 
consistent with non-alcoholic fatty liver disease (NAFLD) diagnosis by ultrasound. 
Women with higher HSI score had significantly increased risk of developing GDM 
later in pregnancy (Lee et al., 2019). More interestingly, this study demonstrated 
that abnormal hepatic steatosis indices correlated positively with GDM risk when the 
analysis was confined to those women with normal liver ultrasound (Lee et al., 
2019). The mechanism linking the development of GDM and hepatic steatosis 
during pregnancy is not known yet. However, it is likely that these are two metabolic 
diseases that share a metabolic dysfunction such as insulin resistance.  
Overweight and obesity increases the risk for GDM substantially and also 
independently affects adipocyte function. To account for this, the GDM and the 
control groups in this study were BMI-matched. I collected adipose tissue biopsies 
at Caesarean section in order to obtain larger adipose tissue biopsies than could be 
obtained by needle biopsy and to allow collection of both SAT and VAT biopsies to 
address the regional differences in adipocyte size and in vitro lipolytic function of 
isolated adipocytes. Since dysfunctional adipocyte lipolysis is key to my central 
hypothesis, I aimed to study isolated adipocytes and their basal and beta 
adrenergic-stimulated lipolysis and the inhibitory effects of insulin. To isolate 
adipocytes, I selected to use the collagenase digestion method, a standard method 
carried out by the landmark original studies into lipolytic function (Rodbell, 1964) 
and the more recent study of adipocyte function in pre-eclampsia carried out in my 
laboratory (Huda et al., 2014). I was also able to measure adipocyte size. Glycerol 
and NEFA are the end products of TAG hydrolysis such that their release from 
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adipocytes can be used as an index of adipocyte lipolysis. There is no consensus 
in the literature on the presentation of lipolysis data in terms of correcting for cell 
number/ or tissue weight and most lipolysis data are corrected for different factors 
such as tissue weight, cell number, lipid weight or DNA content in different studies. 
In this study, DNA content was used as an index of the tissue cellularity which 
enabled us to directly compare metabolic effects independently of fat cell size i.e. 
on a per adipocyte basis. It could be argued that lipolysis rates measured in isolated 
adipocytes in cellular preparations are not similar to lipolysis in adipose tissue 
pieces ex vivo due to presence of other SVF cells which could contribute to the 
lipolytic response. However, it was reported previously that there is strong 
correlation between basal lipolysis rate of isolated adipocyte and ex vivo adipose 
tissue samples (Rydén and Arner, 2017). Furthermore, my hypothesis focusses on 
the adipocyte in the key initiator of adipose tissue dysfunction. While adipocytes are 
capable of NEFA re-uptake and re-esterification, this is not the case for glycerol due 
to the limited availability of the glycerol kinase enzyme in adipocytes. Thus, glycerol 
is suggested to be a better measure of total lipolysis (Rydén et al., 2019) while NEFA 
measures net lipolysis. NEFA/ glycerol ratio is a measure of FA reuptake where a 
lower ratio indicates re-uptake of NEFA and the maximum value of 3.0 indicates full 
breakdown of the triglyceride molecule. Whether depot differences in insulin action 
on lipolysis and NEFA re-esterification occur in adipocytes from different depot 
remains to be established (Zierath et al., 1998). 
To explore the relationship between adipocyte cell size, lipolytic function and fat 
deposition in the liver during pregnancy, a relationship not explored before to our 
knowledge, hepatic steatosis index (HSI) was used. This is a simple non-invasive 
screening tool for non-alcoholic fatty liver disease (NAFLD) previously used in 
pregnancy (Lee et al., 2019). Moreover, it was suggested that HSI could have more 
predictive value in women with mild or moderate NAFLD (Lee et al., 2019) than 
ultrasound assessment since ultrasound is only able to detect positive results when 
the liver fat content exceeds 30% (McCullough, 2004). Plasma lipids, insulin, 
glucose, and liver function enzymes were measured and their relationship to 
adipocyte function was explored. 
Integrating these structural and functional elements of adipocyte function, along with 
a biomarker of liver fat accumulation, this study was performed to determine the 
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relative contribution of adipocyte function to the underlying pathophysiology of GDM 
compared to a healthy BMI-matched control group.  
4.2 Aim 
The aim of this chapter was to compare subcutaneous (SAT) and visceral (VAT) 
adipocyte diameter and lipolytic function and a biomarker of liver fat accumulation 
(HIS) in pregnant women with and without GDM 
4.2.1 Hypotheses 
• That women with GDM have larger subcutaneous adipocytes than healthy 
BMI-matched controls 
• That SAT adipocytes from GDM women have higher basal lipolysis than 
those from healthy BMI matched controls 
• That adipocytes from women with GDM have higher NEFA release in 
response to catecholamine stimulation of lipolysis than those from healthy 
BMI matched controls 
• That adipocytes from women with GDM have lower insulin suppression of 
lipolysis those from healthy BMI matched controls i.e. are more insulin 
resistant. 
• That women with GDM have higher HSI compared healthy controls, i.e. have 
higher liver fat. 
4.2.2 Specific research questions 
• How are adipocyte diameter and volume affected by GDM?  
• Which adipose tissue depot is more dysfunctional in women with GDM? 
• Do adipocytes from women with GDM have increased insulin resistance 
resulting in increased lipolysis compared to BMI matched controls? 
• What are the depot differences in lipolytic function? 
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• How are plasma lipids and liver function affected if there is enhanced 
adipocyte lipolysis in GDM? 
4.3 Methods 
4.3.1 Adipocyte isolation and sizing 
The study participants were recruited as outlined in the Methods Chapter section 
2.1.1. Subcutaneous and visceral adipose tissue samples were processed as 
outlined in section 2.2. After two hours incubation, two 300µl aliquots of the medium 
below the adipocyte suspensions were collected and stored at -20°C for later 
analysis of NEFA and glycerol concentration as outlined in section 2.4.3. Glycerol 
and NEFA concentrations were corrected for cell number by dividing by DNA 
concentration of a known volume of adipocytes as outlined in method section 2.2.3. 
The values were then expressed in mmol/hr/ug of DNA. Adipocyte sizing was 
carried out as detailed in section 2.3. Maternal lipids, markers of insulin sensitivity 
and liver function enzymes were measured as outlined in section 2.7. 
4.3.2 Adipocyte lipolysis assay 
Adipocyte lipolysis assay was carried out as outlined in 2.4.The degree of lipolysis 
stimulation by isoproterenol was calculated as the percentage of release of NEFA 
or glycerol in the presence of isoprotenerol relative to basal lipolysis i.e. Percentage 
stimulation= ((lipolysis rate in presence of isoproterenol – basal lipolysis) / basal 
lipolysis)*100. The degree of lipolysis suppression by insulin was calculated as the 
percentage of release of NEFA or glycerol in the presence of insulin relative to basal 
release i.e. ((basal lipolysis – lipolysis rate in the presence of insulin) / basal 
lipolysis)*100. FCISI is a direct measure of adipocyte insulin sensitivity. It can be 
calculated as the percentage suppression of isoproterenol stimulated lipolysis by 
insulin measured either as NEFA or glycerol release i.e. FCISI= ((lipolysis rate in 
presence of isoproterenol  – lipolysis rate in presence of isoproterenol and insulin) / 
(lipolysis rate in presence of isoproterenol  – basal lipolysis))*100. 
4.3.3 Hepatic steatosis index (HSI) 
HSI was calculated using the following equation (Lee et al., 2010): 
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HSI= 8*ALT (IU/l) / AST (IU/l) + BMI (kg/m2) + 2 (if T2DM) + 2 (if female) 
Where ALT is alanine aminotransferase, AST is aspartate aminotransferase and 
T2DM is type 2 diabetes. Taking the conservative approach, GDM women in our 
study were not considered as T2DM in the above equation. The participants were 
classified into three groups according to the HSI: low risk of steatosis (HSI <30); 
intermediate risk (30≤ HSI ≤36) and high risk (HSI >36).  
4.3.4 Statistical analysis 
The statistical analysis was carried out as outlined in section 2.9. The following 
variables were log transformed: fasting glucose level at OGTT, plasma insulin, 
HOMA-IR, GGT, HSI, SAT basal lipolysis (SAT-basal), SAT lipolysis rate in 
presence of isoprotenerol (SAT-ISO), SAT lipolysis rate in presence of insulin and 
isoprotenerol (SAT-ISO+INS), VAT basal lipolysis (VAT-basal), VAT lipolysis rate in 
presence of isoprotenerol (VAT-ISO) and VAT lipolysis rate in presence of insulin 
and isoprotenerol (VAT-ISO+INS). The following variables were square root 
transformed: SAT total volume and VAT total volume. The following variables were 
not normally distributed and analyzed non-parametrically: plasma glucose, plasma 
glycerol, ALT, AST,  SAT lipolysis rate in presence of insulin (SAT-INS), VAT 
lipolysis rate in presence of insulin (VAT-INS), percentage stimulation of lipolysis by 
isoprotenerol, percentage suppression of lipolysis by insulin and fat cell insulin 
sensitivity index (FCISI).  
4.4 Results 
4.4.1 Study participants  
The study participants in GDM (n=22) and control group (n=22) had similar BMI and 
age reflecting the study design (table 1-1). Ethnicity, parity, smoking history, blood 
pressure, birthweight and fetal sex did not differ between control and GDM 
pregnancy. GDM mothers delivered six days earlier than controls (p=0.001). 
Diagnostic OGTT tests were carried out in the second trimester and as expected, 
women in the GDM group had higher fasting OGTT blood glucose (p= 0.0001). 
However, there was only 4 women in the control group who were screened for GDM 
due to having an obese BMI and a family history of T2DM. 
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Table 4-1 Characteristics of GDM women and BMI matched controls 
  
 
Data are expressed as mean (SD) for continuous variables. Categorical variables are expressed as 
number (percent). Comparisons were made by unpaired two sample t-test except ***chi-squared 
test. only 4 women in the control group had an OGTT test. BMI=body mass index; SBP=systolic 
blood pressure and DBP=diastolic blood pressure prior to caesarean section. 
4.4.2 Maternal plasma glucose, lipids, insulin sensitivity and 
markers of liver function 
Plasma glucose and HOMA-IR were significantly higher in the GDM group 
compared to the control group. Maternal third trimester plasma triglycerides at term 
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were significantly higher in women with GDM compared to control (p= 0.045). 
Plasma cholesterol, NEFA and glycerol were not different between groups. Plasma 
levels of liver enzymes GGT, ALT and AST were not different between the groups 
(Table 4-2). 
Table 4-2 Maternal plasma lipids, markers of insulin resistance and liver function test for GDM 
and control groups at third trimester 
   
 
Data are expressed as mean (SD) for continuous variables. Comparisons were made by two sample 
t-test except **Mann-Whitney. HOMA-IR= homeostasis model assessment for insulin resistance, 
NEFA= non-esterified fatty acids, GGT= gamma- glutamyl transferase, ALT= alanine 
aminotransferase, AST= aspartate aminotransferase. *log transformed variable. 
4.4.3 Hepatic steatosis index (HSI) 
In our cohort, HSI was not different between the control and the GDM group 
(39.7[9.6] vs 41.7[9.8], p=0.46) although both groups were classified as high risk. 
HSI correlated positively with maternal BMI in the control group (r=0.86, p=0.0001) 
and the GDM group (r= 0.96, p=0.0001) (Figure 4-1), insulin level in the control 
group (r=0.68, p=0.004) and the GDM group (r= 0.65, p=0.004) (Figure 4-2) and 
HOMA-IR in the control group (r=0.55, p=0.017) and the GDM group (r= 0.70, 
p=0.002) (Figure 4-3). Only in the GDM group was maternal glucose level positively 
correlated with HSI (r= 0.52, p=0.039) (Figure 4-4). 
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Figure 4-1 The relationship maternal BMI and HSI in GDM and control groups 
Maternal BMI correlated positively with HSI in the control and GDM group (control group: r=0.96, 
p=0.0001) (GDM group: r= 0.86, p=0.0001) 
 
 
Figure 4-2 The relationship maternal insulin level and HSI in GDM and control group 
Maternal BMI correlated positively with HSI in the control and GDM group (control group: r=0.68, 
p=0.004) (GDM group: r= 0.65, p=0.004) 
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Figure 4-3 The relationship maternal HOMA-IR and HSI in GDM and control group 
Maternal HOMA-IR correlated positively with HSI in the control and GDM group (control group: 
r=0.70, p=0.017) (GDM group: r= 0.55, p=0.002) 
 
 
Figure 4-4 The relationship maternal glucose level and HSI in GDM and control group 
Maternal BMI correlated positively with HSI in the GDM group only (r= 0.52, p=0.039) 
 
4.4.4 Adipocyte cell size and volume in GDM and healthy 
pregnancy  
4.4.4.1 Subcutaneous adipocytes 
SAT adipocyte diameter was not different between control and GDM pregnancy 
(85.9[12.7] vs 91.9[10.2] µm, p=0.11) (Figure 4-5).  
SAT adipocyte total volume was not different between control and GDM pregnancy 
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volume distribution across the range of cell diameters was investigated to examine 
whether how much lipid was stored in cells of different diameter. SAT total volume 
distribution potentially demonstrated a small shift to the right in GDM group 
compared to control but the mean volume was not different between groups(Figure 
4-6). 
  
Figure 4-5 Subcutaneous adipocyte size distribution in GDM and controls 
There was no difference in mean SAT adipocyte diameter between control and GDM pregnancy 
(GDM: n=22, control: n=22). Comparisons were made using two sample t test and results were 
displayed as mean. 
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Figure 4-6 Subcutaneous adipocyte volume distribution in GDM and controls 
There is no difference in SAT total adipocyte volume in control and GDM pregnancy (GDM: n=22, 
control: n=22). However, SAT volume distribution was slightly shifted to the right in GDM compared 
to control group. Comparisons were made using two sample t test and results were displayed as 
mean. 
4.4.4.2 Visceral adipocytes  
VAT adipocyte diameter was significantly larger in the GDM group compared to the 
control group ((control) 62.9[3.8] vs (GDM) 75.5[11.6] µm, p=0.004) (Figure 4-7). 
Similarly, VAT adipocyte total volume was greater in GDM compared to control 
group ((control) 0.00007[0.00000002] vs (GDM) 0.00012[0.0000005] mm3, 
p=0.003) (Figure 4-8). GDM VAT adipocyte volume distribution showed a clear shift 
to the right compared to controls hence the mean volume was different between 
groups (Figure 4-8).  
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Figure 4-7 Visceral adipocyte size distribution in GDM and controls 
VAT adipocyte diameter in GDM group was significantly larger than control group (p=0.004) (GDM: 
n=22, control: n=22). Comparisons were made using two sample t test and results were displayed 
as mean. 
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Figure 4-8 Visceral adipocyte volume distribution in GDM and controls 
VAT adipocyte volume was significantly greater in GDM compared to control group (p= 0.003) (GDM: 
n=22, control: n=22). Similarly, VAT volume distribution was shifted to the right in GDM compared to 
control group. Comparisons were made using two sample t test and results were displayed as mean. 
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4.4.5 In vitro adipocyte lipolysis in GDM and in healthy pregnancy 
4.4.5.1 In vitro SAT adipocyte lipolysis in GDM compared to healthy 
pregnancy 
Isoprotenerol (200nM) significantly stimulated basal total and net lipolysis rate in 
SAT adipocytes from GDM and control groups (p<0.0001). Insulin (10nM) 
significantly suppressed basal total and net lipolysis rate in SAT adipocytes from 
GDM and control groups (p<0.0001). 
There was no difference in basal SAT lipolysis between isolated adipocytes from 
GDM and controls when expressed as either total lipolysis (0.12[0.11] vs 0.16[0.13] 
glycerol mmol/hr/ug of DNA, p=0.10) (Figure 4-9) or net lipolysis (0.24[0.44] vs 
0.58[0.44] NEFA mmol/hr/ug of DNA, p=0.33) (Figure 4-10). Similarly, lipolysis rates 
in the presence of 200nM isoprotenerol were not different between GDM and 
controls when expressed as either total lipolysis (0.36[0.23] vs 0.42[0.19] glycerol 
mmol/hr/ug of DNA, p=0.18) (Figure 4-9) or net lipolysis (0.24[0.44] vs 0.58[0.44] 
NEFA mmol/hr/ug of DNA, p=0.25) (Figure 4-10). 
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Figure 4-9 Total basal lipolysis and isoprotenerol-stimulated total lipolysis in SAT adipocytes 
from GDM and control groups. 
There was no significant difference in SAT adipocyte total basal or isoprotenerol-stimulated lipolysis 
in GDM compared to the control group (GDM: n=22, control: n=22). Comparisons were made using 
two sample t test on log transformed data and results were displayed as mean (SD). SAT-Basal= 
SAT basal release of glycerol and SAT-ISO= lipolysis rate in presence of 200nM isoproterenol. 
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Figure 4-10 Net basal and net isoprotenerol-stimulated lipolysis in SAT adipocytes from GDM 
and control groups. 
There was no significant difference in SAT adipocyte net basal lipolysis or isoprotenerol-stimulated 
lipolysis in GDM compared to the control group (GDM: n=22, control: n=22). Comparisons were 
made using two sample t test on log transformed data and results were displayed as mean (SD). 
SAT-Basal= SAT basal release of NEFA and SAT-ISO= lipolysis rate in presence of 200nM 
isoprotenerol. 
Basal lipolysis rates in the presence of 10nM insulin were not different between 
GDM and control groups when expressed as either total lipolysis (0.07[0.06] vs 
0.11[0.09] glycerol mmol/hr/ug of DNA, p=0.081) (Figure 4-11) or net lipolysis 
(0.22[0.24] vs 0.39[0.30] NEFA mmol/hr/ug of DNA, p=0.59) (Figure 4-12) release. 
In the presence of both 200nM isoprotenerol and 10nM insulin, lipolysis rates were 
not different between the GDM and the control groups when expressed as either 
total lipolysis (0.28[0.18] vs 0.33[0.18] glycerol mmol/hr/ug of DNA, p=0.27) (Figure 
4-11) or net lipolysis(0.93[0.58] vs 1.13[0.61] NEFA mmol/hr/ug of DNA, p=0.31) 
(Figure 4-12) release. 
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Figure 4-11 Basal total lipolysis, total lipolysis rate in presence of 200nM isoprotenerol, total  
lipolysis rate in the presence of 10nM insulin and total  lipolysis rate in the presence of of 
200nM isoprotenerol  and 10nM insulin conditions in SAT adipocytes from GDM and control 
groups. 
SAT total lipolysis in all experimental conditions was not different between GDM and control group 
(GDM: n=22, control: n=22). Comparisons were made using two sample t tests on log transformed 
data and results were displayed as mean (SD). SAT-Basal= SAT adipocytes basal (unstimulated) 
release of glycerol, SAT-ISO= SAT adipocytes lipolysis rate in presence of 200nM isoprotenerol, 
SAT-INS= SAT adipocytes lipolysis rate in presence of 10nM insulin and SAT-ISO+INS= SAT 
adipocytes lipolysis rate in presence of 200nM isoprotenerol and 10nM insulin.  
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Figure 4-12 Basal net lipolysis, net lipolysis rate in presence of 200nM isoprotenerol, net 
lipolysis rate in presence of 10nM insulin and net lipolysis rate in presence of 200nM 
isoprotenerol  and 10nM insulin conditions measured by NEFA release  in SAT adipocytes 
from GDM and control group. 
SAT adipocytes lipolysis in all experimental conditions was not different between GDM and control 
group (GDM: n=22, control: n=22). Comparisons were made using two sample t test on log 
transformed data and results were displayed as mean (SD). SAT-Basal= SAT adipocytes basal 
(unstimulated) release of NEFA, SAT-ISO= SAT adipocytes lipolysis rate in presence of 200nM 
isoprotenerol, SAT-INS= SAT adipocytes lipolysis rate in presence of 10nM insulin and SAT-
ISO+INS= SAT adipocytes lipolysis rate in presence of 200nM isoprotenerol and 10nM insulin.  
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The percentage stimulation of SAT adipocytes total and net lipolysis by 200nM 
isoprotenerol was not different between the GDM and the control groups (350[279] 
vs 248[206] %glycerol, p=0.36) and  (224[250] vs 215[206] %NEFA, p=0.95) (Figure 
4-13) respectively. 
 
 
 
Figure 4-13 Percentage stimulation of lipolysis by 200nM isoprotenerol expressed as A) total 
lipolysis and B) net lipolysis in SAT adipocytes from GDM and controls 
There was no difference in percentage stimulation of total and net lipolysis by 200nM isoprotenerol 
in SAT adipocytes between GDM and control groups (GDM: n=22, control: n=22). Comparisons were 
made using two sample t test on log transformed data and results were displayed as mean (SD). 
SAT-%ISO= SAT adipocyte percentage stimulation of lipolysis by 200nM isoprotenerol measured by 
glycerol or NEFA release. 
Percentage insulin suppression of SAT adipocyte basal total lipolysis was not 
different between GDM and control groups (33[38] vs 25[33] %glycerol, p=0.27) 
(Figure 4-14). GDM SAT adipocytes had lower percentage insulin suppression of  
net lipolysis than controls but this failed to reach statistical significance (46[36] vs 
21[38] %NEFA, p=0.050) (Figure 4-14). 
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Figure 4-14  Percentage suppression of SAT adipocyte lipolysis by 10nM insulin expressed 
as A) total lipolysis and B) net lipolysis in SAT adipocytes from GDM and controls 
There was no difference in percentage suppression of total lipolysis by 10nM insulin in SAT 
adipocytes between GDM and control groups as expressed by glycerol release. However, the GDM 
group had reduced percentage insulin suppression of net lipolysis compared to controls but failed to 
reach statistical significance (46[36] vs 21[38] %NEFA, p=0.050) (GDM: n=22, control: n=22). For 
glycerol SAT-%INS, comparisons were made using Mann-Whitney test for non-parametric data and 
results were displayed as mean (SD). For NEFA SAT-%INS, comparisons were made using two 
sample t test on log transformed data and results were displayed as mean (SD). SAT-%INS= SAT 
percentage suppression of lipolysis by 10nM insulin measured by glycerol or NEFA release. 
There was no difference in SAT adipocyte FCISI between the GDM and the control 
groups when expressed as total lipolysis (33[23] vs 39[26] FCISI, p=0.83) (Figure 
4-15) or as net lipolysis  (33[23] vs 31[28] FCISI, p=0.51) (Figure 4-15). 
  
 
Figure 4-15 SAT adipocyte FCISI expressed as A) total lipolysis and B) net lipolysis in GDM 
and controls 
There was no difference in SAT adipocyte FCISI between GDM and control groups (GDM: n=22, 
control: n=22). Comparisons were made using Mann-Whitney test and results were displayed as 
mean (SD). SAT-FCISI= SAT adipocyte fat cell insulin sensitivity index measured by glycerol or 
NEFA release. 
4.4.5.2 In vitro VAT adipocyte lipolysis in GDM compared to healthy 
pregnancy 
Isoprotenerol (200nM) significantly stimulated basal total and net lipolysis in VAT 
adipocytes from the GDM and control groups (p<0.0001). Insulin (10nM) 
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suppressed basal total and net lipolysis in VAT adipocytes from GDM and control 
groups (p<0.0001). 
Basal VAT adipocyte total and net lipolysis was significantly higher in the GDM 
compared to the control group (0.02[0.02] vs 0.07[0.07] glycerol mmol/hr/ug of DNA, 
p=0.001) (Figure 4-16) and (0.06[0.07] vs 0.26[0.30] NEFA mmol/hr/ug of DNA, 
p=0.004) (Figure 4-17) respectively. Isoprotenerol-stimulated total and net lipolysis 
was significantly higher in the GDM compared to the control group (0.15[0.13] vs 
0.32[0.34] glycerol mmol/hr/ug of DNA, p=0.014) (Figure 4-16) and (0.50[0.39] vs 
1.09[1.01] NEFA mmol/hr/ug of DNA, p=0.023) (Figure 4-17) respectively. 
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Figure 4-16 Total basal lipolysis and total lipolysis rate in presence of 200nM isoprotenerol in 
VAT adipocytes from GDM and control groups. 
VAT adipocyte total basal and total lipolysis rate in presence of 200nM isoprotenerol were 
significantly higher in the GDM compared to control group (GDM: n=22, control: n=22). Comparisons 
were made using two sample t test on log transformed data and results were displayed as mean 
(SD). VAT-Basal= VAT adipocytes basal release of glycerol and VAT-ISO= VAT adipocytes lipolysis 
rate in presence of 200nM isoprotenerol. 
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Figure 4-17  Net basal lipolysis and net lipolysis rate in presence of 200nM isoprotenerol in 
VAT adipocytes from GDM and control group. 
VAT adipocytes net basal lipolysis and net lipolysis rates in presence of 200nM isoprotenerol was 
significantly greater in GDM compared to control group (GDM: n=22, control: n=22). Comparisons 
were made using two sample t test on log transformed data and results were displayed as mean 
(SD). VAT-Basal= VAT adipocytes basal release of NEFA and VAT-ISO= VAT adipocyets lipolysis 
rate in presence of 200nM isoprotenerol. 
Total lipolysis in the presence of 10nM insulin was significantly higher in the GDM 
compared to the control group (0.03[0.03] vs 0.06[0.07] glycerol mmol/hr/ug of DNA, 
p=0.033) (Figure 4-18) but net lipolysis was not different (0.07[0.10] vs 0.28[0.33] 
NEFA mmol/hr/ug of DNA, p=0.12) (Figure 4-19).  
Isoprotenerol-stimulated total and net lipolysis In presence of 10nM insulin was 
significantly higher in the GDM group compared to the control group  (0.13[0.10] vs 
0.27[0.29] glycerol mmol/hr/ug of DNA, p=0.021) (Figure 4-18) and (0.43[0.31] vs 
0.96[0.91] NEFA mmol/hr/ug of DNA, p=0.010) (Figure 4-19) respectively. 
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Figure 4-18 Total basal lipolysis, total lipolysis in presence of 200nM isoprotenerol, total 
lipolysis in presence of 10nM insulin and total lipolysis in presence of 200nM isoprotenerol  
and 10nM insulin conditions in VAT adipocytes from GDM and control group. 
Lipolysis rate in presence of 10nM insulin only and both 200nM isoprotenerol and 10nM insulin was 
significantly higher in GDM compared to control group (GDM: n=22, control: n=22). Comparisons 
were made using two sample t test on log transformed data and results were displayed as mean 
(SD). VAT-Basal= VAT adipocytes basal release of glycerol, VAT-ISO= VAT adipocytes lipolysis in 
presence of 200nM isoprotenerol, VAT-INS= VAT adipocytes lipolysis in presence of 10nM insulin 
and VAT-ISO+INS= VAT adipocytes lipolysis in presence of 200nM isoprotenerol and 10nM insulin, 
all expressed as glycerol release. 
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Figure 4-19 Net basal lipolysis, net lipolysis in presence of 200nM isoprotenerol, net lipolysis 
in presence of 10nM insulin and net lipolysis rate in presence of 200nM isoprotenerol  and 
10nM insulin conditions in VAT adipocytes from GDM and control group. 
Lipolysis rate in presence of both 200nM isoprotenerol and 10nM insulin was significantly higher in 
GDM compared to control group (GDM: n=22, control: n=22). Comparisons were made using two 
sample t test on log transformed data and results were displayed as mean (SD). VAT-Basal= VAT 
adipocytes basal release of NEFA, VAT-ISO= VAT adipocytes lipolysis in presence of 200nM 
isoprotenerol, VAT-INS= VAT adipocytes lipolysis in presence of 10nM insulin and VAT-ISO+INS= 
VAT adipocytes lipolysis in presence of 200nM isoprotenerol and 10nM insulin. 
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The percentage stimulation of VAT adipocyte total and net lipolysis by 200nM 
isoproterenol is not different between GDM and control groups (729[579] vs 
467[397] %glycerol, p=0.14) and (315[406] vs 230[293] %NEFA, p=1.00) (Figure 
4-20) respectively. 
  
 
Figure 4-20 Percentage stimulation of lipolysis by 200nM isoproterenol expressed as A) total 
lipolysis and B) net lipolysis in VAT adipocytes from GDM and controls 
There is no difference in percentage stimulation of total and net lipolysis by 200nM isoproterenol in 
VAT adipocytes between GDM and control groups (GDM: n=22, control: n=22). Comparisons were 
made using Mann-Whitney test for non-parametric data and results were displayed as mean (SD). 
VAT-%ISO= VAT adipocytes percentage stimulation of lipolysis by 200nM isoproterenol measured 
by glycerol or NEFA release. 
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The percentage suppression by insulin of total and net VAT adipocyte basal lipolysis 
is not different between the GDM and control groups (1[60] vs -4[90] %glycerol, 
p=0.72) and net lipolysis (19[75] vs 9[57] %NEFA, p=0.69) (Figure 4-21) 
respectively.
 
Figure 4-21 The percentage suppression of lipolysis by 10nM insulin expressed as A) total 
lipolysis and B) net lipolysis in VAT adipocytes from GDM and controls 
There is no difference in percentage suppression of total and net lipolysis by 10nM insulin in VAT 
adipocytes between GDM and control group (GDM: n=22, control: n=22). Comparisons were made 
using Mann-Whitney test for non-parametric data and results were displayed as mean (SD). VAT-
%INS= VAT adipocytes percentage suppression of lipolysis by insulin measured by glycerol or NEFA 
release. 
VAT adipocyte FCISI was not different between GDM  and controls when measured 
as total lipolysis (62[204] vs 35[52] FCISI, p=0.61) (Figure 4-22) or net lipolysis 
(64[219] vs 11[32] FCISI, p=0.86) (Figure 4-22). 
  
 
Figure 4-22 VAT adipocytes FCISI expressed as A) total lipolysis and B) net lipolysis in GDM 
and controls 
There is no difference in VAT adipocytes FCISI between GDM and control group (GDM: n=22, 
control: n=22). Comparisons were made using Mann-Whitney test for non-parametric data and 
results were displayed as median (IQR). VAT-FCISI= VAT adipocytes fat cell insulin sensitivity index 
measured by glycerol or NEFA release. 
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4.4.6 Depot specific differences in adipocyte size and lipolysis in 
the healthy control group 
SAT adipocyte diameter was significantly larger than VAT adipocyte diameter in the 
control group ((SAT) 85.9[12.7] vs (VAT) 62.9[13.8] µm, p<0.0001). Similarly, SAT 
adipocyte total volume was greater than VAT adipocytes total volume in the control 
group ((SAT) 0.08[0.03] vs (VAT) 0.03[0.02] mm3, p<0.0001). Regarding the depot 
differences in adipocyte lipolytic function between SAT and VAT in the control group, 
SAT adipocytes had significantly higher basal lipolysis compared to VAT adipocytes 
(Table 4-3). Although control VAT FCISI was double that in SAT adipocytes from 
the control group, it did not reach statistical significance. SAT adipocytes also had 
a higher percent stimulation of lipolysis in response to isoprotenerol that was not 
significant.  
Table 4-3 Lipolysis rates in SAT and VAT adipocytes from healthy pregnancy 
 
 
Data are expressed as mean (SD). Comparisons were made by paired t-test except **Mann-
Whitney. *log transformed variable. 
4.4.7  Depot specific differences in adipocyte size and lipolysis in 
the GDM group 
SAT adipocyte diameter was significantly larger than VAT adipocyte diameter in the 
GDM group ((SAT) 91.9[10.2] vs (VAT) 75.5[11.6] µm, p<0.0001). Similarly, SAT 
adipocyte total volume was greater than VAT adipocyte total volume in the GDM 
group ((SAT) 0.09[0.03] vs (VAT) 0.05[0.02] mm3, p<0.0001). SAT adipocytes had 
significantly higher basal total, but not net, lipolysis compared to VAT adipocytes 
(Table 4-4). VAT FCISI was 67% lower that SAT FCISI for net lipolysis, suggesting 
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that there is a trend for lower NEFA re-esterification in VAT adipocytes compared to 
SAT adipocytes from women with GDM.   
Table 4-4 Lipolysis rates in SAT and VAT adipocytes from GDM pregnancy 
 
 
Data are expressed as mean (SD). Comparisons were made by paired t-test except **Mann-
Whitney. *log transformed variable. 
4.4.8 Relationships between SAT and VAT adipocyte cell size and 
adipocyte characteristics in control and GDM pregnancies 
4.4.8.1 Adipocyte size and maternal BMI 
In controls, higher BMI was associated with larger adipocyte diameter in both SAT 
(SAT diameter: r=0.57, p=0.006: Figure 4-23) and VAT  (VAT diameter: r=0.60, 
p=0.005: Figure 4-24). There was no suggestion of a different relationship of 
adipocyte diameter to BMI in women with GDM compared to controls (interaction 
term GDM*BMI:  SAT p=0.80; VAT p=0.35). 
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Figure 4-23 The relationship between BMI and SAT adipocyte diameter in GDM and control 
groups 
SAT diameter correlated positively with BMI in the control group (r=0.57, p=0.006). There was no 
similar correlation in GDM group (r=0.29, p=0.26) with no suggestion of different relationship between 
BMI and SAT diameter in women with GDM vs controls (interaction term GDM*BMI:  p=0.80)   
 
 
Figure 4-24 The relationship between BMI and VAT adipocyte diameter in GDM and control 
groups 
VAT diameter correlated positively with BMI in the control group (r=0.60, p=0.005). Correlation in 
GDM group (r=0.48, p=0.042) with no suggestion of different relationship between BMI and VAT 
diameter in women with GDM vs controls (interaction term GDM*BMI:  p=0.35)   
 
4.4.8.2 Adipocyte size and insulin sensitivity measures 
SAT adipocyte diameter was not associated with maternal HOMA-IR and insulin 
level in both groups. In contrast, VAT adipocyte diameter was closely related to 
measures of maternal whole body insulin sensitivity including insulin levels (Figure 
4-25) and HOMA-IR (Figure 4-26) in the control and GDM group. There was a 
suggestion of  different relationship between VAT adipocyte diameter and  HOMA-
20 25 30 35 40 45
60
80
100
120
BMI
S
A
T
 d
ia
m
e
te
r 
(u
m
)
Control
GDM
0 20 40 60
0
50
100
150
BMI
V
A
T
 d
ia
m
e
te
r 
(u
m
) Control
GDM
Chapter 4  128 
 
IR in women with GDM compared to controls, but not with insulin level (interaction 
term GDM*insulin level: VAT p=0.22, GDM*HOMA-IR: VAT p=0.12).  
 
Figure 4-25 The relationship between VAT adipocytes diameter and maternal insulin level in 
GDM and control group 
Maternal insulin level correlated positively with VAT adipocytes diameter in the control and GDM 
group (control group: r=0.55, p=0.021) (GDM group: r= 0.61, p=0.022) with no suggestion of different 
relationship between insulin level and VAT diameter in women with GDM vs controls (interaction 
term GDM*insulin level:  p=0.22)   
 
Figure 4-26 The relationship between VAT adipocytes diameter and maternal HOMA-IR in 
GDM and control group 
Maternal HOMA-IR correlated positively with VAT adipocytes diameter in the control and GDM group 
(control group: r=0.51, p=0.037) (GDM group: r= 0.65, p=0.012) with a suggestion of different 
relationship between HOMA-IR and VAT diameter in women with GDM vs controls (interaction term 
GDM*HOMA-IR:  p=0.12)   
 
4.4.8.3 Adipocyte size and maternal plasma lipids (glycerol, NEFA and TAG) 
There was no correlation between SAT and VAT adipocyte diameter and maternal 
plasma NEFA, glycerol and TAG levels in either group. 
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4.4.8.4 Adipocyte size and maternal liver function enzymes (ALT, AST and 
GGT) and hepatic steatosis index 
SAT and VAT adipocyte size was not related to liver enzymes. In controls, higher 
HSI was associated with larger adipocyte diameter in both the SAT (SAT diameter: 
r=0.53, p=0.025: Figure 4-27) and VAT (VAT diameter: r=0.61, p=0.010: Figure 
4-28).  There was no suggestion of a different relationship of adipocyte diameter to 
HSI in women with GDM compared to controls (interaction term GDM*HSI:  SAT 
p=0.26; VAT p=0.47). There were no correlations between SAT and VAT adipocyte 
size and HSI in the GDM group. 
 
Figure 4-27 The relationship between SAT adipocytes diameter and maternal HSI in GDM and 
control group 
SAT diameter correlated positively with HSI in the control group (r=0.53, p=0.025). There was no 
similar correlation in GDM group (r=0.02, p=0.95) with no suggestion of different relationship between 
HSI and SAT diameter in women with GDM vs controls (interaction term GDM*HSI:  p=0.47)   
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Figure 4-28 The relationship between VAT adipocytes diameter and maternal HSI in GDM and 
control group 
VAT diameter correlated positively with HSI in the control group (r=0.61, p=0.010). There was no 
similar correlation in GDM group (r=0.48, p=0.08) with no suggestion of different relationship between 
HSI and VAT diameter in women with GDM vs controls (interaction term GDM*HSI:  p=0.26)   
4.4.8.5 Adipocyte size and pregnancy hormones (estradiol and progesterone) 
There were no correlations between SAT and VAT adipocyte diameter and estradiol 
or progesterone levels in either control or GDM groups.  
4.4.9 Relationships between SAT and VAT adipocyte lipolytic 
function and maternal characteristics in control and GDM 
pregnancies  
4.4.9.1 Adipocyte lipolytic function and maternal characteristics 
The percentage of isoprotenerol stimulation of lipolysis, the percentage suppression 
of insulin suppression of lipolysis and FCISI was not correlated with maternal BMI 
in SAT and VAT adipocytes in both groups. 
4.4.9.2 Adipocyte lipolytic function and maternal insulin sensitivity measures 
In GDM group, higher HOMA-IR, insulin and glucose level was associated with 
lower percentage stimulation of net lipolysis by isoprotenerol SAT depot (HOMA-IR: 
r=-0.79, p=0.001: Figure 4-29) (insulin: r=-0.77, p=0.002: Figure 4-30) (glucose: r=-
0.76, p=0.002: Figure 4-31).  There was no suggestion of a different relationship of 
HOMA-IR, insulin or glucose level to percentage stimulation of net lipolysis by 
isoprotenerol in SAT in women with GDM compared to controls (interaction term 
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GDM*HOMA-IR: p=0.64; GDM*insulin: p=0.95; GDM*glucose: p=0.47). Maternal 
insulin sensitivity measures were not correlated with VAT net lipolysis measures in 
all conditions. There were no correlations between SAT and VAT adipocyte total 
lipolysis rates and measures of insulin sensitivity in both groups. 
 
 
Figure 4-29 The relationship between maternal HOMA-IR and SAT percentage stimulation of 
lipolysis by isoprotenerol expressed as NEFA release in GDM and control group 
Maternal HOMA-IR correlated negatively with SAT percentage stimulation of lipolysis by 
isoprotenerol in the GDM group only (r= -0.79, p=0.001). Correlation in the control group (r=-0.11, 
p=0.65) with no suggestion of different relationship of HOMA-IR to percentage stimulation of net 
lipolysis by isoprotenerol in SAT depot in women with GDM vs controls (interaction term 
GDM*HOMA-IR:  p=0.64)   
 
Figure 4-30 The relationship between maternal insulin level and SAT percentage stimulation 
of lipolysis by isoprotenerol  expressed as NEFA release in GDM and control group 
Maternal insulin level correlated negatively with SAT percentage stimulation of lipolysis by 
isoprotenerol in the GDM group only (r= -0.77, p=0.002). Correlation in the control group (r=-0.15, 
p=0.55) with no suggestion of different relationship of insulin level to percentage stimulation of net 
lipolysis by isoprotenerol in SAT depot in women with GDM vs controls (interaction term 
GDM*insulin:  p=0.95) 
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Figure 4-31 The relationship between maternal glucose level and SAT percentage stimulation 
of lipolysis by isoprotenerol  expressed as NEFA release in GDM and control group 
Maternal glucose level correlated negatively with SAT percentage stimulation of lipolysis by 
isoprotenerol in the GDM group only (r= -0.76, p=0.002). Correlation in the control group (r=-0.39, 
p=0.11) with no suggestion of different relationship of glucose level to percentage stimulation of net 
lipolysis by isoprotenerol in SAT depot in women with GDM vs controls (interaction term 
GDM*glucose:  p=0.47). 
 
4.4.9.3 Adipocyte lipolytic function and maternal plasma lipids (plasma 
glycerol, NEFA and TAG) 
Interestingly, maternal plasma glycerol level was consistently positively correlated 
with SAT lipolytic function including total basal lipolysis (Figure 4-32), total lipolysis 
rate in presence of isoprotenerol (Figure 4-33) and total lipolysis rate in presence of 
both isoprotenerol and insulin (Figure 4-34) in the control group only. This 
association was lacking for SAT in GDM group. However, maternal plasma glycerol 
level was not correlated with SAT net lipolysis in both groups. Maternal plasma 
glycerol level was not correlated with VAT total lipolysis. Maternal NEFA and TAG 
levels was not associated with SAT or VAT adipocyte lipolytic function in both 
groups.  
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Figure 4-32 The relationship between maternal plasma glycerol level and SAT basal release 
of glycerol in GDM and control group 
Maternal plasma glycerol level correlated positively with SAT basal glycerol release in the control 
group only (r=0.52, p=0.028). The correlation in the GDM group (r=-0.21, p=0.49) 
 
Figure 4-33 The relationship between maternal plasma glycerol level and SAT glycerol release 
in presence of isoproterenol in GDM and control group 
Maternal plasma glycerol level correlated positively with SAT glycerol release in presence of 
isoproterenol in the control group only (r=0.58, p=0.011). The correlation in the GDM group (r=-0.15, 
p=0.62) 
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Figure 4-34 The relationship between maternal plasma glycerol level and SAT glycerol release 
in presence of isoproterenol and insulin in GDM and control group 
Maternal plasma glycerol level correlated positively with SAT glycerol release in presence of 
isoproterenol and insulin in the control group only (r=0.62, p=0.006). The correlation in the GDM 
group (r=-0.21, p=0.48) 
 
4.4.9.4 Adipocyte lipolytic function and maternal liver function enzymes (ALT, 
AST and GGT) and hepatic steatosis index 
Liver enzymes including AST, ALT and GGT was not associated with SAT and VAT 
adipocytes lipolytic function in both groups. However, HSI showed a consistent very 
strong positive correlation with SAT adipocytes lipolytic function in GDM group 
including basal lipolysis (Figure 4-35) (Figure 4-36), lipolysis rate in presence of 
isoprotenerol (Figure 4-37) (Figure 4-38), lipolysis rate in presence of insulin (Figure 
4-39) (Figure 4-40) and lipolysis rate in presence of isoprotenerol and insulin (Figure 
4-41) (Figure 4-42) total and net lipolysis release. The percentage of stimulation of 
lipolysis by isoprotenerol and the percentage suppression of lipolysis by insulin of 
SAT and VAT adipocytes was not associated with HSI in both groups. VAT 
adipocytes lipolytic function was not associated with HSI in both groups.  
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Figure 4-35 The relationship between maternal HSI and SAT adipocytes total basal lipolysis 
in GDM and control group 
Maternal HSI correlated positively with SAT adipocytes total basal lipolysis in GDM group only (r= 
0.73, p=0.004). The correlation in the control group (r=0.36, p=0.15) 
 
  
Figure 4-36 The relationship between maternal HSI and SAT adipocytes net basal lipolysis in 
GDM and control group 
Maternal HSI correlated positively with SAT adipocytes net basal lipolysis in GDM group only (r= 
0.79, p=0.001). The correlation in the control group (r=0.20, p=0.45) 
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Figure 4-37 The relationship between maternal HSI and SAT adipocytes total lipolysis in 
presence of 200nM isoproterenol in GDM and control group 
Maternal HSI correlated positively with SAT adipocytes total lipolysis rate in presence of 200nM 
isoprotenerol expressed as glycerol release in GDM group only (r= 0.73, p=0.004). The correlation 
in the control group (r=0.39, p=0.11) 
 
  
Figure 4-38 The relationship between maternal HSI and SAT adipocytes net lipolysis in 
presence of 200nM isoproterenol in GDM and control group 
Maternal HSI correlated positively with SAT adipocytes net lipolysis rate in presence of 200nM 
isoprotenerol expressed as NEFA release in GDM group only (r= 0.73, p=0.005). The correlation in 
the control group (r=0.43, p=0.08). 
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Figure 4-39 The relationship between maternal HSI and SAT adipocytes total lipolysis in 
presence of 10nM  insulin in GDM and control group 
Maternal HSI correlated positively with SAT adipocytes total lipolysis rate in presence of 10nM insulin 
expressed as glycerol release in GDM group only (r= 0.80, p=0.001). The correlation in the control 
group (r=0.44, p=0.09) 
 
  
Figure 4-40 The relationship between maternal HSI and SAT adipocytes net lipolysis in 
presence of insulin in GDM and control group 
Maternal HSI correlated positively with SAT adipocytes net lipolysis rate in presence of 10nM insulin 
expressed as NEFA release in GDM group only (r= 0.87, p=0.0001). The correlation in the control 
group (r=0.31, p=0.39) 
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Figure 4-41 The relationship between maternal HSI and SAT adipocytes total lipolysis in 
presence of 200nM isoproterenol and 10nM insulin in GDM and control group 
Maternal HSI correlated positively with SAT adipocytes total lipolysis rate in presence of 200nM 
isoprotenerol and 10nM insulin expressed as glycerol release in GDM group only (r= 0.81, p=0.001). 
The correlation in the control group (r=0.36, p=0.14) 
 
  
Figure 4-42 The relationship between maternal HSI and SAT adipocytes net lipolysis in 
presence of 200nM isoproterenol and 10nM insulin in GDM and control group 
Maternal HSI correlated positively with SAT adipocytes net lipolysis rate in presence of 200nM 
isoprotenerol and 10nM insulin expressed as NEFA release in GDM group only (r= 0.82, p=0.001). 
The correlation in the control group (r=0.38, p=0.12) 
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4.4.9.5 Adipocyte lipolytic function and pregnancy hormones (estradiol and 
progesterone) 
There was no correlation between progesterone level and SAT lipolytic function in 
both groups. In GDM group, higher progesterone level was associated with lower 
net lipolysis FCISI (progesterone: r=-0.68, p=0.005: Figure 4-43) in VAT depot. 
There was no suggestion of a different relationship of progesterone level to net 
lipolysis FCISI in VAT in women with GDM compared to controls (GDM*VAT net 
lipolysis FCISI: p=0.17). Maternal estradiol level was not associated with adipocytes 
lipolytic function in SAT and VAT in both groups. 
 
 
 
Figure 4-43 The relationship between maternal progesterone level and VAT adipocytes net 
lipolysis FCISI expressed as NEFA release in GDM and control group 
Maternal plasma progesterone level correlated negatively with VAT adipocytes net lipolysis FCISI in 
the GDM group only (r= -0.68, p=0.005). Correlation in the control group (r=0.03, p=0.92) with no 
suggestion of different relationship of progesterone level to net lipolysis FCISI in VAT depot in women 
with GDM vs controls (interaction term GDM*net lipolysis FCISI in VAT:  p=0.17) 
 
4.5 Discussion 
To the best of our knowledge, this is the first study reporting detailed data on 
adipocyte lipolytic function in pregnancies complicated with GDM and exploring the 
relationship between depot-specific adipose tissue phenotype (i.e. adipocyte size 
and lipolysis) and whole-body insulin resistance (HOMA-IR), plasma lipids (TAG, 
NEFA and glycerol) and fatty liver (HSI). A key finding of this study was that in GDM, 
there was a significant increase in VAT adipocyte diameter compared to BMI-
matched healthy controls. This was a surprising finding, as it suggests there is 
significant hypertrophy of VAT adipocytes in response to the metabolic challenge of 
GDM rather than SAT adipocytes hypertrophy as was hypothesised. Contrary to our 
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expectation, VAT adipocytes (rather than SAT) had higher total and net basal 
lipolysis rate in women with GDM compared to the control group. However, FCISI 
was not different in SAT and VAT adipocytes between the GDM and the control 
group.  
Although a 6 µm increase in SAT adipocyte diameter demonstrated a trend towards 
a larger SAT adipocyte in the GDM group compared to the healthy controls, this 
difference was not significant. Under the proposed hypothesis, women with GDM 
were expected to have larger SAT adipocyte diameter, resulting from hypertrophic 
expansion of SAT adipocyte in the face of the metabolic challenge of GDM to store 
excess lipid, consequently leading to adipocyte dysfunction and spill over of fatty 
acids in VAT adipocytes and maybe storage ectopically in other organs resulting in 
systemic insulin resistance and lipotoxicity. The observed increase in VAT adipocyte 
diameter in GDM and the notable shift to the right of VAT adipocyte volume 
distribution suggest that excess lipid is indeed stored in the VAT depot in GDM. 
Possibly we didn’t observe SAT adipocytes hypertrophy because SAT adipocytes 
were already in a state of hypertrophy caused by obesity in our BMI matched control 
group. Therefore, another control group of pregnant women with normal BMI could 
be more informative in drawing conclusion regarding SAT adipocytes size in GDM. 
The observed VAT adipocyte hypertrophy could be a consequence of the limited 
ability of SAT to recruit new adipocytes or to further becoming hypertrophic. Rojas-
Rodriguez et al. (2015) observed similar VAT adipocyte hypertrophy in a smaller 
sample of women (n=5) with GDM compared to healthy pregnant women. The 
previous results suggest that VAT depots are dysfunctional in women with GDM and 
ectopic fat storage might be the consequence.  
Interestingly, in our cohort, maternal BMI was closely related to SAT and VAT 
adipocyte diameter in the control group. The loss of this relationship with SAT 
adipocyte in the GDM group suggests that SAT adipocytes were not able to increase 
in diameter with increasing BMI in the GDM group probably because they are 
already large at each given BMI. Additionally, in our cohort, only VAT adipocyte 
diameter was consistently strongly positively associated with maternal insulin level 
and HOMA-IR in the control and GDM group with significant interactive term of 0.12 
as evidence for a different relationship between control and GDM group. The 
present findings indicate that probably adipocyte hypertrophy in VAT during 
pregnancy in overweight and obese women is associated with whole-body insulin 
Chapter 4  141 
 
resistance. however, the direction of the association cannot be inferred. A similar 
association between VAT hypertrophy and adverse metabolic health was observed 
previously in obese individuals (O'Connell et al., 2010). Moreover, VAT cell size 
increases the total amount of the VAT depot. Although we haven’t measured the 
total size of VAT depot, it was previously shown that VAT thickness measured by 
ultrasound is associated with insulin resistance in early pregnancy (De Souza et al., 
2014) and impaired glucose homeostasis in mid-pregnancy (De Souza et al., 2016) 
(D'Ambrosi et al., 2018) independent of BMI and other risk factors for GDM.  
This study sheds light on the possible aetiological role of defective VAT adipocyte 
expansion in the development of GDM. In this study, several lipolysis measures 
were examined (basal, catecholamine stimulation and insulin suppression of 
lipolysis). Although all measures of lipolysis and SAT FCISI were not different in 
SAT adipocytes in the GDM compared to the control group, both groups had one 
fold lower SAT FCISI net lipolysis when our results were compared with the lean 
control group of a previous similar study conducted by our group on women with PE  
(Huda et al., 2014). The possible explanation for not observing a difference in SAT 
lipolysis between this study groups might be explained by the similar degree of SAT 
adipocytes insulin resistance in both groups due to BMI matching. This is suggesting 
there could be no GDM effect above the obesity effect in SAT adipocytes insulin 
resistance and hypertrophy. Similar to this finding but in non-pregnant T2DM, 
Verboven et al. (2018) observed a similar degree of SAT adipocytes hypertrophy in 
obese men with and without diabetes but this was significantly larger than the mean 
SAT adipocyte diameter of the lean control group in their study. VAT adipocytes in 
GDM were 6 times more insulin resistant compared to control group but failed to 
reach statistical significance probably due to low numbers. This finding was different 
from what our group found previously in PE, in PE there was significant insulin 
resistance in SAT adipocytes compared to healthy women (Huda et al., 2014). PE 
is a metabolic pregnancy complication that shares accelerated insulin resistance 
and poor lipid metabolism handling with GDM. Although PE and GDM are the most 
common metabolic pregnancy complications, it is likely that are both share an 
underlying SAT adipocytes dysfunction but may be at different steps in the 
subsequent pathway. PE is a pregnancy complication with more systemic 
involvement than GDM and SAT adipocytes insulin suppression of lipolysis was 
shown to be defective (Huda et al., 2014). However, GDM is a metabolic 
complication of a milder form than PE with hepatic insulin resistance affecting 
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glucose tolerance. Therefore, the observed VAT adipocyte dysfunction in women 
with GDM in our study could be the missing link between SAT adipocytes and the 
underlying pathophysiology.  
The observed higher basal lipolysis rate in VAT adipocytes in the GDM compared 
to the control group suggests that dysregulation of VAT adipocyte basal lipolysis 
may be an important secondary event to SAT adipocyte hypertrophy contributing to 
the emergence of metabolic dysfunction in women with GDM.  Regarding the 
association between lipolytic function and plasma lipid level, only maternal glycerol 
level was associated with SAT basal lipolysis, lipolysis rate in presence of 
isoprotenerol and lipolysis rate in presence of both isoprotenerol and insulin in the 
control group suggesting that SAT adipocytes glycerol release is an important 
determinant of plasma glycerol level in pregnancy. The maternal plasma NEFA and 
glycerol level was not elevated in the GDM group and did not correlate with HOMA-
IR suggesting that it could be there is a compensatory increase in FA clearance 
from plasma as protective mechanism to reduce the deleterious effects of circulating 
NEFA. 
The adipocyte size and lipolysis results when interpreted together suggest that in 
GDM, in order to store excess lipids which were unable to be stored in SAT 
adipocytes probably due to defective expansion, VAT adipocytes are responding by 
hypertrophy resulting in higher basal lipolysis rates compared to the control group. 
VAT is considered as an alternative depot for fat storage to minimize the deleterious 
effect of circulating NEFA. However, the data does not distinguish whether 
adipocyte dysfunction precedes the insulin resistance in GDM or the opposite. A 
major determinant of metabolic health is SAT’s ability to expand and store excess 
fat safely rather than its accumulation in ectopic sites. Ectopic fat accumulation in 
insulin sensitive organs lead to insulin resistance and T2DM (Ravussin and Smith, 
2002). Thus, it is important to recognize that SAT has a “fat buffering” property, 
which is key to preserving normal level of insulin sensitivity and appropriate 
metabolic responses. 
Data from the current study suggest that expansion of VAT, probably due to 
underlying SAT defective expansion, might lead to consequent ectopic fat 
deposition in other organs (Figure 4-44). Hepatic fat measured by HSI and its 
relationship with adipocyte size during normal or complicated pregnancy was not 
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assessed before in women with GDM. Although HSI was not different between the 
groups, both groups demonstrated high HSI score which could be driven by their 
BMI as we have shown the strong relationship between HSI and BMI. In our cohort, 
HSI is closely related to maternal adiposity and measures of insulin sensitivity in 
normal pregnancy and GDM. Furthermore, SAT and VAT adipocyte diameter was 
closely positively associated with HSI in the control group highlighting the 
importance of adipocyte size as a determinant of metabolic health possibly by 
affecting subsequent lipid deposition in the liver during obese pregnancy following 
adipocytes defective expansion. The strong consistent relationship between HSI 
and SAT lipolytic function in GDM supports the importance of lipid release from SAT 
adipocytes in determining the lipid deposition in the liver and this could be the 
underlying pathophysiology for the previously observed liver insulin resistance in 
GDM pregnancy in several studies (Retnakaran et al., 2011) (Tiikkainen et al., 
2002). A study by Armstrong et al. (2014) represents the first in vivo evidence of 
abdominal SAT dysfunction in the inflammatory form of NAFLD, non-alcoholic 
steatohepatitis (NASH). It was previously reported that the majority of lipid 
accumulation in NASH was attributed to adipose tissue derived NEFA (59%) rather 
than de novo lipogenesis in the liver (26%) (Donnelly et al., 2005). Subcutaneous 
adipose tissue is 10 fold larger than VAT, therefore, it was suggested that there is 
an important SAT mass effect and its lipolytic action compared to VAT. Serum NEFA 
was shown to be strongly related to SAT basal lipolysis in a large cohort of 1066 
subjects (Rydén and Arner, 2017). The previous findings suggest that SAT 
adipocytes may not have a direct impact on metabolic dysfunction, but they still may 
play a key role as the initiating factor in the process of the hypothesized fat overflow 
to ectopic sites. 
VAT adipocyte hypertrophy would be expected to lead to detrimental metabolic 
effects such as fatty liver, possibly due to the drainage of VAT into the portal 
circulation. VAT adipocytes hypertrophy and disturbed adipokine secretion which 
could be transported to the liver through portal circulation may be the link between 
NAFLD and metabolic diseases such as GDM. It was shown in a large population 
study (n=1115) that GDM is strongly associated with non-alcoholic fatty liver 
(NAFLD) disease, and GDM diagnosis could represent an opportunity to prevent the 
development of NAFLD later in life (Ajmera et al., 2016). It was shown that fatty liver 
precedes T2DM in non-pregnant population (Lim et al., 2011). However, similar to 
other parameters of metabolic health, not all women with history of GDM develop 
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NAFLD or T2DM. Other potential sites of ectopic fat deposition such as pancreas, 
heart and placenta are beyond the scope of this study and require further 
investigation.  However, this pathway could be anticipated by the observed maternal 
hypertriglyceridemia in the GDM group in our cohort.   
A limitation of the present study was the cross-sectional design as it will not provide 
information about adipose tissue changes during pregnancy. However, a 
longitudinal design was difficult to perform in pregnant women, especially for VAT 
samples because a repeated intra-abdominal biopsy would be needed to get access 
to adipose tissue, a procedure unlikely to be tolerated by pregnant women. The 
collagenase digestion method was used to obtain mature adipocytes for this study, 
however, it was reported previously that collagenase could lead to small cells 
disruption (Taylor, 1987). Therefore, the same batch of collagenase was used for 
this experiment. Isolated adipocyte lipolytic function may not exactly represent in 
vivo adipose tissue lipolysis because it excludes the extracellular matrix and SVF 
effect. However, in vivo measurement of adipose tissue lipolysis involves 
cumbersome methods such as tracer catheterization which require continuous 
infusion of glucose and glycerol and frequent venous blood sampling which could 
challenging to consent for large sample of pregnant women. Furthermore, this 
technique assesses whole body adipose tissue lipolysis and is not depot specific. 
Another in vivo lipolysis assay is microdialysis, which requires probe insertion in the 
abdomen for minimum of one-centimeter depth and frequent sampling is required 
which can be time consuming and uncomfortable for pregnant women. Furthermore, 
microdialysis allows investigation of SAT only and it is difficult to evaluate VAT 
lipolysis using this technique (Frayn et al., 1997). However, several studies have 
found similar results when SAT lipolysis was compared in vivo (Kolehmainen et al., 
2000) and in vitro (Agustsson et al., 2007). This study involved a small cohort of 
women and there were not enough numbers to look at the effect of GDM treatment 
and glycemic control on adipose tissue lipolysis. The original study was powered for 
30 participants per group but I only managed to collect 22 participants per group, 
which could affect achieving significance level in some of the parameters such as 
FCISI. HSI was used to assess for fatty liver however, liver biopsy is the most 
sensitive measure to assess for fatty liver, but it can be more challenging to perform. 
In this study, it is not possible to exclude the GDM treatment effect on adipose tissue 
function but it was not possible to look at this effect due to relatively small sample 
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of women in each treatment group whether diet only, metformin, insulin or both 
metformin and insulin.  
The strength of this study is the collection of both SAT and VAT samples at 
Caesarean section, while many studies assessing the role of adipose tissue in 
metabolic disease are limited to the study of SAT biopsies obtained by needle or by 
the practicalities and ethics of access to VAT samples. Moreover, access to fat 
samples during intra-abdominal procedures provided us with samples consistently 
biopsied unlike needle biopsy which can provide either superficial or deep SAT 
samples. By design, no differences in age, BMI and most other characteristics 
between the GDM and control groups were observed allowing findings to be 
interpreted independently of BMI and other confounders. The GDM group confirms 
the described metabolic phenotype for pregnancies complicated with GDM. They 
had higher fasting OGTT results with exaggerated hyperlipidemia of pregnancy 
consisting of higher plasma TAG compared to controls. Furthermore, GDM mothers 
were insulin resistant with higher maternal HOMA-IR. As expected, women with 
GDM tend to undergo Caesarean section a couple of days earlier than controls while 
there was no difference in the birthweight between the groups. Adipocyte sizing was 
carried out by two observers and both were blinded to participant grouping. 
In summary, the results of this chapter support the proposed hypothesis of  impaired 
adipose tissue expansion as a component of the underlying pathophysiology of 
GDM (Figure 4-44). An additional adipocyte function component was assessed by 
the study of lipolytic function with observed trend for VAT adipocyte insulin 
resistance in women with GDM. Elevated VAT adipocyte basal lipolysis could be an 
important feature of pregnancies complicated with GDM. VAT adipocytes are 
hypertrophic in women with GDM compared to the healthy BMI matched controls as 
shown in previous study (Rojas-Rodriguez et al., 2015). Although this finding is 
contrary to the proposed hypothesis of SAT adipocytes dysfunction rather than VAT 
adipocytes, but FA accumulation in VAT adipocytes could be a consequence of SAT 
adipocytes dysfunction we did not observe due to BMI matching of the study groups.  
Adding pregnant women with normal weight control group, could enhance our 
understanding of obesity effect on adipocytes and further metabolic disturbance in 
the GDM group. SAT adipocyte lipolytic function was significantly associated with 
the degree of fat in the liver in women with GDM but had no association with other 
metabolic parameters. The immediate consequence of SAT defective storage is 
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outflow of FA to expand the VAT depot or it gets stored in non-adipose tissue organs 
such as the liver. Therefore, longitudinal studies to look at adipose tissue function 
throughout pregnancy are needed, combined with liver ultrasound assessment for 
fatty liver and liver and placenta biopsy at term to assess the evidence for ectopic 
fat deposition in GDM. Studies of a larger cohort of women with GDM would make 
it possible to look at adipose tissue response to GDM treatment. Although placentas 
from GDM pregnancies have been shown to have altered fatty acid composition and 
lipid transporter expression (Segura et al., 2017), an investigation to quantify 
placental lipid storage in GDM compared to controls would be valuable to provide 
evidence for the remaining component of the hypothesised pathway; ectopic fat 
accumulation and any pathological effects it may have on the placenta of women 
with GDM. 
 
Figure 4-44 Regional differences in adipose tissue expansion in GDM 
SAT limited expandability leads to overflow of FA in VAT and other organs such as liver. This possibly 
could lead to rise in plasma lipid level in women with GDM. Adipocytes in VAT depot responded by 
adipocyte hypertrophy and higher basal lipolysis. Increased FA flow in portal circulation could lead 
to fatty liver and increased production of VLDL. Reduced clearance of VLDL particles plasma can 
lead to production of oxLDL. 
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Chapter 5 Adipose tissue inflammation in 
gestational diabetes mellitus 
5.1 Introduction 
Disturbed adipocyte function in the form of adipocyte hypertrophy and enhanced 
basal lipolysis in VAT adipocytes in women with GDM compared to healthy controls 
was observed in the previous chapter. I hypothesised that dysregulated adipokine 
secretion from hypertrophic VAT adipocytes would occur and aimed to examine it in 
this chapter. There is emerging evidence suggesting a role for plasma adipokines 
in the development of insulin resistance and the subclinical inflammation observed 
in women with GDM as discussed in the Introduction Chapter section 1.7. Plasma 
levels of several adipokines such as TNF-α and IL-6 were found to be elevated in 
women with GDM (Christian and Porter, 2014). Adipose tissue has been suggested 
as a source of higher plasma inflammatory cytokine levels in women with GDM. 
While most of the published literature has been about the dysregulated inflammatory 
cytokines markers, direct measurement of adipocytes cytokine secretion was not 
studied before in GDM. Moreover, the underlying mechanism for the increased 
inflammatory cytokine release in women with GDM is not completely understood but 
infiltration of immune cells such as macrophages infiltration in adipose tissue was 
one of the suggested mechanisms. 
It was previously identified that GDM is associated with increased macrophage 
infiltration in omental fat (VAT) rather than SAT compared to healthy control 
pregnancy (Harlev et al., 2014). In the same study, omental fat macrophages 
correlated positively with HOMA-IR suggesting that low grade inflammation 
contributes to the development of insulin resistance in GDM. A similar observation 
in non-pregnant centrally obese individuals suggests that, in GDM, there is a similar 
inflammatory stress in the VAT depot. During pregnancy, macrophage phenotype 
shifts from resident M2 anti-inflammatory phenotype to M1 pro-inflammatory 
phenotype which secretes several pro-inflammatory cytokines as discussed in the 
general introduction through activation of the TLR4/NF-ĸB pathway (Shi et al., 
2006). In adipose tissue, hypertrophic adipocytes release FA, which in turn stimulate  
the  TLR4/NF-ĸβ pathway in the macrophages, thus, participating in a deleterious 
paracrine loop between adipocytes and macrophages (Suganami et al., 2009).  
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Proinflammatory stimuli such as LPS and the proinflammatory cytokines such as IL-
6 and TNFα cause phosphorylation of inhibitor NF-ĸB (IĸB) and subsequent 
translocation of the nuclear transcription factor NF-ĸB to the nucleus. Intra-nuclear 
NFKB induces transcription of proinflammatory cytokines such as TNF-α, IL-6, IL-
1β, adhesion molecules such as ICAM-1 and VCAM-1, chemokines such as MCP-
1. However, the adipocyte’s contribution to the previously observed higher plasma 
levels of adipokines (independent of the paracrine effect of SVF and macrophages) 
has not been studied previously in GDM. In women with PE, where isolated SAT 
and VAT adipocyte secretory function was studied in basal and in stimulated 
conditions (in response to 10µM LPS) there was higher VAT adipocyte release of 
TNF-α and IL-6 in response to LPS stimulation (Huda et al., 2017). In the same 
cohort, a negative correlation was noted between TNF-α secretion from VAT 
adipocytes in response to LPS and VAT adipocyte insulin sensitivity suggesting a 
role of adipocyte inflammation, lipolysis and insulin resistance in the development 
of PE (Huda et al., 2017). TNF-α is known to be an important mediator of insulin 
resistance during pregnancy and in women with GDM (Long et al., 2009). 
Furthermore, TNF-α has a potent lipolytic activity possibly through down-regulation 
of perilipin expression (Souza et al., 2003). Therefore, in addition to the previously 
observed higher VAT basal lipolysis in GDM (chapter 4), it is plausible that there 
could be upregulation of adipokine secretion in VAT adipocytes associated with the 
development of GDM, a condition with accelerated maternal insulin resistance and 
higher plasma level of inflammatory markers.  
Adipocyte size is an important determinant of the expression and secretion of 
adipokines from isolated adipocytes (Skurk et al., 2007). In particular, Skurk et al. 
(2007) have suggested that the secretion of pro-inflammatory adipokines such as 
leptin, IL-6, IL-8, TNF-α, MCP-1, IL-1ra, and adiponectin was significantly elevated 
in larger adipocytes compared to small adipocytes and was positively correlated 
with cell size. In addition, there was a decrease of anti-inflammatory IL-10 secretion 
with increasing cell size. Therefore, the observed VAT adipocytes hypertrophy in 
women with GDM could be hypothesised to regulate the expression level of these 
adipokines in isolated VAT adipocytes. 
In adipocytes, exogenous signals such as fatty acids or LPS induce an inflammatory 
response through activation of TLR4 and the associated intracellular pathway NF-
ĸB (Song et al., 2006). Therefore, in the current study LPS was used to mimic 
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inflammation in isolated adipocytes as previously used in Huda et al. (2017). I 
measured the secretion by adipocytes of several proinflammatory cytokines known 
to be induced in response to NF-ĸB activation such as TNFα, IL-6, IL-1β, MCP-1 
and IFN-gamma. Other anti-inflammatory cytokines such as IL-8 and IL-10 and 
growth factors such as VEGF and PIGF were assessed. Adipokine secretion from 
adipocytes treated with or without LPS was measured using the multiplex array 
technology which allowed detection of numerous analytes in small volume of 
sample, while possible analytes to study can be limited by sample volume when 
using traditional ELISA. Limited by the cost of multiplex technology, adipokine 
secretion was studied in VAT adipocytes only due to the previously observed 
adipocyte dysfunction in the previous chapter, otherwise SAT adipokine secretory 
profile will be of great interest. Furthermore, our group’s previous study in GDM 
showed that the inflammatory dysfunction was found primarily in VAT adipocytes 
(Huda et al., 2014). However, due to the late instigation of LPS stimulated 
experiment conditions throughout our fat biopsy collection, a smaller subset from 
the original cohort used in the lipolysis study (GDM n=22 and control n=22) was 
available for the analysis of adipokine secretion experiment (GDM n=15 and control 
n=12) as detailed in the methods section below. 
In the non-pregnant population different adipose tissue depots are known to 
differentially regulate the expression of inflammatory markers, adipokines, and 
several other genes involved in adipocyte differentiation, lipid storage and insulin 
signalling. There are some data available in GDM. The mRNA expression of the 
anti-inflammatory insulin sensitizing agent, adiponectin is reduced in whole adipose 
tissue from both SAT and VAT in pregnancies complicated with GDM (Lappas et 
al., 2005). In GDM VAT samples, there was increased expression of leptin and the 
proinflammatory cytokines IL-6 and IL-8 (Kleiblova et al., 2010). However, the 
contribution of isolated adipocytes rather than whole adipose tissue to the observed 
disturbed adipokine release and subsequent insulin resistance in women with GDM 
has not been studied previously to the best of our knowledge. Whole adipose tissue 
sample inflammatory mediator production is confounded by the presence of immune 
cells, particularly macrophages in the SVF. 
Adipose tissue expands in the face of a requirement to store additional energy by 
increasing lipid storage in existing adipocytes leading to adipocyte hypertrophy or 
by increasing adipocyte differentiation and recruitment of new adipocytes. PPARγ 
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mRNA expression in abdominal SAT tissue samples has been shown to be reduced 
by 38% in pregnant women and 48% in women with GDM compared to non-
pregnant control women group suggesting a reduced SAT adipocyte differentiation 
ability in the face of the metabolic challenge and insulin resistance of pregnancy and 
GDM (Catalano et al., 2002). Furthermore, this was suggested to be part of the 
molecular mechanisms to accelerate fat catabolism to meet the fetal nutritional 
demands. 
In adipocytes, the insulin receptors are essential to transmit insulin effects on 
glucose and lipid metabolism. There are two isoforms of insulin receptor; insulin 
receptor A (IR-A) and insulin receptor B (IR-B) based on alternative splicing of exon 
11. IR-A promotes cell growth while IR-B is the more active isoform in insulin 
signalling and glucose homeostasis (Belfiore et al., 2009). Insulin receptor 
dysfunction has been implicated in cellular insulin resistance and disturbed 
metabolic function. Few studies have investigated the role of insulin receptor 
different isoforms and its downstream effects on insulin sensitive tissues such as 
muscle and SAT. In women with GDM, there was reduced mRNA expression levels 
of IRB in both SAT and VAT whole tissue samples compared to healthy pregnant 
women. However, this was more pronounced in VAT and the reduction of IRB was 
independent of maternal BMI (Ott et al., 2018). The depot specific regional variation 
of adipocytes insulin receptors isoform expression in women with GDM was not 
studied before to the best of our knowledge.  
Various metabolic pathways are involved in the development of metabolic 
disturbances in women with GDM. The adipocytes intracellular mechanisms 
responsible for insulin suppression of lipolysis are initiated when insulin bind to its 
receptor resulting in tyrosine phosphorylation of insulin receptor substrate 1 (IRS1) 
by insulin receptor tyrosine kinase. Tyrosine phosphorylated IRS1 activates 
phosphoinositide 3-kinase (PI3K) (Czech and Corvera, 1999). Insulin activates PI3K 
activity and mediates the activation of protein kinase Akt which subsequently 
phosphorylates and activates cAMP-phosphodiesterase (PDE3B)(Okada et al., 
1994). This kinase is activated by insulin through binding to insulin receptors 
(PDE3B is the substrate) thus, initiating the antilipolytic effect of insulin. The 
PI3K/AKT pathway further stimulates the translocation of GLUT4 vesicles to the 
plasma membrane and allows the uptake of glucose into the adipose cells. In GDM, 
defective post receptor insulin signalling was suggested in several studies. Studies 
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on adipose and muscle tissue from pregnant GDM women revealed that there was  
defective post-receptor insulin signalling  demonstrated as reduced IRS1 activity 
(Friedman et al., 1999). The protein expression of IRS1 was 43% lower in abdominal 
SAT whole tissue  from women with GDM compared to healthy pregnant controls 
(Catalano et al., 2002). In addition, reduced GLUT4 translocation to plasma 
membrane was demonstrated in women with GDM (Garvey et al., 1993). 
The changes in lipid and glucose metabolism during GDM pregnancy is consistent 
with increased maternal insulin resistance leading to increased FA and TAG 
availability for the fetus (Colomiere et al., 2010). Offspring of GDM mothers were 
shown to have greater risk of obesity and insulin resistance later in life (Catalano et 
al., 2003). Therefore, further understanding adipose tissue lipid metabolism and 
function has become increasingly important in the light of rising obesity and GDM 
incidence. Furthermore, the differential expression of genes involved in other 
adipose tissue functions such as adipose tissue angiogenesis and adipocyte 
apoptosis was of interest to the current study. 
Microarray analysis of genes was a potential method for assessing differences in 
gene expression between healthy control and GDM adipocytes, but this was not 
accessible due to the particularly expensive cost for adipocytes due to the need for 
pre-amplification step and limited fund availability. Alternatively, to avoid selection 
only of genes already reported previously to be differentially expressed in GDM in 
the literature and to explore new pathways, a number of genes was selected by 
Ingenuity pathway analysis (QIAGEN) (discussed in the Methods Chapter section 
1.5.1) involved in several pathways. To quantitate the mRNA expression of target 
genes Taqman qRT PCR was used.  Messenger RNA was extracted from isolated 
adipocytes from SAT and VAT rather than whole adipose tissue samples to avoid 
the confounding effects of SVF cells including macrophages. Preamplification of 
cDNA targets for gene expression analysis was required due to the very small 
quantity of RNA that can be isolated from adipocytes. The uniformity of 
preamplification of genes of interest was controlled for by A ΔΔ CT method, using 
CDKN1B (the recommended endogenous uniformity reference gene). Calculated 
CT values for the target genes and CDKN1B were obtained for different dilutions of 
pre-amplified and non-pre-amplified cDNA. ΔΔ CT value close to zero indicates 
preamplification uniformity, with values within ±1.5 being acceptable.  The cohort 
used for SAT (GDM n=15 and control n=18) and VAT (GDM n=14 and control n=11) 
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gene expression analysis utilizes samples available from the original cohort of 
lipolysis experiments (GDM n=22 and control n=22). There were some samples not 
available for SAT and VAT gene expression analysis from the original cohort and 
this was limited by smaller fat biopsies provided to the researcher which limited the 
number of adipocytes that could be isolated. Priority was given to lipolysis assays. 
Another frequent reason for missing samples especially in VAT depot, was wound 
closure by the surgeon before remembering to take the VAT sample. 
This study explored the expression of several genes involved in different adipocyte 
functions as shown in Table 5-1. 
Chapter 5  153 
 
Table 5-1 Genes included in gene expression analysis 
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5.2 Aim 
• The aim was to compare visceral adipocyte (VAT) basal and LPS-stimulated 
adipokine release in pregnant women with and without GDM.  
• To compare SAT and VAT adipocyte gene expression of thirty-five genes 
involved in adipose tissue inflammation, adipocyte differentiation, lipid 
storage, insulin signaling, glucose metabolism, angiogenesis, and apoptosis 
in pregnant women with and without GDM. 
5.2.1 Hypotheses 
• Women with GDM have higher levels of VAT adipocyte pro-inflammatory and 
lower anti-inflammatory adipokine release under basal and LPS stimulated 
conditions compared to BMI-matched controls  
• There is enhanced expression of genes involved in inflammation, lipid 
storage and apoptosis in VAT adipocytes in women with GDM compared to 
a BMI-matched control group and gene expression are related to adipocyte 
hypertrophy as assessed by adipocyte diameter. 
• Adipocytes in GDM have lower expression of genes involved in adipocyte 
differentiation, angiogenesis and insulin signaling compared to BMI-matched 
controls. 
5.2.2 Specific research questions 
• Is the release of IL-6, IL-8, IL-10, IL-1,TNF- and adiponectin from VAT 
adipocytes altered in women with GDM compared to control? In basal or LPS 
stimulated conditions? 
• Is basal or LPS stimulated release of MCP-1, VEGF, PlGF and INF-gamma 
from VAT adipocytes altered in women with GDM? 
• How does basal or stimulated VAT adipocyte adipokine release relate to 
adipocyte size and lipolytic function? 
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• How does basal or stimulated VAT adipocyte adipokine release relate to 
maternal BMI, whole body insulin sensitivity or plasma cytokine levels? 
• Is there is reduced SAT and VAT adipocyte insulin receptor expression in 
women with GDM compared to healthy BMI matched controls? Which depot 
is affected more? 
• Is the SAT and VAT adipocyte expression level of adipokines and 
inflammatory markers different in women with GDM compared to healthy 
controls? 
5.3 Methods 
A subgroup of the original cohort outlined in Chapter 2 were used for the adipokine 
secretion from adipocytes experiment (GDM n=15 and control n=12). The study 
participants were recruited as outlined in the Methods Chapter section 2.1.1. 
Adipose tissue samples were processed as outlined in the Methods Chapter 2.2. 
After 2 hours incubation, two aliquots of the medium below the adipocyte 
suspension were collected for later adipokines analysis using multiplex technology 
as outlined in the Methods Chapter section 2.6.2. The analytes (IFN-γ, IL-1β, IL-8, 
IL-6, IL-10, MCP-1, VEGF) were measured in one multiplex kit MILLIPEX Map 
Human Cytokine/Chemokine Magnetic Bead Panel (EMD Millipore, Merck, 
HCYTOMAG-60K). PlGF was measured in a singleplex kit MILLIPEX Map Human 
Cardiovascular Disease (CVD) Magnetic Bead Panel 1 to avoid cross reactivity 
(EMD Millipore, Merck, HCVD1MAG-67K). Adiponectin and TNF-α were measured 
by ELISA due to raw material issue with Merck company. Medium adipokines 
concentrations were corrected for the cell number using DNA concentration in a 
known volume of adipocytes as outlined in the Methods Chapter section 2.2.3 and 
expressed as pg/ml/µg DNA. Due to the expense of these kits and limited funds 
available near the end of the project, adipokine analysis was carried out only for 
VAT samples. For adipokine secretion analysis, paired t test was used to compare 
basal and LPS-stimulated release of adipokines within the same group. Two sample 
t test was used to compare the basal release of adipokines between the GDM and 
control group as well as the LPS stimulated adipokine release between the groups. 
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For gene expression analysis, both SAT (GDM n=15 and control n=18) and VAT 
(GDM n=14 and control n=11) adipocytes gene expression was studied in the 
samples available from the original cohort outlined in chapter 2 (Figure 5-1). 
Isolation of RNA was carried out as outlined in the Methods Chapter section 2.5.2. 
The isolated RNA was then reverse transcribed to cDNA. Preamplification of cDNA 
targets for gene of interest and test of preamplification uniformity was then carried 
out as outlined in the Methods Chapter section 2.5.5. The pre-amplified cDNA was 
quantified using TaqMan technology as outlined in the Methods Chapter section 
2.5.7. This analysis was carried out for both SAT and VAT depot. 
 
 
Figure 5-1 Flowchart for the sample number at lipolysis, adipokine secretions and gene 
expression experiment 
 
The statistical analysis was carried out as outlined in the Methods Chapter section 
2.9. Comparisons were made using unpaired 2 sample student t test on log 
transformed data for the following genes: TNF, IL-6, MCP-1, PTGS2, IGFBP3, 
IGFBP5, CEBPB, TGFβ1, SCD, CIDEC, FOXO1, LPL, INSR, IRA, IRS1, LIPE and 
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ICAM1. Two 2 sample student t test on square root transformed data was used for 
IRB and VEGF genes. Unpaired 2 sample student t test on raw normally distributed 
data for the following genes: IGF-1, PPARG, MAPK8, CD36 and IRS1. Mann-
Whitney test for non-parametric data for the following genes: Akt1, FOS, IGFBP2, 
SREBF1, SLC2A1, PCK1, NOS3, PTGS1, F3, DDIT3 and CASP3 at significance 
level of p value of <0.05. A targeted research question approach was used when 
examining the correlation analysis in adipokine secretions from VAT adipocytes 
experiment. Correlation were considered significant if the p value was <0.010 to 
avoid random associations. 
5.4 Results 
5.4.1 Study participants included for adipocyte adipokine 
secretion experiments 
The study participants had similar BMI and age (Table 5-2). Blood pressure did not 
differ between control and GDM pregnancy. GDM mothers delivered six days earlier 
than controls (p= 0.0009). Women diagnosed with GDM in our cohort undergo 
diagnostic OGTT test in the second trimester of their pregnancy. However, only four 
women in the control group was screened for GDM and the results were negative 
and the test was indicated due to high maternal BMI or family history of diabetes. 
Diagnostic OGTT test results as expected, women in the GDM group had higher 
fasting blood glucose (p= 0.0001) and higher 2 hours OGTT blood glucose 
(p=0.035). Women with GDM had babies of lower birthweight compared to controls 
(p=0.006). This subgroup demographic characteristics were similar to the original 
cohort apart from the tendency of women with GDM to have babies of lower birth 
weight compared to controls. 
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Table 5-2 Demographic characteristics of GDM pregnancies and BMI matched controls for 
adipocyte adipokine secretion experiments 
  
Data are expressed as mean (SD) for continuous variables. Categorical variables are expressed as 
number (percent). Comparisons were made by two sample t-test except ***chi-squared test. 
BMI=body mass index; SBP=systolic blood pressure, DBP=diastolic blood pressure prior to 
caesarean section and OGTT= oral glucose tolerance test. *log transformed variable. 
Maternal third trimester plasma triglycerides were higher in women with GDM 
compared to controls. Plasma cholesterol, NEFA and glycerol level were not 
different between women with GDM and the control group. Similarly, plasma 
glucose and HOMA-IR were not different between GDM and control groups, 
however, this was contrary to what we have observed in the original cohort of 
lipolysis study. Plasma markers of inflammation such as CRP, TNF-, IL-6, oxLDL 
and the anti-inflammatory marker adiponectin were not different between the 
groups(Table 5-3). 
Chapter 5  159 
 
Table 5-3 Maternal lipids, plasma markers of insulin resistance and plasma cytokines for GDM 
and control group 
 
Data are expressed as mean (SD) for continuous variables. Categorical variables are expressed as 
number (percent). Comparisons were made by two sample t-test except **Mann-Whitney. HOMA-
IR= homeostasis model assessment for insulin resistance, NEFA= non-esterified fatty acids, CRP= 
C reactive protein, TNF-alpha= tumour necrosis factor alpha, IL-6= interleukin 6 and oxLDL= oxidized 
low density lipoprotein. *log transformed variable. 
5.4.2 Adipokine release from VAT adipocytes in women with GDM 
compared to controls 
Although statistical difference in plasma cytokines were not detected between 
women with GDM and healthy controls in our cohort, it is possible that there could 
be altered adipokine secretion from adipocytes within the adipose tissue contributing 
to adipose tissue inflammation, in a paracrine action. Therefore, adipocyte adipokine 
secretion was studied in VAT adipocytes. 
5.4.2.1 LPS stimulation of basal lipolysis of SAT and VAT adipocytes in GDM 
compared to controls 
LPS (10μM) significantly stimulated basal net lipolysis in SAT adipocytes from the 
control (p<0.0001) and GDM (p<0.0001) group. Furthermore, SAT adipocytes from 
women with GDM had higher LPS stimulated lipolysis compared to the controls 
(p=0.009) (Figure 5-2). 
In contrast in VAT, adipocyte lipolysis was not stimulated by LPS in both GDM and 
controls.  Both basal (p=0.020) and LPS- stimulated (0.040) lipolysis was higher in 
VAT adipocytes from the GDM group compared to the controls (Figure 5-3).  
Glucose (mmol/L)** 4.38(0.31) 4.96(0.59) 0.07
insulin (uU/ml)* 13.68(4.58) 29.61(24.31) 0.093
HOMA-IR** 2.42(0.95) 3.99(11.80) 0.07
Triglycerides (mmol/L) 2.69(0.65) 2.93(0.77) 0.044
Cholesterol (mmol/L) 6.67(1.31) 5.91(1.15) 0.17
plasma glycerol  (umol/L)** 86.72 (64.1) 89.85(37.32) 0.60
plasma NEFA (mmol/L) 0.83(0.31) 0.84(0.26) 0.91
CRP** (mg/L) 2.66(4.43) 2.32(1.24) 0.53
TNF-alpha** (pg/ml) 1.08(0.22) 0.99(0.20) 0.20
IL-6* (pg/ml) 3.15(2.57) 2.34(1.02) 0.41
oxLDL* (U/L) 16.76(3.27) 14.85(3.51) 0.11
Adiponectin** (ng/ml) 179.5(100.5) 260.0(110.1) 0.53
Plasma marker Control (n=12) GDM (n=15) P-value 
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Figure 5-2: Net basal and net lipolysis rate in presence of LPS expressed as NEFA release in 
SAT adipocytes from GDM and control groups. 
SAT adipocytes net basal lipolysis was significantly stimulated by the presence of LPS in both GDM 
(p<0.0001) and control group (p<0.0001). Comparisons were made using paired two sample student 
t test on log transformed basal lipolysis data and normally distributed raw LPS data. Results were 
displayed as mean (SD).  
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Figure 5-3:  Net basal and net lipolysis rate in presence of LPS expressed as NEFA release in 
VAT adipocytes from GDM and control groups. 
VAT adipocytes net basal lipolysis was not stimulated by the presence of LPS in both GDM and 
control group. Comparisons were made using paired two sample student t test on log transformed 
basal lipolysis data and normally distributed raw LPS data. Results were displayed as mean (SD).  
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5.4.2.2 VAT adipocyte TNF- release in GDM compared to controls 
There was no difference between VAT basal and LPS stimulated release of TNF- 
in the control group (p=0.15). Similarly, there was no difference between VAT basal 
and LPS stimulated release of TNF- in the GDM group (p=0.24). There was no 
difference in VAT basal (p= 0.18) or LPS stimulated (p= 0.36) release of TNF- 
between the GDM and control groups (Figure 5-4). 
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Figure 5-4 Comparison of basal and LPS stimulated release of TNF- in VAT adipocytes 
Secretion of TNF- was not different between basal and LPS stimulated lipolysis in both groups. 
Analysis was carried out on log transformed data by paired t-test. There was no difference in TNF-  
secretion in basal lipolysis between GDM and control group. Similarly, there was no difference in 
TNF-  secretion in LPS stimulated lipolysis between GDM and control group, analysis by two sample 
student t-test on log transformed data. Raw data are presented, and data are expressed as mean 
and SD. 
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5.4.2.3 VAT adipocyte IL-6 release in GDM compared to controls 
There was no difference between VAT basal and LPS stimulated release of IL-6 in 
the control group (p=0.59). Similarly, there was no difference between VAT basal 
and LPS stimulated release of IL-6 in the GDM group (p=0.59). There was no 
difference in VAT basal (p= 0.33) or LPS stimulated (p= 0.40) release of IL-6 
between the GDM and control group (Figure 5-5). 
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Figure 5-5 Comparison of basal and LPS stimulated release of IL-6 in VAT adipocytes 
Secretion of IL-6 was not different between basal and LPS stimulated lipolysis in both groups. 
Analysis by two samples t test on log transformed data. There was no difference in IL-6 secretion in 
basal lipolysis between GDM and control group. Similarly, there was no difference in IL-6 secretion 
in LPS stimulated lipolysis between GDM and control group, analysis by two sample t-test. Raw data 
are presented, and data are expressed as mean and SD. 
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5.4.2.4 VAT adipocyte IL-1 release in GDM compared to controls 
There was no difference between VAT basal and LPS stimulated release of IL-1 in 
the control group (p=0.53). Similarly, there was no difference between VAT basal 
and LPS-stimulated release of IL-1 in the GDM group (p=0.14). There was no 
difference in VAT basal (p= 0.52) or LPS-stimulated (p= 0.36) release of IL-1 
between the GDM and control group (Figure 5-6). 
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Figure 5-6 Comparison of basal and LPS stimulated release of IL-1 in VAT adipocytes  
Secretion of IL-1 was not different between basal and LPS stimulated lipolysis in both groups. 
Analysis by paired t-test was carried out on log transformed data. There was no difference in IL-1 
secretion in basal lipolysis between GDM and control group. Similarly, there was no difference in IL-
1 secretion in LPS stimulated lipolysis between GDM and control group, analysis by two sample 
student t-test on log transformed data. Raw data are presented, and data are expressed as mean 
and SD.   
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5.4.2.5 VAT adipocyte IFN-gamma release in GDM compared to controls 
There was no difference between VAT basal and LPS-stimulated release of IFN-
gamma in the control group (p=0.33). Similarly, there was no difference between 
VAT basal and LPS-stimulated release of IFN-gamma in the GDM group (p=0.26). 
There was no difference in VAT basal (p= 0.44) or LPS-stimulated (p= 0.33) release 
of IFN-gamma between the GDM and control group (Figure 5-7). 
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Figure 5-7 Comparison of basal and LPS stimulated release of IFN-gamma in VAT adipocytes  
Secretion of IFN-gamma was not different between basal and LPS stimulated lipolysis in both groups. 
Analysis by paired t-test was carried out on log transformed data. There was no difference in IFN-
gamma secretion in basal lipolysis between GDM and control group. Similarly, there was no 
difference in IFN-gamma secretion in LPS stimulated lipolysis between GDM and control group, 
analysis by two sample t-test was carried out. Raw data are presented, and data are expressed as 
mean and SD. 
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5.4.2.6 VAT adipocyte MCP-1 release in GDM compared to controls 
There was no difference between VAT basal and LPS-stimulated release of MCP-1 
in the control group (p=0.61). Similarly, there was no difference between VAT basal 
and LPS-stimulated release of MCP-1 in the GDM group (p=0.67). There was no 
difference in VAT basal (p= 0.21) or LPS-stimulated (p= 0.45) release of MCP-1 
between the GDM and control group (Figure 5-8). 
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Figure 5-8 Comparison of basal and LPS stimulated release of MCP-1 in VAT adipocytes  
Secretion of MCP-1 was not different between basal and LPS stimulated lipolysis in both groups. 
Analysis by paired t-test was carried out on log transformed data. There was no difference in MCP-
1 secretion in basal lipolysis between GDM and control group. Similarly, there was no difference in 
MCP-1 secretion in LPS stimulated lipolysis between GDM and control group. Analysis by two 
sample t-test was carried out for (LPS MCP-1) and Mann Whitney test for non-parametric data 
(basal MCP-1). Raw data are presented, and data are expressed as mean and SD. 
  
Chapter 5  166 
 
 
5.4.2.7 VAT adipocyte Adiponectin release in GDM compared to controls 
There was no difference between VAT basal and LPS-stimulated release of 
adiponectin in the control group (p=0.35). In the GDM group, VAT LPS-stimulated 
release of adiponectin was higher compared to basal release (basal: 0.27[0.46] vs 
LPS: 0.43[0.33] pg/ml/ug of DNA, p=0.017). There was no difference in VAT basal 
(p= 0.70) or LPS-stimulated (p= 0.93) release of adiponectin between the GDM and 
control group (Figure 5-9). 
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Figure 5-9 Comparison of basal and LPS stimulated release of adiponectin in VAT adipocytes  
Secretion of adiponectin was significantly increased after LPS stimulation of lipolysis in the GDM 
group (p=0.017) but not in the control group. Analysis was carried by Wilcoxon signed rank test. 
There was no difference in adiponectin secretion in basal lipolysis between GDM and control group. 
Similarly, there was no difference in adiponectin secretion in LPS stimulated lipolysis between GDM 
and control group.  Analysis by two sample t-test was carried out for (LPS adiponectin) and Mann 
Whitney test for non-parametric data (basal adiponectin). Raw data are presented, and data are 
expressed as mean and SD *p 0.05. 
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5.4.2.8 VAT adipocyte IL-8 release in GDM compared to controls 
There was no difference between VAT basal and LPS-stimulated release of IL-8 in 
the control group (p=0.67). Similarly, there was no difference between VAT basal 
and LPS-stimulated release of IL-8 in the GDM group (p=0.13). There was no 
difference in VAT basal (p= 0.68) or LPS-stimulated (p= 0.51) release of IL-8 
between the GDM and control group (Figure 5-10). 
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Figure 5-10 Comparison of basal and LPS stimulated release of IL-8 in VAT adipocytes 
Secretion of IL-8 was not different between basal and LPS stimulated lipolysis in both groups. 
Analysis by Wilcoxon signed rank test was carried out. There was no difference in IL-8 secretion in 
basal lipolysis between GDM and control group. Similarly, there was no difference in IL-8 secretion 
in LPS stimulated lipolysis between GDM and control group., analysis by Mann Whitney test for non-
parametric data was carried out. Raw data are presented, and data are expressed as mean and SD. 
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5.4.2.9 VAT adipocyte IL-10 release in GDM compared to controls 
There was no difference between VAT basal and LPS-stimulated release of IL10 in 
the control group (p=0.41). Similarly, there was no difference between VAT basal 
and LPS-stimulated release of IL-10 in the GDM group (p=0.27). There was no 
difference in VAT basal (p= 0.27) or LPS-stimulated (p= 0.34) release of IL-10 
between the GDM and control group (Figure 5-11). 
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Figure 5-11 Comparison of basal and LPS stimulated release of IL-10 in VAT adipocytes  
Secretion of IL-10 was not different between basal and LPS stimulated lipolysis in both groups. 
Analysis by Wilcoxon signed rank test was carried out. There was no difference in IL-10 secretion in 
basal lipolysis between GDM and control group. Similarly, there was no difference in IL-10 secretion 
in LPS stimulated lipolysis between GDM and control group, analysis by Mann Whitney test for non-
parametric data was carried out. Raw data are presented, and data are expressed as mean and SD. 
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5.4.2.10 VAT adipocyte VEGF release in GDM compared to controls 
There was no difference between VAT basal and LPS-stimulated release of VEGF 
in the control group (p=0.70). Similarly, there was no difference between VAT basal 
and LPS-stimulated release of VEGF in the GDM group (p=0.99). There was no 
difference in VAT basal (p= 0.68) or LPS-stimulated (p= 0.86) release of VEGF 
between the GDM and control group (Figure 5-12). 
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Figure 5-12 Comparison of basal and LPS stimulated release of VEGF in VAT adipocytes  
Secretion of VEGF was not different between basal and LPS stimulated lipolysis in both groups. 
Analysis by paired t-test was carried out on log transformed data. There was no difference in VEGF 
secretion in basal lipolysis between GDM and control group. Similarly, there was no difference in 
VEGF secretion in LPS stimulated lipolysis between GDM and control group analysis by two sample 
t-test was carried out. Raw data are presented, and data are expressed as mean and SD. 
5.4.2.11 VAT adipocyte PlGF release in GDM compared to controls 
There was no difference between VAT basal and LPS-stimulated release of PlGF in 
the control group (p=0.98). Similarly, there was no difference between VAT basal 
and LPS-stimulated release of PlGF in the GDM group (p=0.52). There was no 
difference in VAT basal (p= 0.89) or LPS-stimulated (p= 0.79) release of PlGF 
between the GDM and control group (Figure 5-13). 
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Figure 5-13 Comparison of basal and LPS stimulated release of PIGF in VAT adipocytes  
Secretion of PIGF was not different between basal and LPS stimulated lipolysis in both groups. 
Analysis by paired t-test was carried out on log transformed data. There was no difference in PIGF 
secretion in basal lipolysis between GDM and control group. Similarly, there was no difference in 
PIGF secretion in LPS stimulated lipolysis between GDM and control group. Analysis by two sample 
t-test was carried out. Raw data are presented, and data are expressed as mean and SD. 
5.4.3 Relationship between VAT adipocyte adipokine release and 
VAT adipocyte morphological and lipolytic characteristics 
Several correlation analysis were carried out relating VAT adipocyte adipokine 
release with VAT adipocyte diameter and lipolytic function (basal lipolysis, FCISI, 
percentage stimulation of lipolysis by isoprotenerol and percentage suppression of 
lipolysis by insulin). There were no significant correlations at P<0.010 for any of the 
adipokines except TNF-α. In the control group, VAT FCISI was positively correlated 
with LPS stimulated TNF- release (Figure 5-14).  
Chapter 5  171 
 
 
0 100 200 300 400
0
1
2
3
VAT FCISI NEFA (%)
lo
g
 V
A
T
 L
P
S
 T
N
F
a
lp
h
a
 r
e
le
a
s
e
 (
p
g
/m
l/
u
g
 o
f 
D
N
A
)
Control
GDM
 
Figure 5-14 The relationship between VAT LPS stimulated TNF- release and FCISI in GDM 
and control group 
VAT FCISI expressed as NEFA release correlated positively with LPS stimulated release of TNF- 
in the control group only (r= 0.77, p=0.004). Lower number of data points was noted in both groups 
due to zero release of TNF-α from adipocytes of some study subjects. No interaction p=0.41 
 
5.4.4 Relationship between VAT adipocyte adipokine release and 
maternal BMI and HOMA-IR 
Maternal BMI and HOMA-IR level were not related to VAT adipocyte adipokine 
release in basal (Figure 5-15) or LPS stimulated condition (Figure 5-16) in both 
groups. 
 
Figure 5-15 VAT adipocyte basal adipokine release and maternal BMI and HOMA-IR 
relationship 
 
Adipokine Control GDM Control GDM
VAT basal TNF-α Not sig. Not sig. P=0.019, r=-0.72 Not sig.
VAT basal IL-6 Not sig. Not sig. Not sig. Not sig.
VAT basal IL-1β Not sig. Not sig. Not sig. Not sig.
VAT basal IFN-gamma Not sig. Not sig. Not sig. Not sig.
VAT basal MCP-1 Not sig. Not sig. Not sig. Not sig.
VAT basal adiponectin Not sig. Not sig. Not sig. Not sig.
VAT basal IL-8 Not sig. Not sig. Not sig. Not sig.
VAT basal IL-10 Not sig. Not sig. Not sig. Not sig.
VAT basal VEGF Not sig. Not sig. Not sig. Not sig.
VAT basal PIGF Not sig. Not sig. Not sig. Not sig.
BMI HOMA-IR
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Figure 5-16 VAT adipocyte LPS adipokine release and maternal BMI and HOMA-IR relationship 
 
5.4.5 Relationship between VAT adipocyte adipokine release and 
pregnancy hormones  
Maternal plasma estradiol and progesterone concentrations were not related to 
adipokine release in basal (Figure 5-17) or LPS stimulated condition (Figure 5-18)  
in both groups . 
 
Figure 5-17 VAT adipocyte basal adipokine release and pregnancy hormones relationship 
 
Adipokine Control GDM Control GDM
VAT LPS TNF-α Not sig. Not sig. Not sig. Not sig.
VAT LPS IL-6 Not sig. Not sig. Not sig. Not sig.
VAT LPS IL-1β Not sig. Not sig. Not sig. Not sig.
VAT LPS IFN-gamma Not sig. Not sig. Not sig. Not sig.
VAT LPS MCP-1 Not sig. Not sig. Not sig. Not sig.
VAT LPS adiponectin Not sig. Not sig. Not sig. Not sig.
VAT LPS IL-8 Not sig. Not sig. Not sig. Not sig.
VAT LPS IL-10 Not sig. Not sig. Not sig. P=0.025, r=-0.69
VAT LPS VEGF Not sig. Not sig. Not sig. Not sig.
VAT LPS PIGF Not sig. Not sig. Not sig. Not sig.
BMI HOMA-IR
Adipokine Control GDM Control GDM
VAT basal TNF-α Not sig. Not sig. Not sig. Not sig.
VAT basal IL-6 Not sig. Not sig. Not sig. Not sig.
VAT basal IL-1β Not sig. Not sig. Not sig. Not sig.
VAT basal IFN-gamma Not sig. Not sig. Not sig. Not sig.
VAT basal MCP-1 Not sig. Not sig. Not sig. Not sig.
VAT basal adiponectin Not sig. Not sig. Not sig. Not sig.
VAT basal IL-8 Not sig. Not sig. Not sig. Not sig.
VAT basal IL-10 Not sig. Not sig. Not sig. Not sig.
VAT basal VEGF Not sig. Not sig. Not sig. P=0.012, r=10.72
VAT basal PIGF Not sig. Not sig. Not sig. Not sig.
Esterogen Progesterone
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Figure 5-18 VAT adipocyte LPS adipokine release and pregnancy hormones relationship 
 
5.4.6 Study participants included for adipocyte gene expression 
analysis 
5.4.6.1 SAT adipocyte gene expression experiment 
This subgroup was similar to the original cohort for BMI and age matching between 
the groups. Similarly, the higher plasma TAG and glucose levels in  the GDM group 
compared to controls was previously observed in the original lipolysis study cohort 
(Table 5-4).  
Table 5-4: Demographic characteristics and plasma markers of GDM pregnancies and BMI 
matched controls for SAT adipocytes gene expression experiment 
 
Data are expressed as mean (SD) for continuous variables; median (interquartile range) for *log 
transformed and nonparametric data. Categorical variables are expressed as number (percent). 
Comparisons were made by two sample t-test except **Mann-Whitney. HOMA-IR= homeostasis 
model assessment for insulin resistance and NEFA= non-esterified fatty acids. 
Adipokine Control GDM Control GDM
VAT LPS TNF-α Not sig. Not sig. Not sig. Not sig.
VAT LPS IL-6 Not sig. Not sig. Not sig. Not sig.
VAT LPS IL-1β Not sig. Not sig. Not sig. Not sig.
VAT LPS IFN-gamma Not sig. Not sig. Not sig. Not sig.
VAT LPS MCP-1 Not sig. Not sig. Not sig. Not sig.
VAT LPS adiponectin Not sig. Not sig. Not sig. P=0.046, r=-0.58
VAT LPS IL-8 Not sig. Not sig. Not sig. Not sig.
VAT LPS IL-10 Not sig. Not sig. Not sig. Not sig.
VAT LPS VEGF Not sig. Not sig. Not sig. Not sig.
VAT LPS PIGF Not sig. Not sig. Not sig. Not sig.
Estrogen Progesterone
Age (years) 33.8(5.4) 34.9(5.3) 0.58
BMI (kg/m
2
) 32.1(7.8) 31.8(4.8) 0.89
Glucose (mmol/L)** 4.56(0.37) 5.2(0.9) 0.045
insulin (uU/ml)* 14.8(7.6) 25.9(18.7) 0.075
HOMA-IR** 3.02(1.7) 6.60(5.96) 0.066
Triglycerides (mmol/L) 2.61(0.59) 3.26(0.87) 0.04
Cholesterol (mmol/L) 6.34(1.23) 5.91(1.17) 0.37
plasma NEFA (mmol/L) 0.78(0.33) 0.88(0.27) 0.37
Demographic Control (n=18) GDM (n=15) P-value 
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5.4.6.2 VAT adipocyte gene expression experiment 
This subgroup was similar to the original cohort for BMI and age. Similarly, the 
higher TAG in GDM group compared to controls was previously observed in the 
original lipolysis study cohort. However, this subgroup plasma glucose 
concentration and HOMA-IR was not different between women with GDM and 
controls in contrast to what observed in the original lipolysis study (Table 5-5).  
Table 5-5: Demographic characteristics and plasma markers of GDM pregnancies and BMI 
matched controls for VAT adipocytes gene expression experiment 
 
Data are expressed as mean (SD) for continuous variables; median (interquartile range) for *log 
transformed and nonparametric data. Categorical variables are expressed as number (percent). 
Comparisons were made by two sample t-test except **Mann-Whitney. HOMA-IR= homeostasis 
model assessment for insulin resistance and NEFA= non-esterified fatty acids. 
5.4.7 Gene expression of inflammatory genes in SAT and VAT 
adipocytes from women with GDM compared to controls 
5.4.7.1 TNF 
There was no difference in the percentage expression of TNF mRNA expression 
relative to PPIA between GDM and control groups in either SAT (1.1(0.6) vs 1.1(0.9) 
TNF relative to PPIA percentage expression, p= 0.45) (Figure 5-19) or VAT (2.7(1.3) 
vs 2.3(1.9) TNF relative to PPIA percentage expression, p= 0.19) (Figure 5-20)  
5.4.7.2 IL-6 
There was no difference in the percentage expression of IL-6 mRNA expression 
relative to PPIA between GDM and control groups in either SAT (10.4(8.5) vs 
12.3(12.9) IL-6 relative to PPIA percentage expression, p= 0.96) (Figure 5-19) or 
VAT (28.5(17.4) vs 28.0(18.5) IL-6 relative to PPIA percentage expression, p= 0.75) 
(Figure 5-20). 
Age (years) 33.8(5.4) 34.9(5.3) 0.20
BMI (kg/m
2
) 32.1(7.8) 31.8(4.8) 0.87
Glucose (mmol/L)** 4.56(0.37) 5.2(0.9) 0.059
insulin (uU/ml)* 14.8(7.6) 25.9(18.7) 0.14
HOMA-IR** 3.02(1.7) 6.60(5.96) 0.092
Triglycerides (mmol/L) 2.61(0.59) 3.26(0.87) 0.15
Cholesterol (mmol/L) 6.34(1.23) 5.91(1.17) 0.18
plasma NEFA (mmol/L) 0.78(0.33) 0.88(0.27) 0.97
Demographic Control (n=11) GDM (n=14) P-value 
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5.4.7.3 MCP-1 (CCL2) 
There was no difference in the percentage expression of MCP-1 mRNA expression 
relative to PPIA between GDM and control groups in either SAT (20.9(12.6) vs 
21.7(18.2) MCP-1 relative to PPIA percentage expression, p= 0.81) (Figure 5-19) or 
VAT (43.4(26.3) vs 42.4(2.1) MCP-1 relative to PPIA percentage expression, p= 
0.61) (Figure 5-20).  
5.4.7.4 PTGS2 
There was no difference in the percentage expression of PTGS2 mRNA expression 
relative to PPIA between GDM and control groups in either SAT (1.0(0.7) vs 1.9(2.5) 
PTGS2 relative to PPIA percentage expression, p= 0.21) (Figure 5-19) or VAT 
(5.8(4.1) vs 5.8(5.6) PTGS2 relative to PPIA percentage expression, p= 0.48) 
(Figure 5-20).  
 
Figure 5-19 Gene expression of inflammatory genes in SAT adipocytes in controls and GDM 
group 
Inflammatory genes expression relative to the endogenous control gene PPIA in SAT adipocytes 
from women with GDM (n=15) compared to control group (n=18) analyzed by RT-qPCR. The 
percentage expression of TNF-α, IL-6, CCL2, PTGS2 genes relative to PPIA are shown and are 
expressed as mean (SD). 
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Figure 5-20 Gene expression of inflammatory genes in VAT adipocytes in controls and GDM 
group 
Inflammatory genes expression relative to the endogenous control gene PPIA in VAT adipocytes 
from women with GDM (n=14) compared to control group (n=11) analyzed by RT-qPCR. The 
percentage expression of TNF-α, IL-6, CCL2, PTGS2 genes relative to PPIA are shown and are 
expressed as mean (SD). 
5.4.8 Gene exprssion of genes involved in adipocyte lipolysis 
genes in SAT and VAT adipocytes from women with GDM 
compared to controls 
5.4.8.1 LIPE 
There was no difference in the percentage expression of LIPE mRNA expression 
relative to PPIA between GDM and control groups in either SAT (0.6(0.4) vs 0.5(0.4) 
LIPE relative to PPIA percentage expression, p= 0.55) (Figure 5-21) or VAT 
(1.4(1.1) vs 0.9(0.6) LIPE relative to PPIA percentage expression, p= 0.24) (Figure 
5-22). 
5.4.8.2 ATGL 
There was no difference in the percentage expression of ATGL mRNA expression 
relative to PPIA between GDM and control groups in either SAT (166.9(70.5) vs 
157.6(52.1) ATGL relative to PPIA percentage expression, p= 0.65) (Figure 5-21) 
or VAT (166.5(57.6) vs 209.3(186.5) ATGL relative to PPIA percentage expression, 
p= 0.65) (Figure 5-22). 
5.4.8.3 ADRA2A 
There was no difference in the percentage expression of ADRA2A mRNA 
expression relative to PPIA between GDM and control groups in either SAT (0.2(0.2) 
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vs 0.2(0.08) ADRA2A relative to PPIA percentage expression, p= 0.55) (Figure 
5-23) or VAT (0.1(0.09) vs 0.2(0.07) ADRA2A relative to PPIA percentage 
expression, p= 0.25) (Figure 5-24). 
5.4.8.4 ADRB1 
There was no difference in the percentage expression of ADRB1 mRNA expression 
relative to PPIA between GDM and control groups in either SAT (4.9(2.6) vs 3.4(1.1) 
ADRB1 relative to PPIA percentage expression, p= 0.065) (Figure 5-23) or VAT 
(7.6(2.8) vs 6.7(5.9) ADRB1 relative to PPIA percentage expression, p= 0.18) 
(Figure 5-24). 
5.4.8.5 ADRB2 
There was no difference in the percentage expression of ADRB2 mRNA expression 
relative to PPIA between GDM and control groups in either SAT (20.5(9.1) vs 
18.4(7.9) ADRB2 relative to PPIA percentage expression, p= 0.43) (Figure 5-23) or 
VAT (24.9(7.6) vs 24.9(12.4) ADRB2 relative to PPIA percentage expression, p= 
0.72) (Figure 5-24). 
5.4.8.6 ADRB3 
There was no difference in the percentage expression of ADRB3 mRNA expression 
relative to PPIA between GDM and control groups in either SAT (2.2(2.0) vs 1.6(0.9) 
ADRB3 relative to PPIA percentage expression, p= 0.48) (Figure 5-23) or VAT 
(2.0(2.1) vs 0.9(0.4) ADRB3 relative to PPIA percentage expression, p= 0.26) 
(Figure 5-24). 
Chapter 5  178 
 
LI
PE
0.0
0.2
0.4
0.6
0.8
S
A
T
 G
e
n
e
 E
x
p
re
s
s
io
n
(T
a
rg
e
t/
P
P
IA
 (
%
))
CONTROL
GDM
A
TG
L
0
50
100
150
200
S
A
T
 G
e
n
e
 E
x
p
re
s
s
io
n
(T
a
rg
e
t/
P
P
IA
 (
%
))
CONTROL
GDM
 
Figure 5-21 Gene expression of lipolytic enzymes genes in SAT adipocytes in controls and 
GDM group 
Lipolytic enzymes genes expression relative to the endogenous control gene PPIA in SAT adipocytes 
from women with GDM (n=15) compared to control group (n=18) analyzed by RT-qPCR. The 
percentage expression of LIPE and ATGL genes relative to PPIA are shown and are expressed as 
mean (SD). 
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Figure 5-22 Gene expression of lipolytic enzymes genes in VAT adipocytes in controls and 
GDM group 
Lipolytic enzymes genes expression relative to the endogenous control gene PPIA in VAT adipocytes 
from women with GDM (n=14) compared to control group (n=11) analyzed by RT-qPCR. The 
percentage expression of LIPE and ATGL genes relative to PPIA are shown and are expressed as 
mean (SD). 
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Figure 5-23 Gene expression of adrenoreceptors genes in SAT adipocytes in controls and 
GDM group 
Adrenoreceptors gene expression relative to the endogenous control gene PPIA in SAT adipocytes 
from women with GDM (n=15) compared to control group (n=18) analyzed by RT-qPCR. The 
percentage expression of ADRA2A, ADRB1, ARB2 and ADRB3 genes relative to PPIA are shown 
and are expressed as mean (SD). 
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Figure 5-24 Gene expression of adrenoreceptors genes in VAT adipocytes in controls and 
GDM group 
Adrenoreceptors gene expression relative to the endogenous control gene PPIA in VAT adipocytes 
from women with GDM (n=14) compared to control group (n=11) analyzed by RT-qPCR. The 
percentage expression of ADRA2A, ADRB1, ARB2 and ADRB3 genes relative to PPIA are shown 
and are expressed as mean (SD). 
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5.4.9 Gene expression of genes involved in insulin signaling in 
SAT and VAT adipocytes from women with GDM compared to 
controls 
5.4.9.1 INSR 
There was higher percentage expression of INSR mRNA expression relative to 
PPIA in GDM relative to the control group in SAT (9.0(3.1) vs 11.7(3.7) INSR relative 
to PPIA percentage expression, p= 0.031) (Figure 5-25) and VAT (10.8(3.6) vs 
15.8(5.6) INSR relative to PPIA percentage expression, p= 0.022) (Figure 5-26). 
5.4.9.2 IRA 
There was no difference in the percentage expression of IRA mRNA expression 
relative to PPIA between GDM and control groups in either SAT (3.8(1.7) vs 4.1(1.3) 
IRA relative to PPIA percentage expression, p= 0.38) (Figure 5-25) or VAT (8.9(2.5) 
vs 10.0(5.0) IRA relative to PPIA percentage expression, p= 0.91) (Figure 5-26). 
5.4.9.3 IRB 
There was no difference in the percentage expression of IRB mRNA expression 
relative to PPIA between GDM and control groups in either SAT (21.6(9.8) vs 
23.9(8.4) IRB relative to PPIA percentage expression, p= 0.37) (Figure 5-25) or VAT 
(25.1(6.9) vs 28.3(12.9) IRB relative to PPIA percentage expression, p= 0.54) 
(Figure 5-26). 
5.4.9.4 IRS1 
There was no difference in the percentage expression of IRS1 mRNA expression 
relative to PPIA between GDM and control groups in either SAT (9.1(3.4) vs 7.3(5.6) 
IRS1 relative to PPIA percentage expression, p= 0.45) (Figure 5-25) or VAT 
(7.8(2.9) vs 8.9(10.1) IRS1 relative to PPIA percentage expression, p= 0.71) (Figure 
5-26).  
5.4.9.5 IRS2 
There was no difference in the percentage expression of IRS2 mRNA expression 
relative to PPIA between GDM and control groups in either SAT (39.8(9.2) vs 
47.6(15.5) IRS2 relative to PPIA percentage expression, p= 0.10) (Figure 5-25) or 
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VAT (49.3(11.4) vs 61.3(47.7) IRS2 relative to PPIA percentage expression, p= 
0.97) (Figure 5-26). 
5.4.9.6 AKT1 
There was no difference in the percentage expression of AKT1 mRNA expression 
relative to PPIA between GDM and control groups in either SAT (18.5(3.5) vs 
18.8(3.4) AKT1 relative to PPIA percentage expression, p= 0.59) (Figure 5-25) or 
VAT (14.7(4.8) vs 19.4(14.6) AKT1 relative to PPIA percentage expression, p= 0.37) 
(Figure 5-26).  
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Figure 5-25 Gene expression of insulin signaling genes in SAT adipocytes from controls and 
GDM group 
Insulin receptors genes expression relative to the endogenous control gene PPIA in SAT adipocytes 
from women with GDM (n=15) compared to control group (n=18) analyzed by RT-qPCR. The 
percentage expression of INSR, IRA, IRB, IRS-1, IRS-2 and AKT1 genes relative to PPIA are shown 
and are expressed as mean (SD). 
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Figure 5-26 Gene expression of insulin signaling genes in VAT adipocytes from controls and 
GDM group 
Insulin receptors genes expression relative to the endogenous control gene PPIA in VAT adipocytes 
from women with GDM (n=14) compared to control group (n=11) analyzed by RT-qPCR. The 
percentage expression of INSR, IRA, IRB, IRS-1, IRS-2 and AKT1 genes relative to PPIA are shown 
and are expressed as mean (SD). 
 
5.4.10 Gene expression of glucose metabolism genes in SAT 
and VAT adipocytes from women with GDM compared to 
controls 
5.4.10.1 PCK1 
There was no difference in the percentage expression of PCK1 mRNA expression 
relative to PPIA between GDM and control groups in either SAT (19.3(33.6) vs 
45.9(66.9) PCK1 relative to PPIA percentage expression, p= 0.12) (Figure 5-27) or 
VAT (2.2(7.0) vs 8.9(27.3) PCK1 relative to PPIA percentage expression, p= 0.11) 
(Figure 5-28).  
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Figure 5-27 Gene expression of glucose metabolism genes in SAT adipocytes from controls 
and GDM group 
Glucose metabolism genes expression relative to the endogenous control gene PPIA in SAT 
adipocytes from women with GDM (n=15) compared to control group (n=18) analyzed by RT-qPCR. 
The percentage expression of PCK1 gene relative to PPIA are shown and are expressed as mean 
(SD). 
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Figure 5-28 Gene expression of glucose metabolism genes in VAT adipocytes from controls 
and GDM group 
Glucose metabolism genes expression relative to the endogenous control gene PPIA in VAT 
adipocytes from women with GDM (n=14) compared to control group (n=11) analyzed by RT-qPCR. 
The percentage expression of PCK1 gene relative to PPIA are shown and are expressed as mean 
(SD). 
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5.4.11 Gene expression of adipocyte differentiation genes in 
SAT and VAT adipocytes from women with GDM compared to 
controls 
5.4.11.1 IGF-1 
There was no difference in the percentage expression of IGF-1 mRNA expression 
relative to PPIA between GDM and control groups in either SAT (74.8(20.1) vs 
70.4(20.5) IGF-1 relative to PPIA percentage expression, p= 0.56) (Figure 5-29) or 
VAT (49.5(24.4) vs 54.0(21.4) IGF-1 relative to PPIA percentage expression, p= 
0.65) (Figure 5-30).  
5.4.11.2 PPARG 
There was no difference in the percentage expression of PPARG mRNA expression 
relative to PPIA between GDM and control groups in either SAT (57.9(11.7) vs 
57.4(10.5) PPARG relative to PPIA percentage expression, p= 0.90) (Figure 5-29) 
or VAT (69.6(14.8) vs 58.8(21.9) PPARG relative to PPIA percentage expression, 
p= 0.18) (Figure 5-30).  
5.4.11.3 FOS 
There was no difference in the percentage expression of FOS mRNA expression 
relative to PPIA between GDM and control groups in either SAT (420.1(154.0) vs 
387.8(132.2) FOS relative to PPIA percentage expression, p= 0.65) (Figure 5-29) 
or VAT (441.9(109.9) vs 429.8(237.4) FOS relative to PPIA percentage expression, 
p= 0.20) (Figure 5-30).  
5.4.11.4 IGFBP2 
There was no difference in the percentage expression of IGFBP2 mRNA expression 
relative to PPIA between GDM and control groups in either SAT (1.4(1.0) vs 2.4(2.3) 
IGFBP2 relative to PPIA percentage expression, p= 0.11) (Figure 5-29) or VAT 
(26.5(12.9) vs 44.1(42.4) IGFBP2 relative to PPIA percentage expression, p= 0.82) 
(Figure 5-30).  
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5.4.11.5 IGFBP3 
There was no difference in the percentage expression of IGFBP3 mRNA expression 
relative to PPIA between GDM and control groups in either SAT (20.5(14.1) vs 
38.8(38.2) IGFBP3 relative to PPIA percentage expression, p= 0.051) (Figure 5-29) 
or VAT (56.4(34.8) vs 90.3(84.3) IGFBP3 relative to PPIA percentage expression, 
p= 0.31) (Figure 5-30).  
5.4.11.6 IGFBP5 
There was no difference in the percentage expression of IGFBP5 mRNA expression 
relative to PPIA between GDM and control groups in either SAT (86.4(50.5) vs 
87.7(47.4) IGFBP5 relative to PPIA percentage expression, p= 0.91) (Figure 5-29) 
or VAT (96.5(32.3) vs 123.1(77.1) IGFBP5 relative to PPIA percentage expression, 
p= 0.55) (Figure 5-30).  
5.4.11.7 CEBPB 
There was no difference in the percentage expression of CEBPB mRNA expression 
relative to PPIA between GDM and control groups in either SAT (60.1(30.1) vs 
70.6(27.9) CEBPB relative to PPIA percentage expression, p= 0.17) (Figure 5-29) 
or VAT (63.7(35.4) vs 104.9(86.7) CEBPB relative to PPIA percentage expression, 
p= 0.24) (Figure 5-30).  
5.4.11.8 MAPK8 
There was no difference in the percentage expression of MAPK8 mRNA expression 
relative to PPIA between GDM and control groups in either SAT (1.9(0.4) vs 1.9(0.5) 
MAPK8 relative to PPIA percentage expression, p= 0.89) (Figure 5-29) or VAT 
(2.4(0.5) vs 2.3(0.7) MAPK8 relative to PPIA percentage expression, p= 0.61) 
(Figure 5-30).  
5.4.11.9 TGFβ1 
There was no difference in the percentage expression of TGFβ1 mRNA expression 
relative to PPIA between GDM and control groups in either SAT (1.4(0.7) vs 1.6(0.7) 
TGFβ1 relative to PPIA percentage expression, p= 0.45) (Figure 5-29) or VAT 
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(4.8(2.1) vs 5.3(3.1) TGFβ1 relative to PPIA percentage expression, p= 0.69) 
(Figure 5-30). 
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Figure 5-29 Gene expression of adipocytes differentiation genes in SAT adipocytes from 
controls and GDM group 
Adipocyte differentiation genes expression relative to the endogenous control gene PPIA in SAT 
adipocytes from women with GDM (n=15) compared to control group (n=18) analyzed by RT-qPCR. 
The percentage expression of IGF-1, PPARG, FOS, IGFBP2, IGFBP3, IGFBP5, CEBPB, MAPK8, 
TGFβ1 genes relative to PPIA are shown and are expressed as mean (SD). 
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Figure 5-30 Gene expression of adipocytes differentiation genes in VAT adipocytes from 
controls and GDM group 
Adipocyte differentiation genes expression relative to the endogenous control gene PPIA in VAT 
adipocytes from women with GDM (n=14) compared to control group (n=11) analyzed by RT-qPCR. 
The percentage expression of IGF-1, PPARG, FOS, IGFBP2, IGFBP3, IGFBP5, CEBPB, MAPK8, 
TGFβ1 genes relative to PPIA are shown and are expressed as mean (SD).  
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5.4.12 Gene expression of lipid storage genes in SAT and VAT 
adipocytes from women with GDM compared to controls 
5.4.12.1 SCD 
There was no difference in the percentage expression of SCD mRNA expression 
relative to PPIA between GDM and control groups in either SAT (577.7(219.7) vs 
690.3(297) SCD relative to PPIA percentage expression, p= 0.38) (Figure 5-31) or 
VAT (751.1(327.7) vs 579.3(524.1) SCD relative to PPIA percentage expression, p= 
0.17) (Figure 5-32). 
5.4.12.2 CIDEC 
There was no difference in the percentage expression of CIDEC mRNA expression 
relative to PPIA between GDM and control groups in either SAT (420.5(132.0) vs 
445.4(141.7) CIDEC relative to PPIA percentage expression, p= 0.69) (Figure 5-31) 
or VAT (272.9(94.1) vs 341.7(160.1) CIDEC relative to PPIA percentage expression, 
p= 0.31) (Figure 5-32). 
5.4.12.3 FOXO1 
There was no difference in the percentage expression of FOXO1 mRNA expression 
relative to PPIA between GDM and control groups in either SAT (22.3(7.1) vs 
30.5(19.3) FOXO1 relative to PPIA percentage expression, p= 0.25) (Figure 5-31) 
or VAT (30.7(9.7) vs 33.9(16.8) FOXO1 relative to PPIA percentage expression, p= 
0.95) (Figure 5-32). 
5.4.12.4 SREBF1 
There was no difference in the percentage expression of SREBF1 mRNA 
expression relative to PPIA between GDM and control groups in either SAT 
(24.7(9.4) vs 20.2(9.5) SREBF1 relative to PPIA percentage expression, p= 0.26) 
(Figure 5-31) or VAT (22.5(10.9) vs 33.7(49.9) SREBF1 relative to PPIA percentage 
expression, p= 0.77) (Figure 5-32).  
5.4.12.5 LPL 
There was no difference in the percentage expression of LPL mRNA expression 
relative to PPIA between GDM and control groups in either SAT (394.7(103.1) vs 
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423.7(141.5) LPL relative to PPIA percentage expression, p= 0.64) (Figure 5-31) or 
VAT (382.8(89.2) vs 437.1(279.2) LPL relative to PPIA percentage expression, p= 
0.97) (Figure 5-32). 
5.4.12.6 CD36 
There was no difference in the percentage expression of CD36 mRNA expression 
relative to PPIA between GDM and control groups in either SAT (317.5(71.1) vs 
320.3(83.8) CD36 relative to PPIA percentage expression, p= 0.92) (Figure 5-31) or 
VAT (263.4(71.5) vs 247.9(103.0) CD36 relative to PPIA percentage expression, p= 
0.69) (Figure 5-32).  
5.4.12.7 SLC2A1 
There was no difference in the percentage expression of SLC2A1 mRNA expression 
relative to PPIA between GDM and control groups in either SAT (2.5(0.9) vs 3.9(3.4) 
SLC2A1 relative to PPIA percentage expression, p= 0.14) (Figure 5-31) or VAT 
(7.9(4.6) vs 10.4(7.6) SLC2A1 relative to PPIA percentage expression, p= 0.62) 
(Figure 5-32).  
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Figure 5-31 Gene expression of lipid storage genes in SAT adipocytes from controls and GDM 
group 
Lipid storage genes expression relative to the endogenous control gene PPIA in SAT adipocytes 
from women with GDM (n=15) compared to control group (n=18) analyzed by RT-qPCR. The 
percentage expression of SCD, SLC2A1, CIDEC, FOXO1, SREBF1, LPL and CD36 genes relative 
to PPIA are shown and are expressed as mean (SD). 
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Figure 5-32 Gene expression of lipid storage genes in VAT adipocytes from controls and GDM 
group 
Lipid storage genes expression relative to the endogenous control gene PPIA in VAT adipocytes 
from women with GDM (n=14) compared to control group (n=11) analyzed by RT-qPCR. The 
percentage expression of SCD, SLC2A1, CIDEC, FOXO1, SREBF1, LPL and CD36 genes relative 
to PPIA are shown and are expressed as mean (SD). 
5.4.13  Gene expression of angiogenesis genes in SAT and 
VAT adipocytes from women with GDM compared to controls 
5.4.13.1 VEGFA 
There was no difference in the percentage expression of VEGFA mRNA expression 
relative to PPIA between GDM and control groups in either SAT (71.7(51.7) vs 
90.4(87.9) VEGFA relative to PPIA percentage expression, p= 0.34) (Figure 5-33) 
or VAT (169.4(85.6) vs 166.4(90.5) VEGFA relative to PPIA percentage expression, 
p= 0.88) (Figure 5-34). 
5.4.13.2 ICAM1 
There was no difference in the percentage expression of ICAM1 mRNA expression 
relative to PPIA between GDM and control groups in either SAT (8.8(5.8) vs 
13.2(12.3) ICAM1 relative to PPIA percentage expression, p= 0.46) (Figure 5-33) or 
VAT (36.8(23.8) vs 48.4(38.5) ICAM1 relative to PPIA percentage expression, p= 
0.99) (Figure 5-34). 
5.4.13.3 NOS3 
There was no difference in the percentage expression of NOS3 mRNA expression 
relative to PPIA between GDM and control groups in either SAT (0.5(1.5) vs 0.2(0.2) 
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NOS3 relative to PPIA percentage expression, p= 0.30) (Figure 5-33) or VAT 
(0.8(0.8) vs 1.12(1.04) NOS3 relative to PPIA percentage expression, p= 0.62) 
(Figure 5-34).  
5.4.13.4 PTGS1 
There was no difference in the percentage expression of PTGS1 mRNA expression 
relative to PPIA between GDM and control groups in either SAT (1.0(0.7) vs 1.9(2.5) 
PTGS1 relative to PPIA percentage expression, p= 0.62) (Figure 5-33) or VAT 
(0.9(0.6) vs 0.8(0.7) PTGS1 relative to PPIA percentage expression, p= 0.58) 
(Figure 5-34).  
5.4.13.5 F3 
There was no difference in the percentage expression of F3 mRNA expression 
relative to PPIA between GDM and control groups in either SAT (25.5(6.9) vs 
31.2(17.5) F3 relative to PPIA percentage expression, p= 0.80) (Figure 5-33) or VAT 
(58.9(19.2) vs 58.5(18.9) F3 relative to PPIA percentage expression, p= 0.62) 
(Figure 5-34).  
 
Figure 5-33 Gene expression of angiogenesis genes in SAT adipocytes from controls and 
GDM group 
Angiogenesis genes expression relative to the endogenous control gene PPIA in SAT adipocytes 
from women with GDM (n=15) compared to control group (n=18) analyzed by RT-qPCR. The 
percentage expression of VEGFA, ICAM1, NOS3, PTGS1 and F3 genes relative to PPIA are shown 
and are expressed as mean (SD). 
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Figure 5-34 Gene expression of angiogenesis genes in VAT adipocytes from controls and 
GDM group 
Angiogenesis genes expression relative to the endogenous control gene PPIA in VAT adipocytes 
from women with GDM (n=14) compared to control group (n=11) analyzed by RT-qPCR. The 
percentage expression of VEGFA, ICAM1, NOS3, PTGS1 and F3 genes relative to PPIA are shown 
and are expressed as mean (SD). 
 
5.4.14 Gene expression of apoptosis genes in SAT and VAT 
adipocytes from women with GDM compared to controls 
5.4.14.1 DDIT3  
SAT mRNA expression of DDIT3 was down regulated in the GDM compared to 
control group (6.8(3.2) vs 5.3(3.3) DDIT3 relative to PPIA percentage expression, 
p= 0.041) (Figure 5-35). There was no difference in the percentage expression of 
DDIT3 mRNA expression relative to PPIA between GDM and control groups in VAT 
(7.5(3.4) vs 7.8(8.1) DDIT3 relative to PPIA percentage expression, p= 0.20) (Figure 
5-36). 
5.4.14.2 CASP3 
There was no difference in the percentage expression of CASP3 mRNA expression 
relative to PPIA between GDM and control groups in either SAT (3.7(0.5) vs 3.9(1.3) 
CASP3 relative to PPIA percentage expression, p= 0.48) (Figure 5-35) or VAT 
(4.0(0.9) vs 4.2(2.1) CASP3 relative to PPIA percentage expression, p= 0.72) 
(Figure 5-36).  
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Figure 5-35 Gene expression of angiogenesis genes in SAT adipocytes from controls and 
GDM group 
Apoptosis genes expression relative to the endogenous control gene PPIA in SAT adipocytes from 
women with GDM (n=15) compared to control group (n=18) analyzed by RT-qPCR. The percentage 
expression of DDIT3 and CASP3 genes relative to PPIA are shown and are expressed as mean 
(SD). 
 
Figure 5-36 Gene expression of apoptosis genes in VAT adipocytes from controls and GDM 
group 
Apoptosis genes expression relative to the endogenous control gene PPIA in VAT adipocytes from 
women with GDM (n=14) compared to control group (n=11) analyzed by RT-qPCR. The percentage 
expression of DDIT3 and CASP3 genes relative to PPIA are shown and are expressed as mean 
(SD). 
5.5 Discussion 
The key observation of this study is that VAT adipocytes from women with GDM are 
less responsive to LPS stimulation in terms of NEFA release compared to SAT 
adipocytes in both GDM and control groups. However, against our hypothesis, there 
was no evidence for higher VAT adipocytes inflammatory adipokine release in either 
basal conditions or in response to LPS in GDM compared to controls. On the 
D
D
IT
3
C
A
S
P
3
0
2
4
6
8
S
A
T
 G
e
n
e
 E
x
p
re
s
s
io
n
(T
a
rg
e
t/
P
P
IA
 (
%
))
CONTROL
GDM
*
D
D
IT
3
C
A
S
P
3
0
5
10
15
V
A
T
 G
e
n
e
 E
x
p
re
s
s
io
n
(T
a
rg
e
t/
P
P
IA
 (
%
))
CONTROL
GDM
Chapter 5  194 
 
contrary, there was higher release of adiponectin, an anti-inflammatory agent, from 
VAT adipocytes in response to LPS in women with GDM compared to controls. 
Consistent with the adipokine secretion from VAT adipocytes findings, there was no 
evidence for differential inflammatory gene expression in either SAT or VAT 
adipocytes from GDM compared to controls. Similarly, other genes involved in 
adipocyte differentiation, lipid storage, lipid and glucose metabolism and 
angiogenesis gene expression were not different in GDM compared to control. 
However, there was a higher expression of the insulin receptor gene INSR in both 
SAT and VAT adipocytes from women with GDM compared to controls. In addition, 
the apoptosis gene DDIT3 was downregulated in SAT adipocytes from women with 
GDM compared to controls.  
In this study, VAT adipocyte inflammatory cytokine release was not responsive to 
LPS stimulation in either GDM or controls. It has previously been observed in lean 
non-pregnant women that SAT explants demonstrated a greater sensitivity to LPS 
induced NF-ĸB activation whereas VAT explants were only mildly responsive to LPS 
(Vatier et al., 2012). Higher SAT sensitivity to LPS  led  to reduced NEFA re-
esterification and increased FA release, potentially resulting in the expansion of VAT 
and ectopic fat deposition in other organs (Vatier et al., 2012). Furthermore, the 
expression of TLR4 in adipocytes from different depots was not studied previously. 
The lack of response to LPS in VAT adipocytes may indicate a lack of TLR4 
receptors.  Our previous study in PE showed that VAT adipocytes were responsive 
to LPS stimulation in terms of  higher release of TNF-α and IL-6 in PE compared to 
controls, a phenomena that were not seen in SAT adipocytes in PE (Huda et al., 
2017). A potential explanation could be that in PE SAT adipocytes are insulin 
resistant (Huda et al., 2014) leading to VAT expansion and progression of 
inflammatory VAT adipocytes demonstrating higher sensitivity to LPS and possibly 
contributing to ectopic fat. However, in VAT adipocytes of GDM women, we have 
not observed higher release of inflammatory adipokines in response to LPS. It could 
be that GDM is a metabolic complication of milder form than PE affecting glucose 
tolerance and increased VAT adipocyte release of FA, rather than inflammatory 
adipokines. However, this conclusion should be drawn with caution due low sample 
number in our study and there was no difference in the metabolic parameters 
between the healthy and GDM group including plasma glucose level and HOMA-IR. 
Therefore, more sample size is needed. Although TNFα secretion in response to 
LPS was one-fold higher in GDM this was not statically significant and was 88% 
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powered. However, there was higher release of adiponectin in response to LPS in 
GDM compared to controls. This release was not correlated with adipocyte diameter 
and does not suggest its related to hypertrophied VAT adipocytes. Probably, the 
higher adiponectin release from VAT adipocytes in our cohort can be related to the 
treatment of GDM with metformin or insulin. Metformin has anti-inflammatory 
properties which are found to be exerted irrespective of the diabetes status 
(Cameron et al., 2016). Furthermore, insulin, another GDM treatment, was found to 
antagonize IL-6 signaling and it has anti-inflammatory effect on 3T3-L1 adipocytes 
(Andersson et al., 2007). Adipokine release from VAT adipocytes was not correlated 
with maternal BMI, HOMA-IR, adipocyte size and lipolytic function. 
The lack of any differences in gene expression of inflammatory genes is consistent 
with our observation of lack of differences in VAT adipocytes adipokine release of 
women with GDM compared to controls. There was no difference in SAT and VAT 
adipocytes inflammatory gene expression including TNF between GDM and 
controls . Dong et al. (2018) have observed increased macrophage infiltration and 
gene expression of TNFα from VAT explants in women with GDM compared to 
pregnant healthy controls. Similarly, Rancourt et al. (2020) recently have shown 
increased gene expression of the inflammatory markers TNFα and suppressor of 
cytokine signaling (SOCS3) in VAT tissue from women with GDM compared to 
healthy pregnant controls. However, the previous studies used whole adipose tissue 
samples rather than isolated adipocytes which are confounded by the demonstrated 
increased VAT macrophage infiltration in GDM. Contrary to our results, increased 
gene expression of IL-6 was demonstrated previously in SAT tissue samples in 
women with GDM compared to controls (Kleiblova et al., 2010).  
Lipolytic activity in vitro and in vivo depends on the functional efficiency of lipolytic 
and antilipolytic regulators of lipolysis such as lipases and adrenoreceptors.   
Expression of the lipolysis enzymes ATGL and LIPE were not different between 
GDM and controls in both SAT and VAT adipocytes. Similarly, gene expression of 
lipolytic adrenoreceptors (ADRB1 and ADRB2) and the antilipolytic adrenoreceptor 
(ADRA2A) were not different between GDM and controls in both SAT and VAT 
adipocytes. However, although the gene expression of ADRB3 was one-fold lower 
in VAT adipocytes in GDM compared to controls, this was not statically significant 
with 78% power. These results did not explain the observed higher VAT adipocytes 
basal lipolysis in GDM compared to controls (Chapter 4), however, other changes 
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at protein or receptor activity level cannot be ruled out. Furthermore, other 
underlying mechanisms such as the role perilipin1 and other lipid droplet associated 
proteins have not explored in this project. Gene expression of perilipin1 was not 
measured in this study and would be of interest to find out if its expression is related 
to higher VAT adipocyte lipolysis in GDM compared to controls. 
In the insulin signalling pathway, there was higher expression of the insulin receptor 
gene INSR in SAT and VAT adipocytes in GDM compared to controls. Then, using 
the method described by Huang et al. (2011) I designed probes to measure the two 
insulin receptor isoforms IRA and IRB gene expression in order to have a better 
understanding of whether there is a role for a specific isoform in the observed 
increase in INSR expression in SAT and VAT adipocytes in GDM. There was no 
difference in IRA and IRB gene expression in GDM compared to controls in both 
SAT and VAT adipocytes. This is suggesting there is total increase in insulin 
receptors in SAT and VAT adipocytes from women with GDM compared to controls 
without specific increase in one of the insulin receptors isoforms. The higher 
expression of insulin receptors in both SAT and VAT adipocytes in women with GDM 
could be an adaptive mechanism to the accelerated insulin resistance especially for 
IR-B. Furthermore, this possibly could explain why we did not find evidence for VAT 
adipocytes insulin resistance (FCISI) in our cohort in the previous chapter. We also 
cannot rule out the effect of GDM treatment among our treated cohort. The insulin 
sensitizing effects of both metformin (Cameron et al., 2016) and insulin (Das, 2001) 
could contribute to improvement of adipocyte insulin sensitivity and availability of 
insulin receptors. Alterations in INSR splicing are associated with insulin resistance 
and T2DM (Sesti et al., 1991). However, other studies did not show any significant 
alterations in the IRA and IRB expression in various conditions of insulin resistance 
(Moller et al., 1989). The role of the distinct insulin receptors isoforms in the function 
of human adipose tissue is not yet fully understood. Gene expression of insulin 
receptors substrates IRS1 and IRS2 was not different in either SAT or VAT 
adipocytes in GDM compared to control group. However, we did not measure the 
protein level of IRS1 which has been reported previously to be 43% lower in 
abdominal SAT tissue from women with GDM compared to healthy pregnant 
controls (Catalano et al., 2002).This reduction in IRS1 expression was suggested to 
be responsible for the failure of insulin to suppress lipolysis as well as reduced 
insulin-stimulated glucose transport in GDM in adipose tissue. Similarly, in isolated 
SAT adipocytes from T2DM patients, IRS-1 protein expression is markedly reduced 
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in SAT adipocytes, resulting in decreased IRS-1-associated PI3-kinase activity 
(Rondinone et al., 1997). 
Previous studies have shown that the roles of PCK1 in white adipose tissue in 
glyceroneogenesis and re-esterification of FFA to generate TAG are vital for the 
prevention of T2DM (Millward et al., 2010). Glyceroneogenesis is the de novo 
synthesis of glycerol-3-phosphate from gluconeogenic precursors such as pyruvate, 
alanine and lactate.  Glyceroneogenesis is considered to be a shorter version of 
gluconeogenesis that is induced by fasting in both liver and adipose tissue. Each 
glycerol-3-phosphate product is used to esterify three fatty acyl-CoAs to form a 
molecule of TAG as explained in the introduction Chapter. The function of adipose 
tissue glyceroneogenesis is to regulate the release of FAs via a TAG/FA cycle within 
the adipocyte. In the current study, PCK1 gene expression demonstrated a trend for 
higher expression in SAT and VAT adipocytes from GDM compared to controls but 
this was not a statically significant difference in both SAT and VAT. PCK1 encodes 
an essential enzyme involved in the NEFA re-esterification (glyceroneogensis). 
Increased expression of PCK1 decrease serum FA while increasing stored TAG and 
promote obesity. In T2DM, regions near the PCK1 locus on chromosome 20 have 
also been implicated in obesity. Furthermore, mice that overexpress PCK1 in 
adipocytes have reduced circulating FFA levels and normal insulin sensitivity, which 
has been associated with increased fat depots due to enhanced FA re-esterification 
(Franckhauser et al., 2002). The gene expression of the PCK1 was found to be 
reduced in SAT and VAT explants from lean women in response to LPS induced 
inflammation consequently, the FA release during lipolysis was higher, SAT was far 
more sensitive than VAT (Vatier et al., 2012). 
Although the results from the expression analysis of genes involved in adipocyte 
differentiation present no statistically significant difference to support our hypothesis 
of  failure of adipocytes differentiation in GDM, it should be considered that by 
investigating mature adipocytes which are terminally differentiated, as we did in our 
experiment, we may be investigating the wrong stage of the cell. Deficiencies in 
potential for differentiation could be detected in preadipocytes which are present in 
the stromal vascular fraction of the adipose tissue explants. Decreased 
preadipocyte differentiation capacity has been demonstrated in in T2DM (van 
Tienen et al., 2011). To evaluate whether the adipocyte differentiation process is 
impaired in GDM and limiting the hyperplastic expansion of the adipose tissue, it will 
Chapter 5  198 
 
be more valuable to assess preadipocyte gene expression analysis and in vitro 
differentiation capacity in future studies. 
Gene expression of adipogenic and angiogenic genes was not different in both SAT 
and VAT adipocytes in GDM compared to controls. Apoptosis gene expression 
DDIT3 was lower in SAT adipocytes from women with GDM compared to controls. 
Several autophagic genes were found to be down regulated during obesity in non-
pregnant population including Atg7, Atg5 and Ulk1. AMPK positively regulate 
autophagy to decrease the accumulation of mitochondrial ROS by increased 
clearance of dysfunctional mitochondria (Egan et al., 2011). Saturated FA decrease 
AMPK activity leading to defective autophagy response and increased ROS in 
adipocytes (Wen et al., 2011). Thus, the measurement of ROS in the current study 
isolated adipocytes will be an interesting follow on study. 
This study main limitation was the small sample size especially for subgroup 
analysis when we had less than 50% of the proposed n=30 per group. There was 
an inherent difficulties in VAT tissue collection such as the closure of wound by the 
surgeon before remembering to take the VAT samples in the way out.  Furthermore, 
this study was limited by the measurement of adipokine release from one depot 
(VAT adipocytes) rather than both depots (SAT and VAT adipocytes). This was due 
to limited resources. SAT adipocytes adipokine release would be of a great interest 
to reflect if there is underlying SAT adipocyte inflammation. Furthermore, we used 
a GDM treated population therefore, our adipokine release and gene expression 
results could be confounded by this. However, the number of GDM women at each 
treatment category (diet only, metformin only, insulin only and both metformin and 
insulin) were too small to look at statically meaningful analysis for treatment effect. 
Alternatively, we could have used women treated with diet only, but this would have 
lengthen the time period for tissue collection. With regards to gene expression 
analysis, microarray analysis would be of great interest to this project, but we were 
again limited by resource because of the requirement form pre-amplification of 
cDNA. therefore, Ingenuity Pathway Analysis to look for novel genes was chosen 
as an alternative approach. Collection of placenta and cord blood samples would 
have enhanced our results to look at other potential source of inflammation in GDM 
other than adipose tissue but this was not accessible during this project due to 
limited personnel available to handle fresh samples.  
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A particular strength of the present study that to the best of our knowledge this is 
the first study that examined isolated VAT adipocytes adipokine release in both 
basal and LPS stimulated conditions. Furthermore, I used isolated VAT adipocytes 
rather than whole adipose tissue samples to examine adipocyte per se contribution 
to the hypothesized adipose tissue inflammation in women with GDM. The multiplex 
technique was used to look at several adipokines using small volume rather than 
using ELISA to look at different adipokine release which requires larger volume 
which might limit the adipokines we are able to investigate. The differential 
expression of insulin receptors isoforms IRA and IRB has not previously been 
studied in adipocytes from women with GDM.  
In conclusion, although our data present no evidence for VAT adipocytes 
inflammation in women with GDM, however, we had a small sample size in this 
subgroup analysis which might limit our ability to detect significant differences. SAT 
adipocytes adipokines secretion was not studied yet, but gene expression analysis 
did not show that there could be SAT adipocytes contribution to inflammation in 
GDM. Other potential mechanism than inflammation could be underlying adipose 
tissue dysfunction in women with GDM. However, other potential sites such as 
placenta could be contributing to the observed higher inflammatory markers in GDM 
(Feng et al., 2016). 
 
  200 
 
Chapter 6 Maternal VLDL lipid and fatty acid 
composition in early pregnancy 
6.1 Introduction 
The long chain polyunsaturated fatty acids (LC-PUFA), particularly 
docosahexaenoic acid (DHA, 22:6n-3) and arachidonic acid (AA, 20:4n-6) are of 
particular importance in fetal neurological development (Sattar et al., 1998). AA is 
particularly important for the synthesis of eicosanoids, which are involved in the 
development of the fetal nervous, visual, and immune systems (Duttaroy, 2009). 
DHA is a key membrane component of nervous tissue (Parletta et al., 2013). DHA 
is highly concentrated in the fetal brain and retina and is essential for the 
development of the fetal nervous and visual system (Duttaroy, 2009). The 
importance of maternal DHA mobilisation at latter stages of pregnancy are well 
established as demonstrated by the link between premature birth  and 
neurodevelopmental disorders (Johnson et al., 2015).  
During pregnancy, maternal transport of DHA to the rapidly growing fetus via the 
placenta is not very well understood (Freeman and Meyer, 2017). Knowing that the 
first primitive fetal brain cells are formed around 15 days of gestation and that neural 
tube closure occurs at 28 days of gestation, early DHA availability for the growing 
fetus appears to be very critical. The maternal-fetal circulation is established around 
9-13 weeks of gestation to allow transport of nutrients to the growing fetus. The 
placenta has been shown to preferentially transport DHA from the maternal plasma 
to the fetus, suggesting an important role for DHA in fetal development (Al et al., 
1995). However, the precursors of LC-PUFA, linoleic acid (LA, 18:2n6) and alpha-
linolenic acid (ALA, 18:3n-3) are at best minimally transferred to the fetus from 
maternal plasma (De Groot et al., 2004).  
Essential fatty acids derived from maternal diet are transported as TAG in TAG-rich 
lipoproteins in maternal plasma. There is no direct placental transfer of maternal 
lipoproteins and essential FA need to be made available to the fetus (Herrera et al., 
2006). The presence of the scavenger-receptors for VLDL, LDL and HDL allows 
these lipoproteins to be taken up by the placenta. In addition, placental tissue 
expresses LPL activity which may release FA from maternal plasma lipoproteins 
(Haggarty, 2002). Subsequently, the constituent FA of maternal TAG in plasma 
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lipoproteins are re-esterified to synthesize glycerolipids in the fetal circulation 
(Coleman and Haynes, 1987). Subsequent hydrolysis of glycerolipids releases FA 
into fetal plasma, where they bind to the α-fetoprotein and are transported to the 
fetal liver. Although LC-PUFAs may be taken up by the syncytiotrophoblast via 
passive diffusion, the placental plasma membrane fatty acid binding protein 
(pFABPpm), which has a preferential affinity for AA and DHA is also implicated in 
this transport (Araújo et al., 2013). Moreover, intracellular fatty acid binding proteins 
(FABPs) are responsible for guiding FA to their specific intracellular locations 
(Duttaroy, 2009). The exact mechanisms by which these protein carriers facilitate 
the transcellular transport of LC-PUFAs remain not well understood. 
Luteinizing hormone (LH) is hormone secreted by the gonadotropic cells in the 
anterior pituitary gland. LH acute rise (LH surge) in females trigger ovulation. The 
LH surge biologically indicates day zero of pregnancy whereas the clinical day zero 
of pregnancy is taken as the day of the last menstrual period, approximately 14 days 
prior to the LH surge. It was previously shown that the plasma concertation of DHA 
was uniquely increased, compared to other LC-PUFA, prior to 28 day of gestation 
(between 18 and 29 days post-LH surge, in women who had a successful pregnancy 
after frozen embryo transfer (FET)  (Meyer et al., 2016).  This higher DHA 
concentration coincides with the time of neural tube closure at early pregnancy. 
Maternal erythrocyte DHA content, an indicator of maternal DHA plasma 
concentration over the previous three months, was found to be increased by 17% 
at the end of the first trimester (Stewart et al., 2007a). Thus, maternal DHA 
concentrations in plasma and erythrocytes are increased by the end of the first 
trimester and are available for placental transport to the fetus. This could potentially 
be very important for early fetal neurological development.    
The early increase in maternal plasma DHA concentration could be achieved either 
through increased DHA release from maternal stores, increased DHA de novo 
synthesis in the liver or from increased dietary consumption. There are several 
observations from the Meyer et al. (2016) study that suggest there is an increased 
synthesis of DHA from its precursors (ALA) at the critical time of neural tube closure. 
Firstly, the increase in DHA concentration between 18 and 29 days post-LH surge 
was correlated positively with an index of delta-6 desaturase activity (20:3n6/ 18:2n6 
ratio) during this time point only. Secondly, there was a significant 10% reduction in 
plasma LA, the precursor for the n-6 series of LC-PUFA, in those women who 
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became pregnant after FET but not in those who did not, from pre-pregnancy to 18 
days post-LH surge. Together these findings suggest an increased ability to convert 
ALA to DHA in very early pregnancy.  
The main plasma carrier that delivers LC-PUFA in the maternal circulation to the 
placenta is not yet known. DHA is primarily transported on HDL particles in the non-
pregnant population (Augustine et al., 2014). However, during pregnancy, there is 
a three-fold increase in VLDL synthesis by the liver (Huda et al., 2009). Moreover, 
the liver is the primary site for de novo LC-PUFA synthesis which is suggested to 
be increased in early pregnancy (Meyer et al., 2016). Thus, VLDL may be an 
important transporter of plasma LC-PUFA during pregnancy. I hypothesised that in 
pregnancy, as compared to the non-pregnant state, DHA is carried in higher 
concentration than other FA in the VLDL lipoprotein fraction. The assessment of 
maternal FA changes from pre-pregnancy to the first weeks of gestation is difficult 
in a free-living population. Therefore, these changes were assessed in a population 
of women undergoing natural cycle-frozen embryo transfer as a means of achieving 
accurately timed periconceptual sampling. 
6.2 Aim 
The aim of this study was to determine the distribution of fatty acids, particularly 
DHA, in the VLDL plasma fraction prior to pregnancy and throughout early gestation. 
6.2.1 Hypothesis 
1. That pregnant women have higher VLDL particle number compared to non-
pregnant controls. 
2. That pregnant women have VLDL enriched with TAG compared to non-
pregnant controls. 
3. That maternal VLDL is enriched in DHA relative to other FA. 
6.2.2 Specific research questions 
• Is there is an early pregnancy increase in VLDL particle number and/or TAG 
enrichment? 
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• How is VLDL composition related to plasma pregnancy hormone 
concentrations? 
• How does VLDL FA composition change in early pregnancy? 
• Is there DHA enrichment of VLDL in early pregnancy? 
6.3 Methods 
This study utilized plasma samples from an archival collection of women undergoing 
frozen embryo transfer (FET) (Meyer et al., 2016) as discussed in the Methods 
Chapter sections 2.8.1 and 2.8.2. Fasting blood samples were collected 
approximately day 10 after last menstrual period (LMP) (pre-LH surge) and on days 
18, 29, and 45 post-LH surge. Plasma was collected by low-speed centrifugation 
and frozen at -80°C within 2 hours. At day 18 post-LH surge the women who were 
not successful in getting pregnant tended to not come for more study visits and 
withdrew from the study. Therefore, there were no blood samples for non-pregnant 
women at days 29 and 45 post-LH surge. VLDL isolation was carried out by 
sequential density ultracentrifugation as outlined in the Methods Chapter section 
2.8.2.2. VLDL lipoprotein fraction triglyceride (TAG), phospholipid (PL), total 
cholesterol (TC), free cholesterol (FC), apo-B and cholesteryl ester (CE), were 
analysed by autoanalyzer as outlined in Methods Chapter section 2.8.2.3. Apo-B is 
an indicator of VLDL particle number because each VLDL particle contains a single 
molecule of apo-B. VLDL TAG/Apo-B ratio and VLDL CE/Apo-B ratio (VLDL TAG 
and CE concentrations divided by VLDL Apo-B concentration respectively) were 
calculated to express TAG and CE content by VLDL particle number. FA extraction 
was carried out as outlined in the Methods Chapter section 2.8.3. VLDL FA 
composition was analysed by flame-ionization gas chromatography as outlined in 
the Methods Chapter section 2.8.4. 
Data were tested for normal distribution using a Ryan Joiner test and log or square 
root transformed when necessary. Values for continuous variables are given as 
mean (SD) or number (%) for categorical variables. Differences in VLDL apo-B 
concentration, VLDL TG/Apo-B ratio and VLDL CE/Apo-B ratio over time were 
assessed by one-way ANOVA for repeated measures, with between group 
comparison using post hoc Tukey-Kramer honest significant difference (HSD) test. 
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The rate of change of fatty acids between time points was calculated as the 
difference between the fatty acid concentration at the second time point and at the 
first time point divided by the difference in time (days) between the two time points. 
The results are expressed as nmol/mL plasma per day. Incremental area under the 
concentration (pre-LH surge to 45 d post-LH surge) x time curve (iAUC) were 
calculated using the trapezium method for FA change in concentration (Matthews 
et al., 1990). The results are expressed as nmol/mL x day. Differences in 
concentrations of fatty acids over time were assessed by one-way ANOVA for 
repeated measures, with between-group comparison using post-hoc Tukey-Kramer 
HSD. Statistical analysis was performed using Minitab version 18. 
6.4 Results 
6.4.1 Study participants 
A total of 196 FET cycles were started in the original study cohort (Meyer et al., 
2016), of which 161 were completed, from which there were 38 pregnancies: two 
were excluded as being a repeat attempt at FET treatment within the study and nine 
were excluded as they did not have complete data for all visits; therefore, 27 
pregnant women were included. Of the 161 FET cycles completed, there were 123 
failed pregnancies, of which 35 had full fatty-acid data (Figure 6-1). Frozen plasma 
aliquots were available from these n=27 pregnant women and n=35 non-pregnant 
women and were used for the current analysis.  
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Figure 6-1 Consort diagram of the study 
Consort diagram illustrating women enrolled in the study, showing unsuccessful and successful 
pregnancies as well as reasons for withdrawal and exclusions. Taken with the publisher permission 
(pending) from (Meyer et al., 2016) 
The demographic characteristics of the 27 pregnant women and 35 women not 
successful in getting pregnant are shown in Table 6-1. There were no significant 
differences between the two groups of pregnant and non-pregnant women 
entering the study. 
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Table 6-1 Demographic characteristics of the study participants 
 
Values are mean and standard deviation (SD) for continuous variables or number (%) for 
categorical variables. 
6.4.2 Maternal pregnancy hormones, plasma lipids, insulin and 
HOMA-IR 
As expected, the pregnancy hormones estradiol, progesterone and human chorionic 
gonadotropin (HCG) levels rise progressively throughout gestation (Table 6-2). 
Plasma TAG show significant rise at 45 days post-LH surge compared to pre-LH 
levels. Plasma total cholesterol (TC) levels were lower in 18, 29, 45 days post-LH 
surge compared to pre-LH levels. Plasma insulin and HOMA-IR were not changed 
across the study period in pregnant women.  
 
Age at FET (years) 34.5(4.1) 33.6(5.2) 0.81
BMI (kg/m
2
) 26.0(3.7) 26.7(5.2) 0.91
BMI category, n (%) 
Normal weight 12(44.4) 15(42.9)
Overweight 9(33.3) 14(40.0)
Obese 5(18.5) 6(17.1)
SIMD quantiles, n (%)
Q1: least deprived 2(7.4) 8(22.9)
Q2 8(29.6) 8(22.9)
Q3 7(25.9) 5(14.3)
Q4 3(11.1) 5(14.3)
Q5: Most deprived 7(25.9) 9(25.7)
SBP (mmHg) 115.2(14.0) 116.1(11.5) 0.77
DBP (mmHg) 64.4(6.7) 66.4(9.7) 0.21
Smoking, n (%)
Current smoker 3(11.1) 6(17.1)
Non-smoker 24(88.8) 27(77.1)
History of smoking 0(0) 2(5.7)
0.25
0.41
Demographic Pregnant  (n=27)
non-pregnant 
(n=35)
P-value 
0.32
 
 
Table 6-2 Maternal pregnancy hormones, plasma lipids, insulin and HOMA, mean (SD) across the study period (from pre-LH surge to 45 days post-LH surge). 
 
Values are mean and standard deviation (SD) for continuous variables or number (%) for categorical variables. a,b indicate differences between individual groups using 
post-hoc Tukey-Kramer at significance level P < .05, there is a significant difference where superscript letters are different and where superscript letters are shared there is 
no difference. # log transformed * square root transformed variable.
Plasma variable Pre-LHS P 18 Days Post-LHS P 29 Days Post-LHS P 45 Days Post-LHS P P  value P
Estradiol (pmol/L)* 594(482)
a
820(344)
b
1473(584)
b,c
3701(2110)
c <0.0001
Progesterone (nmol/L)* 0.53(1.28)
a
73.65 (39.16)
a
66.84 (25.62)
a
64.69(17.50)
b <0.0001
HCG (IU/L) 0 (0)
a
686(602)
b
21706(13541)
b
102046(60756)
b <0.0001
Plasma TAG (mmol/L)
# 1.10(0.40)
a
0.86(0.38)
a,b
0.96(0.39)
a,b
1.18(0.41)
b 0.025
Plasma TC (mmol/L) 4.80(0.65)
a
4.28(0.58)
b
4.32(0.62)
b
4.30(0.59)
b 0.008
Plasma insulin (mU/L)
8.99(8.76) 11.87(10.61) 10.38(7.86) 11.41(10.62) 0.69
HOMA-IR 1.96(1.96) 2.75(2.64) 2.22(1.72) 2.72(2.82) 0.53
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6.4.3 Plasma VLDL composition in pregnant and non-pregnant 
women 
6.4.3.1 VLDL particle number 
In a pure VLDL fraction, apo-B concentration is indicative of VLDL particle number. 
In pregnant women, apo-B concentration at 18 days post LH surge were significantly 
lower than baseline pre-pregnant levels (p<0.001) then levels started to rise at 29 
days post LH surge but did not reach statistical significance until 45 days post LH 
surge compared to 18 days post-LH surge level (p<0.003) (Figure 6-2). There was 
no significant difference in apo-B concentration between visits in non-pregnant 
women. 
 
Figure 6-2 VLDL apo-B concentration  
Plotted data are Mean (SD). One-way ANOVA was used to study the variance across timeline. 
6.4.3.2 VLDL lipid content 
In pregnant women, VLDL TC concentration at 18 days was significantly lower than 
baseline levels (p<0.001) (Figure 6-3). Then, the levels in 29 and 45 days remain 
not significantly different from the baseline levels. There was no significant 
difference in VLDL TC concentration between visits in non-pregnant women. 
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Figure 6-3 VLDL TC concentration 
Plotted data are Mean (SD). One-way ANOVA was used to study the variance across timeline. 
In pregnant women, VLDL TAG concentration at 18 days were significantly lower 
than baseline levels (p<0.001) (Figure 6-4). At 29 and 45 days post-LH surge VLDL 
TG remained similar to baseline levels. There was no significant difference in VLDL 
TG concentration between visits in non-pregnant women. 
  
Figure 6-4 VLDL TAG concentration 
Plotted data are Mean (SD). One-way ANOVA was used to study the variance across timeline. 
6.4.3.3 VLDL particle composition  
VLDL TAG/Apo-B ratio and VLDL CE/Apo-B ratio are shown in (Figure 6-5 and 
Figure 6-6). There was no significant difference in TAG/Apo-B or CE/Apo-B between 
visits in pregnant women. There was no significant difference in TAG/Apo-B and 
CE/Apo-B ratios between visits in non-pregnant women. 
Chapter 6  210 
 
  
Figure 6-5 TAG/ apo-B ratio 
Plotted data are Mean (SD). One-way ANOVA was used to study the variance across timeline. 
  
Figure 6-6 CE/apo-B ratio 
Plotted data are Mean (SD). One-way ANOVA was used to study the variance across timeline.  
6.4.3.4 Relationship between pregnancy hormones, VLDL composition and 
plasma lipids 
The relationship between the pregnancy hormones estradiol, progesterone and 
human chorionic gonadotropin (HCG) and VLDL composition at all time points is 
shown in Table 6-3. The significance level considered is p <0.010. The pregnancy 
hormones did not correlate with VLDL apo-B, VLDL TAG and VLDL TC. However, 
plasma TAG levels correlated positively with VLDL apo-B, VLDL TAG and VLDL 
TC levels. Moreover, the plasma insulin and HOMA-IR levels correlated positively 
with plasma TAG levels at early pregnancy. Similarly, VLDL TAG correlated with 
plasma insulin and HOMA-IR levels.
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Table 6-3 Correlations between pregnancy hormones (estrogen, progesterone and HCG), VLDL composition (VLDL apo-B, VLDL TAG and VLDL TC) and 
plasma lipids (TAG and TC) at all time points. 
 
# log transformed * square root transformed variable. Significance level p<0.010.
R
2
 Adj P value R
2
 Adj P value R
2 
Adj P value R
2
 Adj P value R
2
 Adj P value
Estradiol (pmol/L)* 0.0% 0.49 0.0% 0.89 0.8% 0.18 0.0% 0.41 1.2% 0.14
Progesterone (nmol/L)*
0.4% 0.23 0.5% 0.22 3.3% 0.040 0.6% 0.19 6.6% 0.006
HCG (IU/L)
0.6% 0.2 1.9% 0.091 0.0% 0.85 1.2% 0.14 0.7% 0.19
Plasma TAG (mmol/L)
# 53.1% <0.0001 78.2% <0.0001 55.3% <0.0001 -      -      -      -      
Plasma TC (mmol/L) 5.4% 0.010 1.7% 0.97 2.9% 0.046 -      -      -      -      
Plasma insulin (mU/L) 0.8% 0.17 9.9% 0.001 4.2% 0.022 17.6% <0.0001 0.0% 0.38
HOMA-IR 1.0% 0.16 10.9% <0.0001 4.7% 0.016 17.8% <0.0001 0.0% 0.42
VLDL apo-B VLDL TAG VLDL TC Plasma TAG Plasma TC
Plasma variable
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6.4.3.5 VLDL FA concentrations over the first 45 days post-LH surge 
VLDL FA concentrations over time for women who were successful in getting 
pregnant and non-pregnant women are shown in Table 6-4.. 
 
 
Table 6-4 VLDL FA concentrations from pre-LH surge to 45 days post-LH surge in pregnant women (P, n=27) and women who were unsuccessful in getting 
pregnant (NP, n=35) 
 
Abbreviations: LHS, luteinizing hormone surge; MUFA, monounsaturated fatty acids; NP, not successful in becoming pregnant; P, successful pregnancy; PUFA, 
polyunsaturated fatty acids; SAFA, saturated fatty acids. Means (SD) are shown. Differences between concentrations were tested using one-way ANOVA for repeated 
measures, across sampling from pre-LH surge (pre-pregnancy) to 18, 29, and 45 d post-LH surge and P values are given. NP women withdrew from the study after blood 
pregnancy testing at day 18 post-LH surge and therefore 29 and 45 d post-LH surge samples are not available for these women. a,b indicate differences between 
individual groups using post-hoc Tukey-Kramer at significance level P < .05, there is a significant difference where superscript letters are different and where superscript 
letters are shared there is no difference. 
Fatty Acid (nmol/mL) Pre-LHS P 18 Days Post-LHS P 29 Days Post-LHS P 45 Days Post-LHS P P  value P Pre-LHS NP 18 Days Post-LHS NP P value NP
SAFA
16:0 palmitic 505 (223)
a
375 (108)
a
395 (207)
a
525 (284)
a 0.037 457 (276) 454 (243) 0.91
18:0 stearic 127 (40)
a
102 (40)
a
102 (38)
a
124 (50)
a 0.047 115 (45) 124 (70) 0.70
24:0 lignoceric 3.95 (2.54)
a
2.54 (1.41)
a,b
2.86 (1.47)
a,b
3.15 (1.96)
b 0.039 3.52 (1.82) 3.43 (2.23) 0.64
MUFA
18:1n-9 oleic 556 (274) 404 (214) 453 (220) 591 (317) 0.064 545 (316) 612 (473) 0.76
PUFA n-6
18:2n-6 linoleic 395 (191) 291 (141) 331 (152) 384 (201) 0.13 382 (203) 418 (335) 0.75
18:3n-6 ϒ- linolenic 9 (6) 6 (5) 7 (4) 6 (4) 0.12 10 (8) 10 (9) 0.91
20:3n-6 dihomo-ϒ-linolenic 16 (11) 13 (9) 14 (7) 19 (12) 0.17 15 (9) 17 (16) 0.67
20:4n-6 arachidonic 59 (27) 47 (25) 51 (24) 62 (32) 0.17 53 (31) 60 (50) 0.89
22:4n-6 adrenic 3 (1) 3 (1) 2 (1) 3 (1) 0.46 3 (1) 3 (2) 0.083
22:5n-6 docosapentaenoic 1 (1) 1 (1) 2 (1) 3 (1) 0.11 1 (1) 1 (1) 0.93
PUFA n-3
18:3n-3 α-linolenic 21 (13) 16 (10) 16 (11) 16 (11) 0.074 23 (16) 26 (25) 0.56
20:5n-3 eicosapentaenoic 21 (57) 11 (11) 29 (69) 11 (13) 0.44 59 (119) 36 (96) 0.37
22:5n-3 docosapentaenoic 8 (4) 6 (3) 6 (3) 7 (4) 0.24 8 (4) 8 (6) 0.93
22:6n-3 docohexaenoic 21 (10) 17 (8) 22 (12) 26 (14) 0.17 17 (13) 25 (34) 0.15
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In pregnant women, lignoceric acid (24:0) concentration significantly changed over 
time in VLDL particles of pregnant women, with 45 days post-LH surge being 
significantly lower than the pre-LH surge level. Although palmitic (16:0) and stearic 
(18:0) acid concentration changed significantly over time in VLDL particles, there 
were no subgroup differences in the post-hoc analysis. For the monounsaturated 
fatty acid (MUFA), n−6 PUFAs and n−3 PUFAs, there was no change over time in 
FAs concentrations in VLDL in pregnant women. Interestingly, DHA (22:6n−3) 
concentration in VLDL particles was not changed from pre-LH surge to 45 days post-
LH surge. There was no change in DHA (22:6n−3) concentration per apo-B (p= 
0.29) (Figure 6-7). In the women who were not successful in getting pregnant, there 
were no significant changes in plasma VLDL FA concentration from pre-LH surge 
to day 18 post-LH surge. 
0.0
0.2
0.4
0.6
0.8
1.0
Days post LHS
D
H
A
/ 
a
p
o
-B
18 29 45
DHA/ apo-B
 
Figure 6-7 DHA per apo-B 
Plotted data is Mean. One-way ANOVA was used to study the variance across timeline. 
6.4.3.6 Rate of change of maternal VLDL FA concentrations and iAUC over 
the first 45 days post-LH surge 
The rate of change in concentration in VLDL lignoceric acid (24:0) significantly 
decreased from 18 days to 45 days post-LH surge (p=0.031) (Figure 6-8). The iAUC 
was negative indicating that VLDL lignoceric acid concentration decreased over this 
time period (Figure 6-9). The rate of change in VLDL palmitic and stearic acid 
concentration was not significantly changed.  
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Figure 6-8 Rates of change of maternal FA concentration in VLDL:16:0, 18:0 and 24:0 
The rate of change of fatty acids were calculated as the difference between the fatty acid on day 18 
post-LH surge and pre-LH surge and then divided by the difference in time (day) between day 18 
post-LH surge and pre-LH surge. This was then repeated for all other time points, ie, day 29 post-
LH surge and day 18 post-LH surge and then day 45 post-LH surge and day 29 post-LH surge. The 
results are expressed as nmol/mL plasma per day. One-way ANOVA was used to study the variance 
across timeline. 
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Figure 6-9 iAUC of maternal FA concentration in VLDL lignoceric acid (24:0) 
Incremental areas under the time (pre-LH surge to 45 d post-LH surge) x concentration curve was 
calculated using the trapezium method 
Chapter 6  216 
 
6.5 Discussion 
Our main finding is that there was no change in VLDL DHA concentration or VLDL 
DHA enrichment from pre-LH surge to 45 days post-LH surge. However, there was 
reduced VLDL particle number by 18 days post-LH surge in pregnant women only. 
These findings suggest that VLDL is not the main lipoprotein carrier for DHA which 
was contrary to our hypothesis. Other lipoproteins such as HDL could be an 
important carrier of DHA similar to the non-pregnant population. Therefore, isolation 
of other lipoprotein fractions throughout gestation and the subsequent study of their 
FA composition would be of interest to identify the primary carrier of DHA in maternal 
plasma.  
The reduction in VLDL particle number by 18 days post-LH surge was an 
unexpected finding. VLDL assembly and secretion is a process highly regulated by 
TAG availability in the liver (Fisher and Ginsberg, 2002). The TAG sources for the 
liver include circulating FA bound to albumin, VLDL and chylomicron remnants and 
de novo hepatic synthesis of TAG. TAG entry into the pool for VLDL secretion is 
regulated by insulin and microsomal triglyceride transfer protein (MTTP) (Pan and 
Hussain, 2007). In the presence of lipids, nascent apo-B is lipidated by MTTP to 
increase VLDL secretion by the liver (Fisher et al., 2001). In contrast, the absence 
of lipids leads to a reduction in MTTP activity, subsequent apo-B degradation and 
reduced VLDL secretion (Fisher et al., 2001). In early pregnancy, there is a 
physiological increase in insulin sensitivity which leads to increased LPL activity and 
increased FA storage. Furthermore, the enhanced insulin sensitivity in early 
pregnancy inhibits adipocyte lipolysis by inhibition of HSL. Interestingly, plasma 
TAG levels were reduced by 18- and 29-days post-LH surge. However, the 
underlying mechanism for this early reduction in plasma TAG is not clear but it could 
be used as an energy source for the rapidly growing fetus. The reduction in plasma 
TAG was partially mediated by HOMA-IR and plasma insulin level in early 
pregnancy. Moreover, the reduction in TAG availability to the liver in early pregnancy 
might contributed to the observed reduction in VLDL particle number by subsequent 
apo-B degradation and reduced VLDL secretion. This relationship was suggested 
by the observed correlation between VLDL particle number and plasma TAG. Thus, 
we hypothesise that the early pregnancy changes in insulin sensitivity and the 
subsequent reduction in TAG availability to the liver could probably explain the 
current study observation of reduced VLDL particle number at 18 days post-LH 
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surge, an effect probably mediated through reduced MTTP activity and subsequent 
apo-B degradation.  
Other lipoprotein fractions were not studied by the researcher. However, this has 
since been carried out in collaboration with Wollongong University. The current 
study cohort was analysed along with other study cohort plasma samples collected 
longitudinally throughout gestation at 16, 25, 35 weeks of gestation and 13 weeks 
postnatal  to examine the lipoprotein fractions VLDL, IDL, LDL, HDL and LPDP FA 
composition prior to pregnancy, throughout gestation and in the post-partum period. 
The results revealed that DHA is carried primarily in HDL throughout gestation and 
the HDL particles are enriched in DHA similar to the non-pregnant population 
(Augustine et al., 2014). This was observed as a consistently increasing 
concentration of DHA carried by HDL peaking at 25 weeks of gestation, a higher 
proportion of DHA carried in the HDL fraction than any other lipoprotein fraction and 
the progressive enrichment of HDL in DHA peaking at 25 weeks of gestation 
(Samani et al unpublished data). In contrast, DHA concentrations in the other 
lipoprotein fractions do not change throughout pregnancy. HDL is an ideal vehicle 
to carry the additional DHA required for transfer to the fetus because of its very well-
known anti-oxidant and anti-inflammatory properties which are increased during 
pregnancy as a protective mechanism against the pregnancy associated oxidative 
stress (Sulaiman et al., 2016).  The observed peak concentration of DHA carried by 
HDL at 25 weeks of gestation coincides with the previously observed higher CETP 
activity in the second trimester which then declines in third trimester (Iglesias et al., 
1994). Therefore, it is possible that the maternal DHA packaged into VLDL is 
incorporated into HDL by the transfer from other lipoproteins via CETP. 
Furthermore, the observed increased concentration of DHA carried by HDL peaking 
at 25 weeks of gestation (Samani et al unpublished data), coincides with a second 
peak of increased head circumference growth velocity which peaks twice during 
gestation, (14 weeks and 19-21 weeks of gestation) (Grantz et al., 2018). This 
evidence supports the importance of HDL in delivering the DHA required for fetal 
neurological development.  
The concentration of DHA in neonates of mothers with GDM have been found to be 
low compared to healthy women (Thomas et al., 2005). Several studies have related 
reduced DHA concentration to reduced placental transfer to the fetus (Wijendran et 
al., 2000). GDM pregnancy is characterized by greater FA flux from adipose tissue 
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stores as we have shown in Chapter 4. The maternal FA flux affects the placental 
lipid uptake. In GDM, there was a higher accumulation of lipid droplets in placental 
tissue (Tewari et al., 2011) and reduced mitochondrial FA oxidation by 20% in 
placenta, contributing to enhanced TAG content within the placenta. This might 
affect the placental function and may affect the fetal levels of important FA such as 
DHA. These changes could adversely affect the fetal metabolism and predispose 
the fetus to future metabolic diseases and other adverse implications on the fetal 
neurodevelopment. However, another study has attributed the reduced DHA 
concentration in neonates of mothers with GDM to increased fetal utilization 
(Ortega-Senovilla et al., 2009). Additionally, the previous study proposed that 
augmented utilization of LC-PUFA could contribute to increase in the fetus body fat 
mass and subsequent tendency to develop macrosomia (Ortega-Senovilla et al., 
2009). The study of HDL FA composition, the main carrier of DHA in pregnancy, to 
determine the GDM effect on DHA concentration compared to healthy pregnancy 
was not carried out before.  
A particular strength of the current study was the prospective design and repeated 
within individual sampling up to 45 days post-LH surge. This early time period is 
rarely studied in early pregnancy because it is difficult to assess in a free-living 
population and is very critical for embryo neuronal development. Additionally, the 
comprehensive analysis of VLDL FA measuring absolute concentrations allowed 
me to draw conclusions regarding different subtypes of FAs. The main limitation of 
the current study was that the women participants were undergoing in vitro 
fertilization, and this might not be considered a “normal” pregnancy population. 
However, the women had a natural menstrual cycle, meaning there was no 
interference of exogenous hormones used in cycle reconstruction on their metabolic 
adaptation to pregnancy. Indeed, the study of this population provided us with 
accurately timed periconceptual and early pregnancy blood samples that would be 
extremely difficult to achieve from a free-living population. Unfortunately, there was 
no dietary intake data, no direct measure of δ6-desaturase activity and no 
assessment of embryonal accrual of FA. Inferences on changes in VLDL FA 
metabolism were made using serial steady state plasma VLDL FA concentrations. 
Although I could observe increases and decreases in plasma VLDL FA 
concentration, it does not fully establish whether these changes in concentration 
were due to changes in rates of entry into or removal from plasma compartments as 
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would be described by kinetic tracer studies, which are clearly extremely difficult to 
perform in pregnant women.  
In conclusion, my results have shown that contrary to our hypothesis, VLDL is not 
the carrier for DHA in the first 45 days post-LH surge as evidenced by unchanged 
DHA concentration in VLDL, unchanged DHA enrichment per VLDL particle and 
reduced VLDL particle number. Subsequent analysis of the study cohort by our 
collaborator has shown that HDL, and not VLDL, is the preferred lipoprotein in terms 
of DHA transport across the pregnancy timeline possibly because of HDL important 
antioxidant and anti-inflammatory properties that may protect DHA from oxidation. 
 
  220 
 
Chapter 7 Discussion 
Given the increased obesity rates among the general population, it is unsurprising 
that maternal obesity rates are on an increasing trend. In Scotland, the proportion 
of women who were obese at their booking visit rose from 9.4% to 18.9% between 
1990 and 2002–2004 (Kanagalingam et al., 2005). Similar trends were also 
observed in England (Heslehurst et al., 2010b). Given the association between 
maternal obesity and maternal and fetal adverse outcomes, this rising trend is a 
major concern. The increase in adiposity has been linked to several cardiometabolic 
complications, including insulin resistance and impaired glucose and lipid 
metabolism. The main and unique function of adipocytes is the storage of FFA under 
conditions of positive energy supply, and their release during conditions of negative 
energy balance. However, the concept of a primary mechanistic role for adipose 
tissue in the development of metabolic abnormalities has emerged over the last 
decade, which involves adipose tissue expandability, fat distribution (specifically the 
role of VAT), ectopic fat deposition, lipotoxicity and low-grade inflammation. The 
work presented in this thesis firstly aimed to examine the current trends in maternal 
obesity and GDM rates at the population level among pregnant women in Greater 
Glasgow and Clyde. The recent advances in robust recording of maternal BMI and 
its associated adverse events make this a timely analysis. Secondly, the thesis 
aimed to test the hypothesis that in women with GDM, SAT adipocytes show 
adipocyte hypertrophy and increased lipolysis, which would provide evidence for the 
failure of adipocyte expansion in GDM, consistent with that observed in T2DM. 
Thirdly, the work presented in this thesis aimed to assess the role of VLDL in early 
pregnancy as a potential maternal plasma carrier of the extremely important long 
chain polyunsaturated fatty acid docosahexaenoic acid (DHA), required by the fetus 
for neuronal development. Infants born to mothers with GDM had lower DHA levels, 
and were shown to have lower cognitive performance, partly attributed to lower 
placental transfer of DHA in GDM. However, the underlying mechanism for defective 
DHA metabolism and transport in GDM pregnancy is not fully understood. 
The first objective of this thesis was to explore the epidemiological evidence that 
among the population of the overall study, women with maternal obesity are at 
greater risk of GDM and adverse maternal and fetal outcomes. This analysis 
provided robust background information on the clinical characteristics of the 
population in which the adipocyte function and DHA transportation studies were 
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undertaken. The prevalence of maternal obesity in the current study was 22.3%, 
suggesting that maternal obesity is on an increasing trend in the Glasgow population 
when compared to earlier studies (Kanagalingam et al., 2005). Although the 
prevalence of GDM (2.2%) remains low in the Glasgow population compared to the 
worldwide prevalence of GDM (from 0.5 to 15%), the associated risks observed 
represent a great burden on NHS resources. The current study showed that mothers 
with obesity and GDM receive a higher number of obstetric interventions, including 
operative and earlier delivery. Moreover, despite the higher rate of medical 
interventions among obese and GDM mothers, the average birthweight for offspring 
is significantly higher for GDM mothers. Further analysis of this data to address the 
economic costs associated with obesity and GDM diagnosis during pregnancy, 
including maternal hospital costs for the mother and her neonate, will provide 
insights to inform clinical practice decision-making and national pregnancy care 
planning. Wider analysis of maternal obesity rates at a national level could be 
beneficial in informing clinical practice for the management of maternal obesity 
during pregnancy. Moreover, a national analysis of maternal obesity rates and 
subsequent outcomes will provide an evaluation of the current therapeutic 
strategies, and might provide firm evidence regarding the optimal 
treatment/management for maternal obesity during pregnancy and better direction 
of NHS resources. Prospective follow-up analysis of the current study cohort might 
provide more insight about the long-term complications in the mother and her fetus 
in this population. Future experimental studies are required to provide better 
understanding of the underlying pathophysiology linking high maternal BMI and the 
associated adverse pregnancy outcomes. 
The second objective of this thesis was to ascertain whether adipocyte size and 
adipocyte lipolytic function (basal and β-adrenergic-stimulated lipolysis, and insulin 
suppression of lipolysis) in SAT and VAT adipocytes were different between women 
with GDM and healthy BMI-matched controls. In this study, contrary to our 
hypothesis that adipocyte hypertrophy would be observed in SAT adipocytes, 
significantly higher adipocyte diameter and basal lipolysis were observed in VAT 
adipocytes in GDM women than in BMI-matched healthy controls. This suggests 
that failure of adipocyte expansion occurs in the VAT depot in women with GDM. 
Due to the study design (cross-sectional in the third trimester), pre-gestation or early 
gestation hypertrophic changes in SAT adipocytes caused by overweight and 
obesity, which might have proceeded VAT adipocyte hypertrophy, would not be 
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observed. Thus, our revised hypothesis is that VAT adipocyte hypertrophy in the 
third trimester of pregnancy could be a consequence of failed SAT expandability, 
which occurs earlier and represents SAT adipocyte overspill stored “ectopically” in 
VAT adipocytes. Studying another control group of healthy pregnant women with 
normal BMI would help in drawing conclusions regarding hypertrophy in SAT 
adipocytes. One could hypothesise that in healthy-weight women in pregnancy, SAT 
hypertrophy may occur in response to gestational weight gain, at least in a subset 
of women, but may never reach the stage of fatty acid overspill. In such healthy 
women with low pre-pregnancy BMI or limited gestational weight gain, either they 
have full potential for adipocyte differentiation to occur, or, even in a situation of 
limited adipocyte differentiation capacity, hypertrophy of SAT is sufficient to buffer 
excessive gestational fatty acid flux without VAT hypertrophy. In healthy pregnant 
women with normal BMI, SAT hypertrophy could be reversed after delivery (Figure 
7-1). The failure of adipocyte expansion results from a reduced ability to recruit new 
adipocytes. Adipocyte differentiation was not measured in the current study, and 
assessment of this in pre-adipocytes collected pre-pregnancy, in early gestation and 
in late gestation, would be very informative. This would be a valuable, but difficult to 
execute, next study. 
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Figure 7-1 Revised hypothesis of adipocyte expansion during pregnancy in GDM, healthy 
obese and normal-weight pregnancy. 
In GDM, there is defective SAT adipocyte expansion in response to increased FA storage in early 
pregnancy. Subsequently, SAT defective expansion results in FA overspill in VAT adipocytes with 
subsequent VAT adipocyte hypertrophy and higher basal lipolysis. In healthy obese pregnancy there 
is SAT adipocyte hypertrophy in response to increased FA storage in early pregnancy, but it does 
not reach the stage of FA overspill into VAT. In healthy normal-weight pregnancy, there is efficient 
FA storage, either by SAT hypertrophy or hyperplasia in response to increased FA storage in early 
pregnancy, but there is no VAT storage of NEFA. 
The finding that there was higher basal lipolysis in VAT adipocytes from women with 
GDM than controls suggests that there is reduced ability for efficient storage and 
retention of FFA in VAT adipocytes in GDM. Thus, dysfunctional VAT adipocyte fat 
storage may be an important factor contributing to ectopic fat accumulation in other 
tissues, leading to the emergence of metabolic dysfunction in women with GDM. 
Increased VAT mass in obese insulin-resistant individuals has been proposed to 
represent a marker of reduced SAT ability to store fat (Després and Lemieux, 2006). 
Increased VAT mass could also be a surrogate marker, rather than a necessary 
causal factor for downstream ectopic fat accumulation and the development of 
metabolic risk. When the storage capacity of adipocytes is exceeded, increased FFA 
flux to ectopic tissues may not be balanced by an increase in FA oxidation in those 
tissues, leading to accumulation of unoxidised FFA in non-adipose tissue, as 
suggested by the “spill over” hypothesis. Lipids can be deposited in other organs, 
such as the liver, pancreas, and skeletal and cardiac muscle, which can lead to the 
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development of metabolic syndrome features. According to the portal hypothesis, 
the anatomical location of the VAT depot exposes the liver to increased flux of FFA 
and adipokines via the portal vein. Higher VAT adipocyte FFA release potentially 
contributes to ectopic fat deposition in the liver, and to hepatic insulin resistance 
(Boden, 2008). This is consistent with the current study, finding that both women 
with GDM and overweight/obese control groups had high HSI scores. In our cohort, 
HSI was closely related to maternal adiposity and measures of insulin sensitivity in 
normal pregnancy and GDM. There was a strong, consistent relationship between 
SAT adipocyte lipolysis and HSI score in women with GDM, probably suggesting 
the importance of SAT adipocyte expansion ability as an initiating factor for the 
subsequent increase in VAT mass and ectopic fat deposition in the liver. Therefore, 
the measurement of liver fat during routine antenatal ultrasound for pregnant women 
at risk of pregnancy metabolic complications may be of clinical utility. Further studies 
that examine maternal liver fat deposition longitudinally throughout gestation in 
women with GDM, in comparison to a healthy pregnant control group using 
magnetic resonance spectroscopy, are needed to assess the evidence for ectopic 
fat deposition in the liver in women with GDM. 
This thesis provided support for the theory that adipose tissue distribution during 
pregnancy is associated with maternal metabolic health. The importance of visceral 
obesity as either a marker of or facilitator in developing subsequent maternal and 
fetal complications should be recognised among clinicians. Visceral distribution of 
fat pre-pregnancy, or accumulation of visceral fat during pregnancy, may identify 
women most at risk of an adverse outcome. If so, there is a need to revise the clinical 
approach towards obesity categorisation and treatment during pregnancy. 
Measuring VAT could be a novel strategy that would assist in more effectively 
directing medical resources to those women at greater risk. Screening for visceral 
adiposity in pregnant populations is not an easy task. BMI does not account for 
differences in body fat distribution among different populations. BMI is not a precise 
measure of body composition, and cannot distinguish lean or fat tissue or the 
location of fat. Abdominal waist circumference has been used as a measure of 
central obesity and a marker of visceral fat in large-scale epidemiological studies. 
Sattar et al. (2001) assessed abdominal waist circumference at 16 weeks’ gestation, 
and found that larger waist circumferences (>80cm) were associated with an 
increased risk of pregnancy-induced hypertension and pre-eclampsia. At 20–24 
weeks of gestation, waist circumference values in the range of 86–88 cm were 
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shown to represent a predictor of GDM in the population of Brazilian women 
(Bolognani et al., 2014). Sattar et al. (2001) suggested that waist circumference is 
a simple measure which could form the basis for health promotion among women 
who are planning to get pregnant, indicating a need for weight reduction. Further 
epidemiological studies are warranted to determine whether abdominal waist 
circumference is as sensitive as BMI for predictions of pregnancy complications 
associated with maternal obesity and GDM. Newer techniques to measure visceral 
fat, which are convenient and quick to perform in busy antenatal clinics, include the 
use of bioimpedance assessment (Khalil et al., 2014). Bioimpedance analysis can 
be used to identify the visceral fat compartment, which highly correlates with VAT 
measurements obtained by computed tomography (Yamakage et al., 2014). A new 
screening tool – used to define the obesity-associated risk of adverse pregnancy 
outcomes using a composite phenotype measure, taking into account maternal BMI, 
plasma TAG as a surrogate marker for effective fat storage in adipocytes, adipose 
tissue distribution, adipose tissue inflammation status, and ectopic fat – would 
represent a novel strategy and could be highly beneficial. 
Adipose tissue is an active endocrine organ, secreting many adipokines shown to 
be linked to obesity, insulin resistance and T2DM in the non-pregnant population. 
This thesis explored isolated VAT adipocyte adipokine secretion in basal or 
activated (LPS-stimulated) conditions in healthy and BMI-matched GDM women. In 
this study, there was no evidence for higher VAT adipocyte inflammatory adipokine 
release in either basal or stimulated conditions in GDM compared to controls. 
However, this conclusion can only be drawn with caution, as there was insufficient 
recruitment for the study to be sufficiently representative to identify significant 
differences. If similar results were confirmed with larger sample size, this data might 
suggest that adipokine release is related to obesity, and due to BMI-matching of our 
groups we did not observe differences between GDM and control groups. 
Alternatively, adipokine release could have been altered in SAT, which was not 
assessed in this study. Furthermore, pregnancy is considered to be a state of low-
grade inflammation, especially in the third trimester, and it is not clear whether there 
is a difference in adipokine levels from adipocytes in response to obesity in 
pregnancy. In the current study, consistent with the adipokine secretion from VAT 
adipocyte findings, there were no significant differences in inflammatory gene 
expression in either SAT or VAT adipocytes from GDM compared to controls. 
Similarly, other genes involved in adipocyte differentiation, lipid storage, lipid and 
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glucose metabolism, and angiogenesis gene expression were not different in GDM 
compared to controls. 
The data collected on adipocyte inflammation is limited by the incomplete analysis 
of all tissues, and low sample size. At present, the data provides no evidence for the 
role of VAT inflammation in GDM. This could suggest that adipocytes are not the 
main contributing factor per se to the low-grade inflammation observed in obese and 
GDM pregnancy. This is probably because infiltrating inflammatory cells may be of 
more importance than adipocyte cytokine production. Other studies have focused 
more on the role of inflammatory cells that infiltrate adipose tissue. Gene profile 
analysis of isolated SAT adipocytes and SVF from obese non-pregnant individuals, 
after following a very low-calorie diet for 28 days, revealed that only 13% of 
differentially expressed genes related to inflammation were expressed in adipocytes 
in obese individuals compared to lean controls (Clément et al., 2004). The 
inflammation-related genes are mainly expressed in cells of the SVF of adipose 
tissue, which include the macrophages (Clément et al., 2004). However, it would be 
useful to discount the adipocyte’s role in inflammatory cytokine production if the 
results presented here could be confirmed by a larger sample size. Further studies 
of inflammatory gene expression on the isolated SVF fraction or whole adipose 
tissue explants could provide insight into adipose tissue inflammation in GDM. 
Adipocytes could be viewed as the primary initiating factor for macrophage 
activation and recruitment when adipose tissue becomes dysfunctional, which 
subsequently leads to adipose tissue inflammation through enhanced macrophage 
and immune cell recruitment. Therefore, the determination of adipose tissue cell 
densities of activated (cfms+) and total (CD68+) macrophages could be an 
interesting analysis to perform on the current study samples. Furthermore, a wide 
range of protein factors, including various chemokines, which are known to be 
secreted from adipose tissue to attract immune cells, could be studied further, such 
as MCP-1 and Stromal cell-derived factor 1 (SDF1). SDF1 is a novel chemotactic 
factor secreted from adipose tissue, mainly by cells of SVF, and might be involved 
in the recruitment of lymphocytes. 
The placenta is another potential site of inflammation during pregnancy. The 
placenta is able to produce inflammatory cytokines, and has the capability to 
respond to a variety of inflammatory stimuli. It was found that the secretory function 
of the placenta contributes to local and systemic cytokine levels. The placenta 
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secretes cytokines similar to those derived from adipose tissue. Under the 
hypothesis suggesting that the activation of inflammatory pathways is necessary to 
induce gestational insulin resistance towards the third trimester, placental cytokines 
could contribute to low-grade inflammation at the third trimester of pregnancy. 
Alternatively, placental hormones could enhance the pre-pregnancy inflammatory 
status of adipose tissue in pregnancies complicated by maternal obesity and GDM. 
However, the relative contribution of the placenta to low-grade inflammation in 
obese and GDM pregnancy is yet to be determined. Under the proposed overspill 
hypothesis, ectopic fat in the placenta could enhance the inflammatory status. FFA 
deposition in the placenta could potentially contribute to macrophage accumulation 
in the placenta. Thus, the study of the placental contribution to low-grade 
inflammation in women with GDM might provide insight into the potential 
mechanisms for communicating the metabolic disease to the fetus. Unfortunately, 
in the current study, we could not collect placenta samples due to having limited lab 
personnel able to assist with its collection. 
The final objective of this thesis was to test whether VLDL could be the main carrier 
for DHA at the critical time of neural tube closure. Given that the liver is the primary 
site for de novo LC-PUFA synthesis, and there was a three-fold increase in VLDL 
synthesis by the liver during pregnancy, we hypothesised that DHA is carried out by 
VLDL in early pregnancy. However, our analysis showed that, contrary to our 
hypothesis, DHA was not carried out by VLDL in early pregnancy. Subsequent 
analysis of these samples by our collaborator showed that HDL is the primary carrier 
of DHA throughout gestation, similar to the non-pregnant population. HDL is an ideal 
carrier for DHA at the very important time of neuronal development, as its 
antioxidant and anti-inflammatory properties could protect DHA from oxidation. 
Considering the important role played by LC-PUFAs in fetal visual, behavioural and 
cognitive development, the study of DHA metabolism in pregnancies complicated 
by GDM is of interest. Thomas et al. (2005) showed that offspring of mothers with 
GDM have lower plasma DHA level than neonates of healthy mothers. Infants born 
to mothers with GDM demonstrate lower cognitive performance (Hod et al., 1999), 
attention span, and face more than twice the risk of language impairment than 
infants born to mothers without diabetes (Dionne et al., 2008). This was attributed 
to reduced placental transfer of DHA in GDM (Wijendran et al., 2000). However, the 
underlying mechanisms for reduced placental DHA transfer to the fetus of GDM 
mothers are not known yet. It is not known whether placental inflammation interferes 
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with lipid metabolism pathways, affecting the transfer of DHA in women with GDM. 
Thus, further investigation of the influence of placental inflammation on the 
regulation of maternal–fetal DHA transport is warranted. Furthermore, the study of 
HDL composition in GDM pregnancy to determine the DHA concentration compared 
to healthy pregnancy has not yet been researched. DHA supplementation of 600 mg 
DHA was found to enhance maternal but not fetal DHA status in pregnancy 
complicated by GDM (Min et al., 2016). This suggests that the transfer of DHA 
across the placenta is impaired in GDM. Further investigation of the clinical 
implications of reduced DHA level in offspring of mothers with GDM, and the optimal 
clinical management to reduce the neurodevelopmental impact on GDM neonates, 
is warranted. 
There were significant strengths to this study. The epidemiology study provided 
detailed demographic and obstetric outcomes analysis among the greatly diverse 
Greater Glasgow and Clyde population, using data linkage analysis of two robust 
datasets. The associations between maternal obesity and a wide range of adverse 
pregnancy outcomes were examined, and the effect of race and social economic 
status on various obstetric outcomes was accounted for – factors which were not 
usually studied in previous research. The study of SAT and VAT adipocytes in 
women with GDM compared to BMI-matched controls provided, for the first time, 
extensive adipocyte functional measures in women with GDM, including adipocyte 
size, and lipolytic and secretory function. We have studied isolated adipocytes rather 
than whole adipose tissue samples to clearly identify the role of the adipocyte in the 
development of insulin resistance during GDM pregnancy. Thus, our results were 
not confounded by immune and other cells in the adipose tissue. This is an area 
where the current available literature is very limited, especially in the context of 
pregnancy and GDM. The VLDL FA composition study provided samples from the 
early pregnancy period, which is rarely studied in pregnancy, because it is difficult 
to assess in a free-living population, a very critical for embryo neuronal 
development. The strengths of the methodologies employed in this study were 
discussed in detail in the relevant chapters. 
The limitations of the current study should also be considered. In the epidemiology 
study, BMI was used as a measure of obesity. However, alternative measures of 
abdominal obesity such as waist circumference, waist/hip ratio and skin-fold 
thickness could have been used, but were not available in the dataset I used, are 
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difficult to record at a population level, and can be unreliable in pregnant women. 
Moreover, this study might not be representative of other settings, or generalisable 
to other populations, but it does confirm the work of multiple previous investigations. 
The study of adipocyte function in GDM was limited by the cross-sectional design, 
which does not provide any information about the adipose tissue changes during 
pregnancy. However, a longitudinal study design would be difficult to conduct with 
pregnant women, because the required repeated intra-abdominal procedure during 
pregnancy would be difficult for pregnant women to tolerate. Another limitation 
involved adipose tissue inflammation only being assessed in adipocytes, which may 
not be the main cell contributing to adipokine secretion in adipose tissue. The main 
limitation of the VLDL FA composition in the early pregnancy study was that the 
women participants were undergoing in vitro fertilisation, and this might not be 
considered a “normal” pregnancy population. However, the women had a natural 
menstrual cycle, meaning there was no interference of exogenous hormones used 
in cycle reconstruction on their metabolic adaptation to pregnancy. The study of this 
population provided us with accurately timed periconceptual and early pregnancy 
blood samples that would be extremely difficult to obtain from a free-living 
population. 
In this thesis, much useful data was collected, which has a bearing on current 
ongoing research in maternal obesity, GDM and clinical practice. Although the 
epidemiology study provided evidence that GDM prevalence remains low in the 
Greater Glasgow and Clyde population, maternal obesity and its associated risks 
still represent a great burden on clinical resources. The study of adipocyte function 
in GDM adds evidence to the existing literature, showing that adipocyte dysfunction 
in GDM could be one of the underlying pathophysiological mechanisms for GDM 
and adverse pregnancy complications among obese mothers. The early pregnancy 
study provides evidence that VLDL is not the carrier of DHA in early pregnancy. 
In conclusion, in a single health board of Scotland’s population, there was a notable 
risk of maternal obesity and GDM, which predisposes mothers to several obstetric 
complications and adverse outcomes. Furthermore, this study provides evidence 
that VAT adipocytes are dysfunctional in GDM pregnancy compared to healthy BMI-
matched controls. Our data did not provide evidence of adipocyte inflammation in 
GDM pregnancy. However, the effects of SVF and macrophages were not studied; 
therefore, their possible contribution to adipose tissue inflammation cannot be 
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disregarded. Further collection of samples is recommended to improve the power 
of the current study in order to reach conclusions regarding VAT FCISI and 
adipocyte inflammation, as the current study was underpowered with regard to 
detecting significant differences. Finally, the data presented in this thesis has shown 
that HDL, and not VLDL, is the preferred lipoprotein in terms of DHA transport across 
the pregnancy timeline, possibly because of HDL’s important antioxidant and anti-
inflammatory properties that may protect DHA from oxidation. Therefore, the study 
of HDL metabolism in GDM pregnancy could be of particular importance to provide 
insight into the neurodevelopmental impacts of reduced DHA levels in the neonates 
of mothers with GDM.  
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We would like to invite you to take part in a research study. Before you decide you 
need to understand why the research is being done and what it would involve for 
you. Please take time to read the following information carefully. Talk to others about 
the study if you wish. 
 
Part 1 tells you the purpose of this study and what will happen to you if you take part.  
Part 2 gives you more detailed information about the conduct of the study. 
Part 3 provides information on the General Data Protection Regulations (GDPR) 
 
Ask us if there is anything that is not clear, or, if you would like more information. 
Take time to decide whether or not you wish to take part. 
 
PART 1 
 
1. What is the purpose of the study? 
We are interested in how blood, fat tissue and the afterbirth (placenta) function in 
pregnancy and how these tissues can influence blood vessel function in the mother 
and the baby. This is important as blood, fat tissue and blood vessel function may 
play a prominent role in achieving a successful outcome i.e. a healthy mother and 
baby. In some instances, we are interested in obtaining fat tissue from different body 
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locations. In other words, our question is does fatty tissue from the lower part of the 
body influence blood vessels in a different way to fat from the abdomen?” The 
effects of blood, fat tissue on the blood vessels may produce conditions such as 
high blood pressure in pregnancy (preeclampsia), diabetes in pregnancy and 
problems affecting the growth of the baby. We are keen to understand how these 
and other conditions develop through vessels not working properly or failing to form 
new blood vessels. Sometimes we use the tissue to provide training and to set up 
the techniques used in this research. 
 
2. Why have I been chosen? 
We wish to study pregnant women at third trimester, like you, with no current medical 
conditions unrelated to pregnancy, who are undergoing either elective or emergency 
caesarean-section. We are recruiting women of different ages and weights. We are 
recruiting mothers with a healthy pregnancy and mothers with pregnancies 
complicated by preeclampsia, gestational diabetes mellitus and intrauterine growth 
restriction. 
 
3. Do I have to take part? 
No.   
It is up to you to decide whether or not to take part.  If you do, you will be given this 
information sheet to keep and be asked to sign a consent form.  You are still free to 
withdraw at any time and without giving a reason.  A decision to withdraw at any 
time, or a decision not to take part, will not affect the standard of care you receive. 
 
4. What will happen to me if I take part? 
If you choose to take part in the study we will collect a sample of blood, about 2 
tablespoons, at the time that you have a drip inserted as part of the preparation to 
give you an anaesthetic. This is part of the routine procedure prior to caesarean 
section.  
 
We will then collect some fat tissue samples during your C-section and we will collect 
placenta, umbilical cord tissue and cord blood after your baby is delivered.  
 
5. How will the tissue samples be collected? 
(A) Fat tissue samples 
We are interested in how fat cells and the blood vessels that supply them work in 
different sites of the body.  We would like to obtain small samples (a biopsy) of fat 
at your C-section delivery while you are still under anaesthesia. At most we would 
take four small samples although this may not be required in every patient. 
 
The first and second samples are taken from just under the skin (subcutaneous fat) 
after the C-section cut has been made. The third is from fat tissue within the 
abdominal cavity (visceral fat) after the womb has been stitched closed, but before 
the skin is stitched closed. This is an additional procedure that takes approximately 
4-5 minutes. It will not significantly lengthen the time of your operation.  
 
In some instances, the fourth will be a biopsy of fat from your upper, outer thigh 
using a biopsy needle and syringe. This procedure will take approximately 5 
minutes. 
 
If you require a caesarean section because of concern about you or your baby’s 
wellbeing or your surgeon does not consider it appropriate, we may not collect 
any/some of these samples. 
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(B)Samples from the placenta (afterbirth) 
We would like to gain information about how the placenta (afterbirth) functions 
during pregnancy and we would like to use umbilical cord cells to understand how 
blood vessels function. Normally the placenta and its attached umbilical cord are 
delivered after the baby and it is discarded because it has completed its function. In 
our study, instead of the afterbirth being discarded, the blood retained in the cord 
will be collected and the placental and umbilical cord tissue will be passed onto the 
laboratory where it will be studied.   
 
6. What do I have to do? 
Your participation in the study will end once the aforementioned samples have been 
collected. 
 
7. What are the possible disadvantages and risks of taking part? 
There are no disadvantages to your baby by taking part in this study. There is a 
minimal extra risk to you of abdominal bleeding from small vessels in the fat layers 
over and above that associated with a Caesarean section when the fat samples are 
collected. As noted above it may also extend your operation by a few minutes. There 
is a very small risk of bruising associated with the needle biopsy from your upper 
thigh should this sample be collected; however this is no greater than what would 
be expected following a blood sample taken from the arm. 
 
8. What are the possible benefits of taking part? 
There is no direct benefit for you in taking part in this study. We hope that the 
information we get from this study will help improve the care of women who develop 
problems in pregnancy. 
 
10. What if there is a problem? 
The samples will be collected at the discretion of the surgeon responsible for your 
care. If at any point the surgeon feels it is not appropriate to take samples then they 
will not be taken. If you have a concern about any aspect of this study, you should 
ask to speak with the researchers who will do their best to answer your questions.  
The contact numbers are provided on this form. If you remain unhappy and wish to 
complain formally, you can do so through the NHS complaints procedure. Details 
can be obtained from the hospital.   
 
11. Will my taking part in the study be kept confidential? 
Yes. All the information which we collect will remain completely confidential.  
 
If the information in Part 1 has interested you and you are considering participation, 
please read the additional information in Part 2 and Part 3 before making any 
decision. 
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PART 2 
 
12. What if relevant new information becomes available?  
Since your participation in the study involves a one-off collection of tissue future new 
information will not affect the tissue collection. New information may suggest 
modifications and improvement to our laboratory analysis which will not directly 
affect you. 
 
13. What will happen if I don’t want to carry on with the study? 
If you withdraw from the study, we will retain the data that has been collected up to 
your withdrawal. However, should you wish for samples and data to be destroyed 
we will comply with this request. 
  
14. What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak with 
the researchers who will do their best to answer your questions.  The contact 
numbers are provided on this form. If you remain unhappy and wish to complain 
formally, you can do so through the NHS complaints procedure.  Details can be 
obtained from the hospital.   
 
In the event that something does go wrong and you are harmed during the research 
study, there are no special compensation arrangements.  If you are harmed and this 
is due to someone’s negligence, then you may have grounds for a legal action for 
compensation against NHS Greater Glasgow and Clyde, but you may have to pay 
your legal costs. The normal National Health Service complaints mechanisms will 
still be available to you. 
 
15. Will my taking part in this study be kept confidential? 
Yes. All the information which we collect will remain completely confidential. Any 
information about you which leaves the hospital will have your name and address 
removed so you cannot be identified from it. 
 
If you join the study, some of the data collected for the study may be looked at by 
authorised persons from the University of Glasgow. They may also be looked at by 
people or representatives of regulatory authorities and by authorised people to 
check that the study is being carried out correctly. 
 
16. What will happen to any tissue samples or data that I give? 
Data and tissue samples collected from the study are retained by the University of 
Glasgow. Sometimes new research indicates further tests that would expand the 
knowledge coming from the study and we can use the archived material to carry out 
additional tests. This allows us to maximise the amount of information on pregnancy 
complications that we can get from the study. Anonymised data and samples may 
be shared with collaborators in other institutions who may be able to offer 
specialised techniques that we do not have in Glasgow.   
 
17. What will happen to the results of the research study? 
New information that we gain from the study will be published in scientific journals.  
No specific individual from whom we have collected tissue will be identified in these 
publications.  These publications are available for all to read. 
 
18. Who is organising and funding the research? 
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This research will be funded by grants from the Saudi Arabian Cultural Bureau, the 
Siriraj hospital, Mahidol University, Thailand and the Glasgow Children’s Hospital 
Charity to the University of Glasgow. This work is supervised by Dr Dilys Freeman 
from Institute of Cardiovascular and Medical Sciences, University of Glasgow.  
 
19. Who has reviewed the study? 
All research in the NHS is looked at by an independent group of people, called a 
Research Ethics Committee to protect your safety, rights, wellbeing and dignity. This 
study has been reviewed and given favourable opinion by the West of Scotland 
Research Ethics Committee 4. 
 
20. Further Information 
Further information about this study may be obtained from Dr Amaal Alrehaili, Dr 
Sharon Mackin, Dr Patamat Panatapirunhakit, Dr Kirsten Mitchell or Dr Dilys 
Freeman 
 
Should you require independent advice regarding this study you can contact 
 
Professor Mary Ann Lumsden 
Level 2, Reproductive & Maternal 
Medicine, Glasgow Royal Infirmary, 
New Lister Building 
Tel: 0141 201 8616  
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PART 3 General Data Protection Regulation (GDPR) Information 
 
NHS Greater Glasgow & Clyde is the sponsor for this study based in Scotland. We 
will be using information from your medical records in order to undertake this study 
and will act as the data controller for this study. This means that we are responsible 
for looking after your information and using it properly. NHS Greater Glasgow and 
Clyde will keep identifiable information about you for 10 years after the study has 
finished. 
Your rights to access, change or move your information are limited, as we need to 
manage your information in specific ways in order for the research to be reliable and 
accurate. If you withdraw from the study, we will keep the information about you that 
we have already obtained. To safeguard your rights, we will use the minimum 
personally-identifiable information possible. 
You can find out more about how we use your information by contacting Dr Dilys 
Freeman 
NHS Greater Glasgow and Clyde will collect information about you for the Adipose 
Tissue, Blood Vessel and Placental Function in Pregnancy from your maternity 
medical notes. This information will include your name, NHS number, postcode and 
date of birth and health information, which is regarded as a special category of 
information. We will use this information to relate our study findings to maternal 
characteristics (e.g. how does maternal age affect the research findings?) and to 
delivery characteristics (e.g. how are the research finding’s related to baby birth 
weight?). 
When you agree to take part in a research study, the information about your health 
and care may be provided to researchers running other research studies in this 
organisation and in other organisations. These organisations may be universities, 
NHS organisations or companies involved in health and care research in this country 
or abroad. Your information will only be used by organisations and researchers to 
conduct research in accordance with the UK Policy Framework for Health and Social 
Care Research.  
This information will not identify you and will not be combined with other information 
in a way that could identify you. The information will only be used for the purpose of 
health and care research, and cannot be used to contact you or to affect your care. 
It will not be used to make decisions about future services available to you, such as 
insurance. 
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Adipose Tissue, Blood Vessel and Placental Function in Pregnancy 
(Pregnant Participants) 
 
Your Consent Please initial 
box 
I confirm that I have read and understand the patient information sheet 
dated 18th September 2018 (Pregnant Participants, Version 7) for the 
above study. I have had the opportunity to consider the information, 
ask questions and have had these answered satisfactorily.  
 
I understand that my participation is voluntary and that I am free 
to withdraw without giving any reason, without my medical care 
or legal rights being affected. 
 
I understand that relevant sections of my medical notes and data 
collected during the study may be looked at by individuals from the 
University of Glasgow, from regulatory authorities or from the NHS 
Trust, where it is relevant to my taking part in this research. I give 
permission for these individuals to have access to my records. 
 
I understand that data and samples used in this study may be used in 
relevant future research. I give my consent for this. 
 
I consent to the collection of a blood sample before delivery and tissue 
samples at delivery. These samples will be retained by the Institute of 
Cardiovascular and Medical Sciences (ICAMS) at the University of 
Glasgow. 
 
I consent to the collection, processing, reporting and transfer 
within and outside Europe of my anonymised data for healthcare 
and/or medical research purposes. 
 
I agree to take part in the above study  
 
 
_______________   ________________  _________________ Name of Patient 
  Date     Signature  
 
 
_______________   ________________  __________________ 
Name of Person   Date     Signature  
obtaining consent  
 
 
 
 
When completed, 1 for patient; 1 for researcher site file; 1 (original) to be kept in medical notes  
  
 
STUDY IDENTIFICATION 
NUMBER______________ 
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